研究者を探す
西岡 安彦
徳島大学
2024年4月26日更新
- 職名
- 教授
- 電話
- 088-633-7127
- 電子メール
- yasuhiko@tokushima-u.ac.jp
- 学歴
- 1988/3: 徳島大学医学部医学科卒業
1993/3: 徳島大学大学院医学研究科博士課程修了 - 学位
- 博士(医学) (徳島大学) (1993年3月)
- 職歴・経歴
- 1988/5: 徳島大学医学部附属病院第三内科医員
1995/1: 徳島大学医学部助手
1996/6: 米国ピッツバーグ大学外科学·分子遺伝学教室研究員
1998/6: 徳島大学医学部助手
1999/10: 徳島大学医学部講師
2007/11: 徳島大学大学院ヘルスバイオサイエンス研究部准教授
2008/7: 米国テキサス大学M.D.アンダーソン癌センター癌生物学部門客員准教授
2011/11: 徳島大学大学院ヘルスバイオサイエンス研究部教授
2015/4: 徳島大学大学院医歯薬学研究部教授
2019/4: 徳島大学病院副院長
2022/4: 徳島大学医学部長
- 専門分野・研究分野
- 呼吸器内科学 (Respiratory Medicine)
2024年4月26日更新
- 専門分野・研究分野
- 呼吸器内科学 (Respiratory Medicine)
- 担当経験のある授業科目
- アレルギー・自己免疫コース (学部)
アレルギー・自己免疫コース(3年) (学部)
医学概論 (共通教育)
呼吸器コース (学部)
呼吸器コース(3年) (学部)
呼吸器コース,アレルギー・自己免疫コース (学部)
呼吸器・膠原病内科学 (大学院)
呼吸器・膠原病内科学(4年) (学部)
呼吸器・膠原病内科学演習 (大学院)
生体防御腫瘍医学実験実習・臨床研究実習 (大学院)
臨床医学 (学部) - 指導経験
- 5人 (博士)
2024年4月26日更新
- 専門分野・研究分野
- 呼吸器内科学 (Respiratory Medicine)
- 研究テーマ
- 肺線維症に対する分子標的治療の開発に関する研究, 肺癌に対する特異的免疫療法の開発に関する研究 (肺線維症 (pulmonary fibrosis), 間質性肺疾患 (interstitial lung disease), 肺癌 (lung cancer), 癌免疫療法 (cancer immunotherapy))
- 著書
- 佐藤 正大, 西岡 安彦 :
進行性線維化を伴う間質性肺疾患の診断と治療,
南江堂, 2023年3月. 西岡 安彦 :
特発性肺線維症,
株式会社 医学書院, 2023年1月. 西岡 安彦 :
呼吸器疾患のバイオマーカー,
朝倉書店, 2022年3月. 佐藤 正大, 西岡 安彦 :
特発性間質性肺炎,
日本臨牀社, 東京, 2021年10月. 佐藤 正大, 西岡 安彦 :
呼吸細気管支炎を伴う間質性肺疾患(RB-ILD),
株式会社 中外医学社, 東京, 2021年8月. 佐藤 正大, 西岡 安彦 :
非特異性間質性肺炎(NSIP),
株式会社 中外医学社, 東京, 2021年8月. 西岡 安彦 :
呼吸器疾患のバイオマーカー,
朝倉書店, 東京, 2021年3月. 佐藤 正大, 西岡 安彦 :
特発性器質化肺炎(COP/BOOP),
南江堂, 東京, 2021年3月. 佐藤 正大, 西岡 安彦 :
Nintedanibの使い方と副作用対策,
南江堂, 東京, 2020年6月. 豊田 優子, 西岡 安彦 :
ステロイド,
メディカルレビュー社, 東京, 2020年4月. 西岡 安彦 :
肺胞微石症,
株式会社 医学書院, 2020年3月. 佐藤 正大, 西岡 安彦 :
サルコイドーシス,
株式会社 医学書院, 2020年3月. 佐藤 正大, 西岡 安彦 :
特発性間質性肺炎(その他の非特異性間質性肺炎，器質化肺炎),
日本医事新報社, 2019年7月. 佐藤 正大, 西岡 安彦 :
間質性肺炎・過敏性肺炎,
株式会社 南山堂, 2019年5月. 河野 弘, 西岡 安彦 :
膠原病の肺病変,
南江堂, 2019年4月. 後東 久嗣, 西岡 安彦 :
血管新生阻害薬耐性機構,
南江堂, 2019年4月. 西岡 安彦 :
好酸球性肺炎,
株式会社 医学書院, 2019年1月. 小山 壱也, 西岡 安彦 :
テロメア伸長と肺線維症,
株式会社 中山書店, 東京, 2018年10月. Hisatsugu Goto and Yasuhiko Nishioka :
ALK and Others: How Important Are ALK and Other Mutations in the Management of Lung Cancer?,
Springer, Jul. 2018. 西岡 安彦 :
過敏性肺炎,
株式会社 医学書院, 2018年1月. 豊田 優子, 西岡 安彦 :
ランゲルハンス細胞組織球症,
2017年10月. 埴淵 昌毅, 西岡 安彦 :
分子生物学的にみた間質性肺炎および肺癌,
2017年10月. 後東 久嗣, 西岡 安彦 :
肺胞微石症,
2017年10月. 埴淵 昌毅, 西岡 安彦 :
じん肺症(珪肺，アスベスト肺),
2017年7月. 西岡 安彦 :
間質性肺炎の急性増悪,
2017年1月. 西岡 安彦 :
非特異性間質性肺炎(NSIP),
2016年12月. 西岡 安彦 :
特発性肺線維症の基礎,
2016年3月. 西岡 安彦 :
特発性間質肺炎,
2016年1月. Yasuhiko Nishioka :
Pathogenesis of IPF. Is abnomal repair of epithelial damage involved in the basic pathogenesis of this disease?,
Springer, 2016. Yasuhiko Nishioka :
Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease?,
Springer,Tokyo, 2016. 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
先端医療シリーズ46. 呼吸器疾患診療の最先端. 全国主要呼吸器診療施設一覧. 徳島大学病院呼吸器・膠原病内科,
東京, 2015年8月. 佐藤 正大, 西岡 安彦 :
細胞生物学，分子病態,
2015年. 岸 潤, 河野 弘, 西岡 安彦 :
強皮症,
2014年9月. 西岡 安彦 :
細胞・分子生物,
2014年5月. 西岡 安彦, 青野 純典 :
安定期と増悪期の対応.,
克誠堂出版 株式会社, 2013年8月. 西岡 安彦 :
特発性器質化肺炎.,
朝倉書店, 東京, 2013年6月. 西岡 安彦 :
Fibrocyteと呼吸器疾患.,
医歯薬出版 株式会社, 東京, 2013年4月. 西岡 安彦 :
症状と病態生理,
ヌーヴェルヒロカワ, 2013年3月. 西岡 安彦 :
副腎皮質ステロイド薬,
南江堂, 2013年2月. 西岡 安彦 :
肺線維化におけるfibrocyteの役割,
株式会社 中外医学社, 2013年1月. 西岡 安彦 :
薬物療法,
株式会社 メジカルビュー社, 2012年5月. 西岡 安彦 :
膠原病の肺合併症-検査の基本-,
医薬ジャーナル社, 大阪, 2012年2月. 西岡 安彦 :
ベバシズマブ, --- 分子標的治療薬-最新の選び方・使い方- ---,
総合医学社, 2011年. 木下 勝弘, 西岡 安彦 :
強勉の仕方-文献検索の仕方，医学論文の読み方・書き方，学会への取り組み方，大学院・医学博士・留学について， 呼吸器科医にとっての研究とは何か?-,
株式会社 診断と治療社, 2011年. 中瀧 恵実子, 西岡 安彦 :
各種ガイドラインにおけるVAPの位置づけ,
2010年7月. 西岡 安彦, 曽根 三郎 :
「肺サルコイドーシス」「過敏性肺炎」「肺胞蛋白症」「じん肺」,
南江堂, 東京, 2010年4月. 西岡 安彦, 曽根 三郎 :
「肺サルコイドーシス」「過敏性肺炎」「肺胞蛋白症」「じん肺」,
南江堂, 2010年4月. 西岡 安彦 :
膠原病における肺合併症の検査の基本,
2010年3月. 中屋 豊, 桑波田 雅士, 丹黒 章, 土井 俊夫, 竹谷 豊, 野間 喜彦, 武田 英二, 東 博之, 島田 光生, 栗田 信浩, 大森 哲郎, 西 正晴, 青野 純典, 西岡 安彦, 吉本 勝彦, ほか 65名 :
NST用語ハンドブック,
メディカルレビュー社, 東京, 2006年2月. 西岡 安彦, 兼松 貴則, 曽根 三郎 :
これだけは知っておきたい 癌の免疫化学療法, --- 免疫化学療法の目的とその評価法 ---,
医薬ジャーナル社, 大阪, 2005年5月. 鵜飼 桃代, 西岡 安彦, 曽根 三郎 :
認定NSTガイドブック 日本病態栄養学会編, --- 呼吸器疾患に対する栄養管理 ---,
メディカルレビュー社, 2004年9月. 西岡 安彦, 曽根 三郎 :
別冊『医学のあゆみ』 ARDSのすべて, --- ARDSと肺の繊維化 ---,
医歯薬出版 株式会社, 東京, 2004年3月. 西岡 安彦, 曽根 三郎 :
よくわかる肺炎のすべて, --- 人工呼吸器関連肺炎 ---,
株式会社 永井書店, 大阪, 2003年12月. 西岡 安彦 :
ダイナミック・メディシン 4, --- 胸壁・横隔膜腫瘍 ---,
西村書店, 2003年7月. 西岡 安彦 :
ダイナミック・メディシン 4, --- 胸膜腫瘍 ---,
西村書店, 2003年7月. 西岡 安彦 :
ダイナミック・メディシン 4, --- 胸膜炎 ---,
西村書店, 2003年7月. 西岡 安彦 :
樹状細胞 ∼基礎から臨床へ∼, --- 樹状細胞の臨床応用 C.樹状細胞を標的とした免疫療法 1-b.遺伝子導入 ---,
南江堂, 東京, 2000年10月. 西岡 安彦, 大串 文隆, 曽根 三郎 :
別冊 日本臨牀 領域別症候群シリーズ31, --- 免疫症候群 -その他の免疫疾患を含めて - (上巻) 特発性間質性肺炎・肺線維症 ---,
日本臨牀社, 大阪, 2000年. T. Tutling, L. Zitvogel and Yasuhiko Nishioka :
DENDRITIC CELLS,
Academic Press, London, 1999. 西岡 安彦, 曽根 三郎 :
Molecular Medicine 症候・病態の分子メカニズム, --- 肺転移 ---,
株式会社 中山書店, 東京, 1998年12月. 西岡 安彦, 小倉 剛 :
気管支肺胞洗浄[BAL]法の臨床ガイドライン, --- 肺癌 ---,
克誠堂出版 株式会社, 東京, 1995年11月. - 論文
- Motoki Sugasaki, S Nakamura, K Teramoto, M Urushihara, Y Inoue, T Nakao, Yasuhiko Nishioka and Masataka Sata :
Lupus anticoagulant hypoprothrombinemia syndrome with multiple and high-titer antiphospholipid antibodies strongly interfered with coagulation assays,
Blood Coagulation & Fibrinolysis, Vol.35, No.3, 149-153, 2024.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1097/MBC.0000000000001282.
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38557935
- ● Search Scopus @ Elsevier (PMID): 38557935
- ● Search Scopus @ Elsevier (DOI): 10.1097/MBC.0000000000001282.
(DOI: 10.1097/MBC.0000000000001282., PubMed: 38557935) Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Thi Na Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara and Yasuhiko Nishioka :
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.,
Journal of Thoracic Oncology, Vol.15, No.5, 369-378, 2023.- (要約)
- 5-FU induced cell surface expression of CRT and ATP secretion most efficiently among the several chemotherapeutic agents. This effect was enhanced when it was combined with platinum. In the antitumor vaccination assay in vivo, we found that vaccination with dying-AB1-HA (a murine malignant mesothelioma cell line) cells treated with 5-FU, but neither PEM nor PTX, reduced the tumor growth of living-AB1-HA cells inoculated 1 week after vaccination by recruiting CD3
- (キーワード)
- Humans / Animals / Mice / Carcinoma, Non-Small-Cell Lung / Immune Checkpoint Inhibitors / CD8-Positive T-Lymphocytes / Platinum / Immunogenic Cell Death / Lung Neoplasms / Pemetrexed / Antimetabolites / Cell Line, Tumor / Taxoids / Fluorouracil / Adenosine Triphosphate / Tumor Microenvironment
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/1759-7714.15200
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38146645
- ● Search Scopus @ Elsevier (PMID): 38146645
- ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15200
(DOI: 10.1111/1759-7714.15200, PubMed: 38146645) Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Thi Na Nguyen, Hiroshi Nokihara, Seidai Satou, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, K Mika Kaneko, Yukinari Kato and Yasuhiko Nishioka :
Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.,
Cancer Science, Vol.115, No.2, 357-368, 2023.- (要約)
- -f and CTLA-4 blockade in vivo. These findings indicated the essential role of NK cells in novel combination immunotherapy targeting PDPN and shed light on the therapeutic strategy in advanced MPM.
- (キーワード)
- Rats / Mice / Animals / Cricetinae / Mesothelioma, Malignant / Antibodies, Monoclonal / CTLA-4 Antigen / Membrane Glycoproteins / Mesothelioma / Killer Cells, Natural / Cricetulus / CHO Cells
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/cas.16046
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38148492
- ● Search Scopus @ Elsevier (PMID): 38148492
- ● Search Scopus @ Elsevier (DOI): 10.1111/cas.16046
(DOI: 10.1111/cas.16046, PubMed: 38148492) Eiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.,
Journal of Thoracic Oncology, Vol.15, No.3, 248-257, 2023.- (要約)
- ICI-treated NSCLC patients with an increased REC after 4 weeks of treatment had a better DCR and prognosis than the other patients examined.
- (キーワード)
- Humans / Aged / Carcinoma, Non-Small-Cell Lung / Immune Checkpoint Inhibitors / Lung Neoplasms / Eosinophils / Retrospective Studies / Biomarkers
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/1759-7714.15191
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38087769
- ● Search Scopus @ Elsevier (PMID): 38087769
- ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15191
(DOI: 10.1111/1759-7714.15191, PubMed: 38087769) Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka :
A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect.,
Respiratory Investigation, Vol.61, No.6, 781-792, 2023.- (要約)
- For senescent cells, ARV825 induced the expression of an apoptosis marker while reducing the expression of BRD4 and senescence markers. On the other hand, for early passage pre-senescent cells, ARV825 reduced the expression of collagen type 1 and α-smooth muscle actin. In an experimental mouse model of lung fibrosis, ARV825 attenuated lung fibrosis and improved lung function. Immunohistochemical staining revealed a significant decrease in the number of senescent alveolar type 2 cells in lung tissue due to ARV825 treatment.
- (キーワード)
- Humans / Mice / Animals / Nuclear Proteins / Senotherapeutics / Transcription Factors / Lung / Idiopathic Pulmonary Fibrosis / Bleomycin / Collagen / Mice, Inbred C57BL / Cell Cycle Proteins
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2023.08.003
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37741093
- ● Search Scopus @ Elsevier (PMID): 37741093
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2023.08.003
(DOI: 10.1016/j.resinv.2023.08.003, PubMed: 37741093) Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Satou, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.,
Thoracic cancer, Vol.14, No.32, 3232-3239, 2023.- (要約)
- The median age at initiating chemotherapy was 80 years old. Almost all patients (92.6%) had adenocarcinoma histology. The median number of cycles administered was 6, and the objective response rate was 40.7%. The median progression-free survival, overall survival and 1-year survival were 8.8 months, 27.2 months and 79%, respectively. The treatment was well-tolerated, and no treatment-related death was observed.
- (キーワード)
- Humans / Aged / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Pemetrexed / Bevacizumab / Lung Neoplasms / Treatment Outcome / Antineoplastic Combined Chemotherapy Protocols
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/1759-7714.15115
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37718463
- ● Search Scopus @ Elsevier (PMID): 37718463
- ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15115
(DOI: 10.1111/1759-7714.15115, PubMed: 37718463) Eiji Takeuchi, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.,
Thoracic Cancer, Vol.14, No.30, 3042-3050, 2023.- (要約)
- OS was significantly longer in ICI-treated NSCLC patients with a pretreatment eosinophil count of 100 ≤ Eo <500 than in the other patients and, thus, has potential as a new predictive biomarker.
- (キーワード)
- Humans / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Immune Checkpoint Inhibitors / Eosinophils / Retrospective Studies / Biomarkers
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/1759-7714.15100
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37669914
- ● Search Scopus @ Elsevier (PMID): 37669914
- ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15100
(DOI: 10.1111/1759-7714.15100, PubMed: 37669914) Saki Harada, Takeshi Imakura, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka :
A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report.,
The journal of medical investigation : JMI, Vol.70, No.3.4, 516-520, 2023.- (要約)
- Immune checkpoint inhibitors (ICIs) have shown impressive anti-tumor effects against multiple types of malignancies. Among the wide variety of immune-related adverse events (irAEs), immune-related thrombocytopenia (ITP) is relatively rare but often clinically significant and life-threatening. However, the appropriate treatment for severe ITP has not been determined. We herein report an 82-year-old male patient with non-small-cell lung cancer who developed severe ITP three weeks after starting the third course of atezolizumab. The initial combination therapy with high-dose prednisolone, intravenous immunoglobulin and platelet transfusion was ineffective. However, additional treatment with eltrombopag, a thrombopoietin receptor agonist, resulted in remarkable improvement in the thrombocytopenia. J. Med. Invest. 70 : 516-520, August, 2023.
- (キーワード)
- Male / Humans / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.70.516
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940542
- ● Search Scopus @ Elsevier (PMID): 37940542
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.516
(DOI: 10.2152/jmi.70.516, PubMed: 37940542) Taku Takahashi, Yasushi Sato, Takanori Kashihara, Yoshihiro Miyata, Yasuteru Fujino, Yasuhiro Mitsui, Koichi Okamoto, Hiroshi Miyamoto, Yasuhiko Nishioka and Tetsuji Takayama :
Nintedanib-Induced Gastric Antral Vascular Ectasia in Patients with Idiopathic Pulmonary Fibrosis.,
ACG Case Reports Journal, Vol.10, e01107, 2023.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.14309/crj.0000000000001107
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.14309/crj.0000000000001107
(DOI: 10.14309/crj.0000000000001107) Hiroki Takahashi, Hirokazu Ogino, Hiroki Bando, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka :
FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma.,
Respiratory Medicine Case Reports, Vol.45, 101893, 2023.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.rmcr.2023.101893
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37485237
- ● Search Scopus @ Elsevier (PMID): 37485237
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2023.101893
(DOI: 10.1016/j.rmcr.2023.101893, PubMed: 37485237) Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka :
A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis.,
Respiratory Research, Vol.24, No.1, 2023.- (要約)
- These findings suggest that targeting PLK1 may be a novel therapeutic approach for pulmonary fibrosis by inhibiting lung fibroblast proliferation without affecting lung epithelial cells. In addition, while in silico screening is useful, it is essential to fully determine the biological activities of candidates by wet-lab validation studies.
- (キーワード)
- Mice / Animals / Drug Repositioning / Thiophenes / Benzimidazoles / Lung / Idiopathic Pulmonary Fibrosis / Fibroblasts / Bleomycin
- (徳島大学機関リポジトリ)
- ● Metadata: 119057
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1186/s12931-023-02446-x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37269004
- ● Search Scopus @ Elsevier (PMID): 37269004
- ● Search Scopus @ Elsevier (DOI): 10.1186/s12931-023-02446-x
(徳島大学機関リポジトリ: 119057, DOI: 10.1186/s12931-023-02446-x, PubMed: 37269004) Yasuhiko Nishioka, Sakae Homma, Takashi Ogura, Seidai Satou, Naoki Arai, Keisuke Tomii, Koichiro Kamio, Susumu Sakamoto, Yasunari Miyazaki, Hiromi Tomioka, Shu Hisata, Tomohiro Handa and Arata Azuma :
Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis.,
Respiratory Investigation, Vol.61, No.4, 498-507, 2023.- (要約)
- In this exploratory phase 2 study, IPF patients with a percent predicted forced vital capacity (%FVC) decline ≥5% acquired within the previous 6 months were enrolled. Patients were divided into three pre-treatment cohorts, namely, treatment-naïve, pirfenidone, or nintedanib. TAS-115 was administered orally at 200 mg/day with a 5-day on and 2-day off regimen. After 13 weeks of treatment, patients entered a 13-week extension treatment period where the efficacy was evaluated. The primary endpoint was the difference in slope of %FVC decline at Week 13 from baseline. Safety was also evaluated.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2023.04.008
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37263115
- ● Search Scopus @ Elsevier (PMID): 37263115
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2023.04.008
(DOI: 10.1016/j.resinv.2023.04.008, PubMed: 37263115) Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, Tania Afroj, Thi Na Nguyen, Hiroto Yoneda, Kenji Otsuka, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Masaki Hanibuchi, Hiromitsu Takizawa, Tsutomu Shinohara and Yasuhiko Nishioka :
Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade.,
Cell Reports, Vol.42, No.3, 112162, 2023.- (要約)
- fibrocytes is enhanced by anti-PD-L1 antibody. Peritumoral implantation of fibrocytes enhances the antitumor effect of PD-L1 blockade in vivo; CD86
- (キーワード)
- Humans / 血管内皮増殖因子 (vascular endothelial growth factor) / Neoplasms / B7-H1 Antigen / 免疫療法 (immunotherapy) / Tumor Microenvironment
- (徳島大学機関リポジトリ)
- ● Metadata: 118888
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.celrep.2023.112162
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36870329
- ● Search Scopus @ Elsevier (PMID): 36870329
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.celrep.2023.112162
(徳島大学機関リポジトリ: 118888, DOI: 10.1016/j.celrep.2023.112162, PubMed: 36870329) Masaki Hanibuchi, Atsushi Mitsuhashi, Atsuro Saijo, Tatsuya Kajimoto, Seidai Satou, Tetsuya Kitagawa and Yasuhiko Nishioka :
A case of atopic cough with aphonia showed a prominent response to a histamine H1 receptor antagonist.,
The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 281-284, 2023.- (要約)
- -RA, a diagnosis of AC was made. To the best of our knowledge, this is the first report of an AC patient who presented severe cough with aphonia. J. Med. Invest. 70 : 281-284, February, 2023.
- (キーワード)
- 成人 (adult) / 女性 (female) / Humans / Aphonia / Cough / Histamine H1 Antagonists
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.70.281
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164735
- ● Search Scopus @ Elsevier (PMID): 37164735
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.281
(DOI: 10.2152/jmi.70.281, PubMed: 37164735) Momoyo Azuma, Kazunori Oishi, Yukihiro Akeda, Saeko Morino, Yumi Motoki, Masaki Hanibuchi and Yasuhiko Nishioka :
Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.,
Vaccine, Vol.41, No.5, 1042-1049, 2022.- (要約)
- The 1.0-y interval provided better booster effects induced by PPSV23 than those of the 0.5-y interval in a sequential administration in pneumococcal vaccine-naïve adults aged ≥ 65 years. No difference was found in the safety profile between both intervals.
- (キーワード)
- Humans / Antibodies, Bacterial / Double-Blind Method / Immunogenicity, Vaccine / Immunoglobulin G / Pneumococcal Infections / Pneumococcal Vaccines / Streptococcus pneumoniae / Vaccines, Conjugate
- (徳島大学機関リポジトリ)
- ● Metadata: 118625
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.vaccine.2022.12.060
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36593171
- ● Search Scopus @ Elsevier (PMID): 36593171
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.vaccine.2022.12.060
(徳島大学機関リポジトリ: 118625, DOI: 10.1016/j.vaccine.2022.12.060, PubMed: 36593171) Seiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, Keiko Haji, Kozo Kagawa, Kojin Murakami, Masato Mima, Yu Aoi, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka :
Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.,
Respiratory Medicine Case Reports, Vol.41, 101797, 2022.- (要約)
- A man with non-small-cell lung cancer who was negative for anti-nuclear antibodies was admitted for dyspnea after immune checkpoint inhibitor (ICI) administration. Computed tomography (CT) showed complexed radiologic features, including subpleural and basal predominant reticular shadow with cystic structures and peribronchovascular consolidation. Although we treated him with high-dose steroid under a diagnosis of ICI-related pneumonitis, he developed acute exacerbation of pneumonitis with progressive fibrosis and volume loss. A re-evaluation identified anti-aminoacyl-tRNA synthetase antibody in the serum collected before ICI administration. This case highlights the importance of re-evaluating pre-existing autoimmune disorders in patients who develop ICI-related pneumonitis with atypical radiologic features.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.rmcr.2022.101797
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36583061
- ● Search Scopus @ Elsevier (PMID): 36583061
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2022.101797
(DOI: 10.1016/j.rmcr.2022.101797, PubMed: 36583061) Masaki Hanibuchi, Atsushi Mitsuhashi, Tatsuya Kajimoto, Atsuro Saijo, Seidai Satou, Tetsuya Kitagawa and Yasuhiko Nishioka :
Clinical significance of fractional exhaled nitric oxide and periostin as potential markers to assess therapeutic efficacy in patients with cough variant asthma.,
Respiratory Investigation, Vol.61, No.1, 16-22, 2022.- (要約)
- Our observations indicate the usefulness of FeNO and periostin as potential "therapeutic" markers for CVA. To the best of our knowledge, this is the first report demonstrating the clinical significance of these factors as potential biomarkers to assess therapeutic efficacy in patients with CVA.
- (キーワード)
- Humans / Cough / Fractional Exhaled Nitric Oxide Testing / Prospective Studies / Clinical Relevance / ROC Curve / 一酸化窒素 (nitric oxide) / Exhalation / Asthma / Biomarkers / Breath Tests
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2022.10.006
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36463016
- ● Search Scopus @ Elsevier (PMID): 36463016
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2022.10.006
(DOI: 10.1016/j.resinv.2022.10.006, PubMed: 36463016) Muneo Numasaki, Koyu Ito, Kiyoshi Takagi, Kengo Nagashima, Hirotsugu Notsuda, Hirokazu Ogino, Rika Ando, Yoshihisa Tomioka, Takashi Suzuki, Yoshinori Okada, Yasuhiko Nishioka and Michiaki Unno :
Diverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8.,
Cellular Immunology, Vol.383, 104652, 2022.- (要約)
- In this study, we sought to elucidate the roles of the interleukin (IL)-32β and IL-32γ in mesothelioma cell growth, and vascular endothelial growth factor (VEGF)-A and C-X-C motif chemokine ligand 8 (CXCL8) expression. IL-32 elicited a growth-promoting effect against one of the six mesotheliomas lines and exerted diverse regulatory functions in VEGF-A and CXCL8 secretion from mesotheliomas stimulated with or without IL-17A. Retroviral-mediated transduction of mesothelioma lines with IL-32γ resulted in enhanced IL-32β expression, which facilitated or suppressed the in vitro growth, and VEGF-A and CXCL8 expression. Overexpressed IL-32β-augmented growth and VEGF-A and CXCL8 production were mainly mediated through the phosphatidylinositol-3 kinase (PI3K) signaling pathway. On the other hand, overexpressed IL-32β-deceased growth was mediated through mitogen-activated protein kinase (MAPK) pathway. NCI-H2373IL-32γ tumors grew faster than NCI-H2373Neo tumors in a xenograft model, which was associated with increased vascularity. These findings indicate that IL-32 are involved in the regulation of growth and angiogenic factor production in mesotheliomas.
- (キーワード)
- Humans / Interleukins / Mesothelioma, Malignant / Protein Isoforms / Vascular Endothelial Growth Factor A / Interleukin-8
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.cellimm.2022.104652
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36516653
- ● Search Scopus @ Elsevier (PMID): 36516653
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.cellimm.2022.104652
(DOI: 10.1016/j.cellimm.2022.104652, PubMed: 36516653) Ryo Okuda, Takashi Ogura, Shu Hisata, Tomohisa Baba, Yasuhiro Kondoh, Takafumi Suda, Takeshi Johkoh, Tae Iwasawa, Hiromi Tomioka, Masashi Bando, Arata Azuma, Yoshikazu Inoue, Toru Arai, Yutaro Nakamura, Atsushi Miyamoto, Yasunari Miyazaki, Hirofumi Chiba, Haruyuki Ishii, Naoki Hamada, Yasuhiro Terasaki, Ichiro Kuwahira, Shinji Sato, Shingo Kato, Takuji Suzuki, Susumu Sakamoto, Yasuhiko Nishioka, Noboru Hattori, Naozumi Hashimoto, Satoshi Morita, Nao Ichihara, Hiroaki Miyata, Koichi Hagiwara, Toshihiro Nukiwa and Kunihiko Kobayashi :
Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry.,
Respiratory Investigation, Vol.61, No.1, 95-102, 2022.- (要約)
- ClinTrials.gov Registry (NCT03041623, first posted on February 3, 2017).
- (キーワード)
- Humans / Biomarkers / Idiopathic Interstitial Pneumonias / Idiopathic Pulmonary Fibrosis / Lung / Lung Diseases, Interstitial / Registries / 日本 (Japan)
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2022.08.009
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36580379
- ● Search Scopus @ Elsevier (PMID): 36580379
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2022.08.009
(DOI: 10.1016/j.resinv.2022.08.009, PubMed: 36580379) T Na Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Tania Afroj, Seidai Satou, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor.,
Cancer Science, Vol.114, No.2, 384-398, 2022.- (要約)
- Myeloid-derived suppressor cells (MDSCs) have been known to play a pivotal role in the induction of immune tolerance, which limits the benefits of immune checkpoint inhibitors (ICIs). Recent studies revealed that several chemotherapeutic agents decreased tumor-infiltrating MDSCs. Therefore, combination therapy with cytotoxic chemotherapeutic agents and ICIs was approved for first-line treatment for lung cancer. However, the impact of chemotherapeutic agents on MDSCs and an optimal partner of ICIs has not been fully investigated in thoracic tumors, including lung cancer and malignant pleural mesothelioma. In the present study, we found that treatment with 5-FU and its oral formulation, S-1, suppressed tumor progression and inhibited the accumulation of MDSCs in thoracic tumor-bearing mice. Tumor-infiltrating T cells and dendritic cells were significantly expanded in S-1-treated mice. 5-FU suppressed the ability of tumor cells to recruit MDSCs, while it did not suppress the survival and differentiation of mouse MDSCs in vitro. We also revealed that 5-FU or S-1 significantly downregulated the expression of tumor-derived Bv8 and S100A8. The knockdown of Bv8 or S100A8 in tumor cells suppressed tumor growth and MDSC recruitment in vivo. Furthermore, in comparison with pemetrexed, administration of S-1 improved the synergistic therapeutic efficacy of anti-PD-1 antibodies with or without carboplatin. Our findings revealed a novel mechanism wherein S-1 primed a favorable tumor microenvironment to provide the rationale for combination therapy with S-1 and ICIs as the optimal therapy for thoracic cancer.
- (キーワード)
- Mice / Animals / Myeloid-Derived Suppressor Cells / Calgranulin A / Tリンパ球 (T lymphocytes) / Thoracic Neoplasms / Lung Neoplasms / Tumor Microenvironment / Cell Line, Tumor
- (徳島大学機関リポジトリ)
- ● Metadata: 118295
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/cas.15620
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36285504
- ● Search Scopus @ Elsevier (PMID): 36285504
- ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15620
(徳島大学機関リポジトリ: 118295, DOI: 10.1111/cas.15620, PubMed: 36285504) Naoki Kimura, Takuya Kawahara, Yukari Uemura, Tatsuya Atsumi, Takayuki Sumida, Toshihde Mimura, Yasushi Kawaguchi, Hirofumi Amano, Yukiko Iwasaki, Yuko Kaneko, Toshihiro Matsui, Yoshinao Muro, Yoshitaka Imura, Takashi Kanda, Yoshiya Tanaka, Atsushi Kawakami, Masatoshi Jinnin, Tomonori Ishii, Keiju Hiromura, Yusuke Miwa, Hiroshi Nakajima, Masataka Kuwana, Yasuhiko Nishioka, Akio Morinobu, Hideto Kameda and Hitoshi Kohsaka :
Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial.,
Rheumatology, Vol.61, No.11, 4445-4454, 2022.- (要約)
- Forty-seven patients were randomized either to the TK-98 (n = 24) or placebo (n = 23) group. The changes of MMT scores at 12 weeks were 0.70 (0.19) [mean (s.e.m.)] and 0.69 (0.18), respectively (P = 0.98). Thirteen patients from the TK-98 group and 12 from the placebo group were enrolled in the extension study. The MMT scores in both groups improved similarly. The increase of the FI scores of the shoulder flexion at 12 weeks was significantly greater in the TK-98 group [27.9 (5.67) vs 12.8 (5.67) for the right shoulder flexion, and 27.0 (5.44) vs 13.4 (5.95) for the left shoulder; P < 0.05]. Frequencies of adverse events up to 12 weeks were similar.
- (キーワード)
- 成人 (adult) / Humans / Amino Acids, Branched-Chain / Dermatomyositis / Double-Blind Method / Muscle Strength / Polymyositis / Treatment Outcome
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1093/rheumatology/keac101
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35179548
- ● Search Scopus @ Elsevier (PMID): 35179548
- ● Search Scopus @ Elsevier (DOI): 10.1093/rheumatology/keac101
(DOI: 10.1093/rheumatology/keac101, PubMed: 35179548) Kozo Kagawa, Seidai Satou, Kazuya Koyama, Takeshi Imakura, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirohisa Ogawa, Hiroshi Kawano and Yasuhiko Nishioka :
The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-β production in regulatory T-cells.,
PLoS ONE, Vol.17, No.10, e0275987, 2022.- (要約)
- These results suggest that Lck inhibition attenuated lung fibrosis by suppressing TGF-β production in Tregs and support the role of Tregs in the pathogenesis of lung fibrosis.
- (キーワード)
- Mice / Animals / 肺線維症 (pulmonary fibrosis) / T-Lymphocytes, Regulatory / Transforming Growth Factor beta1 / Bleomycin / Transforming Growth Factor beta / Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Mice, Inbred C57BL
- (徳島大学機関リポジトリ)
- ● Metadata: 118786
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1371/journal.pone.0275987
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36301948
- ● Search Scopus @ Elsevier (PMID): 36301948
- ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0275987
(徳島大学機関リポジトリ: 118786, DOI: 10.1371/journal.pone.0275987, PubMed: 36301948) Makoto Tobiume, Atsushi Mitsuhashi, Atsuro Saijo, Hirokazu Ogino, Tania Afroj, Hirohisa Ogawa, Hisatsugu Goto, Seidai Satou, Akane Abe, Keiko Haji, Ryohiko Ozaki, Hiromitsu Takizawa and Yasuhiko Nishioka :
Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer.,
Oncology Letters, Vol.24, No.5, 417, 2022.- (要約)
- Fibrocytes, which are bone marrow-derived collagen-producing cells, have been reported to be involved in pathogenesis of pulmonary fibrosis. Our previous study reported that tumor-infiltrating fibrocytes play a role in tumor progression and drug resistance in lung cancer. The present study therefore examined chemotactic factors for fibrocytes in tissues of non-small cell lung cancer (NSCLC) and their prognostic significance. Surgically resected tumor tissues were examined for the expression of chemotactic factors, including C-X-C motif chemokine 12 (CXCL12), CCL2, platelet-derived growth factor (PDGF)-AA and PDGF-BB, as well as tumor-infiltrating fibrocytes by immunostaining. The chemotactic ability of fibrocytes in response to each factor was evaluated using a migration assay by counting the migrated cells microscopically, and expression of receptors for chemotactic factors were analyzed by flow cytometry. The expression of CXCL12, but not CCL2, PDGF-AA, or PDGF-BB, was associated with the number of tumor-infiltrating fibrocytes in lung adenocarcinoma (LUAD), but not lung squamous cell carcinoma (LUSQ). In addition, patients with an increased expression of CXCL12 in LUAD but not LUSQ showed a significantly poorer prognosis compared with those with a decreased expression. However, the expression of CCL2, PDGF-AA and PDGF-BB was not correlated with the prognosis of patients with NSCLC. The number of fibrocytes was associated with a poor prognosis in LUAD. Fibrocytes derived from the peripheral blood of healthy subjects as well as patients with lung cancer expressed higher levels of CXCR4 compared with CCR2, PDGF and receptor-α and receptor-β. Overall, these results suggested that targeting tumor-infiltrating fibrocytes via the CXCL12/CXCR4 axis may be a useful strategy for controlling the progression of NSCLC, particularly LUAD.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3892/ol.2022.13537
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245829
- ● Search Scopus @ Elsevier (PMID): 36245829
- ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13537
(DOI: 10.3892/ol.2022.13537, PubMed: 36245829) Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.,
Thoracic Cancer, Vol.13, No.21, 2978-2984, 2022.- (要約)
- Thirty-five patients received two or more regimens. Thirty-four patients were male and the median age at the initiation of second-line chemotherapy was 70 years. Almost all patients had a smoking history. Fourteen patients had adenocarcinoma and 15 had squamous cell carcinoma histology. Stages III and IV were observed in 20 and 11 patients, respectively. With respect to the type of ILD, 12 patients had usual interstitial pneumonia (UIP). The overall response rate and disease control rate were 11.4 and 68.6%, respectively. The median progression-free and median overall survival were 4.1 and 6.4 months, respectively. The AE of ILD was observed in eight patients, five of whom died. UIP and low percentage vital capacity were detected as significant risk factors for the AE of ILD.
- (キーワード)
- Humans / 男性 (male) / Aged / 女性 (female) / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Retrospective Studies / Lung Diseases, Interstitial / Antineoplastic Combined Chemotherapy Protocols
- (徳島大学機関リポジトリ)
- ● Metadata: 118615
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/1759-7714.14645
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36106507
- ● Search Scopus @ Elsevier (PMID): 36106507
- ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14645
(徳島大学機関リポジトリ: 118615, DOI: 10.1111/1759-7714.14645, PubMed: 36106507) Yasuhiko Nishioka, Yuko Toyoda, Ryoko Egashira, Takeshi Johkoh, Yasuhiro Terasaki, Akira Hebisawa, Kinya Abe, Tomohisa Baba, Yuji Fujikura, Etsuo Fujita, Naoki Hamada, Tomohiro Handa, Yoshinori Hasegawa, Koko Hidaka, Takeshi Hisada, Shu Hisata, Chisato Honjo, Kazuya Ichikado, Yoshikazu Inoue, Shinyu Izumi, Motoyasu Kato, Takumi Kishimoto, Masaki Okamoto, Keisuke Miki, Masamichi Mineshita, Yutaro Nakamura, Susumu Sakamoto, Masaaki Sano, Yoshikazu Tsukada, Mari Yamasue, Yoshimi Bando, Sakae Homma, Koichi Hagiwara, Takafumi Suda and Naohiko Inase :
Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype.,
BMJ Open Respiratory Research, Vol.9, No.1, e001337, 2022.- (要約)
- Twenty-two cases of IDPO were identified. Most subjects (82%) were male, aged 22-56 years (mean (SD), 37.9 (9.1)) at diagnosis. Nearly 80% of the subjects were asymptomatic, and the condition was discovered during a medical check-up. However, 36% of the subjects showed a decline in forced vital capacity (%FVC) predicted <80% at diagnosis. The typical radiological features of high-resolution CT (HRCT) are calcified branching structures that are predominantly distributed in the lower lung fields without any other conspicuous finding. Histopathological analysis also showed dendriform ossified lesions from the intraluminal areas to interstitial areas. Notably, during the follow-up period of 20 years, disease progression was found in 88% on HRCT and more than 50% on pulmonary function tests (FVC and/or forced expiratory volume in 1 s). Two cases with rapid decline of 10% /year in %FVC predicted were observed.)) at diagnosis. Nearly 80% of the subjects were asymptomatic, and the condition was discovered during a medical check-up. However, 36% of the subjects showed a decline in forced vital capacity (%FVC) predicted <80% at diagnosis. The typical radiological features of high-resolution CT (HRCT) are calcified branching structures that are predominantly distributed in the lower lung fields without any other conspicuous finding. Histopathological analysis also showed dendriform ossified lesions from the intraluminal areas to interstitial areas. Notably, during the follow-up period of 20 years, disease progression was found in 88% on HRCT and more than 50% on pulmonary function tests (FVC and/or forced expiratory volume in 1 s). Two cases with rapid decline of 10% /year in %FVC predicted were observed.
- (キーワード)
- Disease Progression / Female / Humans / Idiopathic Pulmonary Fibrosis / Male / Osteogenesis / Phenotype / Vital Capacity
- (徳島大学機関リポジトリ)
- ● Metadata: 118569
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1136/bmjresp-2022-001337
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36162917
- ● Search Scopus @ Elsevier (PMID): 36162917
- ● Search Scopus @ Elsevier (DOI): 10.1136/bmjresp-2022-001337
(徳島大学機関リポジトリ: 118569, DOI: 10.1136/bmjresp-2022-001337, PubMed: 36162917) Masaki Hanibuchi, Atsuro Saijo, Atsushi Mitsuhashi, Tatsuya Kajimoto, Tetsuya Kitagawa and Yasuhiko Nishioka :
The efficacy of mass screening for chronic obstructive pulmonary disease using screening questionnaires in a medical health check-up population.,
Respiratory Investigation, Vol.60, No.6, 815-821, 2022.- (要約)
- Mass screening for COPD using screening questionnaires, particularly the COPD-PS questionnaire, might be useful to identify the early stages of COPD in a medical health check-up population.
- (キーワード)
- Humans / Forced Expiratory Volume / Cross-Sectional Studies / Reproducibility of Results / Pulmonary Disease, Chronic Obstructive / Spirometry / Mass Screening / Surveys and Questionnaires
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2022.07.005
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36057534
- ● Search Scopus @ Elsevier (PMID): 36057534
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2022.07.005
(DOI: 10.1016/j.resinv.2022.07.005, PubMed: 36057534) Takashi Ogura, Takafumi Suda, Naohiko Inase, Yasuhiko Nishioka, Arata Azuma, Masaki Okamoto, Ayako Takizawa, Tomohiro Ito, B Klaus Rohr and Yoshikazu Inoue :
Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.,
Respiratory Investigation, Vol.60, No.6, 787-797, 2022.- (要約)
- ClinicalTrials.gov NCT02999178.
- (キーワード)
- Humans / Disease Progression / Idiopathic Pulmonary Fibrosis / Indoles / 日本 (Japan) / Lung Diseases, Interstitial / Vital Capacity
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2022.06.009
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35927208
- ● Search Scopus @ Elsevier (PMID): 35927208
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2022.06.009
(DOI: 10.1016/j.resinv.2022.06.009, PubMed: 35927208) Yoshitoyo Ueno, Saki Harada, Koji Sato, Kazuki Momota, Hiroki Sato, Yusuke Akimoto, Yuta Arai, Toshiyuki Nunomura, Manabu Ishihara, Natsuki Tane, Taiga Itagaki, Yasuhiko Nishioka and Jun Oto :
Independent lung ventilation for the management of acute allograft rejection after single-lung transplantation for end-stage emphysema.,
The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 323-327, 2022.- (要約)
- Background : We herein report the use of independent lung ventilation (ILV) for managing acute allograft rejection after single-lung transplantation (SLT) for end-stage emphysema. Case presentation : A 54-year-old woman was transferred to our hospital with severe hypoxemia and respiratory distress due to unilateral lung disease with diffuse alveolar damage in the right donor lung associated with acute allograft rejection and with hyperinflation of the left native lung due to emphysema. She was unresponsive to immunosuppressive medications and conventional ventilation strategies, so different ventilator settings for each lung were required. A double-lumen endotracheal tube (DLT) was inserted, and ILV was initiated. The right lung was ventilated with high positive end-expiratory pressure (PEEP), intended for lung recruitment, and the left lung was ventilated with lung protective strategies using a low tidal volume and low levels of PEEP to avoid hyperinflation. Two days later, her lung function was dramatically improved, and the DLT was replaced with a single-lumen endotracheal tube. Gas exchange was maintained, and she was successfully weaned from mechanical ventilation on intensive-care unit day 15. Conclusions : ILV appears to be effective and safe for managing acute allograft rejection after SLT for emphysema. J. Med. Invest. 69 : 323-327, August, 2022.
- (キーワード)
- Allografts / Emphysema / Female / Humans / Lung / Lung Transplantation / Middle Aged / Pulmonary Emphysema / Respiration, Artificial
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.69.323
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244790
- ● Search Scopus @ Elsevier (PMID): 36244790
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.323
(DOI: 10.2152/jmi.69.323, PubMed: 36244790) Eiji Takeuchi, Kensuke Kondo, Yoshio Okano, Michihiro Kunishige, Yoshihiro Kondo, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.,
Journal of Cancer Research and Clinical Oncology, Vol.45, 101893, 2022.- (要約)
- Liver metastases, ECOG PS score ≥ 2, and a non-smoking history are early mortality factors in ICI monotherapy for advanced or metastatic NSCLC.
- (徳島大学機関リポジトリ)
- ● Metadata: 118880
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1007/s00432-022-04215-7
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35871700
- ● Search Scopus @ Elsevier (PMID): 35871700
- ● Search Scopus @ Elsevier (DOI): 10.1007/s00432-022-04215-7
(徳島大学機関リポジトリ: 118880, DOI: 10.1007/s00432-022-04215-7, PubMed: 35871700) Takumi Sakurada, Hiroshi Nokihara, Tadashi Koga, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Fuka Aizawa, Hirokazu Ogino, Seidai Satou, Yasushi Kirino, Hisatsugu Goto, Yasuhiko Nishioka and Keisuke Ishizawa :
Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.,
The Oncologist, Vol.27, No.7, e554-e560, 2022.- (要約)
- This single-arm, phase II study recruited patients with non-squamous non-small cell lung cancer and malignant pleural mesothelioma scheduled to receive chemotherapy including pemetrexed. Patients received 2 mg of dexamethasone daily from days 2 to 6 after chemotherapy with pemetrexed. The primary endpoint was the 3-week incidence of rash eruptions.
- (キーワード)
- Adrenal Cortex Hormones / Carcinoma, Non-Small-Cell Lung / Cisplatin / Dexamethasone / Exanthema / Humans / Lung Neoplasms / Mesothelioma, Malignant / Pemetrexed
- (徳島大学機関リポジトリ)
- ● Metadata: 117391
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1093/oncolo/oyab077
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35325241
- ● Search Scopus @ Elsevier (PMID): 35325241
- ● Search Scopus @ Elsevier (DOI): 10.1093/oncolo/oyab077
(徳島大学機関リポジトリ: 117391, DOI: 10.1093/oncolo/oyab077, PubMed: 35325241) Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, Kensuke Kondo, Ei Ogawa, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Kenji Otsuka and Yasuhiko Nishioka :
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.,
BMC Cancer, Vol.22, No.1, 2022.- (要約)
- A total of 63 patients with EGFR mutated NSCLC were treated with osimertinib; 33 (12 with PE) had no EGFR T790M mutation, while 30 (12 with PE) had EGFR T790M mutation. In EGFR T790M-negative NSCLC, the progression-free survival (PFS) of the patients with PE was comparable to that of the patients without PE (median PFS 19.8 vs. 19.8 months, p = 0.693). In EGFR T790M- positive NSCLC, the PFS and overall survival (OS) of the patients with PE were significantly shorter than those of the patients without PE (median PFS 16.8 vs. 8.3 months, p = 0.003; median OS 44.9 vs. 14.2 months, p = 0.007). In the multivariate analysis, the presence of PE was independently associated with shorter PFS and OS in EGFR T790M-positive NSCLC patients, but not EGFR T790M-negative patients.
- (キーワード)
- Acrylamides / Aniline Compounds / Carcinoma, Non-Small-Cell Lung / ErbB Receptors / Humans / Lung Neoplasms / Mutation / Pleural Effusion / Protein Kinase Inhibitors / Retrospective Studies
- (徳島大学機関リポジトリ)
- ● Metadata: 117282
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1186/s12885-022-09701-2
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35650550
- ● Search Scopus @ Elsevier (PMID): 35650550
- ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-022-09701-2
(徳島大学機関リポジトリ: 117282, DOI: 10.1186/s12885-022-09701-2, PubMed: 35650550) Jun Kako, Masamitsu Kobayashi, Kohei Kajiwara, Yasutaka Kimura, Yasufumi Oosono, Mizuki Takegata, Kimiko Nakano, Yoshinobu Matsuda, Naomi Nakamura, Natsuki Kawashima, Yuta Hirano, Misako Kitae, Kakuhiro Yamaguchi, Hiroshi Iwamoto, Noboru Hattori, Hiroyuki Sawatari, Satoshi Shiono, Hirokazu Ogino, Yasuhiko Nishioka, Koji Amano and Janelle Yorke :
Validity and Reliability of the Japanese Version of the Dyspnea-12 Questionnaire in Patients With Lung Cancer.,
Journal of Pain and Symptom Management, Vol.64, No.2, e83-e89, 2022.- (要約)
- The Japanese version of the Dyspnea-12 questionnaire is a useful and reliable tool to assess the multi-dimensional aspects of dyspnea in patients with lung cancer.
- (キーワード)
- Dyspnea / Humans / 日本 (Japan) / Lung Neoplasms / Psychometrics / Pulmonary Disease, Chronic Obstructive / Reproducibility of Results / Surveys and Questionnaires
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.jpainsymman.2022.04.171
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35452793
- ● Search Scopus @ Elsevier (PMID): 35452793
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.jpainsymman.2022.04.171
(DOI: 10.1016/j.jpainsymman.2022.04.171, PubMed: 35452793) Hitoshi Nishijima, Mizuki Sugita, Natsuka Umezawa, Naoki Kimura, Hirokazu Sasaki, Hiroshi Kawano, Yasuhiko Nishioka, Minoru Matsumoto, Takeshi Oya, Koichi Tsuneyama, Junko Morimoto and Mitsuru Matsumoto :
Development of organ-specific autoimmunity by dysregulated Aire expression.,
Immunology and Cell Biology, Vol.100, No.5, 371-377, 2022.- (要約)
- Deficiency for AIRE/Aire in both humans and mice results in the development of organ-specific autoimmune disease. We tested whether augmented and/or dysregulated AIRE/Aire expression might be also prone to the breakdown of self-tolerance. To define the effect of augmented Aire expression on the development of autoimmunity, antigen-specific clonal deletion and production of clonotypic regulatory T cells (Tregs) in the thymus were examined using mice expressing two additional copies of Aire in a heterozygous state (3xAire-knockin mice: 3xAire-KI). We found that both clonal deletion of autoreactive T cells and production of clonotypic Tregs in the thymus from 3xAire-KI were impaired in a T-cell receptor-transgenic system. Furthermore, 3xAire-KI females showed higher scores of experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein than wild-type littermates, suggesting that augmented Aire expression exacerbates organ-specific autoimmunity under disease-prone conditions. In humans, we found that one patient with amyopathic dermatomyositis showed CD3
- (キーワード)
- Animals / 自己免疫 (autoimmunity) / Clonal Deletion / Encephalomyelitis, Autoimmune, Experimental / 女性 (female) / Humans / Immune Tolerance / Mice / Myelin-Oligodendrocyte Glycoprotein / Thymus Gland
- (徳島大学機関リポジトリ)
- ● Metadata: 117817
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/imcb.12546
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35313042
- ● Search Scopus @ Elsevier (PMID): 35313042
- ● Search Scopus @ Elsevier (DOI): 10.1111/imcb.12546
(徳島大学機関リポジトリ: 117817, DOI: 10.1111/imcb.12546, PubMed: 35313042) Hirohisa Ogawa, Masahiko Azuma, Aya Umeno, Mayuko Shimizu, Kazutoshi Murotomi, Yasukazu Yoshida, Yasuhiko Nishioka and Koichi Tsuneyama :
Singlet oxygen -derived nerve growth factor exacerbates airway hyperresponsiveness in a mouse model of asthma with mixed inflammation.,
Allergology International, Vol.71, No.3, 395-404, 2022.- (要約)
- NGF production and hyperinnervation were higher in Mix-in mice than in conventional eosinophilic-asthmatic mice and were positively correlated with AHR. Asthmatic parameters were inhibited by NGF neutralizing Abs and myeloperoxidase (MPO) inhibition. The 10- and 12-(Z,E)-HODEs levels were increased in the lungs and were positively correlated with MPO activity and NGF production. NGF was produced by bronchial epithelial cells in vitro upon stimulation with singlet oxygen.
- (キーワード)
- Animals / Asthma / Bronchial Hyperreactivity / Disease Models, Animal / Inflammation / Lung / Mice / Mice, Inbred BALB C / Nerve Growth Factor / Respiratory Hypersensitivity / Singlet Oxygen
- (徳島大学機関リポジトリ)
- ● Metadata: 117273
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.alit.2022.02.005
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35346582
- ● Search Scopus @ Elsevier (PMID): 35346582
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.alit.2022.02.005
(徳島大学機関リポジトリ: 117273, DOI: 10.1016/j.alit.2022.02.005, PubMed: 35346582) Hirokazu Ogino, W Jennie Taylor, Takahide Nejo, David Gibson, B Payal Watchmaker, Kaori Okada, Atsuro Saijo, R Meghan Tedesco, Anny Shai, M Cynthia Wong, E Jane Rabbitt, R Michael Olin, L Christopher Moertel, Yasuhiko Nishioka, M Andres Salazar, M Annette Molinaro, J Joanna Phillips, A Nicholas Butowski, L Jennifer Clarke, Ann Bush Nancy Oberheim, L Shawn Hervey-Jumper, Philip Theodosopoulos, M Susan Chang, S Mitchel Berger and Hideho Okada :
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.,
The Journal of Clinical Investigation, Vol.132, No.3, 2022.- (要約)
- BACKGROUNDLong-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy.METHODSWe conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor.RESULTSA total of 17 eligible patients were enrolled - 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8+ T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8+ T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident-like CD8+ T cells with effector memory phenotype in the TME after the neoadjuvant vaccination.CONCLUSIONThe regimen induced effector CD8+ T cell response in peripheral blood and enabled vaccine-reactive CD8+ T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies.TRIAL REGISTRATIONClinicalTrials.gov NCT02549833.FUNDINGNIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science.
- (キーワード)
- 成人 (adult) / Aged / CD8-Positive T-Lymphocytes / Cancer Vaccines / Carboxymethylcellulose Sodium / 女性 (female) / Glioma / Humans / 男性 (male) / Middle Aged / Neoadjuvant Therapy / Poly I-C / Polylysine / Tumor Microenvironment / Vaccination
- (徳島大学機関リポジトリ)
- ● Metadata: 117337
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1172/JCI151239
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34882581
- ● Search Scopus @ Elsevier (PMID): 34882581
- ● Search Scopus @ Elsevier (DOI): 10.1172/JCI151239
(徳島大学機関リポジトリ: 117337, DOI: 10.1172/JCI151239, PubMed: 34882581) Yutaka Morita, Atsuro Saijo, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yoshimi Bando and Yasuhiko Nishioka :
Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer.,
Thoracic Cancer, Vol.13, No.7, 1079-1082, 2022.- (要約)
- T cells, occasionally resulting in a systemic immune response to the tumor outside of the treatment field. The phenomenon of tumor regression at the site distant from irradiated fields is known as the abscopal effect. Several case reports have indicated a potential role of RT in overcoming primary and acquired resistance against immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) and melanoma patients. We herein report an NSCLC patient who developed acquired resistance to an RT-induced abscopal effect and subsequently experienced reactivation of the systemic antitumor immune response by pembrolizumab, an antiprogrammed death 1 antibody. In this case, RT not only induced an abscopal effect but also upregulated the programmed death-ligand 1 expression outside of the irradiated field when the patient developed resistance to the abscopal effect. This case can facilitate our understanding of the mechanism underlying the RT-induced systemic immune response against cancer cells and adaptive resistance mechanism of cancer cells from immune surveillance. These findings highlight the promising results of current clinical trials combining RT and immune checkpoint inhibitors. Ongoing clinical trials will further establish evidence supporting combination therapy with RT and immune checkpoint inhibitors.
- (キーワード)
- B7-H1 Antigen / CD8-Positive T-Lymphocytes / Carcinoma, Non-Small-Cell Lung / Humans / Lung Neoplasms
- (徳島大学機関リポジトリ)
- ● Metadata: 117392
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/1759-7714.14330
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35064748
- ● Search Scopus @ Elsevier (PMID): 35064748
- ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14330
(徳島大学機関リポジトリ: 117392, DOI: 10.1111/1759-7714.14330, PubMed: 35064748) Tamotsu Tanaka, Kazuya Koyama, Naoko Takahashi, Katsuya Morito, Hanif Ali, Momoyo Azuma, Kozo Kagawa, Hiroshi Kawano, Rumana Yesmin, Mutsumi Aihara and Yasuhiko Nishioka :
Lysophosphatidic acid, ceramide 1-phosphate and sphingosine 1-phosphate in peripheral blood of patients with idiophathic pulmonary fibrosis,
The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 196-203, 2022.- (要約)
- Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonias. Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are signaling lipids that evoke growth factor-like responses to many cells. Recent studies revealed the involvement of LPA and S1P in the pathology of IPF. In this study, we determined LPA, S1P and ceramide 1-phosphate (C1P) in peripheral blood plasma of IPF patients, and examined correlation to the vital capacity of lung (VC), an indicator of development of fibrosis. Blood plasma samples were taken from eleven patients with IPF and seven healthy volunteers. The lipids of the sample were extracted and subjected to liquid chromatography-tandem mass spectrometry for analysis. Results showed that there is a significant negative correlation between VC and plasma LPA levels, indicating that IPF patients with advanced fibrosis had higher concentration of LPA in their plasma. Average of S1P levels were significantly higher in IPF patients than those in healthy subjects. Although it is not statistically significant, a similar correlation trend that observed in LPA levels also found between VC and S1P levels. These results indicated that plasma LPA and S1P may be associated with deterioration of pulmonary function of IPF patients. J. Med. Invest. 69 : 196-203, August, 2022.
- (キーワード)
- Ceramides / Fibrosis / Humans / Idiopathic Pulmonary Fibrosis / Lysophospholipids / Sphingosine
- (徳島大学機関リポジトリ)
- ● Metadata: 117621
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.69.196
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244770
- ● Search Scopus @ Elsevier (PMID): 36244770
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.196
(徳島大学機関リポジトリ: 117621, DOI: 10.2152/jmi.69.196, PubMed: 36244770) Masahiro Sako, Hiroshi Nokihara, Kensuke Kondo, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Akane Abe, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Hisanori Uehara and Yasuhiko Nishioka :
A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab.,
Thoracic Cancer, Vol.13, No.1, 129-132, 2021.- (要約)
- Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after therapy with ICIs. When treating patients with ICIs, patient selection is essential, and monitoring and management of immune-related adverse events, including pneumonitis, are needed. We herein report a case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia treated with pembrolizumab, antiprogrammed cell death 1 antibody. Our report highlights important considerations necessary when treating advanced pleomorphic carcinoma patients complicated with interstitial pneumonia. We also review the literature regarding the use of ICIs in such patients.
- (キーワード)
- Aged / Antibodies, Monoclonal, Humanized / Carcinoma, Non-Small-Cell Lung / Humans / Immune Checkpoint Inhibitors / Lung Diseases, Interstitial / Lung Neoplasms / 男性 (male)
- (徳島大学機関リポジトリ)
- ● Metadata: 117393
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/1759-7714.14243
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34859591
- ● Search Scopus @ Elsevier (PMID): 34859591
- ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14243
(徳島大学機関リポジトリ: 117393, DOI: 10.1111/1759-7714.14243, PubMed: 34859591) Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka :
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.,
BMC Pulmonary Medicine, Vol.21, No.1, 2021.- (要約)
- Eleven patients received treatment with nivolumab. Objective response rate was 18.2% and the disease control rate was 90.9%. Median PFS was 6.8 months (95% confidence interval, 1.3 to 11.9 months) and median OS was 15.2 months (95% confidence interval, 8.9 to 21.5 months). IrAEs occurred in eight patients (72.7%), and grade ≥ 2 irAEs occurred in six patients (54.5%). PFS and OS were significantly longer in the grade ≥ 2 irAEs group than in grade < 2 irAEs group (median PFS 13.6 vs. 3.8 months, p = 0.0093; median OS not reached vs. 8.6 months, p = 0.0108).
- (キーワード)
- Aged / Aged, 80 and over / Antineoplastic Agents, Immunological / 女性 (female) / Humans / Immune System Diseases / Male / Mesothelioma, Malignant / Middle Aged / Nivolumab / Retrospective Studies / Survival Analysis / Treatment Outcome
- (徳島大学機関リポジトリ)
- ● Metadata: 117283
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1186/s12890-021-01746-6
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34781910
- ● Search Scopus @ Elsevier (PMID): 34781910
- ● Search Scopus @ Elsevier (DOI): 10.1186/s12890-021-01746-6
(徳島大学機関リポジトリ: 117283, DOI: 10.1186/s12890-021-01746-6, PubMed: 34781910) Toshifumi Tezuka, Masahiko Azuma, Hirohisa Ogawa, Mayo Kondou, Hisanori Uehara, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka :
A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells.,
Experimental Lung Research, Vol.47, No.9, 451-463, 2021.- (要約)
- The RAS signal pathway plays a crucial role in allergen-induced airway remodeling associated with ILC2s. XRP44X may have therapeutic potential for refractory asthma.
- (キーワード)
- Airway Remodeling / Animals / Hypersensitivity / 自然免疫 (innate immunity) / Interleukin-33 / Lymphocytes / Mice
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1080/01902148.2021.1999536
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34739349
- ● Search Scopus @ Elsevier (PMID): 34739349
- ● Search Scopus @ Elsevier (DOI): 10.1080/01902148.2021.1999536
(DOI: 10.1080/01902148.2021.1999536, PubMed: 34739349) Atsushi Mitsuhashi, Kensuke Kondoh, Kazuki Horikawa, Kazuya Koyama, Thi Na Nguyen, Tania Afroj, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker.,
Cancer Science, Vol.112, No.12, 4853-4866, 2021.- (要約)
- Immune checkpoint inhibitor (ICI) programmed death (PD)-1/PD-ligand 1 (PD-L1) blockade has been approved for various cancers. However, the underlying antitumor mechanisms mediated by ICIs and the predictive biomarkers remain unclear. We report the effects of anti-PD-L1/PD-1 Ab in tumor angiogenesis. In syngeneic mouse models, anti-PD-L1 Ab inhibited tumor angiogenesis and induces net-like hypoxia only in ICI-sensitive cell lines. In tumor tissue and serum of ICI-sensitive cell line-bearing mice, interferon-γ (IFN-γ) inducible angiostatic chemokines CXCL10/11 were upregulated by PD-L1 blockade. In vitro, CXCL10/11 gene upregulation by IFN-γ stimulation in tumor cell lines correlated with the sensitivity of PD-L1 blockade. The CXCL10/11 receptor CXCR3-neutralizing Ab or CXCL11 silencing in tumor cells inhibited the antiangiogenic effect of PD-L1 blockade in vivo. In pretreatment serum of lung carcinoma patients receiving anti-PD-1 Ab, the concentration of CXCL10/11 significantly correlated with the clinical outcome. Our results indicate the antiangiogenic function of PD-1/PD-L1 blockade and identify tumor-derived CXCL10/11 as a potential circulating biomarker of therapeutic sensitivity.
- (キーワード)
- Animals / B7-H1 Antigen / Biomarkers, Tumor / Carcinoma, Non-Small-Cell Lung / Cell Line, Tumor / Chemokine CXCL10 / Chemokine CXCL11 / HEK293 Cells / Humans / Immune Checkpoint Inhibitors / Interferon-gamma / Lung Neoplasms / 男性 (male) / Mice, Inbred BALB C / Mice, Inbred C57BL / Mice, Inbred CBA / Mice, Nude / Neoplasms, Experimental / Neovascularization, Pathologic / Programmed Cell Death 1 Receptor / RNA Interference
- (徳島大学機関リポジトリ)
- ● Metadata: 117305
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/cas.15161
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34628702
- ● Search Scopus @ Elsevier (PMID): 34628702
- ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15161
(徳島大学機関リポジトリ: 117305, DOI: 10.1111/cas.15161, PubMed: 34628702) Hirokazu Ogino, Makoto Tobiume, Kozo Kagawa, Hiroshi Kawano, Satoshi Sakaguchi, Atsuro Saijo, Daisuke Matsumoto, Hiromitsu Takizawa, Yuriko Morikawa, Yoshimi Bando, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka :
A Case of Radiation-associated Angiosarcoma Presenting as Massive Pleural Effusion.,
Internal Medicine, Vol.61, No.9, 1393-1397, 2021.- (要約)
- A 67-year-old man was admitted to our hospital for massive pleural effusion. He had a history of mandibular gingival carcinoma treated with radiation therapy (RT). Based on the cytology findings of pleural effusion and a thoracoscopic pleural biopsy, we finally diagnosed him with radiation-associated angiosarcoma. Retrospective cell-block immunocytochemistry with pleural effusion also showed potential utility for the diagnosis. This case highlights the importance of considering the possibility of radiation-associated secondary cancer in patients with pleural effusion who have a history of RT.
- (キーワード)
- Aged / Biopsy / Hemangiosarcoma / Humans / 男性 (male) / Pleural Effusion / Retrospective Studies / Thoracoscopy
- (徳島大学機関リポジトリ)
- ● Metadata: 118013
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.8195-21
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34645765
- ● Search Scopus @ Elsevier (PMID): 34645765
- ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.8195-21
(徳島大学機関リポジトリ: 118013, DOI: 10.2169/internalmedicine.8195-21, PubMed: 34645765) Yasuhiro Kondoh, Shigeki Makino, Takashi Ogura, Takafumi Suda, Hiromi Tomioka, Hirofumi Amano, Masaki Anraku, Noriyuki Enomoto, Takao Fujii, Tomoyuki Fujisawa, Takahisa Gono, Masayoshi Harigai, Hidenori Ichiyasu, Yoshikazu Inoue, Takeshi Johkoh, Hideto Kameda, Kensuke Kataoka, Yasuhiro Katsumata, Yasushi Kawaguchi, Atsushi Kawakami, Hideya Kitamura, Noboru Kitamura, Tomohiro Koga, Kazuhiro Kurasawa, Yutaro Nakamura, Ran Nakashima, Yasuhiko Nishioka, Osamu Nishiyama, Masaki Okamoto, Fumikazu Sakai, Susumu Sakamoto, Shinji Sato, Toshimasa Shimizu, Noboru Takayanagi, Reoto Takei, Tamiko Takemura, Tohru Takeuchi, Yuko Toyoda, Hidehiro Yamada, Hideaki Yamakawa, Yasuhiko Yamano, Yoshioki Yamasaki and Masataka Kuwana :
2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease.,
Respiratory Investigation, Vol.59, No.6, 709-740, 2021.- (要約)
- The prognosis of patients with connective tissue disease (CTD) has improved significantly in recent years, but interstitial lung disease (ILD) associated with connective tissue disease (CTD-ILD) remains a refractory condition, which is a leading cause of mortality. Because it is an important prognostic factor, many observational and interventional studies have been conducted to date. However, CTD is a heterogeneous group of conditions, which makes the clinical course, treatment responses, and prognosis of CTD-ILD extremely diverse. To summarize the current understanding and unsolved questions, the Japanese Respiratory Society and the Japan College of Rheumatology collaborated to publish the world's first guide focusing on CTD-ILD, based on the evidence and expert consensus of pulmonologists and rheumatologists, along with radiologists, pathologists, and dermatologists. The task force members proposed a total of 27 items, including 7 for general topics, 9 for disease-specific topics, 3 for complications, 4 for pharmacologic treatments, and 4 for non-pharmacologic therapies, with teams of 2-4 authors and reviewers for each item to prepare a consensus statement based on a systematic literature review. Subsequently, public opinions were collected from members of both societies, and a critical review was conducted by external reviewers. Finally, the task force finalized the guide upon discussion and consensus generation. This guide is expected to contribute to the standardization of CTD-ILD medical care and is also useful as a tool for promoting future research by clarifying unresolved issues.
- (キーワード)
- Connective Tissue Diseases / Humans / 日本 (Japan) / Lung Diseases, Interstitial / Prognosis / Pulmonologists
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2021.04.011
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34602377
- ● Search Scopus @ Elsevier (PMID): 34602377
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2021.04.011
(DOI: 10.1016/j.resinv.2021.04.011, PubMed: 34602377) Takeshi Imakura, Seidai Satou, Tetsu Tomonari, Kojin Murakami, Naoki Takahashi, Nobuhito Naito, Masato Mima, Kozo Kagawa, Kazuya Koyama, Haruka Nishimura, Hiroshi Kawano, Hiroshi Nokihara, Masahiko Azuma, Tetsuji Takayama and Yasuhiko Nishioka :
Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.,
Internal Medicine, Vol.61, No.8, 1211-1217, 2021.- (要約)
- Lenvatinib is a multi-targeted tyrosine kinase inhibitor available for the treatment of unresectable hepatocellular carcinoma (HCC). We herein report an 84-year-old-man with interstitial pneumonia caused by lenvatinib. Four months after the start of lenvatinib administration for HCC, chest computed tomography revealed bilateral ground-glass opacity. However, he continued to take lenvatinib for four more months until he complained of dyspnea on exertion. This is a case of lenvatinib-induced interstitial pneumonia that progressed relatively slowly with a long asymptomatic period despite the appearance of pneumonia on image findings.
- (キーワード)
- Aged, 80 and over / Carcinoma, Hepatocellular / Humans / Liver Neoplasms / Lung Diseases, Interstitial / 男性 (male) / Phenylurea Compounds / Quinolines
- (徳島大学機関リポジトリ)
- ● Metadata: 118011
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.7300-21
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34544944
- ● Search Scopus @ Elsevier (PMID): 34544944
- ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.7300-21
(徳島大学機関リポジトリ: 118011, DOI: 10.2169/internalmedicine.7300-21, PubMed: 34544944) Yasuhiko Nishioka, Sakae Homma, Takahito Okubo and Arata Azuma :
Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis.,
Contemporary Clinical Trials Communications, Vol.23, 2021.- (要約)
- This is an open-label, intra-patient comparison, exploratory phase 2 study of TAS-115 to evaluate the efficacy and safety in idiopathic pulmonary fibrosis (IPF) patients when orally administered at 200 mg once daily on a 5-day on and 2-day off regimen for 13 weeks. This study consists of three cohorts: previously treated with pirfenidone (Cohort P, n = 20), with nintedanib (Cohort N, n = 20), and treatment naïve (Cohort U, n = 10). Male or female patients aged ≥40 to <80 years who were diagnosed with IPF in the preceding five years and having a percent predicted forced vital capacity (%FVC) decline of ≥5% within the previous 6 months were enrolled in this study. The primary endpoint is change in the slope of %FVC decline at Week 13 from baseline. Key secondary endpoints are safety, change in FVC from baseline, proportion of the %FVC responders and change in percent predicted diffusing capacity of the lung carbon monoxide from baseline, which are assessed at Weeks 6, 13 and 26.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.conctc.2021.100832
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34471721
- ● Search Scopus @ Elsevier (PMID): 34471721
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.conctc.2021.100832
(DOI: 10.1016/j.conctc.2021.100832, PubMed: 34471721) Yoshikazu Inoue, Takafumi Suda, Hideya Kitamura, Masaki Okamoto, Arata Azuma, Naohiko Inase, Masataka Kuwana, Shigeki Makino, Yasuhiko Nishioka, Takashi Ogura, Ayako Takizawa, Hiroyuki Ugai, Susanne Stowasser, Rozsa Schlenker-Herceg and Tsutomu Takeuchi :
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.,
Respiratory Medicine, Vol.187, 2021.- (要約)
- The adjusted annual rates of FVC decline (mL/year) over 52 weeks for Japanese patients were -148.31 (nintedanib) and -240.36 (placebo), adjusted difference: 92.05 (95% CI: -10.69-194.80) and for non-Japanese patients were -67.41 (nintedanib) and -177.65 (placebo), adjusted difference: 110.24 (95% CI: 64.97-155.52). No heterogeneity in treatment effect between Japanese and non-Japanese subgroups was observed (treatment-by-subgroup interaction, p = 0.75). The risks of "acute exacerbation or death" (hazard ratio, 0.30 [95% CI: 0.10-0.91]) and mortality (hazard ratio, 0.54 [95% CI: 0.14-2.11]) in Japanese patients were numerically lower for nintedanib than placebo. There were no new or unexpected safety findings.
- (キーワード)
- Asians / Disease Progression / Double-Blind Method / Humans / Idiopathic Pulmonary Fibrosis / Indoles / Lung Diseases, Interstitial / 安全性 (safety) / Time Factors / Treatment Outcome / Vital Capacity
- (徳島大学機関リポジトリ)
- ● Metadata: 117384
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.rmed.2021.106574
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34564020
- ● Search Scopus @ Elsevier (PMID): 34564020
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmed.2021.106574
(徳島大学機関リポジトリ: 117384, DOI: 10.1016/j.rmed.2021.106574, PubMed: 34564020) Takuma Isshiki, Sakae Homma, Yoshinobu Eishi, Matsuko Yabe, Kazuya Koyama, Yasuhiko Nishioka, Tetsuo Yamaguchi, Keisuke Uchida, Kurara Yamamoto, Kenichi Ohashi, Atsushi Arakawa, Kazutoshi Shibuya, Susumu Sakamoto and Kazuma Kishi :
Usefulness of imunohistochemical detection of Propionibacterium acnes in granulomas for differentiating sarcoidosis from other garanulomatous diseases; comparison between manual and automated immunohistochemical detection methods.,
Microorganisms, Vol.9, No.8, 2021.- (徳島大学機関リポジトリ)
- ● Metadata: 117354
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3390/microorganisms9081668
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34442747
- ● Search Scopus @ Elsevier (PMID): 34442747
- ● Search Scopus @ Elsevier (DOI): 10.3390/microorganisms9081668
(徳島大学機関リポジトリ: 117354, DOI: 10.3390/microorganisms9081668, PubMed: 34442747) Noriyuki Enomoto, Sakae Homma, Naohiko Inase, Yasuhiro Kondoh, Takeshi Saraya, Hajime Takizawa, Yoshikazu Inoue, Hiroshi Ishii, Yoshio Taguchi, Shinyu Izumi, Yasuhiko Yamano, Yoshinori Tanino, Yasuhiko Nishioka, Mikio Toyoshima, Koshi Yokomura, Shiro Imokawa, Naoki Koshimizu, Takehisa Sano, Taisuke Akamatsu, Hiroshi Mukae, Motoyasu Kato, Naoki Hamada, Hirofumi Chiba, Shinobu Akagawa, Shigeo Muro, Hironori Uruga, Hiroyuki Matsuda, Yusuke Kaida, Miho Kanai, Kazutaka Mori, Masafumi Masuda, Hironao Hozumi, Tomoyuki Fujisawa, Yutaro Nakamura, Noriyoshi Ogawa and Takafumi Suda :
Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias.,
Thorax, Vol.77, No.2, 143-153, 2021.- (要約)
- These observations suggest that some patients with IIP show autoimmune features with distinct characteristics and favourable prognosis. However, we were not able to determine the appropriate therapies for these patients.
- (キーワード)
- Female / Humans / Idiopathic Interstitial Pneumonias / Lung Diseases, Interstitial / Prospective Studies / Retrospective Studies / Tomography, X-Ray Computed
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1136/thoraxjnl-2020-216263
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34272335
- ● Search Scopus @ Elsevier (PMID): 34272335
- ● Search Scopus @ Elsevier (DOI): 10.1136/thoraxjnl-2020-216263
(DOI: 10.1136/thoraxjnl-2020-216263, PubMed: 34272335) Keiko Haji, Seidai Satou, Hiroto Yoneda, Toshihiko Nisisho, Hiroshi Nokihara and Yasuhiko Nishioka :
Multidisciplinary treatment of skeletal muscle metastasis from lung cancer: A case of triceps muscle metastasis of lung squamous cell cancer.,
Respiratory Medicine Case Reports, Vol.33, 2021.- (要約)
- A 62-year-old Japanese man presented a hard and painful intramuscular mass in the right upper arm during the chemotherapy for lung squamous cell carcinoma. Initially, this mass containing fluid accumulation was treated by radiotherapy and antibiotics as a muscle metastasis suspected to be complicated with local infection. However, because the swelling and pain of his right arm did not improve, he underwent a surgical debridement of the mass. These local treatments succeeded in relieving the patient's symptoms for a while. However, after temporary remission, the recurrence tumor developed the paralysis of right radial nerve and ulnar nerve in his upper arm. Despite further combined therapy including drainage, additional radiotherapy, and chemotherapy, paralysis made his performance status deteriorated. He was eventually discontinued aggressive treatment due to worsened general condition. We herein report a case of lung cancer followed unusual course due to muscle metastasis in the triceps muscle. Because the paralysis caused by muscle metastasis can be the factor to deteriorate the performance status of patient, the combined therapy including antibiotics, debridement, radiotherapy and chemotherapy as early as possible should be considered to avoid its risk.
- (徳島大学機関リポジトリ)
- ● Metadata: 117385
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.rmcr.2021.101470
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34401306
- ● Search Scopus @ Elsevier (PMID): 34401306
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2021.101470
(徳島大学機関リポジトリ: 117385, DOI: 10.1016/j.rmcr.2021.101470, PubMed: 34401306) Fumie Nakasuka, Sho Tabata, Takeharu Sakamoto, Akiyoshi Hirayama, Hiromichi Ebi, Tadaaki Yamada, Ko Umetsu, Maki Ohishi, Ayano Ueno, Hisatsugu Goto, Masahiro Sugimoto, Yasuhiko Nishioka, Yasuhiro Yamada, Masaru Tomita, T Atsuo Sasaki, Seiji Yano and Tomoyoshi Soga :
TGF-β-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers.,
Communications Biology, Vol.4, No.1, 2021.- (要約)
- Epithelial-mesenchymal transition (EMT)-a fundamental process in embryogenesis and wound healing-promotes tumor metastasis and resistance to chemotherapy. While studies have identified signaling components and transcriptional factors responsible in the TGF-β-dependent EMT, whether and how intracellular metabolism is integrated with EMT remains to be fully elucidated. Here, we showed that TGF-β induces reprogramming of intracellular amino acid metabolism, which is necessary to promote EMT in non-small cell lung cancer cells. Combined metabolome and transcriptome analysis identified prolyl 4-hydroxylase α3 (P4HA3), an enzyme implicated in cancer metabolism, to be upregulated during TGF-β stimulation. Further, knockdown of P4HA3 diminished TGF-β-dependent changes in amino acids, EMT, and tumor metastasis. Conversely, manipulation of extracellular amino acids induced EMT-like responses without TGF-β stimulation. These results suggest a previously unappreciated requirement for the reprogramming of amino acid metabolism via P4HA3 for TGF-β-dependent EMT and implicate a P4HA3 inhibitor as a potential therapeutic agent for cancer.
- (徳島大学機関リポジトリ)
- ● Metadata: 116517
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1038/s42003-021-02323-7
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34168290
- ● Search Scopus @ Elsevier (PMID): 34168290
- ● Search Scopus @ Elsevier (DOI): 10.1038/s42003-021-02323-7
(徳島大学機関リポジトリ: 116517, DOI: 10.1038/s42003-021-02323-7, PubMed: 34168290) Shu Hisata, Masashi Bando, Sakae Homma, Kensuke Kataoka, Takashi Ogura, Shinyu Izumi, Susumu Sakamoto, Kizuku Watanabe, Yoshinobu Saito, Yasuo Shimizu, Motoyasu Kato, Yasuhiko Nishioka, Hiromichi Hara, Yuko Waseda, Yoshinori Tanino, Kazuhiro Yatera, Seishu Hashimoto, Hiroshi Mukae and Naohiko Inase :
Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.,
Respiratory Investigation, Vol.59, No.6, 819-826, 2021.- (要約)
- Real-world data imply that combination therapy with pirfenidone and nintedanib for IPF has a manageable safety/tolerability profile.
- (キーワード)
- Humans / Idiopathic Pulmonary Fibrosis / Indoles / 日本 (Japan) / Pyridones / Retrospective Studies / Treatment Outcome
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2021.04.005
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994347
- ● Search Scopus @ Elsevier (PMID): 33994347
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2021.04.005
(DOI: 10.1016/j.resinv.2021.04.005, PubMed: 33994347) Seidai Satou, Giin Sy Chong, Chandak Upagupta, Toyoshi Yanagihara, Takuya Saito, Chiko Shimbori, Pierre-Simon Bellaye, Yasuhiko Nishioka and Rj Martin Kolb :
Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes.,
Thorax, Vol.76, No.9, 895-906, 2021.- (要約)
- of fibroblasts. Culturing on rigid plates or fibrotic decellularised lung scaffolds increased miR-21-5 p expression compared with soft plates or normal lung scaffolds. Dissolved ECM collected from fibrotic lungs and recombinant TGF-β1 increased miR-21-5 p expression on fibrocytes, and these effects were attenuated on soft plates. Fibrocytes from BALF collected from fibrotic interstitial pneumonia patients showed higher miR-21-5 p expression than those from other patients.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1136/thoraxjnl-2020-215962
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33859055
- ● Search Scopus @ Elsevier (PMID): 33859055
- ● Search Scopus @ Elsevier (DOI): 10.1136/thoraxjnl-2020-215962
(DOI: 10.1136/thoraxjnl-2020-215962, PubMed: 33859055) Hiroshi Mukae, Takeshi Kaneko, Yasushi Obase, Masaharu Shinkai, Toshio Katsunuma, Kiyoshi Takeyama, Jiro Terada, Akio Niimi, Hiroto Matsuse, Kazuhiro Yatera, Yoshihiro Yamamoto, Arata Azuma, Hirokazu Arakawa, Takashi Iwanaga, Haruhiko Ogawa, Kiyoyasu Kurahashi, Yasuhiro Gon, Hirokazu Sakamoto, Yoko Shibata, Tsutomu Tamada, Yasuhiko Nishioka, Shusaku Haranaga, Shigeharu Fujieda, Naoyuki Miyashita, Hiroyuki Mochizuki, Akihito Yokoyama, Shigemi Yoshihara and Jun Tamaoki :
The Japanese respiratory society guidelines for the management of cough and sputum (digest edition).,
Respiratory Investigation, Vol.59, No.3, 270-290, 2021.- (要約)
- Cough and sputum are common complaints at outpatient visits. In this digest version, we provide a general overview of these two symptoms and discuss the management of acute (up to three weeks) and prolonged/chronic cough (longer than three weeks). Flowcharts are provided, along with a step-by-step explanation of their diagnosis and management. Most cases of acute cough are due to an infection. In chronic respiratory illness, a cough could be a symptom of a respiratory infection such as pulmonary tuberculosis, malignancy such as a pulmonary tumor, asthma, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, drug-induced lung injury, heart failure, nasal sinus disease, sinobronchial syndrome, eosinophilic sinusitis, cough variant asthma (CVA), atopic cough, chronic laryngeal allergy, gastroesophageal reflux (GER), and post-infectious cough. Antibiotics should not be prescribed for over-peak cough but can be considered for atypical infections. The exploration of a single/major cause is recommended for persistent/chronic cough. When sputum is present, a sputum smear/culture (general bacteria, mycobacteria), cytology, cell differentiation, chest computed tomography (CT), and sinus X-ray or CT should be performed. There are two types of rhinosinusitis. Conventional sinusitis and eosinophilic rhinosinusitis present primarily with neutrophilic inflammation and eosinophilic inflammation, respectively. The most common causes of dry cough include CVA, atopic cough/laryngeal allergy (chronic), GER, and post-infectious cough. In the last chapter, future challenges and perspectives are discussed. We hope that the clarification of the pathology of cough hypersensitivity syndrome will lead to further development of "pathology-specific non-specific therapeutic drugs" and provide benefits to patients with chronic refractory cough.
- (キーワード)
- Acute Disease / Asthma / Chronic Disease / Cough / 女性 (female) / Gastroesophageal Reflux / Humans / Hypersensitivity / 日本 (Japan) / 男性 (male) / Practice Guidelines as Topic / Pulmonary Medicine / Respiratory Tract Diseases / Societies, Medical / Sputum
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2021.01.007
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33642231
- ● Search Scopus @ Elsevier (PMID): 33642231
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2021.01.007
(DOI: 10.1016/j.resinv.2021.01.007, PubMed: 33642231) Tania Afroj, Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Makoto Tobiume, Thi Na Nguyen, Hisatsugu Goto, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara and Yasuhiko Nishioka :
Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.,
The Journal of Immunology, Vol.206, No.6, 1204-1214, 2021.- (要約)
- T cells when the activity is further enhanced by PD-L1/PD-1 blockade.
- (徳島大学機関リポジトリ)
- ● Metadata: 115981
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.4049/jimmunol.2000909
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33504617
- ● Search Scopus @ Elsevier (PMID): 33504617
- ● Search Scopus @ Elsevier (DOI): 10.4049/jimmunol.2000909
(徳島大学機関リポジトリ: 115981, DOI: 10.4049/jimmunol.2000909, PubMed: 33504617) Susumu Sakamoto, Kensuke Kataoka, Yasuhiro Kondoh, Motoyasu Kato, Masaki Okamoto, Hiroshi Mukae, Masashi Bando, Takafumi Suda, Kazuhiro Yatera, Yoshinori Tanino, Tomoo Kishaba, Noboru Hattori, Yoshio Taguchi, Takefumi Saito, Yasuhiko Nishioka, Kazuyoshi Kuwano, Kazuma Kishi, Naohiko Inase, Shinichi Sasaki, Hajime Takizawa, Takeshi Johkoh, Fumikazu Sakai and Sakae Homma :
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.,
The European Respiratory Journal, Vol.57, No.1, 2021.- (要約)
- 81 patients were randomly assigned in a 1:1 ratio to receive pirfenidone plus inhaled N-acetylcysteine (n=41) or pirfenidone (n=40). The 48-week rate of change in FVC was -300 mL and -123 mL, respectively (difference -178 mL, 95% CI -324--31 mL; p=0.018). Serial change in
- (キーワード)
- Acetylcysteine / Anti-Inflammatory Agents, Non-Steroidal / Humans / Idiopathic Pulmonary Fibrosis / 日本 (Japan) / Pyridones / Treatment Outcome / Vital Capacity
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.00348-2020
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32703779
- ● Search Scopus @ Elsevier (PMID): 32703779
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.00348-2020
(DOI: 10.1183/13993003.00348-2020, PubMed: 32703779) Hiroshi Kawano, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Kozo Kagawa, Seidai Satou, Nobuhito Naito, Hisatsugu Goto, Yutaka Inagaki and Yasuhiko Nishioka :
Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain.,
Immunity, Inflammation and Disease, Vol.9, No.1, 120-127, 2020.- (要約)
- cells.
- (徳島大学機関リポジトリ)
- ● Metadata: 116531
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/iid3.361
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33369271
- ● Search Scopus @ Elsevier (PMID): 33369271
- ● Search Scopus @ Elsevier (DOI): 10.1002/iid3.361
(徳島大学機関リポジトリ: 116531, DOI: 10.1002/iid3.361, PubMed: 33369271) Nobuhito Naito, Hiroshi Kawano, Yuya Yamashita, Mayo Kondou, Shotaro Haji, Ryosuke Miyamoto, Yuko Toyoda, Yasuhisa Kanematsu, Yuishin Izumi, Yoshimi Bando and Yasuhiko Nishioka :
Neuropsychiatric systemic lupus erythematosus with cerebellar vasculitis and obstructive hydrocephalus requiring decompressive craniectomy.,
Modern Rheumatology Case Reports, Vol.5, No.1, 52-57, 2020.- (要約)
- A 36-year-old woman who had been diagnosed with systemic lupus erythematosus (SLE) was admitted to our hospital due to increasing disease SLE activity. Despite the intensification of immunosuppressive treatment, headache newly developed and worsened. Magnetic resonance imaging (MRI) revealed spreading of a high-intensity area along the sulci of the bilateral cerebellar hemispheres. She was diagnosed with neuropsychiatric SLE and methylprednisolone (mPSL) pulse therapy was started. However, consciousness disorder due to cerebellar oedema with obstructive hydrocephalus appeared and required decompressive craniectomy. The histological findings of the biopsy specimens from cerebellar vermis were compatible with features of vasculitis. She was successfully treated adding intravenous cyclophosphamide therapy.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1080/24725625.2020.1826626
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33021438
- ● Search Scopus @ Elsevier (PMID): 33021438
- ● Search Scopus @ Elsevier (DOI): 10.1080/24725625.2020.1826626
(DOI: 10.1080/24725625.2020.1826626, PubMed: 33021438) Momoyo Azuma, Keiji Murakami, Rina Murata, Keiko Kataoka, Hideki Fujii, Yoichiro Miyake and Yasuhiko Nishioka :
Clinical Significance of Carbapenem-Tolerant Pseudomonas aeruginosa Isolated in the Respiratory Tract,
Antibiotics, Vol.9, No.9, 2020.- (要約)
- infections.
- (徳島大学機関リポジトリ)
- ● Metadata: 116480
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3390/antibiotics9090626
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32967210
- ● Search Scopus @ Elsevier (PMID): 32967210
- ● Search Scopus @ Elsevier (DOI): 10.3390/antibiotics9090626
(徳島大学機関リポジトリ: 116480, DOI: 10.3390/antibiotics9090626, PubMed: 32967210) Shun Morizumi, Seidai Satou, Kazuya Koyama, Hiroyasu Okazaki, Yajuan Chen, Hisatsugu Goto, Kozo Kagawa, Hirohisa Ogawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara and Yasuhiko Nishioka :
Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis.,
American Journal of Respiratory Cell and Molecular Biology, Vol.63, No.3, 317-326, 2020.- (要約)
- H]thymidine incorporation assays. The expression of FGFR was analyzed using IB or flow cytometry. We also investigated the effect of BGJ398 on pulmonary fibrosis induced by bleomycin in mice. Both lung fibroblasts and AECs expressed FGFRs. BGJ398 significantly inhibited the proliferation and migration of lung fibroblasts stimulated with FGF2. BGJ398 also reduced the proliferation of AECs in response to FGF2. Although the administration of BGJ398 ameliorated pulmonary fibrosis in bleomycin-treated mice, it increased mortality resulting from alveolar injury and inhibition of AEC regeneration. These data suggest that the total inhibition of FGFR signaling can suppress lung fibrosis by inhibiting fibroblast activities, although alveolar injury is simultaneously caused.
- (キーワード)
- Alveolar Epithelial Cells / Animals / Bleomycin / Fibroblasts / Humans / Idiopathic Pulmonary Fibrosis / Indoles / Lung / Mice / リン酸化 (phosphorylation) / Receptors, Fibroblast Growth Factor / シグナル伝達 (signal transduction)
- (徳島大学機関リポジトリ)
- ● Metadata: 115073
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1165/rcmb.2019-0090OC
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32338990
- ● Search Scopus @ Elsevier (PMID): 32338990
- ● Search Scopus @ Elsevier (DOI): 10.1165/rcmb.2019-0090OC
(徳島大学機関リポジトリ: 115073, DOI: 10.1165/rcmb.2019-0090OC, PubMed: 32338990) Mayo Kondou, Toshifumi Tezuka, Hirohisa Ogawa, Kazuya Koyama, Hiroki Bando, Masahiko Azuma and Yasuhiko Nishioka :
Lysophosphatidic Acid Regulates the Differentiation of Th2 Cells and Its Antagonist Suppresses Allergic Airway Inflammation.,
International Archives of Allergy and Immunology, Vol.182, No.1, 1-13, 2020.- (要約)
- These findings suggest that LPA plays an important role in allergic airway inflammation and that the blockade of LPA2 might have therapeutic potential for bronchial asthma.
- (徳島大学機関リポジトリ)
- ● Metadata: 115394
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1159/000509804
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32846422
- ● Search Scopus @ Elsevier (PMID): 32846422
- ● Search Scopus @ Elsevier (DOI): 10.1159/000509804
(徳島大学機関リポジトリ: 115394, DOI: 10.1159/000509804, PubMed: 32846422) Naoto Okada, Rie Matsuoka, Takumi Sakurada, Mitsuhiro Goda, Masayuki Chuma, Kenta Yagi, Yoshito Zamami, Yasuhiko Nishioka and Keisuke Ishizawa :
Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.,
Scientific Reports, Vol.10, No.1, 2020.- (要約)
- Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD) is a fatal irAE that is difficult to treat; moreover, its incidence is relatively higher in patients with lung cancer. Therefore, early ICI-ILD detection and intervention are important for patient safety. However, a risk assessment method for ICI-ILD has not been established and the prediction of ICI-ILD occurrence is difficult. The aim of our study was to identify the risk factors associated with ICI-ILD. To this end, we retrospectively analysed 102 patients with lung cancer who first received ICI and completed the treatment between April 2016 and December 2019 at Tokushima University Hospital. Nineteen patients had all grades of ICI-ILD and 10 had grade ≥ 3 ICI-ILD. The 30-day mortality rate of patients with grade ≥ 3 ICI-ILD was the highest among all patients (P < 0.01). The multivariate logistic analysis indicated that the performance status ≥ 2 alone and both performance status ≥ 2 and ≥ 50 pack-year were independent risk factors of ICI-ILD of grade ≥ 3 and all grades, respectively. Overall, our study provides insights to predict ICI-ILD occurrence.
- (キーワード)
- Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / B7-H1 Antigen / CTLA-4 Antigen / Carcinoma, Non-Small-Cell Lung / Early Diagnosis / Female / Humans / Immune Checkpoint Inhibitors / Lung Diseases, Interstitial / Lung Neoplasms / Male / Middle Aged / Nivolumab / Programmed Cell Death 1 Receptor / Retrospective Studies / Risk Assessment / Risk Factors
- (徳島大学機関リポジトリ)
- ● Metadata: 116635
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1038/s41598-020-70743-2
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32792640
- ● Search Scopus @ Elsevier (PMID): 32792640
- ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-020-70743-2
(徳島大学機関リポジトリ: 116635, DOI: 10.1038/s41598-020-70743-2, PubMed: 32792640) Sakae Homma, Masahito Ebina, Kazuyoshi Kuwano, Hisatsugu Goto, Fumikazu Sakai, Susumu Sakamoto, Takeshi Johkoh, Keishi Sugino, Teruo Tachibana, Yasahiro Terasaki, Yasuhiko Nishioka, Koichi Hagiwara, Naozumi Hashimoto, Yoshinori Hasegawa and Akira Hebisawa :
Intractable diffuse pulmonary diseases: Manual for diagnosis and treatment.,
Respiratory Investigation, Vol.59, No.1, 8-33, 2020.- (要約)
- This manual has been compiled by a joint production committee with the Diffuse Lung Disease Assembly of the Japanese Respiratory Society (JRS) to provide a practical manual for the epidemiology, diagnosis, and treatment of intractable diffuse pulmonary diseases. The contents are based upon the results of research into these diseases by the Diffuse Pulmonary Diseases Study Group (principal researcher: Sakae Homma) supported by the FY2014-FY2016 Health and Labor Sciences Research Grant on Intractable Diseases. This manual focuses on: 1) pulmonary alveolar microlithiasis, 2) bronchiolitis obliterans, and 3) Hermansky-Pudlak Syndrome with interstitial pneumonia. As these are rare/intractable diffuse lung diseases (2 and 3 were first recognized as specified intractable diseases in 2015), there have not been sufficient epidemiological studies made, and there has been little progress in formulating diagnostic criteria and severity scales; however, the results of Japan's first surveys and research into such details are presented herein. In addition, the manual provides treatment guidance and actual cases for each disease, aiming to assist in the establishment of future modalities. The manual was produced with the goal of enabling clinicians specialized in respiratory apparatus to handle these diseases in clinical settings and of further advancing future research and treatment.
- (キーワード)
- Adolescent / 成人 (adult) / Aged / Bronchiolitis Obliterans / Calcinosis / 女性 (female) / Genetic Diseases, Inborn / Hermanski-Pudlak Syndrome / Humans / 日本 (Japan) / Lung Diseases / Lung Diseases, Interstitial / 男性 (male) / Middle Aged / Practice Guidelines as Topic / Pulmonary Medicine / Societies, Medical / Young Adult
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2020.04.004
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32622842
- ● Search Scopus @ Elsevier (PMID): 32622842
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2020.04.004
(DOI: 10.1016/j.resinv.2020.04.004, PubMed: 32622842) Yuji Minegishi, Akihiko Gemma, Sakae Homma, Kazuma Kishi, Arata Azuma, Takashi Ogura, Naoki Hamada, Hiroyuki Taniguchi, Noboru Hattori, Yasuhiko Nishioka, Kiminobu Tanizawa, Takeshi Johkoh, Takuma Yokoyama, Kazutaka Mori, Yoshio Taguchi, Masahito Ebina, Naohiko Inase, Koichi Hagiwara, Hiroshi Ohnishi, Hiroshi Mukae, Yoshikazu Inoue, Kazuyoshi Kuwano, Hirofumi Chiba, Ken Ohta, Yoshinori Tanino, Fumikazu Sakai and Yukihiko Sugiyama :
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan.,
ERJ Open Research, Vol.6, No.2, 2020.- (要約)
- Of the 396 patients analysed, 13.1% developed chemotherapy-related AEx. Combination chemotherapies of carboplatin plus paclitaxel (CP) or carboplatin plus etoposide (CE) were frequently used as first-line treatments. The lowest incidence of AEx was 3.7% in CE, followed by 8.6% in CP. In the retrospective study, 16.2% of the 278 patients developed a second-line chemotherapy-related AEx. The overall response rate by second-line chemotherapy was 7.4% in NSCLC and 25.7% in SCLC. The median overall survival from second-line and first-line chemotherapy was 8.0 and 14.3 months in NSCLC, and 8.7 and 16.0 months in SCLC, respectively.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/23120541.00184-2019
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32494570
- ● Search Scopus @ Elsevier (PMID): 32494570
- ● Search Scopus @ Elsevier (DOI): 10.1183/23120541.00184-2019
(DOI: 10.1183/23120541.00184-2019, PubMed: 32494570) Kenji Otsuka, Atsushi Mitsuhashi, Hisatsugu Goto, Masaki Hanibuchi, Kazuya Koyama, Hirohisa Ogawa, Hirokazu Ogino, Atsuro Saijo, Hiroyuki Kozai, Hiroto Yoneda, Makoto Tobiume, Masatoshi Kishuku, Keisuke Ishizawa and Yasuhiko Nishioka :
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.,
Lung Cancer, Vol.146, 86-96, 2020.- (要約)
- The combination of anti-PD-1 antibody with CDDP + PEM may be a promising therapy for MPM via inhibiting the accumulation of MDSCs and vessels in tumors.
- (キーワード)
- Animals / Cell Line, Tumor / Lung Neoplasms / Mesothelioma / Mice / Myeloid-Derived Suppressor Cells / Pemetrexed
- (徳島大学機関リポジトリ)
- ● Metadata: 115324
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.lungcan.2020.05.023
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32526602
- ● Search Scopus @ Elsevier (PMID): 32526602
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.lungcan.2020.05.023
(徳島大学機関リポジトリ: 115324, DOI: 10.1016/j.lungcan.2020.05.023, PubMed: 32526602) 福家 麻美, 荻野 広和, 坪井 未希, 近藤 真代, 香川 耕造, 埴淵 昌毅, 山﨑 博輝, 宮本 亮介, 豊田 優子, 西岡 安彦 :
エタンブトールによる脱髄性末梢神経障害により急速進行性の歩行障害を呈した結核性胸膜炎の1例,
日本結核・非結核性抗酸菌症学会, Vol.95, No.2, 73-77, 2020年. Shuichi Abe, Seidai Satou, Yoshinori Aono, Momoyo Azuma, Masami Kishi, Koyama Kazuya, Takahashi Naoki, Kozo Kagawa, Hiroshi Kawano and Yasuhiko Nishioka :
Functional analysis of human fibrocytes derived from monocytes reveals their profibrotic phenotype through paracrine effects,
The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 102-112, 2020.- (要約)
- Fibrocytes, which are bone marrow-derived collagen-producing cells, were reported to play a role in the pathogenesis of pulmonary fibrosis. However, their function in pulmonary fibrosis is unclear. We analyzed their function compared with that of monocytes and localization in fibrotic tissues in patients with idiopathic pulmonary fibrosis (IPF). We compared the gene expression profile of monocyte-derived fibrocytes with that of monocytes by microarray analysis. Proliferation and differentiation into myofibroblasts were examined by 3H-thymidine incorporation assay and Western blotting. We measured the level of growth factors in the culture supernatant of fibrocytes by ELISA. The localization of fibrocytes in lung tissues of patients with IPF was determined by immunofluorescence staining. Compared with monocytes, fibrocytes had higher expression of extracellular matrix- and growth factor-encoding genes, including PDGF-B, FGF-2 and VEGF-B. Although fibrocytes did not proliferate in response to PDGF, co-culture of fibrocytes stimulated the growth of lung fibroblasts through the production of PDGF-BB. In the lung of IPF patients, CD45+Collagen-I+FSP-1+ cells, which have a similar phenotype to fibrocytes, were detected and co-stained with anti-PDGF antibody. This study suggested that fibrocytes function in pulmonary fibrosis partly by producing PDGF in the lungs of IPF patients. J. Med. Invest. 67 : 102-112, February, 2020.
- (徳島大学機関リポジトリ)
- ● Metadata: 114734
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.67.102
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378592
- ● Search Scopus @ Elsevier (PMID): 32378592
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.102
(徳島大学機関リポジトリ: 114734, DOI: 10.2152/jmi.67.102, PubMed: 32378592) Takeshi Imakura, Yuko Toyoda, Seidai Satou, Kazuya Koyama, Haruka Nishimura, Kozo Kagawa, Naoki Takahashi, Nobuhito Naito, Kojin Murakami, Hiroshi Kawano, Masahiko Azuma, Tsutomu Shinohara and Yasuhiko Nishioka :
Distinct improvement of pulmonary function, ground-glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment : a case report with a review of the literature.,
The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 358-361, 2020.- (要約)
- Background : Pirfenidone (PFD), an anti-fibrosis drug for idiopathic pulmonary fibrosis (IPF), suppresses disease progression and delays decline of forced vital capacity. However, this drug rarely makes marked improvement of pulmonary function, chest high-resolution computed tomography (HRCT) findings and hypoxia. Case presentation : A 59 year-old-man, who was a former smoker and had a history of alcoholic liver cirrhosis, developed exertional dyspnea and was referred to our hospital. HRCT showed honeycomb changes with surrounding ground-glass opacity (GGO) in a predominantly basal and subpleural distribution. He was diagnosed with IPF and the treatment with PFD was started. At 16 months after the start of treatment, the predicted forced vital capacity value markedly improved from 82.9% to 98.6%. His resting-state partial pressure of arterial oxygen while breathing room air increased from a minimum of 54.7 mmHg (at 2 months treatment) to 72.5 mmHg. The GGO observed at diagnosis disappeared in HRCT. But after 32 months of treatment, his general condition got worse gradually, and he died from chronic progression of IPF after 48 months of treatment. Conclusion : Our case suggests that a complication of chronic liver disease and the existence of GGO may be characteristics of super-responder to PFD treatment for IPF patients. J. Med. Invest. 67 : 358-361, August, 2020.
- (徳島大学機関リポジトリ)
- ● Metadata: 115454
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.67.358
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148916
- ● Search Scopus @ Elsevier (PMID): 33148916
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.358
(徳島大学機関リポジトリ: 115454, DOI: 10.2152/jmi.67.358, PubMed: 33148916) Akio Takezaki, Shin-ichi Tsukumo, Yasuhiro Setoguchi, G Julie Ledford, Hisatsugu Goto, Kazuyoshi Hosomichi, Hisanori Uehara, Yasuhiko Nishioka and Koji Yasutomo :
A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis.,
The Journal of Experimental Medicine, Vol.216, No.12, 2724-2735, 2019.- (要約)
- promotes necroptosis of AEII cells through JNK-mediated up-regulation of Ripk3, highlighting the necroptosis pathway as a therapeutic target for IPF.
- (徳島大学機関リポジトリ)
- ● Metadata: 114694
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1084/jem.20182351
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31601679
- ● Search Scopus @ Elsevier (PMID): 31601679
- ● Search Scopus @ Elsevier (DOI): 10.1084/jem.20182351
(徳島大学機関リポジトリ: 114694, DOI: 10.1084/jem.20182351, PubMed: 31601679) Takashi Ogura, Nagio Takigawa, Keisuke Tomii, Kazuma Kishi, Yoshikazu Inoue, Eiki Ichihara, Sakae Homma, Kazuhisa Takahashi, Hiroaki Akamatsu, Satoshi Ikeda, Naohiko Inase, Tae Iwasawa, Yuichiro Ohe, Hiromitsu Ohta, Hiroshi Onishi, Isamu Okamoto, Kazumasa Ogawa, Kazuo Kasahara, Hiroki Karata, Takumi Kishimoto, Yuka Kitamura, Akihiko Gemma, Hirotsugu Kenmotsu, Hiroyuki Sakashita, Susumu Sakamoto, Katsutoshi Sekine, Yuichi Takiguchi, Yuji Tada, Shinichi Toyooka, Yuko Nakayama, Yasuhiko Nishioka, Koichi Hagiwara, Masaki Hanibuchi, Junya Fukuoka, Yuji Minegishi, Toyoshi Yanagihara, Nobuyuki Yamamoto, Hiromasa Yamamoto, Mina Gaga, M Kwun Fong, A Charles Powell and Katsuyuki Kiura :
Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.,
Respiratory Investigation, Vol.57, No.6, 512-533, 2019.- (要約)
- Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2019.06.001
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31377122
- ● Search Scopus @ Elsevier (PMID): 31377122
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2019.06.001
(DOI: 10.1016/j.resinv.2019.06.001, PubMed: 31377122) Akihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, Rui Kitadai, Takayuki Takeda, Takanori Kanematsu, Hisatsugu Goto, Hiroto Yoneda, Taishi Harada, Yutaka Kubota, Takahiro Yamada, Koji Date, Shinsuke Shiotsu, Kazuhiro Nagata, Yusuke Chihara, Yoshiko Kaneko, Junji Uchino, Yasuhiko Nishioka and Koichi Takayama :
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.,
Translational Lung Cancer Research, Vol.8, No.4, 450-460, 2019.- (要約)
- Our retrospective study indicated that combination regimens comprising chemotherapy and ICIs followed by Doc and Ram could be an optimal therapeutic option for NSCLC patients regardless of the PD-L1 status of tumors. Further investigations are required to strengthen clinical evidence demonstrating the effectiveness of the combination therapy of Doc plus Ram in previously treated NSCLC patients.
- (徳島大学機関リポジトリ)
- ● Metadata: 116474
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.21037/tlcr.2019.08.07
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31555518
- ● Search Scopus @ Elsevier (PMID): 31555518
- ● Search Scopus @ Elsevier (DOI): 10.21037/tlcr.2019.08.07
(徳島大学機関リポジトリ: 116474, DOI: 10.21037/tlcr.2019.08.07, PubMed: 31555518) M Toby Maher, Susanne Stowasser, Yasuhiko Nishioka, S Eric White, Vincent Cottin, Imre Noth, Moisés Selman, B Klaus Rohr, Andreas Michael, Carina Ittrich, Claudia Diefenbach and Gisli R Jenkins :
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.,
The Lancet. Respiratory Medicine, Vol.7, No.9, 771-779, 2019.- (要約)
- to 4·88 × 10
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/S2213-2600(19)30255-3
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31326319
- ● Search Scopus @ Elsevier (PMID): 31326319
- ● Search Scopus @ Elsevier (DOI): 10.1016/S2213-2600(19)30255-3
(DOI: 10.1016/S2213-2600(19)30255-3, PubMed: 31326319) Hiroyasu Okazaki, Seidai Satou, Kazuya Koyama, Shun Morizumi, Shuichi Abe, Momoyo Azuma, Yajuan Chen, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara, Hiroyuki Kouji and Yasuhiko Nishioka :
The novel inhibitor PRI-724 for Wnt/β-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice.,
Experimental Lung Research, Vol.45, No.7, 188-199, 2019.- (要約)
- These results suggest that the β-catenin/CBP inhibitor PRI-724 is a potent antifibrotic agent that acts by modulating the activity of macrophages in the lungs.
- (徳島大学機関リポジトリ)
- ● Metadata: 113984
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1080/01902148.2019.1638466
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31298961
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85068899202
(徳島大学機関リポジトリ: 113984, DOI: 10.1080/01902148.2019.1638466, PubMed: 31298961, Elsevier: Scopus) Yuko Toyoda, Kazuya Koyama, Hiroshi Kawano, Haruka Nishimura, Kozo Kagawa, Shun Morizumi, Nobuhito Naito, Seidai Satou, Yuya Yamashita, Naoki Takahashi, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka :
Clinical features of interstitial pneumonia associated with systemic lupus erythematosus.,
Respiratory Investigation, Vol.57, No.5, 435-443, 2019.- (要約)
- In SLE cases, IP primarily occurred in male and elderly patients. In addition to the NSIP pattern, the UIP pattern was evident on HRCT scans of IP-related SLE. The survival of SLE patients was unrelated to IP.
- (キーワード)
- Adult / Age of Onset / Aged / Disease Progression / Female / Humans / Incidence / Lung Diseases, Interstitial / Lupus Erythematosus, Systemic / Male / Middle Aged / Retrospective Studies / Sex Factors / Tomography, X-Ray Computed / Young Adult
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2019.04.005
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31235450
- ● Search Scopus @ Elsevier (PMID): 31235450
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2019.04.005
(DOI: 10.1016/j.resinv.2019.04.005, PubMed: 31235450) Masaki Hanibuchi, Akira Kanoh, Takuya Kuramoto, Tatsuro Saito, Makoto Tobiume, Atsuro Saijo, Hiroyuki Kozai, Mayo Kondou, Shun Morizumi, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Kenji Otsuka, Yuko Toyoda, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka :
Development, validation, and comparison of gene analysis methods for detecting mutation from non-small cell lung cancer patients-derived circulating free DNA.,
Oncotarget, Vol.10, No.38, 3654-3666, 2019.- (徳島大学機関リポジトリ)
- ● Metadata: 115668
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.18632/oncotarget.26951
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31217900
- ● Search Scopus @ Elsevier (PMID): 31217900
- ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.26951
(徳島大学機関リポジトリ: 115668, DOI: 10.18632/oncotarget.26951, PubMed: 31217900) Kazuya Koyama, Hisatsugu Goto, Shun Morizumi, Kozo Kagawa, Haruka Nishimura, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Hirohisa Ogawa, Sakae Homma and Yasuhiko Nishioka :
The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.,
American Journal of Respiratory Cell and Molecular Biology, Vol.60, No.4, 478-487, 2019.- (要約)
- The signaling pathways of growth factors, including platelet-derived growth factor, can be considered specific targets for overcoming the poor prognosis of idiopathic pulmonary fibrosis. Nintedanib, the recently approved multiple kinase inhibitor, has shown promising antifibrotic effects in patients with idiopathic pulmonary fibrosis; however, its efficacy is still limited, and in some cases, treatment discontinuation is necessary owing to toxicities such as gastrointestinal disorders. Therefore, more effective agents with less toxicity are still needed. TAS-115 is a novel multiple tyrosine kinase inhibitor that preferably targets platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor, and c-FMS in addition to other molecules. In this study, we evaluated the antifibrotic effect of TAS-115 on pulmonary fibrosis in vitro and in vivo. TAS-115 inhibited the phosphorylation of PDGFR on human lung fibroblast cell line MRC-5 cells and suppressed their platelet-derived growth factor-induced proliferation and migration. Furthermore, TAS-115 inhibited the phosphorylation of c-FMS, a receptor of macrophage colony-stimulating factor, in murine bone marrow-derived macrophages and decreased the production of CCL2, another key molecule for inducing pulmonary fibrosis, under the stimulation of macrophage colony-stimulating factor. Importantly, the inhibitory effects of TAS-115 on both PDGFR and c-FMS were 3- to 10-fold higher than those of nintedanib. In a mouse model of bleomycin-induced pulmonary fibrosis, TAS-115 significantly inhibited the development of pulmonary fibrosis and the collagen deposition in bleomycin-treated lungs. These data suggest that strong inhibition of PDGFR and c-FMS by TAS-115 may be a promising strategy for overcoming the intractable pathogenesis of pulmonary fibrosis.
- (キーワード)
- Animals / Bleomycin / Cell Line / Cell Movement / Cell Proliferation / Humans / Male / Mice / Mice, Inbred C57BL / Phosphorylation / Protein Kinase Inhibitors / Pulmonary Fibrosis / Quinolines / Receptor, Macrophage Colony-Stimulating Factor / Receptors, Platelet-Derived Growth Factor / Receptors, Vascular Endothelial Growth Factor / Thiourea
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1165/rcmb.2018-0098OC
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30540913
- ● Search Scopus @ Elsevier (PMID): 30540913
- ● Search Scopus @ Elsevier (DOI): 10.1165/rcmb.2018-0098OC
(DOI: 10.1165/rcmb.2018-0098OC, PubMed: 30540913) Atsuro Saijo, Masaki Hanibuchi, Hirokazu Ogino, Kenji Otsuka, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka :
Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias.,
Molecular and Clinical Oncology, Vol.10, No.5, 541-546, 2019.- (要約)
- Although first-line chemotherapy is highly sensitive against small-cell lung cancer (SCLC), most patients subsequently experience disease progression. Topotecan is the standard therapy for sensitive-relapsed SCLC patients, and subgroup analysis of a randomized phase III trial suggests that amrubicin is effective for refractory-relapsed SCLC. However, because of the lack of the evidence based on clinical trials, the effectiveness of systemic chemotherapy for relapsed SCLC patients with idiopathic interstitial pneumonias (IIPs) is unclear. In the presentstudy, 17 relapsed SCLC patients with IIPs who received a paclitaxel (PTX)-containing regimen as a second-line chemotherapy were retrospectively reviewed. The overall response rate and the disease control rate of the PTX-containing regimens were 29.4 and 47.1%, respectively. The median progression-free survival and the overall survival of the regimens were 2.7 months [95% confidence interval (CI), 1.6-3.6 months] and 3.6 months (95% CI, 2.3-14.0 months), respectively. Grade 3-4 neutropenia and febrile neutropenia occurred in 12 (70.6%) and 2 (11.8%) patients, respectively. During the treatment period, acute exacerbation (AE) of IIPs was observed in five patients (29.4%). Treatment-associated fatality was observed in 1 patient with febrile neutropenia and in 1 patient with AE of IIPs. PTX had promising anti-tumor activity against refractory-relapsed SCLC with IIPs. However, the survival benefit of the treatment was limited because of the high incidence of AE of IIPs and treatment-related death.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3892/mco.2019.1828
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30967948
- ● Search Scopus @ Elsevier (PMID): 30967948
- ● Search Scopus @ Elsevier (DOI): 10.3892/mco.2019.1828
(DOI: 10.3892/mco.2019.1828, PubMed: 30967948) Taichi Murakami, Masanori Tamaki, Seiji Kishi, Kojiro Nagai, Hideharu Abe, Yoshimi Bando, Yuko Toyoda, Hirokazu Ogino, Yasuhiko Nishioka, Sayo Ueda, Toshio Doi and Motokazu Matsuura :
Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions,
Internal Medicine, Vol.58, No.5, 679-684, 2019.- (要約)
- A 61-year-old man was diagnosed with sarcoidosis involving the lungs, eyes, parotid gland and extrathoracic lymph nodes complicated by chronic kidney injury and hypercalcemia. Kidney biopsy showed non-specific interstitial nephritis and nephrosclerosis. However, immunohistochemical staining of cell surface markers revealed a multinucleated giant macrophage surrounded by T-cells, suggesting granulomatous interstitial nephritis. Corticosteroid improved the kidney function, and reduced the serum levels of calcium and angiotensin-converting enzyme. Sarcoid nephropathy may be caused by the combination of several sarcoidosis-associated pathophysiological conditions and a comprehensive kidney examination should be performed to assess the type of injury when determining a treatment strategy.
- (キーワード)
- Biomarkers / Biopsy / カルシウム (calcium) / Glucocorticoids / Humans / Hypercalcemia / Kidney / 男性 (male) / Middle Aged / Nephritis, Interstitial / Nephrosclerosis / Peptidyl-Dipeptidase A / Radionuclide Imaging / Sarcoidosis
- (徳島大学機関リポジトリ)
- ● Metadata: 114405
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.1558-18
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30449791
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85062415769
(徳島大学機関リポジトリ: 114405, DOI: 10.2169/internalmedicine.1558-18, PubMed: 30449791, Elsevier: Scopus) Hirokazu Ogino, Masaki Hanibuchi, Satoshi Sakaguchi, Yuko Toyoda, Toshifumi Tezuka, Hiroshi Kawano, Soji Kakiuchi, Kenji Otsuka, Atsuro Saijo, Masahiko Azuma, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka :
The clinical features of older patients with lung cancer in comparison with their younger counterparts.,
Respiratory Investigation, Vol.57, No.1, 40-48, 2019.- (要約)
- We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2018.10.003
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30448243
- ● Search Scopus @ Elsevier (PMID): 30448243
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2018.10.003
(DOI: 10.1016/j.resinv.2018.10.003, PubMed: 30448243) Masami Kishi, Yoshinori Aono, Seidai Satou, Kazuya Koyama, Momoyo Azuma, Shuichi Abe, Hiroshi Kawano, Jun Kishi, Yuko Toyoda, Hiroyasu Okazaki, Hirohisa Ogawa, Hisanori Uehara and Yasuhiko Nishioka :
Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice.,
PLoS ONE, Vol.13, No.12, 2018.- (要約)
- Platelet-derived growth factor (PDGF) has been implicated in the pathogenesis of pulmonary fibrosis. Nintedanib, a multi-kinase inhibitor that targets several tyrosine kinases, including PDGF receptor (PDGFR), was recently approved as an anti-fibrotic agent to reduce the deterioration of FVC in patients with idiopathic pulmonary fibrosis (IPF). However, the effects of PDGFR-α or -β on pulmonary fibrosis remain unclear. In an attempt to clarify their effects, we herein used blocking antibodies specific for PDGFR-α (APA5) and -β (APB5) in a bleomycin (BLM)-induced pulmonary fibrosis mouse model. The effects of these treatments on the growth of lung fibroblasts were examined using the 3H-thymidine incorporation assay in vitro. The anti-fibrotic effects of these antibodies were investigated with the Ashcroft score and collagen content of lungs treated with BLM. Their effects on inflammatory cells in the lungs were also analyzed using bronchoalveolar lavage fluid. We investigated damage to epithelial cells and the proliferation of fibroblasts in the lungs. APA5 and APB5 inhibited the phosphorylation of PDGFR-α and -β as well as the proliferation of lung fibroblasts induced by PDGF-AA and BB. The administration of APB5, but not APA5 effectively inhibited BLM-induced pulmonary fibrosis in mice. Apoptosis and the proliferation of epithelial cells and fibroblasts were significantly decreased by the treatment with APB5, but not by APA5. The late treatment with APB5 also ameliorated fibrosis in lungs treated with BLM. These results suggest that PDGFR-α and -β exert different effects on BLM-induced pulmonary fibrosis in mice. A specific approach using the blocking antibody for PDGFR-β may be useful for the treatment of pulmonary fibrosis.
- (徳島大学機関リポジトリ)
- ● Metadata: 113268
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1371/journal.pone.0209786
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30596712
- ● Search Scopus @ Elsevier (PMID): 30596712
- ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0209786
(徳島大学機関リポジトリ: 113268, DOI: 10.1371/journal.pone.0209786, PubMed: 30596712) Hirohisa Ogawa, Masahiko Azuma, Takaaki Tsunematsu, Yuuki Morimoto, Mayo Kondo, Toshifumi Tezuka, Yasuhiko Nishioka and Koichi Tsuneyama :
Neutrophils induce smooth muscle hyperplasia via neutrophil elastase-induced FGF-2 in a mouse model of asthma with mixed inflammation.,
Clinical and Experimental Allergy, Vol.48, No.12, 1715-1725, 2018.- (要約)
- The IL-17/neutrophil axis may play an important role in airway remodelling by contributing to smooth muscle hypertrophy/hyperplasia in mixed allergic inflammation and accordingly represents an attractive therapeutic target for severe asthma.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/cea.13263
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30171733
- ● Search Scopus @ Elsevier (PMID): 30171733
- ● Search Scopus @ Elsevier (DOI): 10.1111/cea.13263
(DOI: 10.1111/cea.13263, PubMed: 30171733) Masaki Hanibuchi, Soji Kakiuchi, Shinji Atagi, Fumitaka Ogushi, Eiji Shimizu, Takashi Haku, Yuko Toyoda, Masahiko Azuma, Mayo Kondo, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka :
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.,
Lung Cancer, Vol.125, 93-99, 2018.- (要約)
- A total of 33 advanced or recurrent NSCLC patients with ILD were prospectively enrolled in this multicenter, open-label, phase II study. Every 4 weeks, CBDCA at a dose of AUC 5 on day 1 and S-1 at a dose of 80 mg/m
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.lungcan.2018.09.007
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30429044
- ● Search Scopus @ Elsevier (PMID): 30429044
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.lungcan.2018.09.007
(DOI: 10.1016/j.lungcan.2018.09.007, PubMed: 30429044) M Toby Maher, Susanne Stowasser, Yasuhiko Nishioka, S Eric White, Vincent Cottin, Imre Noth, Moisés Selman, Zuzana Blahova, Daniel Wachtlin, Claudia Diefenbach and Gisli R Jenkins :
Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial.,
BMJ Open Respiratory Research, Vol.5, No.1, e000325, 2018.- (要約)
- The INMARK® trial is evaluating the effect of nintedanib on the rates of change of biomarkers of ECM turnover in patients with IPF, the value of changes in these biomarkers as predictors of disease progression and whether nintedanib affects the associations between changes in these biomarkers and disease progression. Following a screening period, 347 patients with IPF and FVC ≥80% predicted were randomised 1:2 to receive nintedanib 150 mg two times a day or placebo for 12 weeks, followed by an open-label period in which all patients will receive nintedanib for 40 weeks. The primary endpoint is the rate of change in C reactive protein degraded by MMP-1/8 from baseline to week 12.
- (徳島大学機関リポジトリ)
- ● Metadata: 114353
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1136/bmjresp-2018-000325
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30167310
- ● Search Scopus @ Elsevier (PMID): 30167310
- ● Search Scopus @ Elsevier (DOI): 10.1136/bmjresp-2018-000325
(徳島大学機関リポジトリ: 114353, DOI: 10.1136/bmjresp-2018-000325, PubMed: 30167310) Rao Rajeswara Arasada, Konstantin Shilo, Tadaaki Yamada, Jianying Zhang, Seiji Yano, Rashelle Ghanem, Walter Wang, Shinji Takeuchi, Koji Fukuda, Nobuyuki Katakami, Keisuke Tomii, Fumitaka Ogushi, Yasuhiko Nishioka, Tiffany Talabere, Shrilekha Misra, Wenrui Duan, Paolo Fadda, A Mohammad Rahman, Patrick Nana-Sinkam, Jason Evans, Joseph Amann, E Elena Tchekneva, M Mikhail Dikov and P David Carbone :
Notch3-dependent -catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.,
Nature Communications, Vol.9, No.1, 3198, 2018.- (要約)
- EGFR tyrosine kinase inhibitors cause dramatic responses in EGFR-mutant lung cancer, but resistance universally develops. The involvement of -catenin in EGFR TKI resistance has been previously reported, however, the precise mechanism by which -catenin activation contributes to EGFR TKI resistance is not clear. Here, we show that EGFR inhibition results in the activation of -catenin signaling in a Notch3-dependent manner, which facilitates the survival of a subset of cells that we call "adaptive persisters". We previously reported that EGFR-TKI treatment rapidly activates Notch3, and here we describe the physical association of Notch3 with -catenin, leading to increased stability and activation of -catenin. We demonstrate that the combination of EGFR-TKI and a -catenin inhibitor inhibits the development of these adaptive persisters, decreases tumor burden, improves recurrence free survival, and overall survival in xenograft models. These results supports combined EGFR-TKI and -catenin inhibition in patients with EGFR mutant lung cancer.
- (徳島大学機関リポジトリ)
- ● Metadata: 114785
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1038/s41467-018-05626-2
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30097569
- ● Search Scopus @ Elsevier (PMID): 30097569
- ● Search Scopus @ Elsevier (DOI): 10.1038/s41467-018-05626-2
(徳島大学機関リポジトリ: 114785, DOI: 10.1038/s41467-018-05626-2, PubMed: 30097569) Mayo Kondo, Hirokazu Ogino, Hirohisa Ogawa, Tania Afroj, Yuko Toyoda, Satoshi Sakaguchi, Miki Tsuboi, Yoshimi Bando, Hisatsugu Goto, Koichi Tsuneyama and Yasuhiko Nishioka :
A case of pulmonary pleomorphic carcinoma with malignant phenotypes induced by ZEB1-associated epithelial-mesenchymal transition.,
Respiratory Medicine Case Reports, Vol.25, 119-121, 2018.- (要約)
- A 60-year-old man was admitted to our hospital with non-small cell lung cancer (NSCLC). Imaging and pathological studies revealed NSCLC, not otherwise specified (NOS), at clinical stage T3N1M0 stage IIIA. We started radiotherapy alone because of obstructive pneumonia and end-stage renal disease, but the tumors progressed rapidly and resulted in death due to air obstruction by pharyngeal metastasis. The cancer was diagnosed as pleomorphic carcinoma in an autopsy. Viable lung tumor cells, which were resistant to radiotherapy, and the pharyngeal metastasis had mesenchymal phenotypes and expressed ZEB1 but not SNAI1. These observations indicated that ZEB1-associated epithelial-mesenchymal transition has malignant features including resistance to radiotherapy and aggressive metastatic potential. ZEB1-associated EMT may be an important mechanism to understand the pathophysiology of pleomorphic carcinoma.
- (徳島大学機関リポジトリ)
- ● Metadata: 115710
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.rmcr.2018.07.008
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30112272
- ● Search Scopus @ Elsevier (PMID): 30112272
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2018.07.008
(徳島大学機関リポジトリ: 115710, DOI: 10.1016/j.rmcr.2018.07.008, PubMed: 30112272) Sakae Homma, Masashi Bando, Arata Azuma, Susumu Sakamoto, Keishi Sugino, Yoshiki Ishii, Shinyu Izumi, Naohiko Inase, Yoshikazu Inoue, Masahito Ebina, Takashi Ogura, Kazuma Kishi, Tomoo Kishaba, Takashi Kido, Akihiko Gemma, Yoshihito Goto, Shinichi Sasaki, Takeshi Johkoh, Takafumi Suda, Kazuhisa Takahashi, Hiroki Takahashi, Yoshio Taguchi, Hiroshi Date, Hiroyuki Taniguchi, Takeo Nakayama, Yasuhiko Nishioka, Yoshinori Hasegawa, Noboru Hattori, Junya Fukuoka, Atsushi Miyamoto, Hiroshi Mukae, Akihito Yokoyama, Ichiro Yoshino and Kentaro Watanabe :
Japanese guideline for the treatment of idiopathic pulmonary fibrosis.,
Respiratory Investigation, Vol.56, No.4, 268-291, 2018.- (要約)
- Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of idiopathic interstitial pneumonia. It has a very poor prognosis with a 5-year survival rate of 30% or below, and so far there has been no guideline in Japan offering an established effective therapy based on evidence. In addition to the establishment of basic therapies, there is also an urgent need to establish therapies to deal with complications, as death occurs in many cases due to acute exacerbation or comorbid lung cancer. It was therefore decided to formulate a guideline in order to promote evidence-based clinical practice, to further improve the quality of medical treatment in the clinical setting, and to allow the benefits to be enjoyed by the public.
- (キーワード)
- Acetylcysteine / Administration, Inhalation / Adrenal Cortex Hormones / Antineoplastic Combined Chemotherapy Protocols / Comorbidity / Disease Progression / Drug Therapy, Combination / Evidence-Based Medicine / Glycine / Humans / Idiopathic Pulmonary Fibrosis / Immunosuppressive Agents / Indoles / Japan / Lung Neoplasms / Meta-Analysis as Topic / Practice Guidelines as Topic / Prognosis / Pyridones / Quality of Health Care / Sulfonamides / Survival Rate
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2018.03.003
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29980444
- ● Search Scopus @ Elsevier (PMID): 29980444
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2018.03.003
(DOI: 10.1016/j.resinv.2018.03.003, PubMed: 29980444) Seiji Kishi, Masanori Minato, Atsuro Saijo, Naoka Murakami, Masanori Tamaki, Motokazu Matsuura, Taichi Murakami, Kojiro Nagai, Hideharu Abe, Yasuhiko Nishioka and Toshio Doi :
IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma.,
Internal Medicine, Vol.57, No.9, 1259-1263, 2018.- (要約)
- Immune checkpoint inhibitors (ICIs) are becoming a common and important cancer therapy. ICIs are associated with a unique category of side effects, termed immune-related adverse events (irAEs). We herein report the case of a 72-year-old man with postoperative recurrence of lung squamous cell carcinoma who was treated with nivolumab and who developed proteinuria and a worsening kidney function. A kidney biopsy revealed IgA nephropathy. After drug withdrawal, the proteinuria improved and the deterioration of the patient's renal function was halted. Although renal irAEs are considered to be rare and glomerulonephritis is not typical presentation, physicians need to pay more attention to renal irAEs and glomerular injury.
- (キーワード)
- Aged / Antibodies, Monoclonal / Antineoplastic Agents / Carcinoma, Squamous Cell / Glomerulonephritis, IGA / Humans / Lung Neoplasms / 男性 (male) / Neoplasm Recurrence, Local / Nivolumab / Proteinuria
- (徳島大学機関リポジトリ)
- ● Metadata: 114399
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.9814-17
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29279511
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85046287943
(徳島大学機関リポジトリ: 114399, DOI: 10.2169/internalmedicine.9814-17, PubMed: 29279511, Elsevier: Scopus) Atsuro Saijo, Hisatsugu Goto, Nakano Mayuri, Mitsuhashi Atsushi, Yoshinori Aono, Masaki Hanibuchi, Hirohisa Ogawa, Hisanori Uehara, Kazuya Kondo and Yasuhiko Nishioka :
Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells.,
Cancer Letters, Vol.421, 17-27, 2018.- (要約)
- Cancer stem cells (CSCs) represent a minor population that have clonal tumor initiation and self-renewal capacity and are responsible for tumor initiation, metastasis, and therapeutic resistance. CSCs reside in niches, which are composed of diverse types of stromal cells and extracellular matrix components. These stromal cells regulate CSC-like properties by providing secreted factors or by physical contact. Fibrocytes are differentiated from bone marrow-derived CD14 monocytes and have features of both macrophages and fibroblasts. Accumulating evidence has suggested that stromal fibrocytes might promote cancer progression. However, the role of fibrocytes in the CSC niches has not been revealed. We herein report that human fibrocytes enhanced the CSC-like properties of lung cancer cells through secreted factors, including osteopontin, CC-chemokine ligand 18, and plasminogen activator inhibitor-1. The PIK3K/AKT pathway was critical for fibrocytes to mediate the CSC-like functions of lung cancer cells. In human lung cancer specimens, the number of tumor-infiltrated fibrocytes was correlated with high expression of CSC-associated protein in cancer cells. These results suggest that fibrocytes may be a novel cell population that regulates the CSC-like properties of lung cancer cells in the CSC niches.
- (徳島大学機関リポジトリ)
- ● Metadata: 111437
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.canlet.2018.02.016
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29448000
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85042214220
(徳島大学機関リポジトリ: 111437, DOI: 10.1016/j.canlet.2018.02.016, PubMed: 29448000, Elsevier: Scopus) Sho Tabata, Masatatsu Yamamoto, Hisatsugu Goto, Akiyoshi Hirayama, Maki Ohishi, Takuya Kuramoto, Ryuji Ikeda, Misako Haraguchi, Kohichi Kawahara, Yoshinari Shinsato, Kentaro Minami, Atsuro Saijo, Yuko Toyoda, Masaki Hanibuchi, Yasuhiko Nishioka, Saburo Sone, Hiroyasu Esumi, Masaru Tomita, Tomoyoshi Soga, Tatsuhiko Furukawa and Shin-ichi Akiyama :
Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells.,
Scientific Reports, Vol.8, No.1, 6760, 2018.- (要約)
- Thymidine phosphorylase (TP) is a rate-limiting enzyme in the thymidine catabolic pathway. TP is identical to platelet-derived endothelial cell growth factor and contributes to tumour angiogenesis. TP induces the generation of reactive oxygen species (ROS) and enhances the expression of oxidative stress-responsive genes, such as interleukin (IL)-8. However, the mechanism underlying ROS induction by TP remains unclear. In the present study, we demonstrated that TP promotes NADPH oxidase-derived ROS signalling in cancer cells. NADPH oxidase inhibition using apocynin or small interfering RNAs (siRNAs) abrogated the induction of IL-8 and ROS in TP-expressing cancer cells. Meanwhile, thymidine catabolism induced by TP increased the levels of NADPH and intermediates of the pentose phosphate pathway (PPP). Both siRNA knockdown of glucose 6-phosphate dehydrogenase (G6PD), a rate-limiting enzyme in PPP, and a G6PD inhibitor, dihydroepiandrosterone, reduced TP-induced ROS production. siRNA downregulation of 2-deoxy-D-ribose 5-phosphate (DR5P) aldolase, which is needed for DR5P to enter glycolysis, also suppressed the induction of NADPH and IL-8 in TP-expressing cells. These results suggested that TP-mediated thymidine catabolism increases the intracellular NADPH level via the PPP, which enhances the production of ROS by NADPH oxidase and activates its downstream signalling.
- (徳島大学機関リポジトリ)
- ● Metadata: 114957
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1038/s41598-018-25189-y
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29713062
- ● Search Scopus @ Elsevier (PMID): 29713062
- ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-018-25189-y
(徳島大学機関リポジトリ: 114957, DOI: 10.1038/s41598-018-25189-y, PubMed: 29713062) Shunsuke Itai, Tomokazu Ohishi, K Mika Kaneko, Shinji Yamada, Shinji Abe, Takuro Nakamura, Miyuki Yanaka, Yao-Wen Chang, Shun-Ichi Ohba, Yasuhiko Nishioka, Manabu Kawada, Hiroyuki Harada and Yukinari Kato :
Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.,
Oncotarget, Vol.9, No.32, 22480-22497, 2018.- (要約)
- These results suggested that a core fucose-deficient anti-PODXL mAb could be useful for antibody-based therapy against PODXL-expressing OSCCs.
- (徳島大学機関リポジトリ)
- ● Metadata: 113062
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.18632/oncotarget.25132
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29854293
- ● Search Scopus @ Elsevier (PMID): 29854293
- ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.25132
(徳島大学機関リポジトリ: 113062, DOI: 10.18632/oncotarget.25132, PubMed: 29854293) Hiroyuki Kozai, Yuko Toyoda, Hisatsugu Goto, Jun Kishi, Makoto Tobiume, Yuya Yamashita, Haruka Nishimura, Mayo Kondou, Hiroshi Kawano and Yasuhiko Nishioka :
A case of interstitial pneumonia associated with anti-PL-7 antibody in a patient with rheumatoid arthritis.,
The Journal of Medical Investigation : JMI, Vol.65, No.1,2, 147-150, 2018.- (要約)
- A 65-year-old female had been treated rheumatoid arthritis (RA), interstitial pneumonia (IP) and nephrotic syndrome with prednisolone and cyclosporine. She was emergently admitted to our hospital due to the worsening exertional dyspnea and severe hypoxemia. Chest computed tomography (CT) showed new diffuse ground-glass opacities (GGOs) with slight consolidations along with bronchovascular bundle were observed in addition to pre-existing reticular shadows in both lungs with lower lobe-predominance. An acute exacerbation (AE) of pre-existing IP triggered by an infection was suspected, and the treatment with antibiotics and corticosteroid pulse therapy improved her general condition and chest radiological findings. Because some auto-antibodies associated with acute/subacute onset IP have recently become available in clinic, we examined those including anti-aminoacyl tRNA synthetase (ARS) antibodies, and found that she was positive for anti-PL-7 antibody. We diagnosed her anti-synthetase syndrome (ASS) without symptom of myositis, and her IP was considered to be ASS-related. The careful consideration is necessary to precisely diagnose and treat the patients with RA-associated interstitial lung diseases as the several etiologies may be overlapped in the same patient. J. Med. Invest. 65:147-150, February, 2018.
- (キーワード)
- Aged / Amino Acyl-tRNA Synthetases / Arthritis, Rheumatoid / Autoantibodies / 女性 (female) / Humans / Lung Diseases, Interstitial
- (徳島大学機関リポジトリ)
- ● Metadata: 111454
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.65.147
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29593187
- ● CiNii @ 国立情報学研究所 (CRID): 1390282679224622464
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85044475211
(徳島大学機関リポジトリ: 111454, DOI: 10.2152/jmi.65.147, PubMed: 29593187, CiNii: 1390282679224622464, Elsevier: Scopus) Hitoshi Nishijima, Tatsuya Kajimoto, Yoshiki Matsuoka, Yasuhiro Mouri, Junko Morimoto, Minoru Matsumoto, Hiroshi Kawano, Yasuhiko Nishioka, Hisanori Uehara, Keisuke Izumi, Koichi Tsuneyama, Il-mi Okazaki, Taku Okazaki, Kazuyoshi Hosomichi, Ayako Shiraki, Makoto Shibutani, Kunitoshi Mitsumori and Mitsuru Matsumoto :
Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE).,
Journal of Autoimmunity, Vol.86, 75-92, 2018.- (要約)
- Autoimmunity is prevented by the function of the autoimmune regulator [AIRE (Aire in mice)], which promotes the expression of a wide variety of tissue-restricted antigens (TRAs) from medullary thymic epithelial cells (mTECs) and from a subset of peripheral antigen-presenting cells (APCs). We examined the effect of additive expression of human AIRE (huAIRE) in a model of autoimmune diabetes in NOD mice. Unexpectedly, we observed that mice expressing augmented AIRE/Aire developed muscle-specific autoimmunity associated with incomplete maturation of mTECs together with impaired expression of Aire-dependent TRAs. This led to failure of deletion of autoreactive T cells together with dramatically reduced production of regulatory T cells in the thymus. In peripheral APCs, expression of costimulatory molecules was augmented. We suggest that levels of Aire expression need to be tightly controlled for maintenance of immunological tolerance. Our results also highlight the importance of coordinated action between central tolerance and peripheral tolerance under the common control of Aire.
- (徳島大学機関リポジトリ)
- ● Metadata: 112347
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.jaut.2017.09.006
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28931462
- ● Search Scopus @ Elsevier (PMID): 28931462
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.jaut.2017.09.006
(徳島大学機関リポジトリ: 112347, DOI: 10.1016/j.jaut.2017.09.006, PubMed: 28931462) Hisatsugu Goto, Okano Yoshio, Machida Hisanori, Hatakeyama Nobuo, Ogushi Fumitaka, Haku Takashi, Takanori Kanematsu, Tomoyuki Urata, Souji Kakiuchi, Masaki Hanibuchi, Saburo Sone and Yasuhiko Nishioka :
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer.,
Respiratory Investigation, Vol.56, No.1, 80-86, 2018.- (要約)
- S-1 is an oral fluoropyrimidine that is active in the treatment of non-small cell lung cancer (NSCLC); however, an optimal treatment schedule and appropriate dose adjustments of S-1 in elderly patients have not yet been established. We conducted a phase II trial to evaluate the efficacy and safety of a 2-week S-1 monotherapy treatment followed by a 1-week interval as a first-line treatment of elderly NSCLC patients, by adjusting the dose based on the individual creatinine clearance (Ccr) and body surface area (BSA). The primary endpoint was the disease control rate. Forty patients were enrolled. The disease control and response rates were 89.5% (95% confidence interval [CI] = 79.8-99.2) and 7.9% (95% CI = 0.0-16.4), respectively. The median progression-free survival and overall survival times were 4.4 months (95% CI = 4.2-8.5) and 17.0 months (95% CI = 11.2-18.7), respectively. Neutropenia, anorexia, hyponatremia, hypokalemia, and pneumonia of grade ≥ 3 occurred in 5.0%, 7.5%, 5.0%, 2.5%, and 2.5% of patients, respectively. Among the patient-reported outcomes, most of the individual factors in the patients' quality of life, including upper intestine-related symptoms improved with the treatment, except for dyspnea, which slightly albeit continuously worsened throughout the study. In elderly patients with previously untreated advanced NSCLC, a 2-week S-1 monotherapy treatment, tailored to both the Ccr and BSA, with a 1-week interval was well tolerated and demonstrated promising efficacy. This study was registered at the University Hospital Medical Information Network (UMIN) Center (ID: UMIN000002035), Japan.
- (キーワード)
- Administration, Oral / Aged / Aged, 80 and over / Antimetabolites, Antineoplastic / Body Surface Area / Carcinoma, Non-Small-Cell Lung / Creatinine / Drug Administration Schedule / Drug Combinations / Female / Humans / Lung Neoplasms / Male / Metabolic Clearance Rate / Oxonic Acid / Precision Medicine / Survival Rate / Tegafur / Treatment Outcome
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2017.09.003
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29325686
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85031768203
(DOI: 10.1016/j.resinv.2017.09.003, PubMed: 29325686, Elsevier: Scopus) Chikugo Momoko, Sebe Mayu, Rie Tsutsumi, Iuchi Marina, Jun Kishi, Masashi Kuroda, Nagakatsu Harada, Yasuhiko Nishioka and Hiroshi Sakaue :
Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism.,
The Journal of Medical Investigation : JMI, Vol.65, No.3.4, 166-170, 2018.- (要約)
- Tofacitinib is the first Janus Kinase (JAK) inhibitor to treat moderately to severely active RA. In this study, we investigated whether the effect of tofacitinib have any effects on body composition in mice and female patients with RA. Female C57BL/6 mice fed with a high-fat diet were treated with 30 mg/kg/day tofacitinib or vehicle for 70 days. Following treatment, trunk muscle, subcutaneous fat, and visceral fats were measured using X-ray computed tomography CT scan. Glucose tolerance and insulin sensitivity were assessed. In female RA patients treated with biological disease modified anti-rheumatic-drugs (biological DMARDs) or tofacitinib (n=4 per group), we also evaluated the body composition after 3 months from the start of treatment initiation using bioelectrical impedance analysis. Treatment with tofacitinib did not affect the body weight, and body composition in C57BL/6 mice. It also did not affect glucose, and insulin tolerance in mice. In patients with RA, treatment with biological DMARDs did not affect the body composition whereas the muscle mass was unchanged after receiving tofacitinib and the fat mass was significantly increased. J. Med. Invest. 65:166-170, August, 2018.
- (徳島大学機関リポジトリ)
- ● Metadata: 112232
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.65.166
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30282855
- ● Search Scopus @ Elsevier (PMID): 30282855
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.65.166
(徳島大学機関リポジトリ: 112232, DOI: 10.2152/jmi.65.166, PubMed: 30282855) Seidai Satou, Shinohara Shintaro, Hayashi Shinya, Morizumi Shun, Abe Shuichi, Okazaki Hiroyasu, Chen Yanjuan, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Koyama Kazuya, Nishimura Haruka, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara and Yasuhiko Nishioka :
Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.,
Respiratory Research, Vol.18, No.1, 172, 2017.- (要約)
- Nintedanib, a tyrosine kinase inhibitor that is specific for platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and vascular endothelial growth factor receptors (VEGFR), has recently been approved for idiopathic pulmonary fibrosis. Fibrocytes are bone marrow-derived progenitor cells that produce growth factors and contribute to fibrogenesis in the lungs. However, the effects of nintedanib on the functions of fibrocytes remain unclear. Human monocytes were isolated from the peripheral blood of healthy volunteers. The expression of growth factors and their receptors in fibrocytes was analyzed using ELISA and Western blotting. The effects of nintedanib on the ability of fibrocytes to stimulate lung fibroblasts were examined in terms of their proliferation. The direct effects of nintedanib on the differentiation and migration of fibrocytes were also assessed. We investigated whether nintedanib affected the accumulation of fibrocytes in mouse lungs treated with bleomycin. Human fibrocytes produced PDGF, FGF2, and VEGF-A. Nintedanib and specific inhibitors for each growth factor receptor significantly inhibited the proliferation of lung fibroblasts stimulated by the supernatant of fibrocytes. Nintedanib inhibited the migration and differentiation of fibrocytes induced by growth factors in vitro. The number of fibrocytes in the bleomycin-induced lung fibrosis model was reduced by the administration of nintedanib, and this was associated with anti-fibrotic effects. These results support the role of fibrocytes as producers of and responders to growth factors, and suggest that the anti-fibrotic effects of nintedanib are at least partly mediated by suppression of fibrocyte function.
- (キーワード)
- Animals / Cell Movement / Cells, Cultured / Dose-Response Relationship, Drug / Fibroblasts / Humans / Indoles / Male / Mice / Mice, Inbred C57BL / Pulmonary Fibrosis / Treatment Outcome / Vascular Endothelial Growth Factor A
- (徳島大学機関リポジトリ)
- ● Metadata: 114546
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1186/s12931-017-0654-2
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28915889
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85029541214
(徳島大学機関リポジトリ: 114546, DOI: 10.1186/s12931-017-0654-2, PubMed: 28915889, Elsevier: Scopus) 瀧倉 輝実, 埴淵 昌毅, 豊田 優子, 近藤 真代, 香西 博之, 福家 麻美, 西岡 安彦 :
胸水中に多数のLanghans型巨細胞を認めた胸水IL-6濃度が高値であったMycobacterium avium症に伴う胸膜炎の一例,
結核, Vol.92, No.9, 559-566, 2017年. Mika K Kaneko, Akiko Kunita, Shinji Yamada, Takuro Nakamura, Miyuki Yanaka, Noriko Saidoh, Yao-Wen Chang, Saori Handa, Satoshi Ogasawara, Tomokazu Ohishi, Shinji Abe, Shunsuke Itai, Hiroyuki Harada, Manabu Kawada, Yasuhiko Nishioka, Masashi Fukayama and Yukinari Kato :
Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.,
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol.36, No.4, 157-162, 2017.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1089/mab.2017.0020
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28665782
- ● Search Scopus @ Elsevier (PMID): 28665782
- ● Search Scopus @ Elsevier (DOI): 10.1089/mab.2017.0020
(DOI: 10.1089/mab.2017.0020, PubMed: 28665782) Sho Tabata, Masatatsu Yamamoto, Hisatsugu Goto, Akiyoshi Hirayama, Maki Ohishi, Takuya Kuramoto, Atsushi Mitsuhashi, Ryuji Ikeda, Misako Haraguchi, Kohichi Kawahara, Yoshinari Shinsato, Kentaro Minami, Atsuro Saijo, Masaki Hanibuchi, Yasuhiko Nishioka, Saburo Sone, Hiroyasu Esumi, Masaru Tomita, Tomoyoshi Soga, Tatsuhiko Furukawa and Shin-ichi Akiyama :
Thymidine Catabolism as a Metabolic Strategy for Cancer Survival.,
Cell Reports, Vol.19, No.7, 1313-1321, 2017.- (要約)
- Thymidine phosphorylase (TP), a rate-limiting enzyme in thymidine catabolism, plays a pivotal role in tumor progression; however, the mechanisms underlying this role are not fully understood. Here, we found that TP-mediated thymidine catabolism could supply the carbon source in the glycolytic pathway and thus contribute to cell survival under conditions of nutrient deprivation. In TP-expressing cells, thymidine was converted to metabolites, including glucose 6-phosphate, lactate, 5-phospho-α-D-ribose 1-diphosphate, and serine, via the glycolytic pathway both in vitro and in vivo. These thymidine-derived metabolites were required for the survival of cells under low-glucose conditions. Furthermore, activation of thymidine catabolism was observed in human gastric cancer. These findings demonstrate that thymidine can serve as a glycolytic pathway substrate in human cancer cells.
- (徳島大学機関リポジトリ)
- ● Metadata: 115054
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.celrep.2017.04.061
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28514652
- ● Search Scopus @ Elsevier (PMID): 28514652
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.celrep.2017.04.061
(徳島大学機関リポジトリ: 115054, DOI: 10.1016/j.celrep.2017.04.061, PubMed: 28514652) K Mika Kaneko, Takuro Nakamura, Akiko Kunita, Masashi Fukayama, Shinji Abe, Yasuhiko Nishioka, Shinji Yamada, Miyuki Yanaka, Noriko Saidoh, Kanae Yoshida, Yuki Fujii, Satoshi Ogasawara and Yukinari Kato :
ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.,
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol.36, No.3, 104-112, 2017.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1089/mab.2017.0014
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28504613
- ● Search Scopus @ Elsevier (PMID): 28504613
- ● Search Scopus @ Elsevier (DOI): 10.1089/mab.2017.0014
(DOI: 10.1089/mab.2017.0014, PubMed: 28504613) Mika K Kaneko, Shinji Yamada, Takuro Nakamura, Shinji Abe, Yasuhiko Nishioka, Akiko Kunita, Masashi Fukayama, Yuki Fujii, Satoshi Ogasawara and Yukinari Kato :
Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.,
Cancer Medicine, Vol.6, No.4, 768-777, 2017.- (要約)
- Human podoplanin (hPDPN), a platelet aggregation-inducing transmembrane glycoprotein, is expressed in different types of tumors, and it binds to C-type lectin-like receptor 2 (CLEC-2). The overexpression of hPDPN is involved in invasion and metastasis. Anti-hPDPN monoclonal antibodies (mAbs) such as NZ-1 have shown antitumor and antimetastatic activities by binding to the platelet aggregation-stimulating (PLAG) domain of hPDPN. Recently, we developed a novel mouse anti-hPDPN mAb, LpMab-2, using the cancer-specific mAb (CasMab) technology. In this study we developed chLpMab-2, a human-mouse chimeric anti-hPDPN antibody, derived from LpMab-2. chLpMab-2 was produced using fucosyltransferase 8-knockout (KO) Chinese hamster ovary (CHO)-S cell lines. By flow cytometry, chLpMab-2 reacted with hPDPN-expressing cancer cell lines including glioblastomas, mesotheliomas, and lung cancers. However, it showed low reaction with normal cell lines such as lymphatic endothelial and renal epithelial cells. Moreover, chLpMab-2 exhibited high antibody-dependent cellular cytotoxicity (ADCC) against PDPN-expressing cells, despite its low complement-dependent cytotoxicity. Furthermore, treatment with chLpMab-2 abolished tumor growth in xenograft models of CHO/hPDPN, indicating that chLpMab-2 suppressed tumor development via ADCC. In conclusion, chLpMab-2 could be useful as a novel antibody-based therapy against hPDPN-expressing tumors.
- (徳島大学機関リポジトリ)
- ● Metadata: 115039
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/cam4.1049
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28332312
- ● Search Scopus @ Elsevier (PMID): 28332312
- ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.1049
(徳島大学機関リポジトリ: 115039, DOI: 10.1002/cam4.1049, PubMed: 28332312) Mika K Kaneko, Shinji Abe, Satoshi Ogasawara, Yuki Fujii, Shinji Yamada, Takeshi Murata, Hiroaki Uchida, Hideaki Tahara, Yasuhiko Nishioka and Yukinari Kato :
Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.,
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol.36, No.1, 25-29, 2017.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1089/mab.2016.0047
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28157429
- ● Search Scopus @ Elsevier (PMID): 28157429
- ● Search Scopus @ Elsevier (DOI): 10.1089/mab.2016.0047
(DOI: 10.1089/mab.2016.0047, PubMed: 28157429) Yukinari Kato, Akiko Kunita, Masashi Fukayama, Shinji Abe, Yasuhiko Nishioka, Hiroaki Uchida, Hideaki Tahara, Shinji Yamada, Miyuki Yanaka, Takuro Nakamura, Noriko Saidoh, Kanae Yoshida, Yuki Fujii, Ryusuke Honma, Michiaki Takagi, Satoshi Ogasawara, Takeshi Murata and K Mika Kaneko :
Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.,
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Vol.36, No.1, 20-24, 2017.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1089/mab.2016.0045
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28234556
- ● Search Scopus @ Elsevier (PMID): 28234556
- ● Search Scopus @ Elsevier (DOI): 10.1089/mab.2016.0045
(DOI: 10.1089/mab.2016.0045, PubMed: 28234556) Mika K Kaneko, Takuro Nakamura, Ryusuke Honma, Satoshi Ogasawara, Yuki Fujii, Shinji Abe, Michiaki Takagi, Hiroyuki Harada, Hiroyoshi Suzuki, Yasuhiko Nishioka and Yukinari Kato :
Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.,
Cancer Medicine, Vol.6, No.2, 382-396, 2017.- (要約)
- Human podoplanin (hPDPN), which binds to C-type lectin-like receptor-2 (CLEC-2), is involved in platelet aggregation and cancer metastasis. The expression of hPDPN in cancer cells or cancer-associated fibroblasts indicates poor prognosis. Human lymphatic endothelial cells, lung-type I alveolar cells, and renal glomerular epithelial cells express hPDPN. Although numerous monoclonal antibodies (mAbs) against hPDPN are available, they recognize peptide epitopes of hPDPN. Here, we generated a novel anti-hPDPN mAb, LpMab-21. To characterize the hPDPN epitope recognized by the LpMab-21, we established glycan-deficient CHO-S and HEK-293T cell lines, using the CRISPR/Cas9 or TALEN. Flow cytometric analysis revealed that the minimum hPDPN epitope, in which sialic acid is linked to Thr76, recognized by LpMab-21 is Thr76-Arg79. LpMab-21 detected hPDPN expression in glioblastoma, oral squamous carcinoma, and seminoma cells as well as in normal lymphatic endothelial cells. However, LpMab-21 did not react with renal glomerular epithelial cells or lung type I alveolar cells, indicating that sialylation of hPDPN Thr76 is cell-type-specific. LpMab-21 combined with other anti-hPDPN antibodies that recognize different epitopes may therefore be useful for determining the physiological function of sialylated hPDPN.
- (徳島大学機関リポジトリ)
- ● Metadata: 115040
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/cam4.954
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28101903
- ● Search Scopus @ Elsevier (PMID): 28101903
- ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.954
(徳島大学機関リポジトリ: 115040, DOI: 10.1002/cam4.954, PubMed: 28101903) Atsuro Saijo, Masaki Hanibuchi, Hisatsugu Goto, Yuko Toyoda, Toshifumi Tezuka and Yasuhiko Nishioka :
An analysis of the clinical features of lung cancer in patients with connective tissue diseases.,
Respiratory Investigation, Vol.55, No.2, 153-160, 2017.- (要約)
- LC patients with CTD had a high prevalence of ILD, and the presence of CTD-ILD was significantly associated with poor prognosis.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2016.11.003
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28274531
- ● Search Scopus @ Elsevier (PMID): 28274531
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2016.11.003
(DOI: 10.1016/j.resinv.2016.11.003, PubMed: 28274531) Yoshiyuki Oyama, Noriyuki Enomoto, Yuzo Suzuki, Masato Kono, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura, Shigeki Kuroishi, Koshi Yokomura, Mikio Toyoshima, Shiro Imokawa, Keiji Oishi, Satoshi Watanabe, Kazuo Kasahara, Tomohisa Baba, Takashi Ogura, Hiroshi Ishii, Kentaro Watanabe, Yasuhiko Nishioka and Takafumi Suda :
Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE).,
Respiratory Medicine, Vol.123, 63-70, 2016.- (要約)
- Levels of urinary desmosines were significantly higher in patients with PPFE than those in patients with IPF (48.4 vs. 28.6 ng/mg creatinine, p = 0.034), patients with COPD (8.0 ng/mg creatinine, p < 0.001), or controls (17.4 ng/mg creatinine, p < 0.001). Desmosines discriminated between PPFE and IPF (area under the curve [AUC] = 0.708), and between PPFE and controls (AUC = 0.956). However, levels of desmosines were not correlated with physiological parameters in patients with PPFE.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.rmed.2016.12.013
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28137498
- ● Search Scopus @ Elsevier (PMID): 28137498
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmed.2016.12.013
(DOI: 10.1016/j.rmed.2016.12.013, PubMed: 28137498) Soji Kakiuchi, Masaki Hanibuchi, Toshifumi Tezuka, Atsuro Saijo, Kenji Otsuka, Satoshi Sakaguchi, Yuko Toyoda, Hisatsugu Goto, Hiroshi Kawano, Masahiko Azuma, Fumitaka Ogushi and Yasuhiko Nishioka :
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.,
Respiratory Investigation, Vol.55, No.2, 145-152, 2016.- (要約)
- Although this was a small retrospective study, its findings showed that S-1 and etoposide may be relatively safe options for the treatment of patients with lung cancer and concomitant ILD.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2016.10.008
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28274530
- ● Search Scopus @ Elsevier (PMID): 28274530
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2016.10.008
(DOI: 10.1016/j.resinv.2016.10.008, PubMed: 28274530) Yuko Toyoda, Ryohiko Ozaki, Jun Kishi, Masaki Hanibuchi, Katsuhiro Kinoshita, Toshifumi Tezuka, Hisatsugu Goto, Hiroyuki Ono, Kojiro Nagai, Yoshimi Bando, Toshio Doi and Yasuhiko Nishioka :
An Autopsy Case of Aortic Intimal Sarcoma Initially Diagnosed as Polyarteritis Nodosa.,
Internal Medicine, Vol.55, No.21, 3191-3195, 2016.- (要約)
- A 61-year-old man had hypertension with stenosis in the left renal artery. When his fever, abdominal pain, and renal dysfunction progressed, he was admitted to our hospital. He was diagnosed with polyarthritis nodosa. His renal function rapidly deteriorated despite immunosuppressive therapy. His digestive tract perforated twice, and he subsequently died. An autopsy revealed that aortic intimal sarcoma caused stenosis in multiple arteries. Both polyarteritis nodosa and aortic intimal sarcoma are very rare diseases and the diagnoses are very difficult. It is very important to consider these entities when making a differential diagnosis of vasculitis.
- (キーワード)
- Abdominal Pain / Aorta / Autopsy / Diagnosis, Differential / Fatal Outcome / Fever / Humans / Male / Middle Aged / Polyarteritis Nodosa / Renal Artery Obstruction / Sarcoma / Vascular Neoplasms
- (徳島大学機関リポジトリ)
- ● Metadata: 114395
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.55.7152
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27803418
- ● Search Scopus @ Elsevier (PMID): 27803418
- ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.55.7152
(徳島大学機関リポジトリ: 114395, DOI: 10.2169/internalmedicine.55.7152, PubMed: 27803418) Yasuhiko Nishioka :
Cancer immunotherapy as a promising fourth standard therapy for lung cancer: Beyond 20 years for the development of immunotherapy,
Respiratory Investigation, Vol.54, No.5, 297, 2016.- (キーワード)
- Humans / Immunotherapy / Lung Neoplasms
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2016.08.001
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27566375
- ● Search Scopus @ Elsevier (PMID): 27566375
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2016.08.001
(DOI: 10.1016/j.resinv.2016.08.001, PubMed: 27566375) Hirokazu Ogino, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Toshifumi Tezuka, Yuko Toyoda, Makoto Tobiume, Kenji Otsuka, Satoshi Sakaguchi, Hisatsugu Goto, Kokichi Arisawa and Yasuhiko Nishioka :
Analysis of the prognostic factors of extensive disease small-cell lung cancer patients in Tokushima University Hospital,
The Journal of Medical Investigation : JMI, Vol.63, No.3 4, 286-293, 2016.- (要約)
- Small-cell lung cancer (SCLC) presents aggressive clinical behavior, and its prognosis is still poor. Previously, performance status (PS), or the existence of brain, bone, or liver metastasis were reported to be unfavorable prognostic factors. Given the recent progress of treatment modalities such as radiotherapy techniques and bone modifying agents, the prognostic factors might be different from previous findings. Therefore, we analyzed the prognostic factors of extensive disease SCLC (ED-SCLC) in recent years. ED-SCLC patients treated in Tokushima University Hospital between 2010 and 2016 were analyzed. Log-rank test and the Cox proportional hazards regression model was used in univariate and multivariate analysis, respectively. Totally, 79 patients were analyzed. In the univariate analysis, age, PS, interstitial pneumonia (IP), liver metastasis, pleural dissemination, neutrophil counts, hypoalbuminemia, hypercalcemia and several liver and biliary enzymes were identified as poor prognostic factors. In the multivariate analysis, age, PS, IP, and liver and biliary enzymes were identified. Moreover, the PS in patients with liver metastasis was significantly worsened. In this study, we newly demonstrated that IP was a significant poor prognostic factor of ED-SCLC. Although liver metastasis was not extracted in multivariate analysis, it may have an impact on the prognosis of ED-SCLC. J. Med. Invest. 63: 286-293, August, 2016.
- (徳島大学機関リポジトリ)
- ● Metadata: 111196
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.63.286
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644574
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84987918312
(徳島大学機関リポジトリ: 111196, DOI: 10.2152/jmi.63.286, PubMed: 27644574, Elsevier: Scopus) Shinji Abe, Kato Mika Kaneko, Yuki Tsuchihashi, Toshihiro Izumi, Satoshi Ogasawara, Naoto Okada, Chiemi Sato, Makoto Tobiume, Kenji Otsuka, Licht Miyamoto, Koichiro Tsuchiya, Kazuyoshi Kawazoe, Yukinari Kato and Yasuhiko Nishioka :
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.,
Cancer Science, Vol.107, No.9, 1198-1205, 2016.- (キーワード)
- 癌免疫療法 (cancer immunotherapy) / ADCC / podoplanin
- (徳島大学機関リポジトリ)
- ● Metadata: 112378
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/cas.12985
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27294401
- ● Search Scopus @ Elsevier (PMID): 27294401
- ● Search Scopus @ Elsevier (DOI): 10.1111/cas.12985
(徳島大学機関リポジトリ: 112378, DOI: 10.1111/cas.12985, PubMed: 27294401) K Hasegawa, M Tagawa, K Takagi, H Tsukamoto, Y Tomioka, T Suzuki, Yasuhiko Nishioka, T Ohrui and M Numasaki :
Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-λ2 or IL-29/IFN-λ1.,
Cancer Gene Therapy, Vol.23, No.8, 266-277, 2016.- (要約)
- Interleukin (IL)-28A/interferon (IFN)-λ2 and IL-29/IFN-λ1 have been demonstrated to elicit direct and indirect anti-tumor actions. In this study, we constructed an adenovirus vector expressing either IL-28A/IFN-λ2 (AdIL-28A) or IL-29/IFN-λ1 (AdIL-29) to evaluate the therapeutic properties of intratumoral injection of recombinant adenovirus to apply for the clinical implementation of cancer gene therapy. Despite the lack of an anti-proliferative effect on MCA205 and B16-F10 cells, a retarded growth of established subcutaneous tumors was observed following multiple injections of either AdIL-28A or AdIL-29 when compared with AdNull. In vivo cell depletion experiments displayed that both NK cells and CD8(+) T cells have a major role in AdIL-28A-mediated tumor growth suppression. A significant increase in the number of infiltrating CD8(+) T cells into the tumors treated with either AdIL-28A or AdIL-29 was observed. Moreover, specific anti-tumor cytotoxic T lymphocyte reactivity was detected in spleen cells from animals treated with either AdIL-28A or AdIL-29. In IFN-γ-deficient mice, anti-tumor activities of AdIL-28A were completely impaired, indicating that IFN-γ is critically involved in the tumor growth inhibition triggered by AdIL-28A. IL-12 provided a synergistic anti-tumor effect when combined with AdIL-28A. These results indicate that AdIL-28A and AdIL-29 could be successfully utilized as an alternative cancer immunogene therapy.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1038/cgt.2016.29
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27561689
- ● Search Scopus @ Elsevier (PMID): 27561689
- ● Search Scopus @ Elsevier (DOI): 10.1038/cgt.2016.29
(DOI: 10.1038/cgt.2016.29, PubMed: 27561689) Yuko Toyoda, Masaki Hanibuchi, Jun Kishi, Hiroshi Kawano, Shun Morizumi, Seidai Satou, M Kondo, Terumi Takikura, Toshifumi Tezuka, Hisatsugu Goto and Yasuhiko Nishioka :
Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease.,
The Journal of Medical Investigation : JMI, Vol.63, No.3,4, 294-299, 2016.- (要約)
- Acute exacerbation (AE) of interstitial lung disease is reported to be developed in not only idiopathic pulmonary fibrosis but also connective tissue disease-associated interstitial pneumonia (CTD-IP). As the significance of AE of CTD-IP has not been so widely recognized, its clinical feature is not fully elucidated. In the present study, we investigated the incidence, clinical features and outcome of AE of CTD-IP. We retrospectively reviewed admitted cases in our department with medical record from 2011 to 2015. Among 155 patients with CTD-IP, 10 (6.5%) cases developed AE (6 rheumatoid arthritis, 2 polymyositis/dermatomyositis, 1 systemic lupus erythematosus, 1 Sjögren syndrome), and one died of AE within 30 days. Median survival time after the onset of AE was 169 days in all 10 patients. The treatment with immunosuppressant just before AE onset might improve the prognosis of AE. The median survival time after the onset of AE was significantly longer in patients showing good response to corticosteroid compared with those with poor response to corticosteroid (805 days and 45 days, respectively) (p <0.05), suggesting that there are some cases in CTD-IP, showing the good response to corticosteroid even when AE was complicated. J. Med. Invest. 63: 294-299, August, 2016.
- (徳島大学機関リポジトリ)
- ● Metadata: 111197
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.63.294
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644575
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84987881651
(徳島大学機関リポジトリ: 111197, DOI: 10.2152/jmi.63.294, PubMed: 27644575, Elsevier: Scopus) 山子 泰斗, 埴淵 昌毅, 荻野 広和, 村上 永尚, 梶 龍兒, 西岡 安彦 :
多彩な神経症状を呈した小細胞肺癌に伴う傍腫瘍性神経症候群の1例,
肺癌, Vol.56, No.3, 199-204, 2016年.- (要約)
- <b>背景．</b>傍腫瘍性神経症候群は担癌患者に生じる神経障害であり，腫瘍の転移や浸潤・圧排，代謝異常や栄養障害によるものではなく，自己免疫学的機序による神経系の障害により生じる．傍腫瘍性神経症候群を合併する腫瘍は小細胞肺癌が最も多いとされている．<b>症例．</b>77歳男性．従来自立した生活を送っていたがX年10月頃より倦怠感が出現した．その後歩行障害が進行し排尿障害も出現したため，X+1年5月中旬に当院紹介となった．構音・嚥下障害や両下肢の運動・感覚障害，自律神経失調など多彩な神経症状を認め，精査によりLambert-Eaton症候群と診断された．自己抗体検査では，抗amphiphysin抗体，抗ガングリオシド(GM1，GT1b)抗体が陽性であった．精査にて小細胞肺癌cTXN2M1b(Stage IV)と診断した．PS 4のため化学療法の適応はないと判断した．免疫グロブリン大量療法を施行するも神経所見は改善しなかった．緩和医療目的に近医に転院し，X+1年10月下旬に死亡した．<b>結論．</b>複数の自己抗体が検出され多彩な神経症状を呈した小細胞肺癌に伴う傍腫瘍性神経症候群の1例を経験した．
- (キーワード)
- 傍腫瘍性神経症候群 / 小細胞肺癌 / Lambert-Eaton症候群 / 抗amphiphysin抗体 / 抗ガングリオシド抗体
- (徳島大学機関リポジトリ)
- ● Metadata: 117547
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2482/haigan.56.199
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390001204681086464
- ● Search Scopus @ Elsevier (DOI): 10.2482/haigan.56.199
(徳島大学機関リポジトリ: 117547, DOI: 10.2482/haigan.56.199, CiNii: 1390001204681086464) Seidai Satou, Masaki Hanibuchi, Takahashi Mikiko, Fukuda Yuh, Morizumi Shun, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka :
A patient with idiopathic pleuroparenchymal fibroelastosis showing a sustained pulmonary function due to treatment with pirfenidone,
Internal Medicine, Vol.55, No.5, 497-501, 2016.- (要約)
- The patient was a 68-year-old man presenting with body weight loss and exertional dyspnea. High-resolution computed tomography of the chest showed dense subpleural consolidation with traction bronchiectasis and volume loss predominantly in bilateral apical lesions and upper lobes. A histopathological analysis of a specimen of the right upper lobe showed histological patterns which were consistent with idiopathic pleuroparenchymal fibroelastotis (IPPFE). Treatment with pirfenidone was introduced with the expectation of its potential benefit. The effect of pirfenidone was satisfactory, and a decline in forced vital capacity was inhibited during treatment. This is the first case report suggesting the efficacy of pirfenidone for patients with IPPFE.
- (徳島大学機関リポジトリ)
- ● Metadata: 114388
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.55.5047
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26935370
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84959267460
(徳島大学機関リポジトリ: 114388, DOI: 10.2169/internalmedicine.55.5047, PubMed: 26935370, Elsevier: Scopus) 後東 久嗣, 三橋 惇志, 西岡 安彦 :
線維細胞がかかわる血管新生阻害薬に対する獲得耐性メカニズム,
分子呼吸器病, Vol.20, No.1, 111-114, 2016年.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1520010380299131392
(CiNii: 1520010380299131392) Hirokazu Ogino, Masaki Hanibuchi, Hiromitsu Takizawa, Shoji Sakiyama, Sumitomo Hiroyuki, Seiji Iwamoto, Hitoshi Ikushima, Nakajima Kohei, Shinji Nagahiro, Yamago Taito, Yuko Toyoda, Yoshimi Bando and Yasuhiko Nishioka :
Primary Pulmonary Synovial Sarcoma Showing a Prolonged Survival with Multimodality Therapy,
Internal Medicine, Vol.55, No.4, 381-387, 2016.- (要約)
- A 54-year-old man was referred to our hospital due to a mass shadow noted on a chest X-ray. Thoracoscopic lobectomy yielded a diagnosis of primary pulmonary synovial sarcoma according to the histology and SYT-SSX1 gene analyses. Five months after the thoracic surgery, he developed brain metastasis; therefore, we performed resection of the brain metastatic focus followed by radiotherapy. As a local recurrence in the thoracic cavity concurrently emerged, systemic chemotherapy was also administered. These observations indicated that a multidisciplinary approach may be useful against primary pulmonary synovial sarcoma, although there is presently no established therapeutic strategy due to its rarity and highly aggressive nature.
- (徳島大学機関リポジトリ)
- ● Metadata: 114387
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.55.5169
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26875964
- ● Search Scopus @ Elsevier (PMID): 26875964
- ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.55.5169
(徳島大学機関リポジトリ: 114387, DOI: 10.2169/internalmedicine.55.5169, PubMed: 26875964) Muneo Numasaki, Hiroki Tsukamoto, Yoshihisa Tomioka, Yasuhiko Nishioka and Takashi Ohrui :
A Heterodimeric Cytokine, Consisting of IL-17A and IL-17F, Promotes Migration and Capillary-Like Tube Formation of Human Vascular Endothelial Cells.,
The Tohoku Journal of Experimental Medicine, Vol.240, No.1, 47-56, 2016.- (要約)
- The interleukin (IL)-17 family, consisting of six homodimeric cytokines IL-17A, IL-17B, IL-17C, IL-17D, IL-17E/IL-25, and IL-17F, mediates a variety of biological activities including regulation of chemokine secretion and angiogenesis. Among the IL-17 family members, IL-17A and IL-17E/IL-25 are angiogenesis stimulators, while IL-17B and IL-17F are angiogenesis inhibitors. Recently, IL-17A/F heterodimer, comprised of the IL-17A and IL-17F subunits, was found as another member of the IL-17 cytokine family. However, to date, it has been unknown whether IL-17A/F has biological actions to affect the angiogenesis-related vascular endothelial functions. Therefore, in this study, we investigated the biological effects of IL-17A/F on the growth, migration and capillary-like tube formation of vascular endothelial cells. Recombinant IL-17A/F protein had no direct effects on the growth of human dermal microvascular endothelial cells (HMVECs), whereas, after 4-hour incubation in a modified Boyden Chemotaxicell chamber, IL-17A/F significantly induced migration of HMVECs over a wide range of doses via the phosphatidylinositol-3 kinase (PI3K) signaling pathway. We further investigated the biological effect of IL-17A/F on capillary-like tube formation using a co-culture system of human umbilical vein endothelial cells (HUVECs) and human dermal fibroblasts (HDFs), which mimicked the in vivo microenvironment. In this co-culture system, IL-17A/F significantly promoted capillary-like endothelial tube formation in a dose-dependent fashion via the PI3K and extracellular signal-regulated kinase (ERK) signaling pathways. Additionally, IL-17A/F up-regulated secretion of angiogenic growth factors such as IL-8 and growth-related oncogene (GRO)-α by HDFs. These findings identify a novel biological function for IL-17A/F as an indirect angiogenic agent.
- (キーワード)
- Cell Movement / Cell Proliferation / Chemokines / Dermis / Endothelial Cells / Fibroblasts / Humans / Interleukin-17 / Microvessels / Neovascularization, Physiologic / Protein Multimerization / Up-Regulation / Vascular Endothelial Growth Factor A
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1620/tjem.240.47
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27594509
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84985942530
(DOI: 10.1620/tjem.240.47, PubMed: 27594509, Elsevier: Scopus) 梶田 敬介, 佐藤 正大, 豊田 優子, 坂口 暁, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
クリゾチニブが奏効したperformance status不良anaplastic lymphoma kinase遺伝子転座陽性肺腺癌の1例,
四国医学雑誌, Vol.71, No.5,6, 141-148, 2015年.- (要約)
- A 27-year-old female was referred to our hospital for further examination of hoarseness, cough, and hemoptysis. Positron emission tomography-computed tomography revealed FDG accumulation in a huge mass in the left lower lobe, lymph nodes in the hilum, mediastinum and right cervical lesion left scapula and vertebral body. Further examination yielded the diagnosis of primary lung adenocarcinoma (cT2aN3M1b : Stage IV) harboring the anaplastic lymphoma kinase (ALK) fusion oncogene. Although her general condition was getting worse due to rapid increase of the pleural effusion, crizotinib promptly diminish the pleural effusion and ameliorated the patient's condition. The adverse events of crizotinib, such as nausea, vomiting and visual disturbance, were generally mild and well tolerable during treatment. These findings suggest that crizotinib is a promising candidate for ALK-positive non-small cell lung cancer patients even with poor performances.
- (キーワード)
- crizotinib / anaplastic lymphoma kinase / non-small cell lung cancer / performance status
- (徳島大学機関リポジトリ)
- ● Metadata: 109939
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1050564287418456448
(徳島大学機関リポジトリ: 109939, CiNii: 1050564287418456448) Mitsuhashi Atsushi, Hisatsugu Goto, Atsuro Saijo, Trung The Van, Yoshinori Aono, Hirokazu Ogino, Kuramoto Takuya, Tabata Sho, Hisanori Uehara, Keisuke Izumi, Mitsuteru Yoshida, Kobayashi Hiroaki, Takahashi Hidefusa, Gotoh Masashi, Kakiuchi Soji, Masaki Hanibuchi, Seiji Yano, Yokomise Hiroyasu, Shoji Sakiyama and Yasuhiko Nishioka :
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab,
Nature Communications, Vol.6, 8792, 2015.- (要約)
- Bevacizumab exerts anti-angiogenic effects in cancer patients by inhibiting vascular endothelial growth factor (VEGF). However, its use is still limited due to the development of resistance to the treatment. Such resistance can be regulated by various factors, although the underlying mechanisms remain incompletely understood. Here we show that bone marrow-derived fibrocyte-like cells, defined as alpha-1 type I collagen-positive and CXCR4-positive cells, contribute to the acquired resistance to bevacizumab. In mouse models of malignant pleural mesothelioma and lung cancer, fibrocyte-like cells mediate the resistance to bevacizumab as the main producer of fibroblast growth factor 2. In clinical specimens of lung cancer, the number of fibrocyte-like cells is significantly increased in bevacizumab-treated tumours, and correlates with the number of treatment cycles, as well as CD31-positive vessels. Our results identify fibrocyte-like cells as a promising cell biomarker and a potential therapeutic target to overcome resistance to anti-VEGF therapy.
- (徳島大学機関リポジトリ)
- ● Metadata: 115640
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1038/ncomms9792
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26635184
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84949310071
(徳島大学機関リポジトリ: 115640, DOI: 10.1038/ncomms9792, PubMed: 26635184, Elsevier: Scopus) Hiroshi Kawano, Hitoshi Nishijima, Junko Morimoto, Fumiko Hirota, Ryoko Morita, Yasuhiro Mouri, Yasuhiko Nishioka and Mitsuru Matsumoto :
Aire expression is inherent to most medullary thymic epithelial cells during their differentiation program.,
The Journal of Immunology, Vol.195, No.11, 5149-5158, 2015.- (要約)
- Aire in medullary thymic epithelial cells (mTECs) plays an important role in the establishment of self-tolerance. Because Aire+ mTECs appear to be a limited subset, they may constitute a unique lineage(s) among mTECs. An alternative possibility is that all mTECs are committed to express Aire in principle, but Aire expression by individual mTECs is conditional. To investigate this issue, we established a novel Aire reporter strain in which endogenous Aire is replaced by the human AIRE-GFP-Flag tag (Aire/hAGF-knockin) fusion gene. The hAGF reporter protein was produced and retained very efficiently within mTECs as authentic Aire nuclear dot protein. Remarkably, snapshot analysis revealed that mTECs expressing hAGF accounted for >95% of mature mTECs, suggesting that Aire expression does not represent a particular mTEC lineage(s). We confirmed this by generating Aire/diphtheria toxin receptor knockin mice in which long-term ablation of Aire+ mTECs by diphtheria toxin treatment resulted in the loss of most mature mTECs beyond the proportion of those apparently expressing Aire. These results suggest that Aire expression is inherent to all mTECs but may occur at particular stage(s) and/or cellular states during their differentiation, thus accounting for the broad impact of Aire on the promiscuous gene expression of mTECs.
- (徳島大学機関リポジトリ)
- ● Metadata: 109688
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.4049/jimmunol.1501000
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26503950
- ● Search Scopus @ Elsevier (PMID): 26503950
- ● Search Scopus @ Elsevier (DOI): 10.4049/jimmunol.1501000
(徳島大学機関リポジトリ: 109688, DOI: 10.4049/jimmunol.1501000, PubMed: 26503950) K Fukushima, S Nakamura, Y Inoue, Y Higashiyama, M Ohmichi, T Ishida, K Yoshimura, T Sawai, N Takayanagi, C Nakahama, T Kakugawa, K Izumikawa, N Aoki, Yasuhiko Nishioka, O Kosaka and S Kohno :
Utility of a sputum antigen detection test in pneumococcal and lower respiratory infectious disease in adults,
Internal Medicine, Vol.54, No.22, 2843-2850, 2015.- (要約)
- To compare the utility of Gram staining, a urinary antigen detection kit and a sputum antigen detection kit were examined for the rapid and early detection of pneumococcal pneumonia and lower respiratory infectious diseases. A newly developed sputum pneumococcal antigen detection kit (RAPIRUN), Gram staining, and urinary antigen detection kit (BinaxNOW) were comparatively evaluated for their ability to detect Streptococcus pneumoniae in patients with pneumonia or lower respiratory tract infection. Sputum culture results were used as a standard for comparison. Furthermore, the pneumococcus-positive rates in culture and rapid tests were compared using polymerase chain reaction (PCR) as a reference. Of the 169 patients studied, 54 (32.0%) tested positive for S. pneumoniae in culture. S. pneumoniae detection sensitivities for Gram staining, RAPIRUN, and BinaxNOW were 75.9%, 90.7%, and 53.7%, respectively; thus, RAPIRUN had a significantly higher sensitivity than BinaxNOW (p<0.001). For patients with ≥10(5) copies/μg of pneumococcal surface protein A DNA PCR analysis, the detection rates of culture, Gram staining, and RAPIRUN were 85.2%, 72.1%, and 82.0%, respectively, however, the detection rate of BinaxNOW was only 47.5%. Comparisons among 45 patients with culture-positive pneumococcal pneumonia revealed that RAPIRUN had a significantly higher detection rate than BinaxNOW in the mild cases (p<0.006), regardless of the number of days from onset (p<0.03). RAPIRUN is a rapid testing kit that detects S. pneumoniae in sputum with a high sensitivity and specificity. It is a particularly more useful detection kit than BinaxNOW for early and mild community-acquired pneumonia in pre-treatment patients whose sputum specimens can be obtained.
- (キーワード)
- Adult / Antigens, Bacterial / Community-Acquired Infections / Early Diagnosis / Female / Gentian Violet / Humans / Immunoassay / Japan / Male / Middle Aged / Phenazines / Pneumonia, Pneumococcal / Reagent Kits, Diagnostic / Respiratory Tract Infections / Sensitivity and Specificity / Sputum / Streptococcus pneumoniae
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.54.4082
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26567996
- ● Search Scopus @ Elsevier (PMID): 26567996
- ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.54.4082
(DOI: 10.2169/internalmedicine.54.4082, PubMed: 26567996) Yukinari Kato, Akiko Kunita, Shinji Abe, Satoshi Ogasawara, Yuki Fujii, Hiroharu Oki, Masashi Fukayama, Yasuhiko Nishioka and Mika K. Kaneko :
The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity,
Oncotarget, Vol.6, No.34, 36003-36018, 2015.- (要約)
- Podoplanin (PDPN/Aggrus/T1α) binds to C-type lectin-like receptor-2 (CLEC-2) and induces platelet aggregation. PDPN is associated with malignant progression, tumor metastasis, and poor prognosis in several types of cancer. Although many anti-human PDPN (hPDPN) monoclonal antibodies (mAbs), such as D2-40 and NZ-1, have been established, these epitopes are limited to the platelet aggregation-stimulating (PLAG) domain (amino acids 29-54) of hPDPN. Recently, we developed a novel mouse anti-hPDPN mAb, LpMab-7, which is more sensitive than D2-40 and NZ-1, using the Cancer-specific mAb (CasMab) method. The epitope of LpMab-7 was shown to be entirely different from that of NZ-1, a neutralizing mAb against the PLAG domain according to an inhibition assay and lectin microarray analysis. In the present study, we produced a mouse-human chimeric anti-hPDPN mAb, chLpMab-7. ChLpMab-7 showed high antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Furthermore, chLpMab-7 inhibited the growth of hPDPN-expressing tumors in vivo. Although chLpMab-7 recognizes a non-PLAG domain of hPDPN, it suppressed the hematogenous metastasis of hPDPN-expressing tumors. These results indicated that chLpMab-7 suppressed tumor development and hematogenous metastasis in a neutralization-independent manner. In conclusion, hPDPN shows promise as a target in the development of a novel antibody-based therapy.
- (徳島大学機関リポジトリ)
- ● Metadata: 115672
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.18632/oncotarget.5339
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26416352
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84945548818
(徳島大学機関リポジトリ: 115672, DOI: 10.18632/oncotarget.5339, PubMed: 26416352, Elsevier: Scopus) Takumi Sakurada, Souji Kakiuchi, Soichiro Tajima, Yuya Horinouchi, Ken Konaka, Naoto Okada, Hirotaka Nishisako, Toshimi Nakamura, Kazuhiko Teraoka, Kazuyoshi Kawazoe, Hiroaki Yanagawa, Yasuhiko Nishioka and Keisuke Ishizawa :
Pemetrexed-induced rash may be prevented by supplementary corticosteroids,
Biological & Pharmaceutical Bulletin, Vol.38, No.11, 1752-1756, 2015.- (要約)
- Pemetrexed, a chemotherapeutic drug, is highly active in non-small cell lung cancer and malignant pleural mesothelioma. Unfortunately, rashes are more commonly associated with pemetrexed than other chemotherapies, and it is recommended that patients receive corticosteroids (8 mg/d of dexamethasone) for 3 d, including the day of pemetrexed administration (day 1). However, the efficacy of corticosteroids in this context has not been fully verified. In this retrospective study, we evaluated the medical records of 78 patients who received pemetrexed between April 2009 and March 2014, to confirm whether supplementary corticosteroids prevented rash development. The incidence of rash was lower in the 47 patients who received supplementary corticosteroids (after day 1) compared with the incidence among the 31 patients who did not receive supplementary corticosteroids (19.1% vs. 38.7%). The average cutoff dosage of supplementary corticosteroids on day 2 and day 3 was 1.5 mg/d of dexamethasone, as calculated using the receiver operating characteristic curve, and the odds ratio was 0.33 (95% confidence interval: 0.12-0.94). Administration of ≥1.5 mg of corticosteroids on day 2 and day 3 significantly reduced the severity of the rash compared to no supplementary treatment (grades 2/3, 13.3% vs. 33.3%, p<0.05). However, increasing the dose of corticosteroids had no additional effect on rash development. These results suggest that ≥1.5 mg of supplementary dexamethasone on day 2 and day 3 (in addition to day 1) may be necessary for preventing pemetrexed-induced rash, but high doses of dexamethasone (e.g., 8 mg/d) are unnecessary.
- (キーワード)
- Adrenal Cortex Hormones / Adult / Aged / Aged, 80 and over / Anti-Inflammatory Agents / Antineoplastic Agents / Area Under Curve / Dexamethasone / Exanthema / Female / Humans / Male / Middle Aged / Neoplasms / Odds Ratio / Pemetrexed / ROC Curve / Retrospective Studies / Severity of Illness Index / Treatment Outcome
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1248/bpb.b15-00435
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26521826
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84946902360
(DOI: 10.1248/bpb.b15-00435, PubMed: 26521826, Elsevier: Scopus) 埴淵 昌毅, 西岡 安彦 :
Current topics from major journals-英文抄読会から ALK陽性非小細胞肺癌に対する1次治療でのクリゾチニブと化学療法の比較試験,
日本胸部臨床, Vol.74, No.6, 717, 2015年. Hiroshi Kawano, Masaki Hanibuchi, Yoshijima Terumi, Yuko Toyoda, Jun Kishi, Toshifumi Tezuka and Yasuhiko Nishioka :
A case of atypical Takayasu arteritis initially presenting with peripheral artery disease,
Case Reports in Clinical Pathology, Vol.2, No.2, 34-40, 2015.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.5430/crcp.v2n2p34
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.5430/crcp.v2n2p34
(DOI: 10.5430/crcp.v2n2p34) Kojiro Nagai, Jun Kishi, Shun Morizumi, Jun Minakuchi, Yoshimi Bando, Yasuhiko Nishioka and Toshio Doi :
Henoch-Schönlein purpura nephritis occurring postpartum in a patient with anti-PL-7 anti-synthetase syndrome.,
Modern Rheumatology, Vol.28, 1-4, 2015.- (要約)
- A 37-year-old pregnant woman developed purpura which was subsequently diagnosed as Henoch-Schönlein purpura (HSP). After childbirth, the patient developed proteinuria and hematuria. Further examination revealed that the HSP nephritis (HSPN) was associated with anti-threonyl-tRNA synthetase anti-synthetase syndrome. The onset of HSPN during pregnancy or after childbirth is rare. Moreover, to our knowledge, this is the first case to describe renal involvement in anti-synthetase syndrome.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3109/14397595.2015.1038879
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25867231
- ● Search Scopus @ Elsevier (PMID): 25867231
- ● Search Scopus @ Elsevier (DOI): 10.3109/14397595.2015.1038879
(DOI: 10.3109/14397595.2015.1038879, PubMed: 25867231) 中野 万有里, 吉田 成二, 中山 正, 大串 文隆, 埴淵 昌毅, 西岡 安彦 :
インフルエンザ (H1N1) 2009に伴うARDSにPMX-DHP療法が奏効した1例,
感染症学雑誌, Vol.89, No.3, 416-421, 2015年.- (要約)
- A 51-year-old man was admitted to our hospital because of fever and diarrhea. Chest X-ray revealed consolidation in the left lower lung field. Ceftriaxone and minocycline were given empirically, under the suspicion of bacterial or atypical pneumonia. In spite of treatment with antibiotics, the disease rapidly progressed to systemic inflammatory response syndrome. The diagnosis of acute respiratory distress syndrome (ARDS) accompanied with influenza (H1N1) 2009 was made because of positive findings of real-time polymerase chain reaction. While multidisciplinary treatment was performed, his condition was further deteriorated suggesting the excessive pro-inflammatory mediators. To remove them, we conducted polymyxin-B immobilized column-direct hemoperfusion (PMX-DHP), and his general condition recovered successfully. PMX-DHP may be a useful treatment choice for ARDS accompanied with influenza.
- (キーワード)
- influenza (H1N1) 2009 / ARDS / PMX-DHP
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.11150/kansenshogakuzasshi.89.416
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390282680028294784
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84953344678
(DOI: 10.11150/kansenshogakuzasshi.89.416, CiNii: 1390282680028294784, Elsevier: Scopus) 埴淵 昌毅, 大塚 憲司, 塚﨑 佑貴, 坂下 直実, 功刀 しのぶ, 福田 悠, 西岡 安彦 :
Acute fibrinous and organizing pneumoniaパターンの特発性間質性肺炎が示唆された1例,
THE LUNG perspectives, Vol.23, No.2, 2-5, 2015年. Seidai Satou, Y Kawamata, A Takahashi, Y Imai, A Hanyu, A Okuma, M Takasugi, K Yamakoshi, H Sorimachi, H Kanda, Y Ishikawa, S Sone, Yasuhiko Nishioka, N Otani and E Hara :
Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice,
Nature Communications, Vol.6, 7035, 2015.- (要約)
- The p16(INK4a) tumour suppressor has an established role in the implementation of cellular senescence in stem/progenitor cells, which is thought to contribute to organismal ageing. However, since p16(INK4a) knockout mice die prematurely from cancer, whether p16(INK4a) reduces longevity remains unclear. Here we show that, in mutant mice homozygous for a hypomorphic allele of the α-klotho ageing-suppressor gene (kl(kl/kl)), accelerated ageing phenotypes are rescued by p16(INK4a) ablation. Surprisingly, this is due to the restoration of α-klotho expression in kl(kl/kl) mice and does not occur when p16(INK4a) is ablated in α-klotho knockout mice (kl(-/-)), suggesting that p16(INK4a) is an upstream regulator of α-klotho expression. Indeed, p16(INK4a) represses α-klotho promoter activity by blocking the functions of E2Fs. These results, together with the observation that the expression levels of p16(INK4a) are inversely correlated with those of α-klotho throughout ageing, indicate that p16(INK4a) plays a previously unrecognized role in downregulating α-klotho expression during ageing.
- (キーワード)
- Aging / Animals / Cells, Cultured / Cyclin-Dependent Kinase Inhibitor p16 / Gene Expression Regulation / Genes, p16 / Glucuronidase / Humans / Male / Mice / Mice, Inbred C57BL / Phenotype / Promoter Regions, Genetic
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1038/ncomms8035
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25923845
- ● Search Scopus @ Elsevier (PMID): 25923845
- ● Search Scopus @ Elsevier (DOI): 10.1038/ncomms8035
(DOI: 10.1038/ncomms8035, PubMed: 25923845) H Yamazaki, R Sakai, R Koike, Y Miyazaki, M Tanaka, T Nanki, K Watanabe, S Yasuda, T Kurita, Y Kaneko, Y Tanaka, Yasuhiko Nishioka, Y Takasaki, K Nagasaka, H Nagasawa, S Thoma, M Dohi, T Sugihara, H Sugiyama, Y Kawaguchi, N Inase, S Ochi, H Hagiyama, H Kohsaka, N Miyasaka, M Harigai and Group Study PREVENT :
Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases:A Large-scale Prospective Cohort Study,
The Journal of Rheumatology, Vol.42, No.4, 614-622, 2015.- (要約)
- Pulmonary infections (PI) are leading causes of death in patients with connective tissue diseases (CTD). The PREVENT study (Pulmonary infections in patients REceiving immunosuppressiVE treatmeNT for CTD) assessed risk of PI in patients with active CTD in the contemporary era of advanced immunosuppressive therapy. In patients who started corticosteroids (n = 763), conventional immunosuppressants or biologics for active CTD were enrolled. Clinical and laboratory data, usage of drugs, and occurrence of PI were collected for 12 months. Baseline risk factors were investigated using Cox regression analysis. A nested case-control (NCC) study was performed with 1:2 matched case-control pairs to assess the risk for each drug category. During the observation period, 32 patients died (4.2%) and 66 patients were lost to followup (8.6%). Patients with PI (n = 61, 8%) had a significantly worse accumulated survival rate than patients without (p < 0.01). Cox hazard regression analysis using baseline data showed that these factors were significantly associated with PI: age ≥ 65 years (HR 3.87, 95% CI 2.22-6.74), ≥ 20 pack-years of smoking (2.63, 1.37-5.04), higher serum creatinine level (1.21, 1.05-1.41 per 1.0 mg/dl increase), and maximum prednisolone (PSL) dose during the first 2 weeks of treatment (2.81, 1.35-5.86 per 1.0 mg/kg/day increase). Logistic regression analysis by an NCC study revealed that maximum PSL dose within 14 days before PI (OR 4.82, 95% CI 1.36-17.01 per 1.0 mg/dl increase; 2.57, 1.28-5.16 if ≥ 0.5 mg/kg/day) was significantly associated with the events, while other immunosuppressants were not. Physicians should be aware of the higher risks for corticosteroids of PI than other immunosuppressants and assess these risk factors before immunosuppressive treatment, to prevent PI.
- (キーワード)
- Adrenal Cortex Hormones / Adult / Aged / Connective Tissue Diseases / Female / Humans / Immunosuppressive Agents / Infection / Lung Diseases / Male / Middle Aged / Prospective Studies / Risk / Risk Assessment / Survival Rate
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3899/jrheum.140778
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25641893
- ● Search Scopus @ Elsevier (PMID): 25641893
- ● Search Scopus @ Elsevier (DOI): 10.3899/jrheum.140778
(DOI: 10.3899/jrheum.140778, PubMed: 25641893) Takumi Sakurada, Souji Kakiuchi, Soichiro Tajima, Yuya Horinouchi, Naoto Okada, Hirotaka Nishisako, Toshimi Nakamura, Kazuhiko Teraoka, Kazuyoshi Kawazoe, Hiroaki Yanagawa, Yasuhiko Nishioka, Kazuo Minakuchi and Keisuke Ishizawa :
Characteristics and risk factors of interstitial lung disease induced by chemotherapy for lung cancer,
The Annals of Pharmacotherapy, Vol.49, No.4, 398-404, 2015.- (要約)
- Drug-induced interstitial lung disease (DILD) is generally a serious adverse effect and almost always necessitates the discontinuation of the offending drug. Cancer pharmacotherapy is strongly associated with DILD, and the risk of DILD has been suggested to be higher in patients with lung cancer because of preexisting pneumonic disease. The aim of this retrospective study was to identify the risk factors and prognostic factors for early death from interstitial lung disease (ILD) induced by chemotherapy for lung cancer. The medical records of 459 patients who underwent chemotherapy for lung cancer between April 2007 and March 2013 were analyzed with regard to patient background and DILD development, initial symptoms, and prognosis. A total of 33 patients (7.2%) developed chemotherapy-induced ILD. The most frequently observed initial symptom was dyspnea (94.3%). Preexisting ILD was identified as a risk factor for DILD (odds ratio [OR] = 5.38; 95% CI = 2.47-11.73; P < 0.01). Among the 33 patients who developed DILD, 10 patients suffered an early death despite steroid therapy. Poor prognostic factors included epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) use (OR = 9.26; 95% CI = 1.05-82.0; P < 0.05) and 2 or more prior chemotherapy regimens (OR = 6.95; 95% CI = 1.14-42.3; P < 0.05). Many lung cancer patients have coexisting ILD, and these patients have a high risk of developing chemotherapy-induced ILD. In addition, patients with DILD who underwent EGFR-TKI therapy and 2 or more prior chemotherapy regimens had a higher risk of fatal outcome.
- (キーワード)
- Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Female / Humans / Lung Diseases, Interstitial / Lung Neoplasms / Male / Middle Aged / Odds Ratio / Prognosis / Retrospective Studies / Risk Factors
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1177/1060028014566446
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25565405
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84924872993
(DOI: 10.1177/1060028014566446, PubMed: 25565405, Elsevier: Scopus) 西岡 安彦 :
肺癌,
今日の診療のために ガイドライン外来診療2015 泉孝英編集, 570-572, 2015年. Toshifumi Tezuka, Hirohisa Ogawa, Masahiko Azuma, Hisatsugu Goto, Hisanori Uehara, Yoshinori Aono, Masaki Hanibuchi, Yamaguchi Yoichi, Fujikawa Tomoyuki, Itai Akiko and Yasuhiko Nishioka :
IMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediators,
PLoS ONE, Vol.10, No.3, e0121615, 2015.- (要約)
- Plasminogen activator inhibitor (PAI)-1 is the principal inhibitor of plasminogen activators, and is responsible for the degradation of fibrin and extracellular matrix. IMD-4690 is a newly synthesized inhibitor for PAI-1, whereas the effect on allergic airway inflammation and remodeling is still unclear. We examined the in vivo effects by using a chronic allergen exposure model of bronchial asthma in mice. The model was generated by an immune challenge for 8 weeks with house dust mite antigen, Dermatophagoides pteronyssinus (Dp). IMD-4690 was intraperitoneally administered during the challenge. Lung histopathology, hyperresponsiveness and the concentrations of mediators in lung homogenates were analyzed. The amount of active PAI-1 in the lungs was increased in mice treated with Dp. Administration with IMD-4690 reduced an active/total PAI-1 ratio. IMD-4690 also reduced the number of bronchial eosinophils in accordance with the decreased expressions of Th2 cytokines in the lung homogenates. Airway remodeling was inhibited by reducing subepithelial collagen deposition, smooth muscle hypertrophy, and angiogenesis. The effects of IMD-4690 were partly mediated by the regulation of TGF-, HGF and matrix metalloproteinase. These results suggest that PAI-1 plays crucial roles in airway inflammation and remodeling, and IMD-4690, a specific PAI-1 inhibitor, may have therapeutic potential for patients with refractory asthma due to airway remodeling.
- (キーワード)
- Acetates / Airway Remodeling / Animals / Antigens, Dermatophagoides / Asthma / Biphenyl Compounds / Bronchi / Bronchoalveolar Lavage Fluid / Chronic Disease / Cytokines / Dermatophagoides pteronyssinus / Disease Models, Animal / Eosinophils / Female / Immunoglobulin E / Mice / Neovascularization, Pathologic / Plasminogen Activator Inhibitor 1 / Tissue Plasminogen Activator
- (徳島大学機関リポジトリ)
- ● Metadata: 109460
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1371/journal.pone.0121615
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25785861
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84925425817
(徳島大学機関リポジトリ: 109460, DOI: 10.1371/journal.pone.0121615, PubMed: 25785861, Elsevier: Scopus) Seidai Satou, Masaki Hanibuchi, Makoto Tobiume, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Mikiko Takahashi, Yuh Fukuda and Yasuhiko Nishioka :
A case of IgG4-related interstitial lung disease showing usual interstitial pneumonia pattern: Unusual case for histological features with pathological proof,
Case Reports in Clinical Pathology, Vol.2, No.1, 6-11, 2015.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.5430/crcp.v2n1p6
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.5430/crcp.v2n1p6
(DOI: 10.5430/crcp.v2n1p6) 佐藤 正大, 後東 久嗣, 阿部 秀一, 竹﨑 彰夫, 河野 弘, 青野 純典, 西岡 安彦 :
ヒトfibrocyte分化における遺伝子発現解析と分子標的治療薬による分化制御の検討,
分子呼吸器病, Vol.19, No.1, 135-139, 2015年.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1520854804901101056
(CiNii: 1520854804901101056) Yoshinori Aono, Masami Kishi, Yuki Yokota, Momoyo Azuma, Katsuhiro Kinoshita, Akio Takezaki, Seidai Sato, Hiroshi Kawano, Jun Kishi, Hisatsugu Goto, Hisanori Uehara, Keisuke Izumi and Yasuhiko Nishioka :
Role of PDGF/PDGFR axis in the trafficking of circulating fibrocytes in pulmonary fibrosis,
American Journal of Respiratory Cell and Molecular Biology, Vol.51, No.6, 793-801, 2014.- (要約)
- Circulating fibrocytes have been reported to migrate into the injured lungs, and contribute to fibrogenesis via CXCL12-CXCR4 axis. In contrast, we report that imatinib mesylate prevented bleomycin (BLM)-induced pulmonary fibrosis in mice by inhibiting platelet-derived growth factor receptor (PDGFR), even when it was administered only in the early phase. The goal of this study was to test the hypothesis that platelet-derived growth factor (PDGF) might directly contribute to the migration of fibrocytes to the injured lungs. PDGFR expression in fibrocytes was examined by flow cytometry and RT-PCR. The migration of fibrocytes was evaluated by using a chemotaxis assay for human fibrocytes isolated from peripheral blood. The numbers of fibrocytes triple-stained for CD45, collagen-1, and CXCR4 were also examined in lung digests of BLM-treated mice. PDGFR mRNA levels in fibrocytes isolated from patients with idiopathic pulmonary fibrosis were investigated by real-time PCR. Fibrocytes expressed both PDGFR-α and -β, and migrated in response to PDGFs. PDGFR inhibitors (imatinib, PDGFR-blocking antibodies) suppressed fibrocyte migration in vitro, and reduced the number of fibrocytes in the lungs of BLM-treated mice. PDGF-BB was a stronger chemoattractant than the other PDGFs in vitro, and anti-PDGFR-β-blocking antibody decreased the numbers of fibrocytes in the lungs compared with anti-PDGFR-α antibody in vivo. Marked expression of PDGFR-β was observed in fibrocytes from patients with idiopathic pulmonary fibrosis compared with healthy subjects. These results suggest that PDGF directly functions as a strong chemoattractant for fibrocytes. In particular, the PDGF-BB-PDGFR-β biological axis might play a critical role in fibrocyte migration into the fibrotic lungs.
- (キーワード)
- Animals / Benzamides / Case-Control Studies / Chemotaxis / Drug Evaluation, Preclinical / Female / Humans / Injections, Intraperitoneal / Mice, Inbred C57BL / Piperazines / Platelet-Derived Growth Factor / 肺線維症 (pulmonary fibrosis) / Pyrimidines / Receptor, Platelet-Derived Growth Factor beta / Receptors, CXCR4 / シグナル伝達 (signal transduction)
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1165/rcmb.2013-0455OC
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24885373
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84918792291
(DOI: 10.1165/rcmb.2013-0455OC, PubMed: 24885373, Elsevier: Scopus) Michi Tanaka, Ryuji Koike, Ryoko Sakai, Kazuyoshi Saito, Shintaro Hirata, Hayato Nagasawa, Hideto Kameda, Masako Hara, Yasushi Kawaguchi, Shigeto Tohma, Yoshinari Takasaki, Makoto Dohi, Yasuhiko Nishioka, Shinsuke Yasuda, Yasunari Miyazaki, Yuko Kaneko, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Nobuyuki Miyasaka and Masayoshi Harigai :
Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia,
Modern Rheumatology, Vol.25, No.4, 609-614, 2014.- (要約)
- Connective tissue disease-associated interstitial pneumonia (CTD-IP) significantly affects the mortality of patients with CTD. The purpose of the present study is to identify causes and risk factors for death during hospitalization for immunosuppressive treatment of CTD-IP. A multicenter, retrospective study was conducted that collected data from patients with CTD who had been hospitalized for commencing or intensifying immunosuppressive treatment of CTD-IP using a standardized case report form. Risk factors were identified using the Cox proportional hazard regression model. A total of 322 CTD-IP patients were enrolled with rheumatoid arthritis (n = 84), systemic lupus erythematosus (n = 13), polymyositis (n = 33), dermatomyositis (n = 69), systemic sclerosis (n = 55), mixed connective tissue disease (n = 21), microscopic polyangiitis (n = 19), and overlap syndrome (n = 28). Of the 42 patients who died during hospitalization, 22 died from CTD-IP, 15 from CTD-IP and pulmonary infection, 2 from pulmonary infection, and 3 from other causes. Age ≥ 65 years and development of pulmonary infections after commencing or intensifying immunosuppressive treatments were identified as risk factors for death during hospitalization after adjusting for covariates. Careful consideration of the benefit-risk balance of immunosuppressive treatment for CTD-IP is indispensable for improving the short-term vital prognosis of these patients.
- (キーワード)
- Adolescent / Adult / Aged / Connective Tissue Diseases / Female / Follow-Up Studies / Hospital Mortality / Hospitalization / Humans / Immunosuppressive Agents / 日本 (Japan) / Lung Diseases, Interstitial / Male / Middle Aged / Prognosis / Respiratory Tract Infections / Retrospective Studies / Risk Assessment / Risk Factors / Survival Rate / Time Factors
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3109/14397595.2014.980384
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25496409
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84935016185
(DOI: 10.3109/14397595.2014.980384, PubMed: 25496409, Elsevier: Scopus) Hirohisa Ogawa, G Julie Ledford, Sambuddho Mukherjee, Yoshinori Aono, Yasuhiko Nishioka, J James Lee, Keisuke Izumi and W John Hollingsworth :
Surfactant protein D attenuates sub-epithelial fibrosis in allergic airways disease through TGF-β.,
Respiratory Research, Vol.15, 143, 2014.- (要約)
- Surfactant protein D (SP-D) can regulate both innate and adaptive immunity. Recently, SP-D has been shown to contribute to the pathogenesis of airway allergic inflammation and bleomycin-induced pulmonary fibrosis. However, in allergic airways disease, the role of SP-D in airway remodeling remains unknown. The objective of this study was to determine the contribution of functional SP-D in regulating sub-epithelial fibrosis in a mouse chronic house dust mite model of allergic airways disease. C57BL/6 wild-type (WT) and SP-D-/- mice (C57BL/6 background) were chronically challenged with house dust mite antigen (Dermatophagoides pteronyssinus, Dp). Studies with SP-D rescue and neutralization of TGF-β were conducted. Lung histopathology and the concentrations of collagen, growth factors, and cytokines present in the airspace and lung tissue were determined. Cultured eosinophils were stimulated by Dp in presence or absence of SP-D. Dp-challenged SP-D-/- mice demonstrate increased sub-epithelial fibrosis, collagen production, eosinophil infiltration, TGF-β1, and IL-13 production, when compared to Dp-challenged WT mice. By immunohistology, we detected an increase in TGF-β1 and IL-13 positive eosinophils in SP-D-/- mice. Purified eosinophils stimulated with Dp produced TGF-β1 and IL-13, which was prevented by co-incubation with SP-D. Additionally, treatment of Dp challenged SP-D-/- mice with exogenous SP-D was able to rescue the phenotypes observed in SP-D-/- mice and neutralization of TGF-β1 reduced sub-epithelial fibrosis in Dp-challenged SP-D-/- mice. These data support a protective role for SP-D in the pathogenesis of sub-epithelial fibrosis in a mouse model of allergic inflammation through regulation of eosinophil-derived TGF-β.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1186/s12931-014-0143-9
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25472740
- ● Search Scopus @ Elsevier (PMID): 25472740
- ● Search Scopus @ Elsevier (DOI): 10.1186/s12931-014-0143-9
(DOI: 10.1186/s12931-014-0143-9, PubMed: 25472740) Taisuke Matsuo, Le Tan Dat, Masato Komatsu, Tetsuro Yoshimaru, Kei Daizumoto, Saburo Sone, Yasuhiko Nishioka and Toyomasa Katagiri :
Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes.,
PLoS ONE, Vol.9, No.11, e113606, 2014.- (要約)
- Small cell lung cancer (SCLC) is aggressive, with rapid growth and frequent bone metastasis; however, its detailed molecular mechanism remains poorly understood. Here, we report the critical role of early growth factor 4 (EGR4), a DNA-binding, zinc-finger transcription factor, in cell proliferation of SCLC. EGR4 overexpression in HEK293T cells conferred significant upregulation of specific splice variants of the parathyroid hormone-related protein (PTHrP) gene, resulting in enhancement of the secretion of PTHrP protein, a known mediator of osteolytic bone metastasis. More importantly, depletion of EGR4 expression by siRNA significantly suppressed growth of the SCLC cell lines, SBC-5, SBC-3 and NCI-H1048. On the other hand, introduction of EGR4 into NIH3T3 cells significantly enhanced cell growth. We identified four EGR4 target genes, SAMD5, RAB15, SYNPO and DLX5, which were the most significantly downregulated genes upon depletion of EGR4 expression in all of the SCLC cells examined, and demonstrated the direct recruitment of EGR4 to their promoters by ChIP and luciferase reporter analysis. Notably, knockdown of the expression of these genes by siRNA remarkably suppressed the growth of all the SCLC cells. Taken together, our findings suggest that EGR4 likely regulates the bone metastasis and proliferation of SCLC cells via transcriptional regulation of several target genes, and may therefore be a promising target for the development of anticancer drugs for SCLC patients.
- (キーワード)
- Animals / Cell Line, Tumor / Cell Proliferation / Chromatin Immunoprecipitation / Early Growth Response Transcription Factors / HEK293 Cells / Homeodomain Proteins / Humans / Interleukin-6 / Interleukin-8 / Lung Neoplasms / Mice / Microfilament Proteins / NIH 3T3 Cells / Paracrine Communication / Parathyroid Hormone-Related Protein / RANK Ligand / Small Cell Lung Carcinoma / Transcription Factors / Transcriptional Activation / Up-Regulation / rab GTP-Binding Proteins
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1371/journal.pone.0113606
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25411851
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84912060344
(DOI: 10.1371/journal.pone.0113606, PubMed: 25411851, Elsevier: Scopus) Seidai Satou, Masaki Hanibuchi, Asami Fukuya, Youhei Yabuki, Hiroki Bando, Terumi Yoshijima, Hisatsugu Goto, Hirohisa Ogawa and Yasuhiko Nishioka :
Idiopathic pleuroparenchymal fibroelastosis is characterized by an elevated serum level of surfactant protein-D, but not krebs von den lungen-6,
Lung, Vol.192, No.5, 711-717, 2014.- (要約)
- Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a recently reported rare disease entity characterized by fibrotic thickening of the pleural and subpleural parenchyma predominantly in the upper lobes in idiopathic interstitial pneumonias (IIPs). Because the clinical features of this rare disease are not fully elucidated, we examined the clinical characteristics of IPPFE, especially for serum interstitial biomarkers, surfactant protein-D (SP-D), and Krebs von den Lungen-6 (KL-6). Four consecutive cases of IPPFE who fulfilled the diagnostic criteria were studied. All cases were more than 60 years of age, and were classified as underweight by body mass index. A severe restrictive ventilatory defect was found in all cases on admission. High-resolution computed tomography showed intense pleural thickening associated with fibrosis predominant in upper lobes. Histopathological findings were also confirmed in three out of four cases. Interestingly, the serum level of SP-D was markedly elevated in all cases, while KL-6 was within normal range in three out of four cases. As compared with major IIPs such as idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia, IPPFE significantly showed higher frequency of cases with a unique pattern of serum biomarkers, which is characterized by an elevated level of SP-D with a normal range of KL-6. In IPPFE, SP-D might tend to be elevated, while KL-6 was within a normal range. Further study is required to determine the pathogenesis and clinical significance of the elevated SP-D in IPPFE.
- (キーワード)
- Aged / Autopsy / Biological Markers / Biopsy / Fatal Outcome / Humans / Idiopathic Interstitial Pneumonias / Lung / Male / Middle Aged / Mucin-1 / Pleural Diseases / Pulmonary Surfactant-Associated Protein D / Pulmonary Ventilation / Retrospective Studies / Spirometry / Time Factors / Tomography, X-Ray Computed / Treatment Outcome / Up-Regulation
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1007/s00408-014-9599-0
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24880792
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84931443666
(DOI: 10.1007/s00408-014-9599-0, PubMed: 24880792, Elsevier: Scopus) Masaki Hanibuchi, SJ Kim, IJ Fidler and Yasuhiko Nishioka :
The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives,
The Journal of Medical Investigation : JMI, Vol.61, No.3,4, 241-253, 2014.- (要約)
- Brain metastases occur in 20-40% of patients with advanced malignancies and lung cancer is one of the most common causes of brain metastases. The occurrence of brain metastases is associated with poor prognosis and high morbidity in patients with advanced lung cancer, even after intensive multimodal therapy. Progress in treating brain metastases has been hampered by a lack of model systems, a lack of human tissue samples, and the exclusion of brain metastatic patients from many clinical trials. While the biology of brain metastasis is still poorly understood, it is encouraging to see more efforts are beginning to be directed toward the study of brain metastasis. During the multi-step process of metastasis, functional significance of gene expressions, changes in brain vasculature, abnormal secretion of soluble factors and activation of autocrine/paracrine signaling are considered to contribute to the brain metastasis development. A better understanding of the mechanism of this disease will help us to identify the appropriate therapeutic strategies, which leads to circumvent brain metastases. Recent findings on the biology of lung cancer brain metastases and translational leads identified by molecular studies are discussed in this review.
- (徳島大学機関リポジトリ)
- ● Metadata: 109563
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.61.241
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25264041
- ● Search Scopus @ Elsevier (PMID): 25264041
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.61.241
(徳島大学機関リポジトリ: 109563, DOI: 10.2152/jmi.61.241, PubMed: 25264041) Yuko Toyoda, Sho Tabata, Jun Kishi, Takuya Kuramoto, Atsushi Mitsuhashi, Atsuro Saijo, Hiroshi Kawano, Hisatsugu Goto, Yoshinori Aono, Masaki Hanibuchi, Hideaki Horikawa, Toshihiro Nakajima, Tatsuhiko Furukawa, Saburo Sone, Shin-ichi Akiyama and Yasuhiko Nishioka :
Thymidine Phosphorylase Regulates the Expression of CXCL10 in Rheumatoid Arthritis Fibroblast-like Synoviocytes,
Arthritis & Rheumatology, Vol.66, No.3, 560-568, 2014.- (要約)
- Thymidine phosphorylase (TP) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) is induced by tumor necrosis factor α (TNFα) and other cytokines that have been reported to be major inflammation mediators in RA. We previously demonstrated that TP plays an important role in angiogenesis and tumor growth, invasion, and metastasis. The aim of this study was to investigate whether the role of TP in the pathogenesis of RA is similar to its role in tumors. In FLS obtained from 2 patients with RA, the expression of TP, interferon-γ (IFNγ)-inducible protein 10 (CXCL10), and other cytokines was measured by quantitative real-time polymerase chain reaction, immunoblotting, and enzyme-linked immunosorbent assays. Microarray analysis was performed using FLS transfected with TYMP complementary DNA and treated with a TP inhibitor. The expression of TP in FLS was up-regulated by TNFα, interleukin-1β (IL-1β), IL-17, IFNγ, and lipopolysaccharide. Microarray analysis of FLS overexpressing TP identified CXCL10 as a thymidine phosphorylase-related gene. The expression of CXCL10 was induced by TNFα, and this induction was suppressed by TYMP small interfering RNA and TP inhibitor. Furthermore, the combination of TNFα and IFNγ synergistically augmented the expression of TP and CXCL10. TP-induced CXCL10 expression was suppressed by the antioxidant EUK-8. In the synovial tissue of patients with RA, TP levels were significantly correlated with CXCL10 expression. The combination of TNFα and IFNγ strongly induced the expression of thymidine phosphorylase in RA FLS. The induction of thymidine phosphorylase enhanced the expression of CXCL10, which may contribute to the Th1 phenotype and bone destruction observed in RA.
- (キーワード)
- Arthritis, Rheumatoid / Cells, Cultured / Chemokine CXCL10 / Cytokines / Humans / Interferon-gamma / Synovial Membrane / Thymidine Phosphorylase / Tumor Necrosis Factor-alpha
- (徳島大学機関リポジトリ)
- ● Metadata: 106062
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/art.38263
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24574215
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84896289470
(徳島大学機関リポジトリ: 106062, DOI: 10.1002/art.38263, PubMed: 24574215, Elsevier: Scopus) 木下 勝弘, 青野 純典, 竹崎 彰夫, 岡﨑 弘泰, 吉嶋 輝美, 岸 昌美, 東 桃代, 岸 潤, 泉 啓介, 西岡 安彦 :
ブレオマイシン肺線維症モデルにおけるFAKシグナル阻害薬の抗線維化効果,
分子呼吸器病, Vol.18, No.1, 154-157, 2014年.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1520291855460530048
(CiNii: 1520291855460530048) 中瀬 勝則, 鶴尾 美穂, 島田 久夫, 木下 成三, 豊 纒, 杉野 聡, 浦 聡明, 山下 恵実, 古味 勝美, 小田 芳栄, 服部 順子, 西岡 安彦, 埴淵 昌毅, 吾妻 雅彦 :
徳島市医師会のCOPD対策,
四国医学雑誌, Vol.69, No.5-6, 233-242, 2013年.- (要約)
- In the national project Health Japan 21 (2nd edition) put forward in April 2013, the Ministry of Health, Labour, and Welfare specified chronic obstructive pulmonary disease (COPD) as a targeted lifestyle-related disease, in addition to cancer, heart diseases, and diabetes, and concluded that the establishment of COPD management systems is an important issue to maintain Japanese people's healthy lives, as the number of deaths from this disease is likely to rapidly increase in the future. In Tokushima Prefecture, the mortality rate associated with COPD has been stably high over the past years ; the nation' s highest in 2010 and third highest in 2011. In some regions of the western area, particularly mountainous regions, and southern area of the prefecture, the standardized mortality rate among males is double the national mean, highlighting the necessity of rapidly taking countermeasures. Under such circumstances, the Tokushima City Medical Association regarded COPD management as a priority item when developing annual projects this year, and organized the COPD Management and Smoking Cessation Promotion Committee in May. The medical association also presented a tentative plan to conduct association-led individualized COPD assessment at its own expense to the local government of Tokushima, with a view to materializing COPD assessment projects to clarify, evaluate, and analyze the actual situation, including surveys on citizens' recognition of COPD and those conducted by family doctors to examine the statuses of their patients, involving the local government in the future. During deliberations to examine the feasibility of this plan, the local government proposed a new COPD assessment plan based on the conventional mass pulmonary cancer examination system, in order to deal with those at a high risk of COPD ; following some revisions, the new plan was adopted. The plan consisted of the following steps : > Targeting those meeting the 3 diagnostic criteria specified in the pulmonary cancer interview sheet for COPD assessment : 1) age of 60 or over ; 2) previous smoking habit ; 3) presence of at least one of the subjective COPD symptoms (chronic coughing, sputum, and shortness of breath during activity). > Providing these patients with a free-consultation coupon to undergo assessment in a registered primary medical examination institution. > Conducting airway obstruction evaluation in primary medical examination institutions using the mass COPD screening interview sheet (COPD-PSTM) and spirometry. > Conducting insurance-covered medical examinations, such as the respiratory function test, chest XP, and CT scans, in secondary medical examination institutions (chest physicians) to establish a definite diagnosis. > Reporting the results of these examinations to family doctors. > If treatment is necessary, developing initial pharmacotherapy plans as part of the standardized treatment of COPD for approximately 3 months, which are implemented by family doctors. In consideration of the rapidly aging Japanese population, the number of potential COPD patients aged 40 and over is expected to reach nearly 7 million soon. In order to deal with such a large number of COPD patients, it is primary care physicians' duty to provide early diagnosis and treatment, and local medical associations are charged with promoting spirometry through their activities as part of COPD assessment projects, aiming to establish cooperative systems to manage the disease between primary care physicians providing treatment during the stable period and chest physicians providing it during the exacerbation period. As future perspectives, spirometry-promoting seminars to be held in clinical environments are being considered ; participation in these seminars will be a requirement for registered primary COPD examination institutions, and those who have completed such programs will be Tokushima City Medical Association-certified COPD specialists (tentative name). It is expected that these approaches to carry out the nation's first COPD assessment projects will improve clinical environments in communities, such as support for smoking cessation, medical professionals' knowledge of COPD, and the standardization of diagnosis and treatment.
- (キーワード)
- COPD / COPD management / COPD examination / COPD screening / COPD assessment
- (徳島大学機関リポジトリ)
- ● Metadata: 109731
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1050845762395118848
(徳島大学機関リポジトリ: 109731, CiNii: 1050845762395118848) 東 桃代, 中曽 亜佐美, 西野 さおり, 高開 登茂子, 先山 正二, 加藤 真介, 西岡 安彦 :
医療従事者における泡状アルコール性手指消毒剤の殺菌効果，塗布面積及び使用感に関する検討,
日本環境感染学会誌, Vol.28, No.6, 342-347, 2013年.- (要約)
- Alcohol-based hand rubs are recommended for use by healthcare staff worldwide. In addition to gel and liquid rubs, ethanol-based foam is available for hand hygiene. Ethanol-based foam was launched as the first alcohol-based foaming hand rub available in Japan in June 2011. Ethanol-based foam has gained attention among healthcare staff because ethanol-based foam does not drip from the hands, and allows good visual coverage. This study compared the effectiveness of ethanol-based gel and foam for bacterial removal and the percentage of areas covered with gel or foam. The Parm-Stamp Test was used to prove that ethanol-based foam has the same efficacy against bacteria as gel. To examine if the hands were fully covered with gel or foam, we used the Black Lights device and fluorescence powder. The results showed that the ethanol-based foam provided significantly improved coverage compared with the gel. According to the questionnaire results, ethanol-based foam has a lot of unique benefits, such as no dripping, easy spreading, good visual coverage, and no sticky feeling. Due to the effective cleaning with excellent skin feel during and after use, ethanol-based hand rub foam is very useful in the clinical setting for hand hygiene among healthcare workers.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.4058/jsei.28.342
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390001205297098240
- ● Search Scopus @ Elsevier (DOI): 10.4058/jsei.28.342
(DOI: 10.4058/jsei.28.342, CiNii: 1390001205297098240) Katsuhiro Kinoshita, Yoshinori Aono, Momoyo Azuma, Jun Kishi, Akio Takezaki, Masami Kishi, Hideki Makino, Hiroyasu Okazaki, Hisanori Uehara, Keisuke Izumi, Saburo Sone and Yasuhiko Nishioka :
Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.,
American Journal of Respiratory Cell and Molecular Biology, Vol.49, No.4, 536-543, 2013.- (要約)
- Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase involved in various biological functions, including cell survival, proliferation, migration, and adhesion. FAK is an essential factor for transforming growth factor to induce myofibroblast differentiation. In the present study, we investigated whether the targeted inhibition of FAK by using a specific inhibitor, TAE226, has the potential to regulate pulmonary fibrosis. TAE226 showed inhibitory activity of autophosphorylation of FAK at tyrosine 397 in lung fibroblasts. The addition of TAE226 inhibited the proliferation of lung fibroblasts in response to various growth factors, including platelet-derived growth factor and insulin-like growth factor I, in vitro. TAE226 strongly suppressed the production of type I collagen by lung fibroblasts. Furthermore, treatment of fibroblasts with TAE226 reduced the expression of -smooth muscle actin induced by transforming growth factor , indicating the inhibition of differentiation of fibroblasts to myofibroblasts. Administration of TAE226 ameliorated the pulmonary fibrosis induced by bleomycin in mice even when used late in the treatment. The number of proliferating mesenchymal cells was reduced in the lungs of TAE226-treated mice. These data suggest that FAK signal plays a significant role in the progression of pulmonary fibrosis and that it can become a promising target for therapeutic approaches to pulmonary fibrosis.
- (キーワード)
- Actins / Animals / Bleomycin / Cell Differentiation / Cell Proliferation / Collagen Type I / DNA / Epithelial Cells / Female / Fibroblasts / Focal Adhesion Kinase 1 / Insulin-Like Growth Factor I / Mesenchymal Stromal Cells / Mice / Mice, Inbred C57BL / Morpholines / Myofibroblasts / Phosphorylation / Platelet-Derived Growth Factor / Protein Kinase Inhibitors / Pulmonary Fibrosis / Transforming Growth Factor beta / Tyrosine
- (徳島大学機関リポジトリ)
- ● Metadata: 106054
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1165/rcmb.2012-0277OC
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23642017
- ● Search Scopus @ Elsevier (PMID): 23642017
- ● Search Scopus @ Elsevier (DOI): 10.1165/rcmb.2012-0277OC
(徳島大学機関リポジトリ: 106054, DOI: 10.1165/rcmb.2012-0277OC, PubMed: 23642017) Jun Huang, Sho Tabata, Souji Kakiuchi, Trung Van The, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka :
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.,
Oncotarget, Vol.4, No.8, 1172-1184, 2013.- (要約)
- Despite recent advances in treatment, malignant pleural mesothelioma (MPM) remains a deadly disease. Targeted therapy generated broad interests and is highly expected for the treatment of MPM, yet promising preclinical results have not been translated into substantial clinical benefits for the patients. In this study, we tried to identify the genes which play functional roles in cell migration as well as to test whether they can be used as novel targets for molecular targeted therapy for MPM in preclinical model. In our study, pregnancy-associated plasma protein A (PAPPA) was identified as a gene whose expression level is correlated with MPM cell migration by correlation analysis combining MPM cell migration ability and their gene expression profiles. Highly migratory cells were selected from MPM cell lines, MSTO-211H, NCI-H290 and EHMES-1 in vitro and up-regulation of PAPPA in these cells were confirmed. In vitro, PAPPA was demonstrated to stimulate the MPM cell migration via cleavage of insulin-like growth factor-binding protein-4 and subsequent release of IGF-1. Gene silencing of PAPPA in MPM cells led to reduced migration, invasion and proliferation. Furthermore, PAPPA shRNA transfected NCI-H290 when orthotopically inoculated into pleural cavity of severe combined immunodeficiency recipient mice, failed to develop tumors and produce bloody pleural effusion as control shRNA transfected cells did. Our study suggests that PAPPA plays a functional role in promoting MPM cell migration and it might serve as a potential therapeutic target for the treatment of MPM.
- (キーワード)
- Animals / Cell Growth Processes / Cell Line, Tumor / Cell Movement / Female / Gene Silencing / Genetic Therapy / Heterografts / Humans / Insulin-Like Growth Factor Binding Protein 4 / Insulin-Like Growth Factor I / Lung Neoplasms / Male / Mesothelioma / Mice / Mice, SCID / Neoplasm Transplantation / Pregnancy / Pregnancy-Associated Plasma Protein-A / RNA, Small Interfering / Transfection
- (徳島大学機関リポジトリ)
- ● Metadata: 105907
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.18632/oncotarget.1126
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23896451
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84884321230
(徳島大学機関リポジトリ: 105907, DOI: 10.18632/oncotarget.1126, PubMed: 23896451, Elsevier: Scopus) Akifumi Honjo, Hirohisa Ogawa, Masahiko Azuma, Toshifumi Tezuka, Saburo Sone, Arya Biragyn and Yasuhiko Nishioka :
Targeted reduction of CCR4 cells is sufficient to suppress allergic airway inflammation.,
Respiratory Investigation, Vol.51, No.4, 241-249, 2013.- (徳島大学機関リポジトリ)
- ● Metadata: 105964
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2013.04.007
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24238232
- ● Search Scopus @ Elsevier (PMID): 24238232
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2013.04.007
(徳島大学機関リポジトリ: 105964, DOI: 10.1016/j.resinv.2013.04.007, PubMed: 24238232) Shinji Abe, Yuki Morita, Mika Kato Kaneko, Masaki Hanibuchi, Yuta Tsujimoto, Hisatsugu Goto, Souji Kakiuchi, Yoshinori Aono, Jun Huang, Seidai Sato, Masatoshi Kishuku, Yuki Taniguchi, Mami Azuma, Kazuyoshi Kawazoe, Yoshitaka Sekido, Seiji Yano, Shin-ichi Akiyama, Saburo Sone, Kazuo Minakuchi, Yukinari Kato and Yasuhiko Nishioka :
A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody,
The Journal of Immunology, Vol.190, No.12, 6239-6249, 2013.- (要約)
- Podoplanin (Aggrus), which is a type I transmembrane sialomucin-like glycoprotein, is highly expressed in malignant pleural mesothelioma (MPM). We previously reported the generation of a rat anti-human podoplanin Ab, NZ-1, which inhibited podoplanin-induced platelet aggregation and hematogenous metastasis. In this study, we examined the antitumor effector functions of NZ-1 and NZ-8, a novel rat-human chimeric Ab generated from NZ-1 including Ab-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against MPM in vitro and in vivo. Immunostaining with NZ-1 showed the expression of podoplanin in 73% (11 out of 15) of MPM cell lines and 92% (33 out of 36) of malignant mesothelioma tissues. NZ-1 could induce potent ADCC against podoplanin-positive MPM cells mediated by rat NK (CD161a(+)) cells, but not murine splenocytes or human mononuclear cells. Treatment with NZ-1 significantly reduced the growth of s.c. established tumors of MPM cells (ACC-MESO-4 or podoplanin-transfected MSTO-211H) in SCID mice, only when NZ-1 was administered with rat NK cells. In in vivo imaging, NZ-1 efficiently accumulated to xenograft of MPM, and its accumulation continued for 3 wk after systemic administration. Furthermore, NZ-8 preferentially recognized podoplanin expressing in MPM, but not in normal tissues. NZ-8 could induce higher ADCC mediated by human NK cells and complement-dependent cytotoxicity as compared with NZ-1. Treatment with NZ-8 and human NK cells significantly inhibited the growth of MPM cells in vivo. These results strongly suggest that targeting therapy to podoplanin with therapeutic Abs (i.e., NZ-8) derived from NZ-1 might be useful as a novel immunotherapy against MPM.
- (キーワード)
- Animals / Antibodies, Monoclonal / Flow Cytometry / Humans / Immunohistochemistry / Immunotherapy / Male / Membrane Glycoproteins / Mesothelioma / Mice / Mice, SCID / Pleural Neoplasms / Rats / Rats, Wistar / Recombinant Fusion Proteins / Xenograft Model Antitumor Assays
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.4049/jimmunol.1300448
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23690472
- ● Search Scopus @ Elsevier (PMID): 23690472
- ● Search Scopus @ Elsevier (DOI): 10.4049/jimmunol.1300448
(DOI: 10.4049/jimmunol.1300448, PubMed: 23690472) Tsukasa Okamoto, Yasunari Miyazaki, Takashi Ogura, Kingo Chida, Nobuoki Kohno, Shigeru Kohno, Hiroyuki Taniguchi, Shinobu Akagawa, Yoshiro Mochizuki, Kohei Yamauchi, Hiroki Takahashi, Takeshi Johkoh, Sakae Homma, Kazuma Kishi, Soichiro Ikushima, Satoshi Konno, Michiaki Mishima, Ken Ohta, Yasuhiko Nishioka, Nobuyuki Yoshimura, Mitsuru Munakata, Kentaro Watanabe, Yoshihiro Miyashita and Naohiko Inase :
A nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan.,
Respiratory Investigation, Vol.51, No.3, 191-199, 2013.- (要約)
- The proportion of bird-related HP was higher than that in the previous epidemiological survey, and the proportions of isocyanate-induced HP and farmer's lung were lower. A crucial step in diagnosing chronic HP is to thoroughly explore the possibility of antigen exposure.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2013.03.004
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23978646
- ● Search Scopus @ Elsevier (PMID): 23978646
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2013.03.004
(DOI: 10.1016/j.resinv.2013.03.004, PubMed: 23978646) Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, G Julie Ledford, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages.,
The American Journal of Pathology, Vol.182, No.5, 1843-1853, 2013.- (要約)
- Surfactant protein A (SP-A) is a large multimeric protein found in the lungs. In addition to its immunoregulatory function in infectious respiratory diseases, SP-A is also used as a marker of lung adenocarcinoma. Despite the finding that SP-A expression levels in cancer cells has a relationship with patient prognosis, the function of SP-A in lung cancer progression is unknown. We investigated the role of SP-A in lung cancer progression by introducing the SP-A gene into human lung adenocarcinoma cell lines. SP-A gene transduction suppressed the progression of tumor in subcutaneous xenograft or lung metastasis mouse models. Immunohistochemical analysis showed that the number of M1 antitumor tumor-associated macrophages (TAMs) was increased and the number of M2 tumor-promoting TAMs was not changed in the tumor tissue produced by SP-A-expressing cells. In addition, natural killer (NK) cells were also increased and activated in the SP-A-expressing tumor. Moreover, SP-A did not inhibit tumor progression in mice depleted of NK cells. Taking into account that SP-A did not directly activate NK cells, these results suggest that SP-A inhibited lung cancer progression by recruiting and activating NK cells via controlling the polarization of TAMs.
- (徳島大学機関リポジトリ)
- ● Metadata: 106071
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.ajpath.2013.01.030
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23499372
- ● Search Scopus @ Elsevier (PMID): 23499372
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.ajpath.2013.01.030
(徳島大学機関リポジトリ: 106071, DOI: 10.1016/j.ajpath.2013.01.030, PubMed: 23499372) 青野 純典, 岸 昌美, 岡﨑 弘泰, 竹﨑 彰夫, 西岡 安彦 :
ブレオマイシン誘発肺線維症モデルにおけるPDGFレセプターα，β阻害抗体の抗線維化効果,
分子呼吸器病, Vol.17, No.1, 136-139, 2013年. Shino Yuasa, Harutaka Yamaguchi, Yoshinori Nakanishi, Shingo Kawaminami, Ryo Tabata, Nobuhiko Shimizu, Mitsuhiro Kohno, Teruki Shimizu, Junya Miyata, Mayuko Nakayama, Jun Kishi, Yuko Toyoda, Yasuhiko Nishioka and Kenji Tani :
Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents.,
The Journal of Medical Investigation : JMI, Vol.60, No.1-2, 77-90, 2013.- (要約)
- Biological agents represent an important advancement in for the treatment of rheumatoid arthritis (RA), but there is a subset of patients who do not improve despite therapy. This study aimed to determine the efficacy of biological agents for RA and to identify clinical factors that are associated with their response. We studied 98 patients with RA who started an initiating biological agent which was selected from infliximab, etanercept, adalimumab and tociliximab at 4 medical institutions. Etanercept was the most frequently used biological agent followed by infliximab although there was a difference in the selection of the biological agents among medical institutions. We found that etanercept achieved the highest treatment response, remission rate and drug survival rate. A high disease activity in the baseline disease activity score-c-reactive protein (CRP) was shown to be a negative predictor of the treatment response, and high patient global assessment was significantly less likely to achieve a good response. At week 4, decreases in 28 swollen joint counts and CRP were useful as predictors for sustaining the efficacy up to week 48. These data demonstrate that assessments of the disease activity at baseline and the early treatment response may be useful in predicting the efficacy and drug survival rate of biological agents.
- (徳島大学機関リポジトリ)
- ● Metadata: 111302
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.60.77
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614915
- ● Search Scopus @ Elsevier (PMID): 23614915
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.77
(徳島大学機関リポジトリ: 111302, DOI: 10.2152/jmi.60.77, PubMed: 23614915) Hideki Makino, Yoshinori Aono, Momoyo Azuma, Masami Kishi, Yuki Yokota, Katsuhiro Kinoshita, Akio Takezaki, Jun Kishi, Hiroshi Kawano, Hirohisa Ogawa, Hisanori Uehara, Keisuke Izumi, Saburo Sone and Yasuhiko Nishioka :
Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice.,
The Journal of Medical Investigation : JMI, Vol.60, No.1-2, 127-137, 2013.- (要約)
- Circulating fibrocytes had been reported to migrate into the injured lungs, and contribute to fibrogenesis via chemokine-chemokine receptor systems including CXCL12-CXCR4 axis. Here we hypothesized that blockade of CXCR4 might inhibit the migration of fibrocytes to the injured lungs and the subsequent pulmonary fibrosis. To explore the antifibrotic effects of blockade of CXCR4, we used a specific antagonist for CXCR4, AMD3100, in bleomycin-induced pulmonary fibrosis model in mice. Administration of AMD3100 significantly improved the loss of body weight of mice treated with bleomycin, and inhibited the fibrotic lesion in subpleural areas of the lungs. The quantitative analysis demonstrated that treatment with AMD3100 reduced the collagen content and fibrotic score (Aschcroft score) in the lungs. Although AMD3100 did not affect cell classification in bronchoalveolar lavage fluid on day 7, the percentage of lymphocytes was reduced by AMD3100 on day 14. AMD3100 directly inhibited the migration of human fibrocytes in response to CXCL12 in vitro, and reduced the trafficking of fibrocytes into the lungs treated with bleocmycin in vivo. These results suggest that the blockade of CXCR4 might be useful strategy for therapy of patients with pulmonary fibrosis via inhibiting the migration of circulating fibrocytes.
- (徳島大学機関リポジトリ)
- ● Metadata: 106047
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.60.127
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614921
- ● Search Scopus @ Elsevier (PMID): 23614921
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.127
(徳島大学機関リポジトリ: 106047, DOI: 10.2152/jmi.60.127, PubMed: 23614921) T Yamada, S Takeuchi, N Fujita, A Nakamura, W Wang, Q Li, M Oda, T Mitsudomi, Y Yatabe, Y Sekido, J Yoshida, M Higashiyama, M Noguchi, H Uehara, Yasuhiko Nishioka, Saburo Sone and Seiji Yano :
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations,
Oncogene, Vol.32, No.37, 4427-4435, 2012.- (要約)
- Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung cancer patients always acquire resistance to EGFR-tyrosine kinase inhibitors (TKIs). Gatekeeper T790M mutation in EGFR is the most prevalent genetic alteration underlying acquired resistance to EGFR-TKI, and EGFR mutant lung cancer cells are reported to be addictive to EGFR/Akt signaling even after acquired T790M mutation. Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinositide 3-kinase)/PDK1 (3-phosphoinositide-dependent protein kinase)/Akt that determines receptor signal selectivity for non-mutated EGFR, and assessed its role in EGFR mutant lung cancer with or without gatekeeper T790M mutation. Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M gatekeeper mutation. Silencing of Aki1 induced apoptosis of EGFR mutant lung cancer cells. Treatment with Aki1 siRNA dramatically inhibited growth of H1975 cells in a xenograft model. Moreover, silencing of Aki1 further potentiated growth inhibitory effect of new generation EGFR-TKIs against H1975 cells in vitro. Aki1 was frequently expressed in tumor cells of EGFR mutant lung cancer patients (53/56 cases), including those with acquired resistance to EGFR-TKI treatment (7/7 cases). Our data suggest that Aki1 may be a critical mediator of survival signaling from mutant EGFR to Akt, and may therefore be an ideal target for EGFR mutant lung cancer patients, especially those with acquired EGFR-TKI resistance due to EGFR T790M gatekeeper mutation.
- (キーワード)
- Animals / アポトーシス (apoptosis) / Cell Line, Tumor / Cell Proliferation / Cell Survival / DNA-Binding Proteins / Disease Models, Animal / 遺伝子発現 (gene expression) / Gene Knockdown Techniques / Humans / Ligands / Lung Neoplasms / Mice / Mutation / Protein Binding / Protein Kinase Inhibitors / Receptor, Epidermal Growth Factor / Transplantation, Heterologous
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1038/onc.2012.446
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23045273
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84884210769
(DOI: 10.1038/onc.2012.446, PubMed: 23045273, Elsevier: Scopus) 仙崎 聖子, 廣瀬 憲志, 石上 剛史, 村尾 和俊, 久保 宜明, 西岡 安彦 :
ピルフェニドンによる光線過敏症の2例,
臨床皮膚科, Vol.66, No.12, 945-948, 2012年.- (キーワード)
- ピルフェニドン / 光線過敏症 / 光毒性
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390283684869687680
(CiNii: 1390283684869687680) Seidai Satou, Masaki Hanibuchi, Takuya Kuramoto, Nodoka Yamamori, Hisatsugu Goto, Hirohisa Ogawa, Atsushi Mitsuhashi, The Trung Van, Souji Kakiuchi, Shin-ichi Akiyama, Yasuhiko Nishioka and Saburo Sone :
Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment.,
Clinical & Experimental Metastasis, Vol.30, No.3, 333-344, 2012.- (要約)
- The organ microenvironment significantly affects the processes of cancer metastasis. Elucidating the molecular mechanisms of interaction between tumor cells and the organ microenvironment is crucial for the development of effective therapeutic strategies to eradicate cancer metastases. Macrophage stimulating protein (MSP), an activator of macrophages, regulates a pleiotropic array of effects, including proliferation, cellular motility, invasiveness, angiogenesis, and resistance to anoikis. However, the role of MSP in cancer metastasis is still largely unknown. In this study, the action of MSP on the production of metastases was determined in a multiple-organ metastasis model. The murine MSP gene was transfected into two human SCLC cell lines, SBC-5 and H1048, to establish transfectants secreting biologically active MSP. MSP gene transduction did not affect cell proliferation and motility in vitro. Intravenously inoculated MSP transfectants produced significantly larger numbers of liver metastases than parental cells or vector control clones, while there were no significant differences in bone or lung metastases among them. Immunohistochemical analyses of liver metastases revealed that tumor-associated microvessel density and tumor-infiltrating macrophages were significantly increased in lesions produced by MSP transfectants. MSP could stimulate the migration of murine macrophages and endothelial cells in vitro. Consequently, MSP may be one of the major determinants that affects the properties of tumor stroma and that produces a permissive microenvironment to promote cancer metastasis.
- (キーワード)
- Animals / Base Sequence / Blotting, Western / Cell Line, Tumor / Cell Proliferation / DNA Primers / Hepatocyte Growth Factor / Humans / Liver Neoplasms / Lung Neoplasms / Mice / Mice, SCID / Proto-Oncogene Proteins / Real-Time Polymerase Chain Reaction / Reverse Transcriptase Polymerase Chain Reaction / Transduction, Genetic / Tumor Microenvironment
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1007/s10585-012-9540-y
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23011677
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84875792986
(DOI: 10.1007/s10585-012-9540-y, PubMed: 23011677, Elsevier: Scopus) Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Atsuro Saijo, Souji Kakiuchi, Yoichi Maekawa, Koji Yasutomo, Masaki Hanibuchi, Shin-ichi Akiyama, Saburo Sone and Yasuhiko Nishioka :
Dll4-Fc, an inhibitor of Dll4-Notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity,
Molecular Cancer Therapeutics, Vol.11, No.12, 2578-2587, 2012.- (要約)
- Notch signaling regulates cell-fate decisions during development and postnatal life. Little is known, however, about the role of Delta-like-4 (Dll4)-Notch signaling between cancer cells, or how this signaling affects cancer metastasis. We, therefore, assessed the role of Dll4-Notch signaling in cancer metastasis. We generated a soluble Dll4 fused to the IgG1 constant region (Dll4-Fc) that acts as a blocker of Dll4-Notch signaling and introduced it into human small cell lung cancer (SCLC) cell lines expressing either high levels (SBC-3 and H1048) or low levels (SBC-5) of Dll4. The effects of Dll4-Fc on metastasis of SCLC were evaluated using a mouse model. Although Dll4-Fc had no effect on the liver metastasis of SBC-5, the number of liver metastasis inoculated with SBC-3 and H1048 cells expressing Dll4-Fc was significantly lower than that injected with control cells. To study the molecular mechanisms of the effects of Dll4-Fc on liver metastasis, a PCR array analysis was conducted. Because the expression of NF-κB target genes was affected by Dll4-Fc, we conducted an electrophoretic mobility shift assay and observed that NF-κB activities, both with and without stimulation by TNF-α, were downregulated in Dll4-Fc-overexpressing SBC-3 and H1048 cells compared with control cells. Moreover, Dll4-Fc attenuates, at least in part, the classical and alternative NF-κB activation pathway by reducing Notch1 signaling. These results suggest that Dll4-Notch signaling in cancer cells plays a critical role in liver metastasis of SCLC by regulating NF-κB signaling.
- (キーワード)
- Animals / アポトーシス (apoptosis) / Cell Growth Processes / Cell Movement / Down-Regulation / Humans / Liver Neoplasms, Experimental / Lung Neoplasms / Male / Mice / Mice, SCID / NF-kappa B / Receptors, Notch / Recombinant Fusion Proteins / シグナル伝達 (signal transduction) / Small Cell Lung Carcinoma / Transfection / Xenograft Model Antitumor Assays
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1158/1535-7163.MCT-12-0640
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22989420
- ● Search Scopus @ Elsevier (PMID): 22989420
- ● Search Scopus @ Elsevier (DOI): 10.1158/1535-7163.MCT-12-0640
(DOI: 10.1158/1535-7163.MCT-12-0640, PubMed: 22989420) Kato Mika Kaneko, Akiko Kunita, Shinji Abe, Yuta Tsujimoto, Masashi Fukayama, Kaoru Goto, Yoshihiko Sawa, Yasuhiko Nishioka and Yukinari Kato :
Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.,
Cancer Science, Vol.103, No.11, 1913-1919, 2012.- (要約)
- Podoplanin is a platelet aggregation-inducing factor associated with tumor metastasis, malignant progression, and cancer stem cells. We produced a rat-human chimeric anti-podoplanin mAb, NZ-8, from rat anti-podoplanin mAb (NZ-1). Although both NZ-1 and NZ-8 possess high binding affinities and high neutralizing activities of platelet aggregation, the antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity of NZ-8 were much higher than NZ-1. Furthermore, both NZ-1 and NZ-8 inhibited the growth of podoplanin-expressing tumors in vivo. Both NZ-1 and NZ-8 also suppressed hematogenous metastasis of podoplanin-expressing tumors. These results suggest that anti-podoplanin mAbs suppressed hematogenous metastasis by both neutralization and antibody-dependent cellular cytotoxicity/complement-dependent cytotoxicity activities. Targeting therapy to podoplanin-expressing tumors should be useful as a novel immunotherapy.
- (キーワード)
- Animals / Antibodies, Monoclonal / Antibodies, Neutralizing / Antibody-Dependent Cell Cytotoxicity / Antineoplastic Agents / CHO Cells / Cell Line, Tumor / Complement System Proteins / Cricetinae / Female / Humans / Male / Membrane Glycoproteins / Mice / Mice, Inbred BALB C / Mice, Nude / Neoplasm Metastasis / Neoplasms / Platelet Aggregation / Rats / Rats, Wistar / Recombinant Fusion Proteins
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1349-7006.2012.02385.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22816430
- ● Search Scopus @ Elsevier (PMID): 22816430
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.2012.02385.x
(DOI: 10.1111/j.1349-7006.2012.02385.x, PubMed: 22816430) 矢野 祖, 西條 敦郎, 近藤 真代, 河野 弘, 豊田 優子, 柿内 聡司, 岸 潤, 埴淵 昌毅, 古川 貴大, 藤田 浩司, 西岡 安彦 :
神経根障害で発症した神経サルコイドーシスの一例,
四国医学雑誌, Vol.68, No.3,4, 153-158, 2012年.- (要約)
- A52-year-old woman was referred to our hospital for further examination of thoracolumbarpain. As dysesthesia at Th4level was seen in neurological examination, thoracic radiculopathy ormyelopathy was suspected. Blood examination showed elevated level of serum ACE and lysozyme.Lymphadenopathy was evident in bilateral hila and mediastina with marked FDG and Galliumaccumulation in FDG-PET-CT and Gallium scintigraphy, respectively. The number of lymphocytesand the CD4/CD8ratio were increased in the BALF. Histological findings of specimens obtainedfrom the lung and the skin lesion revealed noncaseating epithelioid granuloma, which yielded thediagnosis of sarcoidosis. The cerebrospinal fluid examinations showed elevated level of cell counts,proteins and β2-microglobulin. Taken together, she was diagnosed as neurosarcoidosis with thoracicradiculopathy. Her symptoms were improved with oral administration of prednisolone, butthey were exacerbated when prednisolone dose was tapered to20mg/day. Combined therapy ofmethotrexate and prednisolone was initiated, thereafter her symptoms disappeared completely.
- (キーワード)
- neurosarcoidosis / radiculopathy / prednisolone / methotrexate
- (徳島大学機関リポジトリ)
- ● Metadata: 102837
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1050845763842119680
(徳島大学機関リポジトリ: 102837, CiNii: 1050845763842119680) Trung The Van, Masaki Hanibuchi, Hisatsugu Goto, Takuya Kuramoto, Sawaka Yukishige, Souji Kakiuchi, Seidai Sato, Satoshi Sakaguchi, Le Tan Dat, Yasuhiko Nishioka, Shin-ichi Akiyama and Saburo Sone :
SU6668, a multiple tyrosine kinase inhibitor, inhibits the progression of human malignant pleural mesothelioma in an orthotopic model,
Respirology, Vol.17, No.6, 984-990, 2012.- (要約)
- Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the mesothelium with high chemotherapeutic resistance. In this study, the preclinical therapeutic activity of the multiple tyrosine kinase inhibitor, SU6668, against MPM was examined. Two human MPM cell lines with different pro-angiogenic cytokine expression, Y-MESO-14 cells that express high levels of vascular endothelial growth factor (VEGF) and MSTO-211H cells that express high levels of basic fibroblast growth factor (bFGF), were orthotopically inoculated into the thoracic cavities of mice with severe combined immunodeficiency. The mice with MPM were treated or not treated with SU6668 (200 mg/kg/day). SU6668 abrogated the proliferation of endothelial cells stimulated by VEGF or bFGF, but did not directly affect the growth of human MPM cells in vitro. In this orthotopic implantation model, treatment with SU6668 effectively reduced tumour weight and pleural effusion volumes, in association with inhibition of the growth of tumour vasculature. More importantly, treatment with SU6668 significantly prolonged survival time in mice with MPM. These findings suggest that SU6668 has a promising therapeutic effect on the progression of MPM in vivo through its anti-angiogenic effects.
- (キーワード)
- Animals / Antineoplastic Agents / Cell Line, Tumor / Cell Proliferation / Fibroblast Growth Factor 2 / Humans / Indoles / Male / Mesothelioma / Mice / Mice, SCID / Neovascularization, Pathologic / Pleural Effusion, Malignant / Pleural Neoplasms / Protein Kinase Inhibitors / Pyrroles / Vascular Endothelial Growth Factor A / Xenograft Model Antitumor Assays
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1440-1843.2012.02193.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22574723
- ● Search Scopus @ Elsevier (PMID): 22574723
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1440-1843.2012.02193.x
(DOI: 10.1111/j.1440-1843.2012.02193.x, PubMed: 22574723) Shinji Takeuchi, Wei Wang, Qi Li, Tadaaki Yamada, Kenji Kita, S Ivan Donev, Takahiro Nakamura, Kunio Matsumoto, Eiji Shimizu, Yasuhiko Nishioka, Saburo Sone, Takayuki Nakagawa, Toshimitsu Uenaka and Seiji Yano :
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.,
The American Journal of Pathology, Vol.181, No.3, 1034-1043, 2012.- (要約)
- Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a serious problem in the management of EGFR mutant lung cancer. We recently reported that hepatocyte growth factor (HGF) induces resistance to EGFR-TKIs by activating the Met/PI3K pathway. HGF is also known to induce angiogenesis in cooperation with vascular endothelial growth factor (VEGF), which is an important therapeutic target in lung cancer. Therefore, we hypothesized that dual inhibition of HGF and VEGF may be therapeutically useful for controlling HGF-induced EGFR-TKI-resistant lung cancer. We found that a dual Met/VEGF receptor 2 kinase inhibitor, E7050, circumvented HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer cell lines by inhibiting the Met/Gab1/PI3K/Akt pathway in vitro. HGF stimulated VEGF production by activation of the Met/Gab1 signaling pathway in EGFR mutant lung cancer cell lines, and E7050 showed an inhibitory effect. In a xenograft model, tumors produced by HGF-transfected Ma-1 (Ma-1/HGF) cells were more angiogenic than vector control tumors and showed resistance to gefitinib. E7050 alone inhibited angiogenesis and retarded growth of Ma-1/HGF tumors. E7050 combined with gefitinib induced marked regression of tumor growth. Moreover, dual inhibition of HGF and VEGF by neutralizing antibodies combined with gefitinib also markedly regressed tumor growth. These results indicate the therapeutic rationale of dual targeting of HGF-Met and VEGF-VEGF receptor 2 for overcoming HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
- (キーワード)
- Aminopyridines / Animals / Antibodies / Antibody Specificity / Cell Line, Tumor / Drug Resistance, Neoplasm / Hepatocyte Growth Factor / Humans / Lung Neoplasms / Mice / Models, Biological / Mutation / Neovascularization, Pathologic / Piperazines / Proto-Oncogene Proteins c-met / Quinazolines / Receptor, Epidermal Growth Factor / Vascular Endothelial Growth Factor A / Vascular Endothelial Growth Factor Receptor-2 / Xenograft Model Antitumor Assays
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.ajpath.2012.05.023
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22789825
- ● Search Scopus @ Elsevier (PMID): 22789825
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.ajpath.2012.05.023
(DOI: 10.1016/j.ajpath.2012.05.023, PubMed: 22789825) Sho Tabata, Ryuji Ikeda, Masatatu Yamamoto, Tatsuhiko Furukawa, Takuya Kuramoto, Yasuo Takeda, Katsushi Yamada, Misako Haraguchi, Yasuhiko Nishioka, Saburo Sone and Shin-ichi Akiyama :
Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells.,
Oncology Reports, Vol.28, No.3, 895-902, 2012.- (要約)
- Thymidine phosphorylase (TP) is an angiogenic factor that plays a pivotal role in tumor angiogenesis. Various kinds of solid tumors express TP and high TP activity is correlated with microvessel density. We have previously reported that TP enhances interleukin-8 (IL-8) expression in KB human epidermoid carcinoma cells. In this study, TP was shown to be involved in enhanced expression of IL-8 in EJ human bladder cancer cells and Yumoto human cervical cancer cells as well as KB human epidermoid carcinoma cells. The enzymatic activity of TP was required for the enhanced expression of IL-8. A degradation product of thymidine was implicated in the enhanced expression of IL-8. TP augmented reactive oxygen species (ROS) generation in KB and Yumoto cells, and the enzymatic activity of TP was again required for the generation of ROS. An antioxidant, N-acetylcysteine (NAC), attenuated the generation of ROS and IL-8 mRNA expression in KB and Yumoto cells, and H2O2 increased IL-8 mRNA expression in Yumoto cells, suggesting that ROS generated by TP caused the increased expression of IL-8 mRNA. Since TP also reduced cellular glutathione levels and transcription of γ-GCS in KB cells, the TP-induced augmentation of ROS may be partially attributed to the decreased glutathione. Our findings suggest that thymidine-derived sugars enhanced ROS generation and consequently increased IL-8 expression.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3892/or.2012.1887
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22751949
- ● Search Scopus @ Elsevier (PMID): 22751949
- ● Search Scopus @ Elsevier (DOI): 10.3892/or.2012.1887
(DOI: 10.3892/or.2012.1887, PubMed: 22751949) 坂本 晋一, 梶浦 耕一郎, 滝沢 宏光, 中川 靖士, 池田 真由美, 古川 尊子, 森本 雅美, 西野 豪志, 後藤 正和, 中川 美砂子, 山本 洋太, 古北 由仁, 武知 浩和, 吉田 光輝, 川上 行奎, 田所 由紀子, 先山 正二, 近藤 和也, 坂東 良美, 岡崎 弘泰, 後東 久嗣, 西岡 安彦, 丹黒 章 :
Erlotinibでinduction therapyを行ったIIIA期非小細胞肺癌の1手術例,
四国医学雑誌, Vol.68, No.5-6, 251-256, 2012年.- (キーワード)
- Carcinoembryonic Antigen(血液)
- (徳島大学機関リポジトリ)
- ● Metadata: 110365
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1050282812441819136
(徳島大学機関リポジトリ: 110365, CiNii: 1050282812441819136) Adel Gomaa Mohammed Gabr, Hisatsugu Goto, Masaki Hanibuchi, Hirohisa Ogawa, Takuya Kuramoto, Minako Suzuki, Atsuro Saijo, Souji Kakiuchi, Van The Trung, Satoshi Sakaguchi, Yoichiro Moriya, Saburo Sone and Yasuhiko Nishioka :
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression,
Clinical & Experimental Metastasis, Vol.29, No.3, 207-216, 2012.- (要約)
- Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) show dramatic antitumor activity in a subset of patients with non-small cell lung cancer who have an active mutation in the epidermal growth factor receptor (EGFR) gene. On the other hand, some lung cancer patients with wild type EGFR also respond to EGFR-TKIs, suggesting that EGFR-TKIs have an effect on host cells as well as tumor cells. However, the effect of EGFR-TKIs on host microenvironments is largely unknown. A multiple organ metastasis model was previously established in natural killer cell-depleted severe combined immunodeficient mice using human lung cancer cells. This model was used to investigate the therapeutic efficacy of erlotinib, an EGFR-TKI, on multiple organ metastases induced by human small cell lung cancer cells (SBC-5 cells) that did not express EGFR. Although erlotinib did not have any effect on the proliferation of SBC-5 cells in vitro, it significantly suppressed bone and lung metastases in vivo, but not liver metastases. An immunohistochemical analysis revealed that, erlotinib significantly suppressed the number of osteoclasts in bone metastases, whereas no difference was seen in microvessel density. Moreover, erlotinib inhibited EGF-induced receptor activator of nuclear factor kappa-B expression in an osteoblastic cell line (MC3T3-E1 cells). These results strongly suggested that erlotinib prevented bone metastases by affecting host microenvironments irrespective of its direct effect on tumor cells.
- (キーワード)
- Animals / Bone Neoplasms / Carcinoma, Small Cell / Cell Line, Tumor / Cell Movement / Cell Proliferation / Epidermal Growth Factor / Humans / Lung Neoplasms / Male / Mice / Neoplasm Metastasis / Neovascularization, Pathologic / Osteoblasts / Osteoclasts / Protein Kinase Inhibitors / Quinazolines / RANK Ligand / Receptor, Epidermal Growth Factor
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1007/s10585-011-9443-3
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22170031
- ● Search Scopus @ Elsevier (PMID): 22170031
- ● Search Scopus @ Elsevier (DOI): 10.1007/s10585-011-9443-3
(DOI: 10.1007/s10585-011-9443-3, PubMed: 22170031) Yoshinori Aono, Julie G. Ledford, Sambuddho Mukherjee, Hirohisa Ogawa, Yasuhiko Nishioka, Saburo Sone, Michael F. Beers, Paul W. Noble and Jo Rae Wright :
Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury.,
American Journal of Respiratory and Critical Care Medicine, Vol.185, No.5, 525-536, 2012.- (要約)
- Surfactant protein (SP)-D and SP-A have been implicated in immunomodulation in the lung. It has been reported that patients with idiopathic pulmonary fibrosis (IPF) often have elevated serum levels of SP-A and SP-D, although their role in the disease is not known. The goal of this study was to test the hypothesis that SP-D plays an important role in lung fibrosis using a mouse model of fibrosis induced by bleomycin (BLM). Triple transgenic inducible SP-D mice (iSP-D mice), in which rat SP-D is expressed in response to doxycycline (Dox) treatment, were administered BLM (100 U/kg) or saline subcutaneously using miniosmotic pumps. BLM-treated iSP-D mice off Dox (SP-D off) had increased lung fibrosis compared with mice on Dox (SP-D on). SP-D deficiency also increased macrophage-dominant cell infiltration and the expression of profibrotic cytokines (transforming growth factor [TGF]-1, platelet-derived growth factor-AA). Alveolar macrophages isolated from BLM-treated iSP-D mice off Dox (SP-D off) secreted more TGF-1. Fibrocytes, which are bone marrow-derived mesenchymal progenitor cells, were increased to a greater extent in the lungs of the BLM-treated iSP-D mice off Dox (SP-D off). Fibrocytes isolated from BLM-treated iSP-D mice off Dox (SP-D off) expressed more of the profibrotic cytokine TGF-1 and more CXCR4, a chemokine receptor that is important in fibrocyte migration into the lungs. Exogenous SP-D administered intratracheally attenuated BLM-induced lung fibrosis in SP-D(-/-) mice. These data suggest that alveolar SP-D regulates numbers of macrophages and fibrocytes in the lungs, profibrotic cytokine expression, and fibrotic lung remodeling in response to BLM injury.
- (キーワード)
- Acute Lung Injury / Airway Remodeling / Animals / Bleomycin / Bronchoalveolar Lavage Fluid / Cytokines / Disease Models, Animal / Idiopathic Pulmonary Fibrosis / Lung / Macrophages / Mice / Mice, Inbred C57BL / Mice, Knockout / Mice, Transgenic / Pulmonary Surfactant-Associated Protein A / Pulmonary Surfactant-Associated Protein D / Rats
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/rccm.201103-0561OC
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22198976
- ● Search Scopus @ Elsevier (PMID): 22198976
- ● Search Scopus @ Elsevier (DOI): 10.1164/rccm.201103-0561OC
(DOI: 10.1164/rccm.201103-0561OC, PubMed: 22198976) Hirohisa Ogawa, Masahiko Azuma, Hisanori Uehara, Tetsuyuki Takahashi, Yasuhiko Nishioka, Saburo Sone and Keisuke Izumi :
Nerve growth factor derived from bronchial epithelium afer chronic mite antigen exposure contributes to airway hyperresponsiveness by inducing hyperinnervaiton, and is inhibited by in vivo siRNA.,
Clinical and Experimental Allergy, Vol.42, No.3, 460-470, 2012.- (要約)
- Bronchial asthma is a chronic allergic airway inflammatory disease. Neurotrophins, including nerve growth factor (NGF), play an important role in the pathogenesis of asthma. However, the effects of NGF derived from epithelium on airway hyperresponsiveness (AHR) after antigen sensitization/exposure remain uncertain. In this study, we examined the role of NGF on AHR after chronic antigen exposure and the effect of inhibiting NGF by in vivo siRNA on AHR exacerbation. We generated chronic mouse models of bronchial asthma using house-dust mite antigen (Dermatophagoides pteronyssinus; Dp). NGF concentrations in bronchoalveolar lavage fluid (BALF), lung histopathology, hyperresponsiveness, and related neuronal peptides and cytokines in supernatants of lung homogenates were determined. NGF in BALF was increased in a dose- and time-dependent manner, and was expressed primarily in bronchial epithelium. Nerve fibres and substance P-positive fibres were detected in subepithelium of Dp-sensitized and challenged mice over 4 weeks of mite antigen exposure. AHR was positively correlated with NGF concentration and nerve fibre innervation. AHR, modulation of innervation, and increased substance P were inhibited by in vivo administration of siRNA that targeted NGF, although the inhibition of NGF did not affect allergic inflammation and subepithelial fibrosis. These findings suggest that NGF derived from bronchial and alveolar epithelium plays an important role in AHR after chronic exposure to mite antigen. NGF inhibition could potentially manage bronchial asthma, including AHR.
- (キーワード)
- Animals / Antigens / Asthma / Bronchial Hyperreactivity / Bronchoalveolar Lavage Fluid / 細胞質分裂 (cytokinesis) / Dermatophagoides pteronyssinus / Disease Models, Animal / Enzyme-Linked Immunosorbent Assay / Female / Fluorescent Antibody Technique / Gene Knockdown Techniques / 免疫組織化学 (immunohistochemistry) / Mice / Mice, Inbred BALB C / Nerve Growth Factor / RNA, Small Interfering / Respiratory Mucosa
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1365-2222.2011.03918.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22168511
- ● Search Scopus @ Elsevier (PMID): 22168511
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1365-2222.2011.03918.x
(DOI: 10.1111/j.1365-2222.2011.03918.x, PubMed: 22168511) Wei Wang, Qi Li, Shinji Takeuchi, Tadaaki Yamada, Hitomi Koizumi, Takahiro Nakamura, Kunio Matsumoto, Naofumi Mukaida, Yasuhiko Nishioka, Saburo Sone, Takayuki Nakagawa, Toshimitsu Uenaka and Seiji Yano :
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.,
Clinical Cancer Research, Vol.18, No.6, 1663-1671, 2012.- (要約)
- Hepatocyte growth factor (HGF) induces resistance to reversible and irreversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in EGFR mutant lung cancer cells by activating Met and the downstream phosphoinositide 3-kinase (PI3K)/Akt pathway. Moreover, continuous exposure to HGF accelerates the emergence of EGFR-TKI-resistant clones. We assayed whether a new Met kinase inhibitor, E7050, which is currently being evaluated in clinical trials, could overcome these three mechanisms of resistance to EGFR-TKIs. The effects of E7050 on HGF-induced resistance to reversible (gefitinib), irreversible (BIBW2992), and mutant-selective (WZ4002) EGFR-TKIs were determined using the EGFR mutant human lung cancer cell lines PC-9 and HCC827 with an exon 19 deletion and H1975 with an T790M secondary mutation. PC-9 cells were mixed with HGF-producing fibroblasts, MRC-5 cells, and subcutaneously inoculated into severe combined immunodeficient mice, and the therapeutic effects of E7050 plus gefitinib were assayed. E7050 circumvented resistance to all of the reversible, irreversible, and mutant-selective EGFR-TKIs induced by exogenous and/or endogenous HGF in EGFR mutant lung cancer cell lines, by blocking the Met/Gab1/PI3K/Akt pathway in vitro. E7050 also prevented the emergence of gefitinib-resistant HCC827 cells induced by continuous exposure to HGF. In the in vivo model, E7050 plus gefitinib resulted in marked regression of tumor growth associated with inhibition of Akt phosphorylation in cancer cells. A new Met kinase inhibitor, E7050, reverses the three HGF-induced mechanisms of gefitinib resistance, suggesting that E7050 may overcome HGF-induced resistance to gefitinib and next-generation EGFR-TKIs.
- (キーワード)
- Aminopyridines / Animals / Antineoplastic Agents / Cell Line, Tumor / Drug Resistance, Neoplasm / Female / Hepatocyte Growth Factor / Humans / Lung Neoplasms / Mice / Mice, SCID / Mutation / Piperazines / Protein-Tyrosine Kinases / Quinazolines / Receptor, Epidermal Growth Factor / Xenograft Model Antitumor Assays
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1158/1078-0432.CCR-11-1171
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22317763
- ● Search Scopus @ Elsevier (PMID): 22317763
- ● Search Scopus @ Elsevier (DOI): 10.1158/1078-0432.CCR-11-1171
(DOI: 10.1158/1078-0432.CCR-11-1171, PubMed: 22317763) Keiko Miyake, Kenji Tani, Souji Kakiuchi, Chiyuki Suzuka, Yuko Toyoda, Jun Kishi, Toshifumi Tezuka, Shino Yuasa, Masaki Hanibuchi, Yoshinori Aono, Yasuhiko Nishioka and Saburo Sone :
Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats,
The Journal of Medical Investigation : JMI, Vol.59, No.1-2, 174-185, 2012.- (要約)
- Gefitinib, an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has been reported to be associated with interstitial lung disorders, and their high incidence and mortality have become a matter of great concern, especially in Japan. In this study, we investigated the effect of gefitinib on different phases of radiation-induced lung disorders in an experimental model. The thoraxes of Wistar rats were irradiated on day 1 with a single X-ray dose of 20 Gy, and gefitinib (50 mg/kg/day) was orally administered from day 1 to 14. The rat lungs were harvested on days 15 and 57 and the bronchoalveolar lavage (BAL) was performed. Gefitinib treatment increased the infiltration of inflammatory cells, which produced more pro-inflammatory cytokines (IL-6, IL-1), in the lungs of the irradiated rats on days 15 and 57, while gefitinib treatment reduced collagen content of the lungs in irradiated rats and decreased proliferation and EGFR expression in the lung fibroblasts from irradiated rats on day 57. In irradiated rats, gefitinib treatment augmented lung inflammation, including inflammatory cell infiltration and pro-inflammatory cytokine expression, while gefitinib treatment attenuated fibrotic lung remodeling due to the inhibition of lung fibroblast proliferation.
- (キーワード)
- Animals / Disease Models, Animal / Male / Protein Kinase Inhibitors / Pulmonary Fibrosis / Quinazolines / Radiation Pneumonitis / Rats / Rats, Wistar / Receptor, Epidermal Growth Factor
- (徳島大学機関リポジトリ)
- ● Metadata: 106019
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.59.174
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22450006
- ● Search Scopus @ Elsevier (PMID): 22450006
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.59.174
(徳島大学機関リポジトリ: 106019, DOI: 10.2152/jmi.59.174, PubMed: 22450006) Le T Dat, Taisuke Matsuo, Tetsuro Yoshimaru, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Takuya Kuramoto, Yasuhiko Nishioka, Saburo Sone and Toyomasa Katagiri :
Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice,
International Journal of Oncology, Vol.40, No.5, 1455-1469, 2012.- (要約)
- Lung cancer is commonly associated with multi-organ metastasis, and the bone is a frequent metastatic site for lung cancer. However, the molecular mechanism of organ-specific metastasis remains poorly understood. To elucidate this issue, we analyzed in this study genome-wide gene expression profiles of 15 metastatic lesions from three organs (bone, lung and liver) in a mouse model with multi-organ metastasis properties of human non-small cell lung cancer cells (ACC-LC319/bone2), using a combination of laser-microbeam microdissection and DNA microarrays. We identified 299 genes that could potentially be involved in the organ-selective nature of lung cancer metastasis. Among them, 77 were bone-specifically expressed elements, including genes involved in cell adhesion, cytoskeleton/cell motility, extracellular matrix remodeling and cell-cell signaling as well as genes already known to be involved in the bone metastasis of breast cancers. Quantitative RT-PCR confirmed the specific upregulation of eight genes in bone metastasis tumors, suggesting that these genes may be involved in bone metastasis. Our findings should be helpful for a better understanding of the molecular aspects of the metastatic process in different organs, and could lead to molecular target-based anticancer drugs and prevention of metastasis, especially bone metastasis.
- (キーワード)
- Animals / Bone Neoplasms / Carcinoma, Non-Small-Cell Lung / Cell Line, Tumor / Cluster Analysis / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Genetic Predisposition to Disease / Genome-Wide Association Study / Humans / Laser Capture Microdissection / Lung Neoplasms / Male / Mice / Mice, SCID / Neoplasm Invasiveness / Neoplasm Transplantation / Oligonucleotide Array Sequence Analysis / Phenotype / Real-Time Polymerase Chain Reaction / Reverse Transcriptase Polymerase Chain Reaction
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3892/ijo.2012.1348
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22294041
- ● Search Scopus @ Elsevier (PMID): 22294041
- ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2012.1348
(DOI: 10.3892/ijo.2012.1348, PubMed: 22294041) 藤岡 啓介, 西條 敦郎, 豊田 優子, 柿内 聡司, 埴淵 昌毅, 吾妻 雅彦, 竹内 恭子, 藤井 志朗, 中村 信元, 宇高 憲吾, 賀川 久美子, 安倍 正博, 水谷 友哉, 西岡 安彦 :
皮膚ランダム生検が診断に有用であった血管内リンパ腫の一例,
四国医学雑誌, Vol.67, No.5,6, 257-262, 2011年.- (要約)
- A62‐year‐old woman was referred to our hospital for further examination of fever of unknownorigin, splenomegaly and pancytopenia. On admission, she had persistent fever and psychologicalsymptoms. Blood examination showed pancytopenia and elevated level of LDH, soluble IL‐2receptorand ferritin. Computed tomography showed multiple low density areas in the spleen, but no systemiclymphadenopathy. In magnetic resonance imaging of the pons, a low and high intensity area onT1‐and T2‐weighted image, respectively, was detected. Taken together these findings, she wassuspected to have hepatosplentic T-cell lymphoma or intravascular large B-cell lymphoma. To makea definite diagnosis, random skin biopsy was performed. Immunohistochemical stainings revealedthe massive infiltration of CD20‐and CD79α‐positive large lymphoid cells inside the vessels, whichyielded the diagnosis of intravascular large B-cell lymphoma.
- (キーワード)
- fever of unknown origin / intravascular large B-cell lymphoma / random skin biopsy
- (徳島大学機関リポジトリ)
- ● Metadata: 97858
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1050001337463886208
(徳島大学機関リポジトリ: 97858, CiNii: 1050001337463886208) Tadaaki Yamada, Hideaki Bando, Shinji Takeuchi, Kenji Kita, Qi Li, Wei Wang, Shiro Akinaga, Yasuhiko Nishioka, Saburo Sone and Seiji Yano :
Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells.,
Cancer Science, Vol.102, No.12, 2157-2163, 2011.- (要約)
- Small-cell lung cancer (SCLC) grows rapidly and metastasizes to multiple organs. We examined the antimetastatic effects of the humanized anti-ganglioside GM2 (GM2) antibodies, BIW-8962 and KM8927, compared with the chimeric antibody KM966, in a SCID mouse model of multiple organ metastases induced by GM2-expressing SCLC cells. BIW-8962 and KM8927 induced higher antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity than KM966 against the GM2-expressing SCLC cell line SBC-3 in vitro. These humanized antibodies inhibited the production of multiple organ metastases, increased the number of apoptotic cells, and prolonged the survival of the SCID mice. Histological analyses using clinical specimens showed that SCLC cells expressed GM2. These findings suggest that humanized anti-GM2 antibodies could be therapeutically useful for controlling multiple organ metastases of GM2-expressing SCLC.
- (キーワード)
- Animals / Antibodies, Monoclonal, Humanized / Antibody-Dependent Cell Cytotoxicity / Apoptosis / Cell Line, Tumor / Cell Proliferation / Complement System Proteins / G(M2) Ganglioside / Humans / Male / Mice / Mice, SCID / Neoplasm Metastasis / Small Cell Lung Carcinoma
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1349-7006.2011.02093.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21895875
- ● Search Scopus @ Elsevier (PMID): 21895875
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.2011.02093.x
(DOI: 10.1111/j.1349-7006.2011.02093.x, PubMed: 21895875) Qi Li, Wei Wang, Tadaaki Yamada, Kunio Matsumoto, Katsuya Sakai, Yoshimi Bando, Hisanori Uehara, Yasuhiko Nishioka, Saburo Sone, Shotaro Iwakiri, Kazumi Itoi, Teruhiro Utsugi, Kazuo Yasumoto and Seiji Yano :
Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.,
The American Journal of Pathology, Vol.179, No.3, 1483-1493, 2011.- (要約)
- The tumor microenvironment is crucial to the progression of various malignancies. Malignant pleural mesothelioma (MPM), which originates from the pleura, grows aggressively in the thoracic cavity. Here we describe an orthotopic implantation SCID mouse model of MPM and demonstrate that α-SMA-positive fibroblast-like cells accumulate in the tumors produced by the human MPM cell lines MSTO-211H and Y-Meso-14. We assessed the interaction between MPM cells and their microenvironments, focusing on tumor-associated fibroblasts. MSTO-211H and Y-Meso-14 cells produced fibroblast growth factor-2 (FGF-2) and/or platelet-derived growth factor-AA (PDGF-AA); they also enhanced growth, migration, and production of hepatocyte growth factor (HGF) by human lung fibroblast MRC-5 cells. MRC-5 cells stimulated HGF-mediated growth and migration of MSTO-211H and Y-Meso-14 cells in an in vitro coculture system. In the orthotopic model, tumor formation by MSTO-211H and Y-Meso-14 cells was significantly inhibited by TSU-68, an inhibitor of FGF, VEGF, and PDGF receptors; imatinib, an inhibitor of PDGF receptors; and NK4, an antagonist of HGF. Histological analyses of clinical specimens from 51 MPM patients revealed considerable tumor-associated fibroblasts infiltration and expression of HGF, together with FGF-2 or PDGF-AA, in tumors. These findings indicate that MPM instigates tumor-associated fibroblasts, promoting tumor progression via a malignant cytokine network. Regulation of this cytokine network may be therapeutically useful for controlling MPM.
- (キーワード)
- Adult / Aged / Aged, 80 and over / Animals / Cell Line, Tumor / Cell Movement / Cytokines / Female / Fibroblast Growth Factor 2 / Fibroblasts / Hepatocyte Growth Factor / Humans / Male / Mesothelioma / Mice / Mice, SCID / Middle Aged / Neoplasm Transplantation / Platelet-Derived Growth Factor / Pleural Neoplasms / Transplantation, Heterologous / Tumor Microenvironment / Vascular Endothelial Growth Factor A
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.ajpath.2011.05.060
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21763682
- ● Search Scopus @ Elsevier (PMID): 21763682
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.ajpath.2011.05.060
(DOI: 10.1016/j.ajpath.2011.05.060, PubMed: 21763682) Trung The Van, Masaki Hanibuchi, Souji Kakiuchi, Seidai Sato, Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Yasuhiko Nishioka, Shin-ichi Akiyama and Saburo Sone :
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.,
Cancer Chemotherapy and Pharmacology, Vol.68, No.2, 497-504, 2011.- (要約)
- Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm. S-1 has been developed as a novel oral antineoplastic agent based on the modulation of 5-fluorouracil (5-FU) bioactivity. This study was conducted to investigate the preclinical therapeutic effect of S-1 on MPM. We used three human MPM cell lines, Y-MESO-14, NCI-H290 and MSTO-211H. In vitro proliferation of human MPM cells was determined by MTT assay. Human MPM cells were orthotopically implanted into thoracic cavity of SCID mice. Tumor-bearing mice were treated with S-1 or vehicle. The combination of 5-FU and 5-chloro-2,4-dihydroxypyridine (CDHP) was more effective than 5-FU alone in inhibiting MPM cell proliferation in vitro. This combination was most effective in Y-MESO-14 cells, which co-expressed high protein level of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP). In vivo data showed that treatment with S-1 significantly reduced thoracic tumors and pleural effusion produced by Y-MESO-14 cells. Moreover, treatment with S-1 prolonged the survival of Y-MESO-14 cell-bearing SCID mice. We demonstrated that S-1 was effective for inhibiting the proliferation of MPM cells, particularly with both DPD and TP expressions, suggesting that S-1 might be therapeutically effective for control of MPM.
- (キーワード)
- Animals / Antimetabolites, Antineoplastic / Antineoplastic Combined Chemotherapy Protocols / Cell Line, Tumor / Dihydrouracil Dehydrogenase (NADP) / Drug Combinations / Enzyme Inhibitors / Humans / Male / Mesothelioma / Mice / Mice, SCID / Neoplasm Proteins / Oxonic Acid / Pentosyltransferases / Pleural Neoplasms / Pyridines / Random Allocation / Survival Analysis / Tegafur / Thymidine Phosphorylase / Tumor Burden / Xenograft Model Antitumor Assays
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1007/s00280-010-1503-x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21079960
- ● Search Scopus @ Elsevier (PMID): 21079960
- ● Search Scopus @ Elsevier (DOI): 10.1007/s00280-010-1503-x
(DOI: 10.1007/s00280-010-1503-x, PubMed: 21079960) Rentsenkhand Batmunkh, Yasuhiko Nishioka, Yoshinori Aono, Momoyo Azuma, Katsuhiro Kinoshita, Jun Kishi, Hideki Makino, Masami Kishi, Akio Takezaki and Saburo Sone :
CCN6 as a profibrotic mediator that stimulates the proliferation of lung fibroblasts via the integrin β1/focal adhesion kinase pathway.,
The Journal of Medical Investigation : JMI, Vol.58, No.3-4, 188-196, 2011.- (要約)
- Idiopathic pulmonary fibrosis is a progressive and lethal disease of the lung that is characterized by the proliferation of fibroblasts and increased deposition of the extracellular matrix. The CCN6/WISP-3 is a member of the CCN family of matricellular proteins, which consists of six members that are involved in many vital biological functions. However, the regulation of lung fibroblasts mediated by CCN6 protein has not been fully elucidated. Here, we demonstrated that CCN6 induced the proliferation of lung fibroblasts by binding to integrin β1, leading to the phosphorylation of FAK(Y397). Furthermore, CCN6 showed a weak, but significant, ability to stimulate the expression of fibronectin. CCN6 was highly expressed in the lung tissues of mice treated with bleomycin. Our results suggest that CCN6 plays a role in the fibrogenesis of the lungs mainly by stimulating the growth of lung fibroblasts and is a potential target for the treatment of pulmonary fibrosis.
- (キーワード)
- Animals / Antigens, CD29 / CCN Intercellular Signaling Proteins / Cell Proliferation / Extracellular Matrix Proteins / Female / Fibroblasts / Focal Adhesion Protein-Tyrosine Kinases / Humans / Lung / Mice / Mice, Inbred C57BL / 肺線維症 (pulmonary fibrosis) / シグナル伝達 (signal transduction)
- (徳島大学機関リポジトリ)
- ● Metadata: 83833
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.58.188
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21921419
- ● Search Scopus @ Elsevier (PMID): 21921419
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.58.188
(徳島大学機関リポジトリ: 83833, DOI: 10.2152/jmi.58.188, PubMed: 21921419) Hisatsugu Goto, Masaki Hanibuchi, Satoshi Sakaguchi, Takanori Kanematsu, Souji Kakiuchi, Hideki Tomimoto, Masahiko Azuma, Toshifumi Tezuka, Hiroya Tada, Yukiyo Miki, Toshimi Nakamura, Saburo Sone and Yasuhiko Nishioka :
Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital.,
The Journal of Medical Investigation : JMI, Vol.58, No.3-4, 219-226, 2011.- (要約)
- Platinum-doublet regimens and docetaxel as first- and second-line chemotherapy, respectively, are shown to prolong the survival of lung cancer patients in various randomized phase III studies. However, the evidence for the efficacy of chemotherapy for lung cancer in the clinical practice is still insufficient. In the present study, we investigated the effectiveness and safety of outpatient chemotherapy for lung cancer in the clinical practice. Ninety-four lung cancer cases were retrospectively analyzed. Among these cases, 67 (71.3%) were non-small cell lung cancer (NSCLC) and 27 (28.7%) were small cell lung cancer (SCLC). The response rates in SCLC and NSCLC patients were 55.6% (15/27) and 16.9% (11/65), respectively. Objective tumor response rates for the patients were found to decrease substantially with each line of treatment as described previously. All adverse events were well tolerated and no treatment-related death was observed. Median time to treatment failures (TTFs) of first-line treatment were 10.1 months and 4.8 months in SCLC and NSCLC, respectively. These findings indicate that even in the setting of clinical practice, the efficacy and safety of chemotherapy is strictly insured by the appropriate therapeutic management.
- (キーワード)
- Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Carcinoma, Non-Small-Cell Lung / Carcinoma, Small Cell / Female / Hospitals, University / Humans / Lung Neoplasms / Male / Middle Aged / Outpatients / Retrospective Studies
- (徳島大学機関リポジトリ)
- ● Metadata: 83836
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.58.219
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21921423
- ● Search Scopus @ Elsevier (PMID): 21921423
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.58.219
(徳島大学機関リポジトリ: 83836, DOI: 10.2152/jmi.58.219, PubMed: 21921423) Hirokazu Ogino, Masaki Hanibuchi, Souji Kakiuchi, Van The Trung, Hisatsugu Goto, Kenji Ikuta, Tadaaki Yamada, Hisanori Uehara, Akihiko Tsuruoka, Toshimitsu Uenaka, Wei Wang, Qi Li, Shinji Takeuchi, Seiji Yano, Yasuhiko Nishioka and Saburo Sone :
E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.,
Molecular Cancer Therapeutics, Vol.10, No.7, 1218-1228, 2011.- (要約)
- While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors improve the prognosis of patients with EGFR mutant lung cancer, the prognosis of patients with nonmutant EGFR lung cancer, especially those with metastases, is still extremely poor. We have assessed the therapeutic efficacy of E7080, an orally available inhibitor of multiple tyrosine kinases including VEGF receptor 2 (VEGFR-2) and VEGFR-3, in experimental multiple organ metastasis of lung cancer cell lines without EGFR mutations. E7080 markedly inhibited the in vitro proliferation of VEGF-stimulated microvascular endothelial cells. Intravenous inoculation into natural killer cell-depleted severe combined immunodeficient mice of the small cell lung cancer cell lines H1048 (producing low amounts of VEGF) and SBC-5 (producing intermediate amounts of VEGF) resulted in hematogenous metastases into multiple organs, including the liver, lungs, kidneys, and bones, whereas intravenous inoculation of PC14PE6, a non-small cell lung cancer cell line producing high amounts of VEGF, resulted in lung metastases followed by massive pleural effusion. Daily treatment with E7080 started after the establishment of micrometastases significantly reduced the number of large (>2 mm) metastatic nodules and the amount of pleural effusion, and prolonged mouse survival. Histologically, E7080 treatment reduced the numbers of endothelial and lymph endothelial cells and proliferating tumor cells and increased the number of apoptotic cells in metastatic nodules. These results suggest that E7080 has antiangiogenic and antilymphangiogenic activity and may be of potential therapeutic value in patients with nonmutant EGFR lung cancer and multiple organ metastases. Mol Cancer Ther; 10(7); 1218-28. ©2011 AACR.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1158/1535-7163.MCT-10-0707
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21551260
- ● Search Scopus @ Elsevier (PMID): 21551260
- ● Search Scopus @ Elsevier (DOI): 10.1158/1535-7163.MCT-10-0707
(DOI: 10.1158/1535-7163.MCT-10-0707, PubMed: 21551260) Ivan S. Donev, Wei Wang, Tadaaki Yamada, Qi Li, Shinji Takeuchi, Kunio Matsumoto, Takao Yamori, Yasuhiko Nishioka, Saburo Sone and Seiji Yano :
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.,
Clinical Cancer Research, Vol.17, No.8, 2260-2269, 2011.- (要約)
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer. However, the responders acquire resistance almost without exception. We recently reported that hepatocyte growth factor (HGF) induces EGFR-TKI resistance by activating MET that restores downstream mitogen activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK)1/2 and phosphoinositide 3-kinase (PI3K)/Akt signaling. The purpose of this study was to determine whether inhibition of PI3K, a downstream molecule of both EGFR and MET, could overcome HGF-mediated EGFR-TKI resistance in EGFR mutant lung cancer cells PC-9 and HCC827. We explored therapeutic effect of a class I PI3K inhibitor PI-103 on HGF-induced EGFR-TKI resistance in vitro and in vivo. Unlike gefitinib or erlotinib, continuous exposure with PI-103 inhibited proliferation of PC-9 and HCC827 cells, even in the presence of HGF. On the other hand, in gefitinib-resistant xenograft model by using PC-9 cells mixed with HGF high producing fibroblasts, PI-103 monotherapy did not inhibit tumor growth. However, PI-103 combined with gefitinib successfully regressed gefitinib-resistant tumor. In vitro experiments by considering short half-life of PI-103 reveal that transient exposure of PI-103 combined with gefitinib caused sustained inhibition of Akt phosphorylation, but not ERK1/2 phosphorylation, resulting in induction of tumor cell apoptosis even in the presence of HGF. These results indicate that transient blockade of PI3K/Akt pathway by PI-103 and gefitinib could overcome HGF-mediated resistance to EGFR-TKIs by inducing apoptosis in EGFR mutant lung cancer.
- (キーワード)
- Animals / Apoptosis / Blotting, Western / Cell Line / Cell Line, Tumor / Cell Proliferation / Cell Survival / Drug Resistance, Neoplasm / Female / Furans / Hepatocyte Growth Factor / Humans / Lung Neoplasms / Mice / Mice, SCID / Mutation / Phosphatidylinositol 3-Kinases / Protein Kinase Inhibitors / Pyridines / Pyrimidines / Quinazolines / Receptor, Epidermal Growth Factor / Signal Transduction / Xenograft Model Antitumor Assays
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1158/1078-0432.CCR-10-1993
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21220474
- ● Search Scopus @ Elsevier (PMID): 21220474
- ● Search Scopus @ Elsevier (DOI): 10.1158/1078-0432.CCR-10-1993
(DOI: 10.1158/1078-0432.CCR-10-1993, PubMed: 21220474) Kenji Yokoi, David Hawke, Carol J. Oborn, Jin-Young Jang, Yasuhiko Nishioka, Dominic Fan, Seung Wook Kim, Sun-Jin Kim and Isaiah J. Fidler :
Identification and validation of SRC and phospho-SRC family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer.,
Translational Oncology, Vol.4, No.2, 83-91, 2011.- (要約)
- There is an urgent need to develop novel markers of pancreatic cancer to facilitate early diagnosis. Pancreatic carcinoma is characterized by marked stroma formation with a high number of infiltrating tumor-associated macrophages (TAMs) that originate from circulating mononuclear cells (MNCs). We hypothesized that differential analysis of protein expression and phosphorylation in circulating MNCs from healthy nude mice and nude mice bearing orthotopic human pancreatic cancer would identify a surrogate marker of pancreatic cancer. These differences were analyzed by two-dimensional gel electrophoresis followed by Western blot analysis using antibody against phosphorylated tyrosine proteins (pY). Protein and phosphorylated protein spots of interest were identified by mass spectrometry and validated by Western blot analysis as candidate markers for pancreatic cancer. We found that the expression and phosphorylation of Src family proteins were significantly higher in circulating MNCs from mice bearing pancreatic cancer than in circulating MNCs from healthy mice. TAMs in mice with pancreatic tumors also had higher Src family protein expression and phosphorylation than resident macrophages in the pancreas of healthy mice. The expression and phosphorylation of Src family proteins were correlated with tumor weight; however, increased Src expression and phosphorylation also occurred in MNCs from mice with chronic pancreatitis. This is the first report to explore novel pancreatic tumor markers in circulating MNCs. Although the specificity of the marker for pancreatic cancer was low, it could be used to monitor the disease or to select high-risk patients with chronic pancreatitis.
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21461171
- ● Summary page in Scopus @ Elsevier: 2-s2.0-79953659625
(PubMed: 21461171, Elsevier: Scopus) Hideki Tomimoto, Masaki Hanibuchi, Fumitaka Ogushi, Yoshio Okano, Tsutomu Shinohara, Hiroyuki Doi, Akiyoshi Yamamoto, Eiji Takeuchi, Akihiko Yamamoto, Masahiko Azuma, Hiroya Tada, Takanori Kanematsu, Souji Kakiuchi, Hisatsugu Goto, Seiji Yano, Yasuhiko Nishioka and Saburo Sone :
A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.,
Oncology Letters, Vol.2, No.3, 465-470, 2011.- (要約)
- S-1 is an oral anticancer fluoropyrimidine agent designed to elevate anticancer activity with a decrease in gastrointestinal toxicity. We conducted a phase II study to evaluate the efficacy and safety of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Chemotherapy-naïve patients were treated with S-1 administered orally at 40 mg/m(2) twice a day for 21 consecutive days, and cisplatin (60 mg/m(2)) infused intravenously on day 8, repeated every 5 weeks. Of the 44 patients enrolled in the study, 40 were assessable for efficacy and safety. The median number of cycles administered was 3 (range 1-9 cycles). Among the 40 assessable patients, 7 partial responses were observed, with an overall response rate (RR) of 17.5% [95% confidence interval (CI), 5.2-29.8]. Patients with squamous cell carcinoma showed a significantly higher RR (55.5%) than those with adenocarcinoma (9.1%) or other types of NSCLC (0%). The median progression-free survival was 4.3 months (95% CI, 3.4-4.9), the median survival time was 17.9 months (95% CI, 15.0-20.8), and the 1- and 2-year survival rates were 63.3 and 27.3%, respectively. Major grade 3-4 hematologic toxicities were leukocytopenia (7.5%), neutropenia (5.0%), anemia (15.0%) and thrombocytopenia (2.5%). No grade 4 non-hematologic toxicity or treatment-related death occurred. These results suggest that combination chemotherapy with S-1 plus cisplatin is a promising therapeutic candidate for patients with advanced NSCLC, particularly squamous cell carcinoma.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3892/ol.2011.266
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22866104
- ● Search Scopus @ Elsevier (PMID): 22866104
- ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2011.266
(DOI: 10.3892/ol.2011.266, PubMed: 22866104) 兼松 貴則, 豊田 優子, 後東 久嗣, 阿部 秀一, 河北 直也, 先山 正二, 西岡 安彦, 曽根 三郎 :
肺多発結節病変を呈した原発性肺平滑筋肉腫の1例,
日本呼吸器学会雑誌, Vol.49, No.3, 167-171, 2011年.- (キーワード)
- Primary lung leiomyosarcoma / Multiple pulmonary nodules / Partial lung resection with Video-assisted Thoracic Surgery (VATS) / Positron Emission Tomography / Computed Tomography (PET / CT)
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1572824499879832192
- ● Summary page in Scopus @ Elsevier: 2-s2.0-79957519695
(CiNii: 1572824499879832192, Elsevier: Scopus) Tohru Sakai, Sakina Furoku, Mariko Nakamoto, Emi Shuto, Toshio Hosaka, Yasuhiko Nishioka and Saburo Sone :
Soy isoflavone equol perpetuates dextran sulfate sodium-induced acute colitis in mice.,
Bioscience, Biotechnology, and Biochemistry, Vol.75, No.3, 593-595, 2011.- (要約)
- The effects of the soy isoflavones, genistein, daidzein and equol, on experimental colitis were examined. Equol severely perpetrated dextran sulfate sodium (DSS)-induced colitis as evaluated by the weight loss. Production of the anti-inflammatory cytokine, IL-10, from T cells was decreased in the equol-treated mice. The results show that the soy isoflavone, equol, played an important role in the inflammatory response in the gastrointestinal tract.
- (キーワード)
- Animals / Body Weight / Colitis / Dextran Sulfate / Disease Models, Animal / Equol / Female / Genistein / Interleukin-10 / Isoflavones / Mice / Mice, Inbred BALB C / Tリンパ球 (T lymphocytes)
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1271/bbb.100710
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21389602
- ● Search Scopus @ Elsevier (PMID): 21389602
- ● Search Scopus @ Elsevier (DOI): 10.1271/bbb.100710
(DOI: 10.1271/bbb.100710, PubMed: 21389602) Jun Kishi, Yasuhiko Nishioka, Tomomi Kuwahara, Souji Kakiuchi, Momoyo Azuma, Yoshinori Aono, Hideki Makino, Katsuhiro Kinoshita, Masami Kishi, R Batmunkh, Hisanori Uehara, Keisuke Izumi and Saburo Sone :
Blockade of Th1 chemokine receptors ameliorates pulmonary granulomatosis in mice.,
The European Respiratory Journal, Vol.38, No.2, 415-424, 2011.- (要約)
- Sarcoidosis is a granulomatous disease of unknown aetiology. We identified immunological targets for the treatment of pulmonary granulomatosis using a murine model generated with Propionibacterium acnes. Sensitisation and challenge using heat-killed P. acnes and dendritic cells (DCs) were performed to produce pulmonary granulomatosis in C57BL/6 mice. Immunological analyses using ELISA as well as cDNA microarray analysis were used to search for cytokines or chemokines associated with the formation of granulomas in the lungs. Co-administration of P. acnes and DCs reproducibly induced the formation of pulmonary granulomas, which resembled sarcoid granulomas. The cDNA microarray assay demonstrated that the gene expression of CXCL9 and CXCL10, ligands for CXCR3, and of CCL4, a ligand for CCR5, was strongly upregulated during granulomatosis. ELISA confirmed that levels of CXCL9 and CXCL10 as well as T-helper (Th)1 cytokines and chemokines including tumour necrosis factor-α and interferon-γ were elevated in bronchoalveolar lavage fluid (BALF). The blockade of Th1 chemokine receptors using TAK-779, a dual blocker for CXCR3 and CCR5, led to reduced numbers of CXCR3+CD4+ and CCR5+CD4+ T-cells in BALF. Furthermore, administration of TAK-779 ameliorated the granulomatosis. The targeted inhibition of Th1 chemokines might be useful for inhibiting Th1-biased granulomatous diseases, including sarcoidosis.
- (キーワード)
- Amides / Animals / Bronchoalveolar Lavage Fluid / CD4-Positive T-Lymphocytes / Chemokine CCL4 / Chemokine CXCL10 / Chemokine CXCL9 / Dendritic Cells / Female / Gene Expression Regulation, Bacterial / Granuloma / Interferon-gamma / Lung Diseases / Mice / Mice, Inbred C57BL / Propionibacterium acnes / Quaternary Ammonium Compounds / Receptors, CXCR3 / Receptors, Chemokine / Th1 Cells / Tumor Necrosis Factor-alpha
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/09031936.00070610
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21273392
- ● Summary page in Scopus @ Elsevier: 2-s2.0-80051520852
(DOI: 10.1183/09031936.00070610, PubMed: 21273392, Elsevier: Scopus) Seiji Yano, Qi Li, Wei Wang, Tadaaki Yamada, Shinji Takeuchi, Emiko Nakataki, Hirokazu Ogino, Hisatsugu Goto, Yasuhiko Nishioka and Saburo Sone :
Antiangiogenic therapies for malignant pleural mesothelioma.,
Frontiers in Bioscience, Vol.16, 740-748, 2011.- (要約)
- Malignant pleural mesothelioma (MPM), arises from the mesothelial cells, is difficult to be diagnosed at an early stage, and is refractory to conventional chemotherapy and radiotherapy. Therefore, the establishment of novel effective therapies is necessary to improve the prognosis for many patients with this disease. Recent studies have demonstrated that angiogenesis plays a significant role in MPM progression, suggesting the importance of tumor vessels as therapeutic targets. To explore molecular pathogenesis and evaluate the efficacy of vascular targeting therapy in MPM, we developed orthotopic implantation SCID mouse models of MPM. We found that selective VEGF inhibitors were effective only in the treatment of high-VEGF-producing MPM models. On the other hand, multiple kinase inhibitor E7080, with inhibitory activity against various angiogenic cytokine receptors, suppressed the progression and prolonged survival of both high-VEGF-producing and low-VEGF-producing MPM models. Further understanding of the functional characteristics of tumor angiogenesis may be essential to improve targeting therapies in MPM. In this review, we introduce current status of clinical strategies and novel therapeutic approaches against angiogenesis in MPM.
- (キーワード)
- Angiogenesis Inhibitors / Animals / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / Antineoplastic Agents / Cell Line, Tumor / Disease Models, Animal / Humans / Mesothelioma / Mice / Mice, SCID / Neoplasm Transplantation / Neovascularization, Pathologic / Phenylurea Compounds / Piperidines / Pleural Effusion, Malignant / Pleural Neoplasms / Quinazolines / Quinolines / Thoracic Cavity / Vascular Endothelial Growth Factors
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2741/3716
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21196199
- ● Search Scopus @ Elsevier (PMID): 21196199
- ● Search Scopus @ Elsevier (DOI): 10.2741/3716
(DOI: 10.2741/3716, PubMed: 21196199) Yasuhiko Nishioka, Yoshinori Aono and Saburo Sone :
Role of tyrosine kinase inhibitors in tumor immunology.,
Immunotherapy, Vol.3, No.1, 107-116, 2011.- (要約)
- Various immune cells are involved in both innate and acquired immunity against tumors. NK cells and cytotoxic T lymphocytes play a role as effector cells to directly kill tumor cells. On the other hand, antigen-presenting cells, particularly dendritic cells, control tumor-specific immune responses. In addition, much focus has been paid on the immune regulatory cells in tumor sites, including CD4(+)CD25(+) regulatory T cells and myeloid-derived suppressor cells. The recent advances in molecular-targeted therapy for cancer have provided small-molecule kinase inhibitors, which are effective for several hematopoietic malignancies as well as solid tumors in the clinical setting. Most drugs generally have inhibitory effects on several kinases, including tyrosine kinases, which are critical molecules for the survival, proliferation, migration and invasion of tumor cells. Since the host immune surveillance against tumors affects tumor progression, it is of interest to understand how these molecular-targeted drugs affect immune function in the tumor-bearing host. Besides this, there are emerging findings that myeloid cells could be involved in tumor angiogenesis. In this article, we address the role of tyrosine kinase inhibitors in tumor immunology by summarizing their effects on myeloid cells, such as antigen-presenting cells and regulatory cells, and their role in tumor immunity and angiogenesis.
- (キーワード)
- Animals / Antigen-Presenting Cells / Antineoplastic Agents / Dendritic Cells / Humans / Indoles / Mice / Myeloid Cells / Neoplasms / Protein Kinase Inhibitors / Pyrroles / T-Lymphocytes, Regulatory / Treatment Outcome
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2217/imt.10.79
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21174561
- ● Search Scopus @ Elsevier (PMID): 21174561
- ● Search Scopus @ Elsevier (DOI): 10.2217/imt.10.79
(DOI: 10.2217/imt.10.79, PubMed: 21174561) 組橋 由記, 埴淵 昌毅, 富本 英樹, 東 桃代, 兼松 貴則, 柿内 聡司, 後東 久嗣, 多田 浩也, 西岡 安彦, 曽根 三郎 :
非小細胞肺癌患者のpatient-reported outcome(PRO)評価法の現状と問題点 ―第III 相臨床試験論文のreview―,
肺癌, Vol.50, No.6, 791-802, 2010年.- (要約)
- 背景．近年，癌患者のquality of life(QOL)評 価は治療法選択に重要な要素として注目されている．欧 米ではQOL を把握する目的からpatient-reported outcome( PRO)が評価項目の1 つとして評価されつつある が，本邦においてはPRO の認知度は低い．目的．非小細 胞肺癌のQOL 評価(PRO)の現状を検討する．対象と方 法．今回，非小細胞肺癌に対する癌薬物療法の有用性を 比較検討した第III 相臨床試験の中から，患者の自己申 告によるQOL 評価であるPRO 評価を評価項目とした 報告(24 試験)を抽出し，PRO の評価方法，評価時期， PRO 評価に対する患者のコンプライアンスなどについ て検討した．結果．対象とした臨床試験の大多数では複 数の評価方法によりPRO 評価が行われており，European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30(EORTC QLQ-C30)が最も頻用されていた(17 試験;70.8%)． PRO 評価の多くは治療開始前，各コース開始直前，治療 終了時，その後1∼3 ヶ月ごとに行われていたが，患者の コンプライアンスは治療経過に伴って有意に低下し，全 身状態の悪化などがその要因と考えられた．考察．PRO評価が，臨床試験における癌薬物療法の優劣を評価する方法の1 つとして十分な情報となるよう問題点の検討を さらに進めていく必要があると思われる．
- (キーワード)
- 肺癌 (lung cancer) / 癌薬物療法 / Patient-reported outcome(PRO) / クオリティ・オブ・ライフ (QOL) / Chemotherapy
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2482/haigan.50.791
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390001204681018368
- ● Summary page in Scopus @ Elsevier: 2-s2.0-78650334692
(DOI: 10.2482/haigan.50.791, CiNii: 1390001204681018368, Elsevier: Scopus) Takanori Kanematsu, Masaki Hanibuchi, Hideki Tomimoto, Shoji Sakiyama, Koichiro Kenzaki, Kazuya Kondo, Bando Hiroyasu, Haku Takashi, Yoneda Kazuo, Hirose Toshiyuki, Toyoda Yuko, Hisatsugu Goto, Sakaguchi Satoshi, Katsuhiro Kinoshita, Momoyo Azuma, Kakiuchi Soji, Jun Kishi, Masahiko Azuma, Tada Hiroya, Sumitomo Masayuki, Yasuhiko Nishioka, Seiji Yano and Saburo Sone :
Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan,
The Journal of Medical Investigation : JMI, Vol.57, No.3,4, 326-333, 2010.- (要約)
- Lung cancer is the leading cause of malignancy-related death worldwide. In the present study, we reviewed the epidemiologic and clinical features of lung cancer in Tokushima Prefecture, Japan. Between January 1999 and December 2009, 2,183 patients with lung cancer were enrolled in this study. One thousand five hundred ninety-one (73%) patients were male and 592 (27%) patients were female. Median age was 70 years, with a range of 15-93 years. Seventy-six percent of patients had smoking history. One thousand nine hundred five (87%) patients were non-small cell lung cancer and the predominant histological type was adenocarcinoma (51%). Among all 2,183 patients, 702 (32%) belonged to elderly population. Four hundred seventy-one (22%), 213 (10%), 24 (1%), 116 (5%), 238 (11%), 370 (17%) and 678 (31%) patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV lung cancer, respectively. In Tokushima University Hospital, 516 (29%), 191 (11%), 58 (3%), 755 (43%) and 216 (12%) patients were initially treated with chemotherapy, chemo-radiotherapy, thoracic radiotherapy, operation and best supportive care, respectively. The median time to progression (TTP) and the median survival time (MST) of patients treated with chemotherapy and chemo-radiotherapy were 3.5 months, 13.0 months and 7.0 months, 18.0 months, respectively. The median TTP and the MST of 33 elderly patients treated with chemotherapy were 3.3 months and 18.0 months, respectively, which were comparable with those of total population. These results indicated the benefit of chemotherapy in elderly patients with advanced lung cancer by proper selection.
- (キーワード)
- Adolescent / Adult / Age Factors / Aged / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Carcinoma, Small Cell / Female / Humans / Japan / Kaplan-Meier Estimate / Lung Neoplasms / Male / Middle Aged / Risk Factors / 喫煙 (smoking) / Young Adult
- (徳島大学機関リポジトリ)
- ● Metadata: 79184
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.57.326
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20847534
- ● Summary page in Scopus @ Elsevier: 2-s2.0-78649676894
(徳島大学機関リポジトリ: 79184, DOI: 10.2152/jmi.57.326, PubMed: 20847534, Elsevier: Scopus) Hirohisa Ogawa, Masahiko Azuma, S Muto, Yasuhiko Nishioka, A Honjo, T Tezuka, Hisanori Uehara, Keisuke Izumi, A Itai and Saburo Sone :
IκB kinase β inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma,
Clinical and Experimental Allergy, Vol.41, No.1, 104-115, 2010.- (要約)
- Nuclear factor (NF)-κB is a transcription factor that regulates cytokine and chemokine production in various inflammatory diseases, including bronchial asthma. IκB kinase (IKK) β is important for NF-κB activation in inflammatory conditions, and is possibly related to airway remodelling. Thus, inhibition of the IKKβ-NF-κB pathway may be an ideal strategy for the management of airway remodelling. We examined the effects of a newly synthesized IKKβ inhibitor, IMD-0354, in a chronic allergen exposure model of bronchial asthma in mice. A chronic mouse model was generated by challenge with house dust mite antigen (Dermatophagoides pteronyssinus). IMD-0354 was administrated intraperitoneally in therapeutic groups. Lung histopathology, hyperresponsiveness and the concentrations of mediators and molecules in supernatants of lung homogenates were determined. NF-κB activation was inhibited by prolonged periods of IMD-0354 administration. IMD-0354 reduced the numbers of bronchial eosinophils. IMD-0354 also inhibited the pathological features of airway remodelling, including goblet cell hyperplasia, subepithelial fibrosis, collagen deposition and smooth muscle hypertrophy. Inhibition of these structural changes by IMD-0354 was the result of the suppressing the production and activation of remodelling-related mediators, such as TGF-β, via inhibition of IKKβ. IMD-0354 inhibited IL-13 and IL-1β production, and it restored the production of IFN-γ. It also ameliorated airway hyperresponsiveness. IKKβ plays crucial roles in airway inflammation and remodelling in a chronic mouse model of asthma. A specific IKKβ inhibitor, IMD-0354, may be therapeutically beneficial for treating airway inflammation and remodelling in chronic asthma.
- (キーワード)
- Airway Remodeling / Animals / Antigens, Dermatophagoides / Asthma / Benzamides / Chronic Disease / Disease Models, Animal / Female / I-kappa B Kinase / Mice / Mice, Inbred BALB C / 分子構造 (molecular structure)
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1365-2222.2010.03564.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20573155
- ● Summary page in Scopus @ Elsevier: 2-s2.0-78649986082
(DOI: 10.1111/j.1365-2222.2010.03564.x, PubMed: 20573155, Elsevier: Scopus) Satoshi Sakaguchi, Hisatsugu Goto, Masaki Hanibuchi, Shinsaku Otsuka, Hirokazu Ogino, Souji Kakiuchi, Hisanori Uehara, Seiji Yano, Yasuhiko Nishioka and Saburo Sone :
Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice.,
Clinical & Experimental Metastasis, Vol.27, No.5, 351-359, 2010.- (要約)
- Lung cancer frequently develops multiple organ metastases, which thus makes this disease a leading cause of malignancy-related death worldwide. A gender difference is reported to affect the incidence and mortality of lung cancer; however, whether and how the gender difference is involved in lung cancer metastasis is unclear. This study evaluated the gender difference in multiple organ metastases in human small cell lung cancer (SBC-5) cells by using natural killer cell-depleted severe combined immunodeficient mice. Among multiple organ metastases, only bone metastasis formation significantly increased in female mice in comparison to males, while no significant difference was observed in the metastases to the liver and lungs. The suppression of androgen by castration or androgen receptor antagonist treatment in male mice also induced a significant increase of bone metastases. The number of osteoclasts in the bone metastatic lesions was greater in female mice and in mice with androgen suppression than in control male. However, there was no significant difference in the serum concentration of parathyroid hormone-related protein (PTHrP) associated with gender or androgen suppression. An in vitro study also indicated that sex steroid treatment had no effect on the proliferation or PTHrP production in SBC-5 cells. These results indicate that the balance of sex steroids therefore plays an important role in the formation of bone metastasis in small cell lung cancer, and suggests diverse mechanisms of interaction between cancer cells and host cells in the bone microenvironment.
- (キーワード)
- Androgens / Animals / Base Sequence / Bone Neoplasms / Carcinoma, Small Cell / Cell Line, Tumor / Cell Proliferation / DNA Primers / 女性 (female) / Humans / Killer Cells, Natural / Lung Neoplasms / Male / Mice / Mice, SCID / Orchiectomy / Parathyroid Hormone-Related Protein / Reverse Transcriptase Polymerase Chain Reaction / Sex Factors
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1007/s10585-010-9333-0
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20464627
- ● Search Scopus @ Elsevier (PMID): 20464627
- ● Search Scopus @ Elsevier (DOI): 10.1007/s10585-010-9333-0
(DOI: 10.1007/s10585-010-9333-0, PubMed: 20464627) Tadaaki Yamada, Kunio Matsumoto, Wei Wang, Qi Li, Yasuhiko Nishioka, Yoshitaka Sekido, Saburo Sone and Seiji Yano :
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.,
Clinical Cancer Research, Vol.16, No.1, 174-183, 2010.- (要約)
- The secondary T790M mutation in epidermal growth factor receptor (EGFR) is the most frequent cause of acquired resistance to the reversible EGFR tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib, in lung cancer. Irreversible EGFR-TKIs are expected to overcome the reversible EGFR-TKI resistance of lung cancer harboring T790M mutation in EGFR. However, it is clear that resistance may also develop to this class of inhibitors. We showed previously that hepatocyte growth factor (HGF) induced gefitinib resistance of lung cancer harboring EGFR-activating mutations. Here, we investigated whether HGF induced resistance to the irreversible EGFR-TKI, CL-387,785, in lung cancer cells (H1975) harboring both L858R activating mutation and T790M secondary mutation in EGFR.
- (キーワード)
- Adenocarcinoma / Drug Resistance, Neoplasm / Fibroblasts / Hepatocyte Growth Factor / Humans / Lung Neoplasms / Mitogen-Activated Protein Kinase 3 / Mutation / Protein Kinase Inhibitors / Protein-Tyrosine Kinases / Proto-Oncogene Proteins c-akt / Proto-Oncogene Proteins c-met / Receptor, Epidermal Growth Factor / Receptors, Growth Factor / Signal Transduction
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1158/1078-0432.CCR-09-1204
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20008840
- ● Search Scopus @ Elsevier (PMID): 20008840
- ● Search Scopus @ Elsevier (DOI): 10.1158/1078-0432.CCR-09-1204
(DOI: 10.1158/1078-0432.CCR-09-1204, PubMed: 20008840) Tohru Sakai, Sakina Furoku, Mariko Nakamoto, Emi Shuto, Toshio Hosaka, Yasuhiko Nishioka and Saburo Sone :
The Soy isoflavone equol enhances antigen-specific IgE production in ovalbumin-immunized BALB/c mice.,
Journal of Nutritional Science and Vitaminology, Vol.56, No.1, 72-76, 2010.- (要約)
- Although an immunomodulatory role of the soy isoflavone genistein has been demonstrated, the effects of other soy isoflavones on induction of antigen (Ag)-specific immune responses are not known. In this study, we therefore investigated the effects of daidzein and equol on ovalbumin (OVA)-specific T cell and B cell responses in BALB/c mice. Mice that had been treated with 20 mg/kg equol showed a significantly higher level of OVA-specific IgE than control mice. Levels of interferon (IFN)-gamma and interleukin (IL)-4 production were not different between the control and equol groups. However, IL-13 production level in mice administered 20 mg/kg equol was significantly higher than that in control mice. Strong induction of OVA-specific IgE production by equol was also observed in ovariectomized BALB/c mice, suggesting that the immunomodulatory effect of equol is not affected by endogenous estrogen.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3177/jnsv.56.72
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20354350
- ● Search Scopus @ Elsevier (PMID): 20354350
- ● Search Scopus @ Elsevier (DOI): 10.3177/jnsv.56.72
(DOI: 10.3177/jnsv.56.72, PubMed: 20354350) Kenji Ikuta, Seiji Yano, Van The Trung, Masaki Hanibuchi, Hisatsugu Goto, Qi Li, Wei Wang, Tadaaki Yamada, Hirokazu Ogino, Soji Kakiuchi, Hisanori Uehara, Yoshitaka Sekido, Toshimitsu Uenaka, Yasuhiko Nishioka and Saburo Sone :
E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.,
Clinical Cancer Research, Vol.15, No.23, 7229-7237, 2009.- (要約)
- Malignant pleural mesothelioma (MPM) is a biologically heterogeneous malignant disease with a poor prognosis. We reported previously that the anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, effectively inhibited the progression of VEGF-high-producing (but not VEGF-low-producing) MPM cells in orthotopic implantation models, indicating the need for novel therapeutic strategies to improve the poor prognosis of this disease. Therefore, we focused on the multi-tyrosine kinase inhibitor E7080 and assessed its therapeutic efficacy against MPM cells with different proangiogenic cytokine production profiles.
- (キーワード)
- Animals / Cell Line, Tumor / 細胞質分裂 (cytokinesis) / Fibroblast Growth Factor 2 / Humans / Male / Mesothelioma / Mice / Mice, SCID / Neoplasm Transplantation / Neovascularization, Pathologic / Phenylurea Compounds / リン酸化 (phosphorylation) / Platelet-Derived Growth Factor / Pleural Neoplasms / Quinolines / Vascular Endothelial Growth Factor A
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1158/1078-0432.CCR-09-1980
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19934291
- ● Search Scopus @ Elsevier (PMID): 19934291
- ● Search Scopus @ Elsevier (DOI): 10.1158/1078-0432.CCR-09-1980
(DOI: 10.1158/1078-0432.CCR-09-1980, PubMed: 19934291) Shinsaku Otsuka, Masaki Hanibuchi, Kenji Ikuta, Seiji Yano, Hisatsugu Goto, Hirokazu Ogino, Tadaaki Yamada, Soji Kakiuchi, Yasuhiko Nishioka, Takashi Takahashi and Saburo Sone :
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.,
Oncology Research, Vol.17, No.11-12, 581-591, 2009.- (要約)
- Lung cancer is commonly associated with multiple-organ metastasis, and bone is a frequent metastatic site for lung cancer. Lung cancer frequently develops osteolytic, and less frequently osteoblastic, metastasis to bone. Osteolytic metastasis models of lung cancer have been reported, but no osteoblastic metastasis model is available for lung cancer. In the present study, we established a reproducible model of human lung cancer with both osteolytic and osteoblastic changes in natural killer cell-depleted severe combined immunodeficient mice. Intravenous inoculation of ACC-LC-319/bone2 cells resulted in the development of metastatic colonies in the lung, liver, and bone of the mice. As assessed sequentially by X-ray photographs, osteolytic bone lesions were observed by day 28, and then osteoblastic lesions were detected by day 35. Histological examination revealed the presence of bony spurs, a hallmark of osteoblastic bone metastasis, where osteoclasts were hardly observed. Treatment with an anti-human vascular endothelial growth factor antibody, bevacizumab, as well as zoledronate, inhibited the number of experimental bone metastases, including osteoblastic changes produced by ACC-LC-319/bone2 cells. These results indicate that our bone metastasis model by ACC-LC319/bone2 might be useful to understand the molecular pathogenesis of osteolytic and osteoblastic metastasis, and to identify molecular targets to control bone metastasis of lung cancer.
- (キーワード)
- Adenocarcinoma / Animals / Antibodies, Monoclonal / Bone Neoplasms / Cell Line, Tumor / Diphosphonates / Disease Models, Animal / Endothelin-1 / Humans / Imidazoles / Killer Cells, Natural / Lung Neoplasms / Male / Mice / Mice, Inbred ICR / Mice, SCID / Osteoblasts / Osteolysis / Vascular Endothelial Growth Factor A
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3727/096504009789745511
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19806789
- ● Search Scopus @ Elsevier (PMID): 19806789
- ● Search Scopus @ Elsevier (DOI): 10.3727/096504009789745511
(DOI: 10.3727/096504009789745511, PubMed: 19806789) Akemi Sugita, Hirohisa Ogawa, Masahiko Azuma, Susumu Muto, Akifumi Honjo, Hiroaki Yanagawa, Yasuhiko Nishioka, Kenji Tani, Akiko Itai and Saburo Sone :
Antiallergic and anti-inflammatory effects of a novel IκB kinase β inhibitor, IMD-0354, in a mouse model of allergic inflammation.,
International Archives of Allergy and Immunology, Vol.148, No.3, 186-198, 2008.- (要約)
- BACKGROUND: Nuclear factor (NF)-kappaB is a transcription factor known to regulate allergy-associated cytokine and chemokine production related to the induction of inflammation. I kappaB kinase beta (IKK beta), which is responsible for activation of the NF-kappaB pathway, may be an ideal molecular target to inhibit this process. IMD-0354 [N-(3,5-bis-trifluoromethyl-phenyl)-5-chloro-2-hydroxy-benzamide] is an attractive novel IKK beta inhibitor that prevents the production of inflammatory cytokines in various diseases, although it is not known if IMD-0354 is effective against allergic inflammation. This study aimed to elucidate the antiallergic effects of a newly synthesized IKK beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. METHODS: We generated ovalbumin (OVA)-sensitized mice which were then challenged with OVA. IMD-0354 was administered intraperitoneally to therapeutic groups. Lung histopathology and the concentrations of cytokines and chemokines in bronchoalveolar lavage fluid (BALF) and supernatants of lung homogenates were determined. RESULTS: Administration of IMD-0354 ameliorated airway hyperresponsiveness and reduced the numbers of bronchial eosinophils and mucus-producing cells in OVA-sensitized mice. The total numbers of cells and eosinophils in BALF were also reduced by treatment with IMD-0354. Treatment with IMD-0354 inhibited the production of Th2 cytokines such as interleukin (IL)-5 and IL-13 and eotaxin in the airways and/or lungs of OVA-sensitized mice, but it did not affect the restoration of Th1 cytokines such as IL-12 and interferon-gamma under the same experimental conditions. IgE production was also inhibited by IMD-0354. CONCLUSION: A specific IKK beta inhibitor, IMD-0354, improved allergic airway inflammation and hyperresponsiveness in mice. IMD-0354 may have therapeutic potential for bronchial asthma.
- (キーワード)
- Airway Resistance / Animals / Anti-Allergic Agents / Anti-Inflammatory Agents / Benzamides / Body Weight / Bronchoalveolar Lavage Fluid / Cell Count / Chemokines / Cytokines / Disease Models, Animal / Eosinophils / Female / I-kappa B Kinase / Immunoglobulin E / Lung / Lymphocytes / Macrophages / Mice / Mice, Inbred BALB C / Ovalbumin / Respiratory Hypersensitivity
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1159/000161579
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18849610
- ● Search Scopus @ Elsevier (PMID): 18849610
- ● Search Scopus @ Elsevier (DOI): 10.1159/000161579
(DOI: 10.1159/000161579, PubMed: 18849610) Kazuhide Yoneda, Junji Ueno, Sadamitsu Nishihara, Tetsuya Tsujikawa, Naomi Morita, Hideki Otsuka, Kaori Furutani, Hiromu Nishitani, Kazuya Kondo and Yasuhiko Nishioka :
Postprocessing technique with MDCT data improves the accuracy of the detection of lung nodules,
Radiation Medicine, Vol.25, No.10, 511-515, 2007.- (要約)
- The aim of this study was to determine whether postprocessing techniques could improve the accuracy of detecting lung nodules. A total of 154 segmented lung volumes of multidetector-row computed tomography (MDCT) data were the subject of the study. Lung nodules were present in 88 volumes and absent in 66 volumes. We prepared four groups: (1) 7- or 10-mm thick-section axial images; (2) 1-mm thin-section axial images; (3) sliding slab maximum intensity projection (MIP) images with a slab thickness of 15 mm; and (4) sliding slab volume rendering (VR) images with a slab thickness of 15 mm. Sixteen physicians reviewed each group in interactive cine mode. The observers' performance in the detection of lung nodule was evaluated by receiver operating characteristic (ROC) analysis. The observers' performance of the MIP and VR groups was significantly better than in other two groups. There was no significant difference statistically between the thin and thick groups. The detectability of lung nodules is improved with the use of sliding slab MIP and VR using thin-section image data. Thin-section volume data are essential for improving diagnostic accuracy, but observation of thin-section images without utilization of image-processing techniques dose not improve diagnostic accuracy.
- (キーワード)
- MD CT / Lung nodule / Sliding slab / MIP / VR / Thin-section image
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1007/s11604-007-0176-9
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18085401
- ● Summary page in Scopus @ Elsevier: 2-s2.0-40349087195
(DOI: 10.1007/s11604-007-0176-9, PubMed: 18085401, Elsevier: Scopus) M. Azuma, Yasuhiko Nishioka, Y. Aono, M. Inayama, H. Makino, Jun Kishi, Masayuki Shono, Katsuhiro Kinoshita, H. Uehara, H. ogushi, K. Izumi and Saburo Sone :
Role of 1-acid glycoprorein in theraqeutic antifibrotic effects of imatinib plus macrolides in mice.,
American Journal of Respiratory and Critical Care Medicine, Vol.176, No.12, 1243-1250, 2007.- (要約)
- Imatinib is an inhibitor of platelet-derived growth factor receptors. We have reported that treatment with imatinib inhibited bleomycin-induced pulmonary fibrosis in mice. However, late treatment with imatinib had no effect. To clarify why imatinib had no antifibrotic effect when its administration was delayed, we focused on alpha(1)-acid glycoprotein (AGP), because it was reported to bind imatinib and mediate drug resistance. The concentration of AGP in serum of mice and patients with idiopathic pulmonary fibrosis was measured by radial immunodiffusion testing. The effects of AGP in vitro were evaluated by assaying the growth of lung fibroblasts. We examined the combined effects of erythromycin (EM) or clarithromycin (CAM) on bleomycin-induced pulmonary fibrosis in mice. Addition of AGP abrogated imatinib-mediated inhibition of the growth of fibroblasts. However, treatment with EM or CAM restored the growth-inhibitory effects of imatinib. The elevated level of AGP was detected in serum and lung homogenates in bleomycin-exposed mice and reached a plateau on Day 14. Imatinib alone did not ameliorate pulmonary fibrosis when treatment was started on Day 15, whereas coadministration of imatinib and EM or CAM significantly reduced the fibrogenesis via inhibition of the growth of fibroblasts in vivo. Serum levels of AGP were higher in patients with idiopathic pulmonary fibrosis than in healthy subjects. AGP is an important regulatory factor modulating the ability of imatinib to prevent pulmonary fibrosis in mice, and combined therapy with imatinib and EM or CAM might be useful for treatment of pulmonary fibrosis.
- (キーワード)
- 1-acid glycoprorein / mice
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/rccm.200702-178OC
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17717205
- ● Search Scopus @ Elsevier (PMID): 17717205
- ● Search Scopus @ Elsevier (DOI): 10.1164/rccm.200702-178OC
(DOI: 10.1164/rccm.200702-178OC, PubMed: 17717205) Ali Jalili, Shuji Ozaki, Tomoko Hara, Hironobu Shibata, Toshihiro Hashimoto, Masahiro Abe, Yasuhiko Nishioka and Toshio Matsumoto :
Induction of HM1.24 peptide specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma,
Blood, Vol.106, No.10, 3538-3545, 2005.- (要約)
- HM1.24 antigen is preferentially overexpressed in multiple myeloma (MM) cells but not in normal cells. To explore the potential of HM1.24 as a target for cellular immunotherapy, we selected 4 HM1.24-derived peptides that possess binding motifs for HLA-A2 or HLA-A24 by using 2 computer-based algorithms. The ability of these peptides to generate cytotoxic T lymphocytes (CTLs) was examined in 20 healthy donors and 6 patients with MM by a reverse immunologic approach. Dendritic cells (DCs) were induced from peripheral-blood mononuclear cells of healthy donors or peripheral-blood stem-cell (PBSC) harvests from patients with MM, and autologous CD8(+) T cells were stimulated with HM1.24 peptide-pulsed DCs. Both interferon-gamma-producing and cytotoxic responses were observed after stimulation with either HM1.24-126 or HM1.24-165 peptides in HLA-A2 or HLA-A24 individuals. The peptide-specific recognition of these CTLs was further confirmed by tetramer assay and cold target inhibition assay. Importantly, HM1.24-specific CTLs were also induced from PBSC harvests from patients with MM and these CTLs were able to kill MM cells in an HLA-restricted manner. These results indicate the existence of functional DCs and HM1.24-specific CTL precursors within PBSC harvests and provide the basis for cellular immunotherapy in combination with autologous PBSC transplantation in MM.
- (キーワード)
- Antigens, CD / Cell Line, Tumor / Dendritic Cells / Female / GPI-Linked Proteins / HLA-A Antigens / HLA-A2 Antigen / HLA-A24 Antigen / Hematopoietic Stem Cells / Humans / Interferon-gamma / Male / Membrane Glycoproteins / Multiple Myeloma / Peptides / Peripheral Blood Stem Cell Transplantation / T-Lymphocytes, Cytotoxic / Transplantation, Homologous
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1182/blood-2005-04-1438
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16037388
- ● Search Scopus @ Elsevier (PMID): 16037388
- ● Search Scopus @ Elsevier (DOI): 10.1182/blood-2005-04-1438
(DOI: 10.1182/blood-2005-04-1438, PubMed: 16037388) Yoshinori Aono, Yasuhiko Nishioka, Mami Inayama, Jun Kishi, Momoyo Ugai, Hisanori Uehara, Keisuke Izumi and Saburo Sone :
Imatinib as a Novel Antifibrotic Agent in Bleomycin-induced Pulmonary Fibrosis in Mice,
American Journal of Respiratory and Critical Care Medicine, Vol.171, No.11, 1279-1285, 2005.- (要約)
- Imatinib mesylate is a potent and specific tyrosine kinase inhibitor against c-ABL, BCR-ABL, and c-KIT, and has been demonstrated to be highly active in chronic myeloid leukemia and gastrointestinal stromal tumors. We examined the antifibrotic effects of imatinib using a bleomycin-induced lung fibrosis model in mice because imatinib also inhibits tyrosine kinase of platelet-derived growth factor receptors (PDGFRs). Imatinib inhibited the growth of primary murine lung fibroblasts and the autophosphorylation of PDGFR-beta induced by PDGF. Administration of imatinib significantly prevented bleomycin-induced pulmonary fibrosis in mice, partly by reducing the number of mesenchymal cells incorporating bromodeoxyuridine. Analysis of bronchoalveolar lavage cells demonstrated that imatinib did not suppress early inflammation on Days 7 and 14 caused by bleomycin. These results suggest that imatinib has the potential to prevent pulmonary fibrosis by inhibiting the proliferation of mesenchymal cells, and that imatinib might be useful for the treatment of pulmonary fibrosis in humans.
- (キーワード)
- Animals / Bleomycin / Bronchoalveolar Lavage Fluid / Disease Models, Animal / Female / Fibroblasts / Intracellular Signaling Peptides and Proteins / Mice / Mice, Inbred C57BL / Piperazines / Pulmonary Fibrosis / Pyrimidines / Reference Values / Treatment Outcome
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/rccm.200404-531OC
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15735062
- ● Search Scopus @ Elsevier (PMID): 15735062
- ● Search Scopus @ Elsevier (DOI): 10.1164/rccm.200404-531OC
(DOI: 10.1164/rccm.200404-531OC, PubMed: 15735062) Yanjmaa Bira, Kenji Tani, Yasuhiko Nishioka, juuya Miyata, Keiko Sato, Akihito Hayashi, Yutaka Nakaya and Saburo Sone :
Transforming growth factor β stimulates rheumatoid synovial fibroblasts via the type receptor,
Modern Rheumatology, Vol.15, No.2, 108-113, 2005.- (要約)
- Transforming growth factor (TGF)-beta regulates the function of fibroblasts, and has been shown to have a role in the pathogenesis of rheumatoid arthritis (RA) because several studies have demonstrated the presence of TGF-beta in the synovial tissue and synovial fluids of RA patients. In this study, we examined the expression of TGF-beta receptors in synovial fibroblasts of patients with RA and demonstrated the significance in functional responses of synovial fibroblasts to TGF-beta in this disorder. Transforming growth factor beta1 stimulated the expression of connective tissue growth factor (CTGF) in fibroblasts of patients with RA more than in those of patients with osteoarthritis (OA). Transforming growth factor beta1 induced the chemotactic migration of RA synovial fibroblasts and inhibited their proliferation significantly more than OA synovial fibroblasts. Both RA and OA synovial fibroblasts expressed detectable amounts of TGF-beta receptor type II mRNA, but the expression was higher in RA patients than in OA patients, as assessed by reverse transcriptase-polymerase chain reaction. There was no significant difference in the expression of TGF-beta receptor type I or type III in synovial fibroblasts between RA and OA patients. These results indicate that synovial fibroblasts of RA patients express the increased TGF-beta receptor type II, which is associated with altered responses to TGF-beta observed in CTGF expression, chemotaxis, and proliferation of RA synovial fibroblasts, and may have an important role in the pathogenesis of RA.
- (キーワード)
- Chemotaxis / Connnective tissue growth factor(CTGF) / Fibroblast / Rheumatoid arthritis(RA) / Transforming growth factor β(TGF-β)
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1007/s10165-004-0378-2
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17029045
- ● Search Scopus @ Elsevier (PMID): 17029045
- ● Search Scopus @ Elsevier (DOI): 10.1007/s10165-004-0378-2
(DOI: 10.1007/s10165-004-0378-2, PubMed: 17029045) Masaki Hanibuchi, Yuka Matsumori, Yasuhiko Nishioka and Saburo Sone :
A case of sarcoidosis accompanying squamous cell carcinoma in the mandibular gingiva,
The Journal of Medical Investigation : JMI, Vol.52, No.1-2, 118-121, 2005.- (要約)
- A 51-year-old man with a history of gingival cancer two years previously was referred to our hospital for further examination of chest abnormal shadow. Bilateral hilar and mediastinal lymphadenopathy, diffuse small nodular opacities and pleural nodules were observed in chest high resolution CT. Serum angiotensin converting enzyme and lysozyme were elevated. Transbronchial lung biopsy specimens demonstrated non-caseous granuloma. CD4-positive lymphocytes were increased in broncho-alveolar lavage (CD4/CD8 ratio 5.47). The patient was diagnosed as having sarcoidosis. Radiological findings were improved and serum angiotensin converting enzyme level was decreased to within the normal range by corticosteroid therapy (prednisolone 30 mg/day). This is the first report of sarcoidosis accompanying the gingival cancer.
- (キーワード)
- Carcinoma, Squamous Cell / Gingival Neoplasms / Humans / Male / Middle Aged / Sarcoidosis, Pulmonary
- (徳島大学機関リポジトリ)
- ● Metadata: 110766
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.52.118
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15751283
- ● Search Scopus @ Elsevier (PMID): 15751283
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.52.118
(徳島大学機関リポジトリ: 110766, DOI: 10.2152/jmi.52.118, PubMed: 15751283) Kazuyoshi Manabe, Yasuhiko Nishioka, Jun Kishi, Mami Inayama, Yoshinori Aono, Yoichi Nakamura, Fumitaka Ogushi, Hiroyasu Bando, Kenji Tani and Saburo Sone :
Elevation of macrophage-derived chemokine in eosinophilic pneumonia: a role of alveolar macrophages,
The Journal of Medical Investigation : JMI, Vol.52, No.1,2, 85-92, 2005.- (要約)
- Macrophage-derived chemokine (MDC/CCL22) and thymus-and activation-regulated chemokine (TARC/CCL17) are ligands for CC chemokine receptor 4. Recently, TARC has been reported to play a role in the pathogenesis of idiopathic eosinophilic pneumonia (IEP). The purpose of this study was to evaluate the role of MDC in IEP and other interstitial lung diseases (ILDs). MDC and TARC in the bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay in patients with ILDs and healthy volunteers (HV). We also examined the expression of MDC mRNA in alveolar macrophages (AM) by real-time quantitative reverse transcriptase-polymerase chain reaction. Both MDC and TARC were detected only in BALF obtained from IEP patients. The concentration of MDC was higher than that of TARC in all cases. The level of MDC in IEP correlated with that of TARC. AM from IEP patients expressed a significantly higher amount of MDC than that from HV at the levels of protein and mRNA. MDC in BALF from IEP dramatically decreased when patients achieved remission. These findings suggest that MDC, in addition to TARC, might be involved in the pathogenesis of IEP, and AM play a role in the elevation of MDC in IEP.
- (キーワード)
- bronchoalveolar lavage fluid / macrophage-derived chemokine / thymus-and activation-regulated chemokine / eosinophilic pneumonia / alveolar macrophages / interstitial lung diseases
- (徳島大学機関リポジトリ)
- ● Metadata: 110761
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.52.85
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15751278
- ● CiNii @ 国立情報学研究所 (CRID): 1390001204244676736
- ● Search Scopus @ Elsevier (PMID): 15751278
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.52.85
(徳島大学機関リポジトリ: 110761, DOI: 10.2152/jmi.52.85, PubMed: 15751278, CiNii: 1390001204244676736) Ning Ge, Yasuhiko Nishioka, Yoichi Nakamura, Yoshio Okano, Kazuo Yoneda, Hirohisa Ogawa, Akemi Sugita, Hiroaki Yanagawa and Saburo Sone :
Synthesis and Secretion of Interleukin-15 by Freshly Isolated Human Bronchial Epithelial Cells,
International Archives of Allergy and Immunology, Vol.135, No.3, 235-242, 2004.- (要約)
- Interleukin-15 (IL-15), which shares many functional activities of IL-2, is proposed as a potential modulator of T and natural killer (NK) cell-mediated inflammatory diseases. Since IL-15 gene is expressed in various cell types including epithelial cells, we examined how proinflammatory modulators affect IL-15 gene expression in both freshly isolated human bronchial epithelial cells (HBECs) and the human bronchial epithelial cell line BEAS-2B. HBECs were obtained from 25 patients with primary lung cancer by bronchial brushing under bronchofiberscopy. The expressions of IL-15 and its receptor were examined using reverse transcription-polymerase chain reaction (RT-PCR), Northern blot analysis and enzyme-linked immunosorbent assay. IL-15 mRNA was constitutively expressed in the cells and was upregulated by several proinflammatory cytokines such as IL-1beta, tumor necrosis factor-alpha, interferon-gamma (IFN-gamma) and lipopolysaccharide. In addition, IFN-gamma but not other cytokines induced the synthesis and secretion of IL-15 protein. Investigation of IL-15 receptor expression using RT-PCR showed that IL-15Ralpha and IL-2Rbeta chains but not IL-2Ralpha or gamma chain were constitutively expressed in these cells. Bronchial epithelial cells may contribute to T and NK cell-mediated airway inflammation through IL-15 production.
- (キーワード)
- Interleukin-15 / Bronchial epithelial cells / Interferon-γ / Interleukin-15 receptor
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1159/000081309
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15467375
- ● Search Scopus @ Elsevier (PMID): 15467375
- ● Search Scopus @ Elsevier (DOI): 10.1159/000081309
(DOI: 10.1159/000081309, PubMed: 15467375) Masato Okamoto, Sachiko Furuichi, Yasuhiko Nishioka, Tetsuya Oshikawa, Tomoyuki Tano, Sharif Uddin Ahmed, Kiyoshi Takeda, Shizuo Akira, Yoshiki Ryoma, Yoichiro Moriya, Motoo Saito, Saburo Sone and Mitsunobu Sato :
Expression of Toll-Like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation,
Cancer Research, Vol.64, No.15, 5461-5470, 2004.- (要約)
- A lipoteichoic acid-related molecule OK-PSA is an active component of OK-432, a Streptococcus-derived anticancer immunotherapeutic agent. In the present study, we first examined the effect of OK-PSA on the maturation of dendritic cells (DCs) in vitro by using the DCs derived from 5 healthy donors and 10 patients with head and neck cancer with or without expression of toll-like receptor 4 (TLR4) or MD-2 mRNA. OK-PSA treatment effectively increased the surface expression of MHC class II, CD80, CD83, and CD86. OK-PSA-stimulated DCs secreted the cytokines that can induce helper T-cell 1 (Th1)-type T-cell response, and stimulated allogeneic T cells to produce IFN-gamma and to elicit an allogeneic antigen-specific cytotoxicity. These activities almost depended on expression of TLR4 and MD-2 genes. We next investigated the in vivo anticancer effect of intratumoral administration of syngeneic DCs followed by OK-PSA against established tumors in mice. C57BL/6 mice, which express wild-type TLR4, and C57BL/6-derived TLR4-knockout (TLR4(-/-)) mice were used. Although OK-PSA accelerated the antitumor effect of intratumoral DC administration in wild-type mice bearing syngeneic tumors, the antitumor effect of OK-PSA as well as of the combination therapy with DCs and OK-PSA was not significant in TLR4(-/-) mice. Interestingly, an administration of wild-type-mouse-derived DCs followed by OK-PSA exhibited a marked antitumor effect even in the TLR4(-/-) mice. These findings suggest that OK-PSA may be a potent adjuvant for local DC therapy, and that DC therapy followed by OK-PSA is able to elicit anticancer activity even in a TLR4-deficient host when TLR4 is expressed only in DCs injected intratumorally.
- (キーワード)
- Adjuvants, Immunologic / Adult / Aged / Animals / Antigens, CD / Antigens, Surface / Antineoplastic Agents / Chemokines / Chromium / Combined Modality Therapy / Cytokines / Dendritic Cells / Female / Head and Neck Neoplasms / Humans / Immunotherapy / Interferon-gamma / Lymphocyte Antigen 96 / Lymphocytes, Tumor-Infiltrating / Male / Membrane Glycoproteins / Mice / Mice, Inbred C57BL / Mice, Knockout / Middle Aged / Neoplasms, Experimental / Picibanil / RNA, Messenger / Receptors, Cell Surface / Streptococcus / T-Lymphocytes, Cytotoxic / Th1 Cells / Toll-Like Receptor 4 / Toll-Like Receptors
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1158/0008-5472.CAN-03-4005
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15289356
- ● Search Scopus @ Elsevier (PMID): 15289356
- ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-03-4005
(DOI: 10.1158/0008-5472.CAN-03-4005, PubMed: 15289356) Toru Asano, Fumitaka Ogushi, Kenji Tani, Hiroyuki Tamiya, Yasuhiko Nishioka and Saburo Sone :
Increased macrophage inflammatory protein-1α and -1β in BAL fluid of bronchiolitis obliterans organizing pneumonia,
Respirology, Vol.8, No.4, 461-466, 2003.- (要約)
- CC chemokines are mainly chemotactic for monocytes and lymphocytes. The aim of this study was to evaluate the involvement of the CC chemokines, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta, in the pathogenesis of bronchiolitis obliterans organizing pneumonia (BOOP). The concentrations of MIP-1alpha and MIP-1beta in BAL fluid (BALF) obtained from patients with BOOP (n = 13) and control patients (CP, n= 18) were measured by enzyme-linked immunosorbent assay. MIP-1alpha in BALF was significantly higher in patients with BOOP (mean +/- SD; 123.8 +/- 98.0 pg/mL) than in CP (62.5 +/- 46.1 pg/mL). Significantly higher MIP-1beta was also detected in patients with BOOP (51.6 +/- 72.5 pg/mL) than in CP (6.4 +/- 3.7 pg/mL). The concentration of MIP-1alpha significantly correlated with the percentage of lymphocytes in BALF, and the concentration of MIP-1beta significantly correlated with the numbers of lymphocytes, neutrophils and eosinophils in BALF. Both MIP-1alpha and MIP-1beta in BALF were decreased after corticosteroid therapy and this was accompanied by decreased lymphocytes in BALF. This study suggests that MIP-1alpha and MIP-1beta may play important roles in the recruitment of immuno-inflammatory cells into the lungs, and may contribute to the pathogenesis of BOOP.
- (キーワード)
- bronchiolitis obliterans organizing pneumonia / BAL fluid / chemokine / macrophage inflammatory protein-1α / macrophage inflammatory protein-1β
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1046/j.1440-1843.2003.00496.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14629649
- ● Search Scopus @ Elsevier (PMID): 14629649
- ● Search Scopus @ Elsevier (DOI): 10.1046/j.1440-1843.2003.00496.x
(DOI: 10.1046/j.1440-1843.2003.00496.x, PubMed: 14629649) H Ogawa, N Nishimura, Yasuhiko Nishioka, M Azuma, Hiroaki Yanagawa and Saburo Sone :
Adenoviral interleukin-12 gene transduction into human bronchial epithelial cells:up-regulation of pro-inflammatory cytokines and its prevention by corticosteroids,
Clinical and Experimental Allergy, Vol.33, No.7, 921-929, 2003.- (要約)
- One of the potential effects of IL-12 is to restore Th1/Th2 balance. Therefore, we investigated the possibility of developing a system for local delivery of IL-12 into the airways by examining protein expression in a human bronchial epithelial cell line (BEAS-2B) after adenoviral IL-12 gene transduction. The effects of dexamethasone on the gene-modified cells were also examined. Adenoviral vectors AxCAegfp and Ax1CIhp40ip35 were used to transduce enhanced green fluorescence protein and IL-12 genes, respectively, into BEAS-2B cells. Wild-type and IL-12 gene-transduced BEAS-2B cells were then incubated with or without dexamethasone, and concentrations of IL-12, IFN-gamma, IL-6, IL-8, granulocyte macrophage-colony stimulating factor and chemokines (TARC and RANTES) in the supernatant were measured by ELISA. IL-12 receptor expression was analysed by flow cytometry and RT-PCR. The efficiency of transgene expression in BEAS-2B cells at a multiplicity of infection of 30 was approximately 80%. Gene-modified BEAS-2B cells produced biologically active IL-12, regardless of dexamethasone treatment. While IL-12 gene transduction led to increased production of IL-6 and IL-8 by BEAS-2B cells, expressions of these proteins were suppressed by dexamethasone. Addition of exogenous IL-12 failed to augment BEAS-2B cell IL-6 and IL-8 production, and IL-12 receptor expression by BEAS-2B cells was not detected. Our findings suggest that adenoviral IL-12 gene transduction may be effective in inducing IL-12 expression in the airways, and could be a potential approach in the management of bronchial asthma.
- (キーワード)
- adenoviral vector / BEAS-2B cell / dexamethasone / gene transduction / human bronchial epithelial cells / IL-12 / IL-8 / IL-6
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1046/j.1365-2222.2003.01702.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12859448
- ● Search Scopus @ Elsevier (PMID): 12859448
- ● Search Scopus @ Elsevier (DOI): 10.1046/j.1365-2222.2003.01702.x
(DOI: 10.1046/j.1365-2222.2003.01702.x, PubMed: 12859448) Seiji Yano, Yasuhiko Nishioka, Hisatsugu Goto and Saburo Sone :
Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules.,
Cancer Science, Vol.94, No.6, 479-485, 2003.- (要約)
- Angiogenesis, neovascularization from pre-existing vasculature, is necessary to supply oxygen and nutrition for tumor growth in both primary and distant organs. It consists of sprouting and non-sprouting (the enlargement, splitting, and fusion of pre-existing vessels) processes, and both can occur concurrently. Growth of solid tumors, including non-small cell lung cancer (NSCLC), is usually dependent on angiogenesis, which is regulated by complex mechanisms involving various angiogenesis-related molecules. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), one of the most potent angiogenic molecules, regulates both angiogenesis and vascular permeability, and hence promotes tumor progression and development of malignant pleural effusions in NSCLC. Signals via epidermal growth factor receptor (EGFR) promote not only the tumor cell cycle, but also the process of angiogenesis. Therefore, these molecules are potential targets for anti-tumor vasculature therapy. Many agents targeting tumor vasculature have been developed, and several compounds have shown anti-tumor potential in preclinical studies. Their efficacy against NSCLC is currently being evaluated in clinical trials.
- (キーワード)
- Angiogenesis Inhibitors / Animals / Antineoplastic Agents / Carcinoma, Non-Small-Cell Lung / Humans / Lung Neoplasms / Neovascularization, Pathologic
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1349-7006.2003.tb01469.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12824870
- ● Search Scopus @ Elsevier (PMID): 12824870
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.2003.tb01469.x
(DOI: 10.1111/j.1349-7006.2003.tb01469.x, PubMed: 12824870) Hiroya Tada, Fumitaka Ogushi, Kenji Tani, Yasuhiko Nishioka, Jun-ya Miyata, Keiko Sato, Toru Asano and Saburo Sone :
Increased binding and chemotactic capacities of PDGF-BB on fibroblasts in radiation pneumonitis,
Radiation Research, Vol.159, No.6, 805-811, 2003.- (要約)
- Although pulmonary fibrosis is a frequent and serious consequence of radiotherapy for thoracic malignant diseases such as lung cancer, the pathogenesis of this radiation-induced lung disorder remains unclear. To clarify the mechanisms underlying radiation pneumonitis and pulmonary fibrosis, we investigated the expression of platelet-derived growth factor receptor (PDGFR) on fibroblasts obtained from irradiated rat lungs and on control fibroblasts. Whole lungs of male Wistar rats were irradiated with a single dose of 15 Gy, and lung fibroblasts were isolated at 4 weeks after the irradiation. The chemotactic response of irradiated lung fibroblasts to PDGF-BB was significantly higher than that of control lung fibroblasts, whereas there was no significant difference between irradiated lung fibroblasts and control lung fibroblasts in the response to PDGF-AA. Receptor binding assay showed more specific binding sites for PDGF-BB on irradiated lung fibroblasts than on control lung fibroblasts, and the displacement of (125)I-labeled PDGF binding to fibroblasts by unlabeled PDGF showed that (125)I-labeled PDGF-BB was displaced by PDGF-BB but not by PDGF-AA. These results suggest that the increased binding sites for PDGF-BB on irradiated lung fibroblasts correspond mainly to PDGFRB. Scatchard analysis of the saturation data demonstrated an approximately twofold increase both in the number of PDGF-BB binding sites and in the binding affinity in irradiated lung fibroblasts compared to that in control lung fibroblasts. Those results suggest that the increased chemotactic response of irradiated lung fibroblasts to PDGF-BB is related to the overexpression of PDGFRB, which may have an important role in the pathogenesis of radiation-induced pneumonitis and pulmonary fibrosis.
- (キーワード)
- Animals / Bronchoalveolar Lavage Fluid / Chemotaxis / Fibroblasts / Lung / Male / Platelet-Derived Growth Factor / Proto-Oncogene Proteins c-sis / Pulmonary Fibrosis / Radiation Pneumonitis / Rats / Rats, Wistar / Receptors, Platelet-Derived Growth Factor
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1667/0033-7587(2003)159[0805:IBACCO]2.0.CO;2
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12751964
- ● CiNii @ 国立情報学研究所 (CRID): 1571698601685680896
- ● Search Scopus @ Elsevier (PMID): 12751964
- ● Search Scopus @ Elsevier (DOI): 10.1667/0033-7587(2003)159[0805:IBACCO]2.0.CO;2
(DOI: 10.1667/0033-7587(2003)159[0805:IBACCO]2.0.CO;2, PubMed: 12751964, CiNii: 1571698601685680896) Yasuhiko Nishioka, Hua Wen, Kayo Mitani, Paul D. Robbins, Michael T. Lotze, Saburo Sone and Hideaki Tahara :
Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide,
Journal of Leukocyte Biology, Vol.73, No.5, 621-629, 2003.- (要約)
- We examined the mechanisms involved in interleukin (IL)-12-mediated suppression of cellular immunity in mice using allogeneic mixed leukocyte reaction (MLR) stimulated by dendritic cells (DCs) in vitro and compared the effect of IL-12 on MLR in mice and humans. Although IL-12 stimulated human MLR, the addition of IL-12 or interferon-gamma (IFN-gamma) resulted in a dose-dependent suppression of MLR in mice. The treatment with N(G)-monomethyl-L-arginine (L-NMMA) completely abrogated IL-12- and IFN-gamma-mediated suppression of MLR in mice. Furthermore, IL-12 enhanced the alloreactive cytolytic T lymphocyte (CTL) induction in human MLR, whereas the addition of L-NMMA was required to generate alloreactive CTLs in the presence of IL-12 in mice. Nitric oxide (NO) was detected only in mouse MLR. Murine DCs could produce NO, but neither human CD34(+) cell- nor monocyte-derived DCs produced a detectable amount of NO. These results suggest that NO produced by DCs might play an important role in IL-12-mediated immune suppression in mice but not in humans.
- (キーワード)
- Animals / Antigen Presentation / Bone Marrow Cells / Dendritic Cells / Female / Humans / Immune Tolerance / Immunity, Cellular / Interferon-gamma / Interleukin-12 / Lymphocyte Culture Test, Mixed / Lymphoma, T-Cell / Mastocytoma / Mice / Mice, Inbred C57BL / Nitric Oxide / Nitric Oxide Donors / S-Nitroso-N-Acetylpenicillamine / Species Specificity / T-Lymphocytes, Cytotoxic / Tumor Cells, Cultured / omega-N-Methylarginine
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1189/jlb.0402205
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12714577
- ● Search Scopus @ Elsevier (PMID): 12714577
- ● Search Scopus @ Elsevier (DOI): 10.1189/jlb.0402205
(DOI: 10.1189/jlb.0402205, PubMed: 12714577) Kayo Mitani, Yasuhiko Nishioka, Kazue Yamabe, Hirohisa Ogawa, Toyokazu Miki, Hiroaki Yanagawa and Saburo Sone :
Soluble Fas in malignant pleural effusion and its expression in lung cancer cells,
Cancer Science, Vol.94, No.3, 302-307, 2003.- (要約)
- Soluble Fas (sFas) has the ability to block Fas-mediated apoptosis, suggesting that sFas at tumor sites might inhibit tumor cell-killing by immune effector cells. We examined the sFas level in pleural effusion associated with lung cancer. The level of sFas in malignant pleural effusion was significantly higher than those in transudate and tuberculous pleural effusion. There was no significant difference in the sFas concentration among various histological types of lung cancer. The cytotoxicity mediated by anti-Fas agonistic antibody against Jurkat cells was inhibited by the addition of malignant pleural effusion, being inversely correlated with the sFas concentration. When Fas expression was examined using flow cytometry, eight of ten (80%) lung cancer cell lines expressed cell surface Fas. On the other hand, sFas protein and mRNA were detected in six of ten (60%) lung cancer cell lines, but there was no correlation between Fas and sFas expression. Furthermore, although the expressions of Fas and sFas were clearly detected in tumor cells derived from malignant effusion, the sFas expression was down-regulated in an in vitro culture. These results suggest that sFas in malignant pleural effusion is at least in part produced by lung cancer cells, and might play a role in local immunosuppression by tumor cells.
- (キーワード)
- Actins / Antigens, CD95 / Base Sequence / Cell Survival / DNA Primers / DNA, Complementary / Humans / Jurkat Cells / Lung Neoplasms / Pleural Effusion / RNA, Messenger / Tuberculosis
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1349-7006.2003.tb01437.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12824926
- ● Search Scopus @ Elsevier (PMID): 12824926
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.2003.tb01437.x
(DOI: 10.1111/j.1349-7006.2003.tb01437.x, PubMed: 12824926) 埴淵 昌毅, 島田 玲香, 西岡 安彦, 篠原 勉, 曽根 三郎 :
三尖弁感染症心内膜炎および化膿性脊椎炎に併発した敗血症性肺塞栓症の1例(症例報告),
日本呼吸器学会雑誌, Vol.41, No.5, 365-369, 2003年. Hiroyoshi Sei, Atsuko Sano, Hiromi Ohno, Kazue Yamabe, Yasuhiko Nishioka, Saburo Sone and Yusuke Morita :
Age-related changes in control of blood pressure and heart rate during sleep in the rat,
Sleep, Vol.25, No.3, 279-285, 2002.- (要約)
- The aim of this study was to determine age-related changes in the control of mean arterial pressure (MAP) and heart rate (HR) during sleep, and its relationship to the baroreflex in aging. MAP, HR, body temperature (TP), spontaneous activity (ACT), and sleeping/waking duration were monitored for 24 hours in groups of young (10-12 wk old) and old (23-24 mo old) rats. The sleep laboratory at the University of Tokushima. Subjects were 8 young (10-12 wk old) and 7 old (23-24 mo old) Wistar rats. Reflex control of HR was evaluated by examining various pressure responses to an intravenous bolus injection of phenylephrine and sodium nitroprusside. MAP and TP were recorded by a radiotelemetry system. HR was detected from the AP signal. ACT was counted by a photo-sensor system. In the case of old rats, the sensitivity of baroreflex control of HR was significantly depressed, and the spontaneous increase of MAP and HR during REM sleep and the MAP drop at the end of REM sleep were significantly enhanced. The old rats showed no large deterioration of the circadian profiles of MAP, HR, TP, and the amount of sleep. The baroreflex dysfunction is considered to appear in an early stage of the aging process, and to affect the control of MAP and HR during sleep.
- (キーワード)
- 加齢 (aging) / rat / arterial pressure / heart rate / 睡眠 (sleep)
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12003158
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0036570598
(PubMed: 12003158, Elsevier: Scopus) Takashi Itokawa, Hiroki Nokihara, Yasuhiko Nishioka, Saburo Sone, Yukihide Iwamoto, Yuji Yamada, Julie Cherrington, Gerald McMahon, Masabumi Shibuya, Michihiko Kuwano and Mayumi Ono :
Antiangiogenic Effect by SU5416 Is Partly Attributable to Inhibition of Flt-1 Receptor Signaling,
Molecular Cancer Therapeutics, Vol.1, No.5, 295-302, 2002.- (要約)
- Interaction between vascular endothelial growth factor (VEGF) and its cognate receptors, KDR/Flk-1 and Flt-1, of vascular endothelial cells is expected to induce an angiogenesis "switch" in tumors and other angiogenesis-associated diseases. SU5416, a selective inhibitor of the KDR/Flk-1 tyrosine kinase, is known to be a potent inhibitor of tumor angiogenesis. In this study, we first observed that SU5416 inhibited Flt-1 tyrosine kinase activity at similar doses, in addition to inhibiting KDR/Flk-1 tyrosine kinase activity in response to VEGF. SU5416 inhibited cell migration of human vascular endothelial cells expressing both Flt-1 and KDR in response to VEGF and also inhibited the cell migration in response to placenta growth factor (PIGF), a specific ligand for Flt-1. Chemotaxis of monocytes expressing only Flt-1 was also inhibited by SU5416 in a dose-dependent manner. Moreover, SU5416 was found to inhibit tyrosine kinase of Flt-1 in response to PIGF in vitro. And angiogenesis induced by PIGF in a Matrigel plug assay was inhibited by administration of SU5416. The antiangiogenic effects by this VEGF receptor-targeting compound appeared to be mediated through interference not only with KDR/Flk-1 but also with Flt-1. Cell migration of vascular endothelial cells and monocytic cells through Flt-1, thus, might play a key role in VEGF-induced tumor angiogenesis in concert with KDR/Flk-1.
- (キーワード)
- 3T3 Cells / Angiogenesis Inhibitors / Animals / Cell Movement / Cells, Cultured / Chemotaxis / Collagen / DNA, Complementary / Dose-Response Relationship, Drug / Drug Combinations / Endothelium, Vascular / Extracellular Matrix Proteins / Humans / Immunoblotting / Indoles / Laminin / Male / Mice / Monocytes / Myosin Heavy Chains / Neovascularization, Pathologic / Nonmuscle Myosin Type IIB / Phosphorylation / Pregnancy Proteins / Protein-Tyrosine Kinases / Proteoglycans / Pyrroles / Transfection / Vascular Endothelial Growth Factor Receptor-1 / Vascular Endothelial Growth Factor Receptor-2
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12489845
- ● Search Scopus @ Elsevier (PMID): 12489845
(PubMed: 12489845) Hirohisa Ogawa, Naoki Nishimura, Yasuhiko Nishioka, Masahiko Azuma, Hiroaki Yanagawa and Saburo Sone :
Interleukin(IL)-12 gene transduction and its functional expression into human bronchial epithelial cells (BEAS-2B) by adenovirus vector,
The Journal of Medical Investigation : JMI, Vol.49, No.1,2, 74-82, 2002.- (要約)
- Interleukin (IL)-12 is known as a cytokine that augments the Th1 type response. Especially in allergic diseases such as a bronchial asthma, IL-12 induced restoration of the balance of the Th1/Th2 type immune response is an attractive strategy. In this study, the functional properties of the human bronchial epithelial cell line (BEAS-2B) transduced by an adenoviral vector encoding the human IL-12 gene were examined. Adenovirus vectors, AxCAegfp and Ax1CIhp40ip35 were transduced into BEAS-2B cells. Wild and gene-transduced BEAS-2B cells were incubated and the concentrations of IL-12 and IFN-gamma produced by co-cultured lymphocytes in the supernatant were measured using ELISA. The expressions of surface adhesion molecules, such as CD54 and CD106 were analyzed using flow cytometry. The efficiency of transgene expression of BEAS-2B cells was in a multiplicity of infection (MOI)-dependent manner and at an MOI of 30, the efficiency was approximately 80%. The gene-modified BEAS-2B cells produced biologically active IL-12 in dose- and time-dependent manners. IL-12 gene transduction did not significantly affect the expression of adhesion molecules (CD 54, CD106 and HLA-A,B,C) by BEAS-2B cells. These results suggest that the IL-12 gene may be successfully transduced into human bronchial epithelial cells by adenoviral vector to express IL-12 activity in vivo.
- (キーワード)
- Adenoviridae / Bronchi / Cell Adhesion Molecules / Cell Line / Genetic Vectors / Humans / Immunophenotyping / Interferon-gamma / Interleukin-12 / Lymphocytes / RNA, Messenger / Respiratory Mucosa / Transduction, Genetic
- (徳島大学機関リポジトリ)
- ● Metadata: 110639
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11901765
- ● CiNii @ 国立情報学研究所 (CRID): 1050564287419556992
- ● Search Scopus @ Elsevier (PMID): 11901765
(徳島大学機関リポジトリ: 110639, PubMed: 11901765, CiNii: 1050564287419556992) Yasuhiko Nishioka, Wen Hua, Naoki Nishimura and Saburo Sone :
Genetic modification of dendritic cells and its application for cancer immunotherapy,
The Journal of Medical Investigation : JMI, Vol.49, No.1,2, 7-17, 2002.- (要約)
- Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs). DCs pulsed with peptides of tumor-associated antigens (TAA) and tumor lysate have been used in cancer immunotherapy. An early clinical study demonstrated the safety of the use of DCs, but the clinical response was not sufficient. The gene-modification of DCs with TAA and soluble factor genes such as cytokine and chemokine genes has been examined to enhance the antigen-presenting capacity of DCs. Viral vectors including retroviruses and adenoviruses have been reported to be useful to obtain a sufficient transduction efficiency into DCs. TAA gene-transduced DCs could have several advantages compared with TAA peptide-pulsed DCs as follows: 1) The use of TAA gene-modified DCs are not restricted by MHC haplotypes. 2) The gene transduction with TAA genes is likely to present the unknown TAA peptides on DCs. 3) The gene-modified DCs show the prolonged presentation of TAA peptides. The transduction of DCs with cytokine genes including IL-12 and GM-CSF have also been reported to argument the antitumor effects of DCs. Although the results in the experimental systems were promising, the clinical application of gene-modified DCs includes several problems such as the standardization of methods of manipulation and gene-transduction of DCs. Approaches to solve them require further studies.
- (キーワード)
- Animals / Dendritic Cells / Humans / Immunotherapy, Adoptive / Neoplasms
- (徳島大学機関リポジトリ)
- ● Metadata: 110629
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11901764
- ● Search Scopus @ Elsevier (PMID): 11901764
(徳島大学機関リポジトリ: 110629, PubMed: 11901764) Y. Suzuki, Hiroaki Yanagawa, Yasuhiko Nishioka, N. Nishimura and Saburo Sone :
Effect generation of dendritic cells from alveolar and pleural macrophages as well as blood monocytes with lung cancer,
Lung Cancer, Vol.34, No.2, 195-205, 2001.- (要約)
- In this study, we investigated the generation of dendritic cells (DCs) from blood monocytes and mature macrophages from untreated primary lung cancer patients. Blood monocytes were separated by adherence from blood mononuclear cells (MNC) from ten lung cancer patients and ten control subjects, and cultured for 7 days in medium with granulocyte/macrophage colony-stimulating factor (GM-CSF) plus interleukin (IL-) 4. In all cases examined, DCs with typical characteristics were obtained even in lung cancer patients after 7 days culture with these cytokines, and there was no significant difference in phenotype and stimulatory activity in allogeneic lymphocyte proliferation between DCs derived from monocytes from lung cancer patients and those from control subjects. Next, we examined whether alveolar and pleural macrophages in malignant pleural effusion separated by magnetic beads could differentiate to immunostimulatory DCs. Conventional culture conditions with GM-CSF and IL-4 did not induce efficient numbers of DCs from mature macrophages, whereas the addition of tumor necrosis factor-alpha (TNF-alpha) to GM-CSF and IL-4 effectively contributed to generate DCs. These findings suggest that both mature macrophages and blood monocytes from lung cancer patients could differentiate to DCs, and might be a useful source of DCs for immunotherapy.
- (キーワード)
- Aged / Cell Culture Techniques / Cell Differentiation / Cell Division / Dendritic Cells / Granulocyte-Macrophage Colony-Stimulating Factor / Humans / Interleukin-4 / Lung Neoplasms / Macrophages, Alveolar / Male / Middle Aged / Monocytes / Phenotype / Pleura
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/S0169-5002(01)00234-3
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11679178
- ● Search Scopus @ Elsevier (PMID): 11679178
- ● Search Scopus @ Elsevier (DOI): 10.1016/S0169-5002(01)00234-3
(DOI: 10.1016/S0169-5002(01)00234-3, PubMed: 11679178) Masaki Hanibuchi, Seiji Yano, Yasuhiko Nishioka, Hiroaki Yanagawa, Toyokazu Miki and Saburo Sone :
Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966.,
Clinical & Experimental Metastasis, Vol.18, No.5, 353-360, 2001.- (要約)
- serum against SBC-3/DOX cells to a similar extent compared with parental SBC-3 cells. Pretreatment of human effector cells with various cytokines induced further enhancement of the KM966-dependent ADCC against SBC-3/DOX cells. Intravenous injection of SBC-3 or SBC-3/DOX cells into natural killer (NK) cell-depleted severe combined immunodeficient (SCID) mice developed metastases in multiple organs (liver, kidneys and lymph nodes). Interestingly, SBC-3/DOX cells produced metastases more rapidly than SBC-3 cells, suggesting more aggressive phenotype of SBC-3/DOX cells than their parental cells in vivo. Systemic treatment with KM966, given on days 2 and 7, drastically inhibited the formation of multiple-organ metastases produced by both SBC-3 and SBC-3/DOX cells, indicating that KM966 can eradicate metastasis by SCLC cells irrespective of MDR phenotype. These findings suggest that the mouse-human chimeric KM966 targets the GM2 antigen, and might be useful for the immunological circumvention of multiple-organ metastases of refractory SCLC.
- (キーワード)
- Animals / Antibodies, Monoclonal / Antineoplastic Agents / Carcinoma, Small Cell / Cytokines / Doxorubicin / Drug Resistance, Multiple / Drug Resistance, Neoplasm / G(M2) Ganglioside / Humans / Lung Neoplasms / Male / Mice / Mice, SCID
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11467766
- ● Search Scopus @ Elsevier (PMID): 11467766
(PubMed: 11467766) Yasuhiko Nishioka, Naoki Nishimura, Yoshihiro Suzuki and Saburo Sone :
Human monocyte-derived and CD83(+) blood dendritic cells enhance NK cell-mediated cytotoxicity.,
European Journal of Immunology, Vol.31, No.9, 2633-2641, 2001.- (要約)
- Dendritic cells (DC) are known to be the most potent APC and to stimulate antigen-specific T cell responses. Recently it was reported that murine DC were also capable of modulating the innate immunity by stimulating NK cells through cell-to-cell contact. In the present study, we examined whether human DC could affect NK activity. Both monocyte-derived and CD83(+) blood DC were tested. The addition of DC to cultures of CD56(+) cells resulted in the significant dose-dependent enhancement of the killing activity against various NK-sensitive targets. The resultant activity was comparable to that induced by optimal concentrations of various cytokines, including IL-2, IL-12, IL-15 and IFN-gamma. Interestingly, DC enhanced the cytotoxicity of CD3(-)CD56(+) NK cells, but not that of CD3(+)CD56(+) T cells. Experiments using transwells clearly demonstrated that the enhancement of NK activity by DC was mediated by soluble factors produced by DC. The culture supernatants of DC also stimulated NK activity. The treatment of both DC and their supernatants with anti-human IL-12 or IL-18 antibodies did not block the enhancement of NK cell-mediated cytolysis by DC, indicating that other factor(s) produced by DC were responsible for the enhancement of NK activity. These results suggest that human myeloid DC can modulate innate immunity by enhancing NK activity.
- (キーワード)
- Antibodies / Antigens, CD / Antigens, CD3 / Antigens, CD56 / Blood / Cells, Cultured / Cytotoxicity Tests, Immunologic / Cytotoxicity, Immunologic / Dendritic Cells / Humans / Immunoglobulins / Immunologic Factors / Interleukin-18 / Interleukin-2 / Killer Cells, Natural / Membrane Glycoproteins / Monocytes / Stem Cells / T-Lymphocytes / Tumor Cells, Cultured
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/1521-4141(200109)31:9<2633::AID-IMMU2633>3.0.CO;2-2
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11536161
- ● Search Scopus @ Elsevier (PMID): 11536161
- ● Search Scopus @ Elsevier (DOI): 10.1002/1521-4141(200109)31:9<2633::AID-IMMU2633>3.0.CO;2-2
(DOI: 10.1002/1521-4141(200109)31:9<2633::AID-IMMU2633>3.0.CO;2-2, PubMed: 11536161) Naoki Nishimura, Yasuhiko Nishioka, Tsutomu Shinohara, Hirohisa Ogawa, Sayaka Yamamoto, Kenji Tani and Saburo Sone :
Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells,
Journal of Immunological Methods, Vol.253, No.1-2, 113-124, 2001.- (要約)
- Dendritic cells (DC) are professional antigen-presenting cells in the immune system. Gene transduction of DC with tumor-associated antigen (TAA) or other genes that enhance the immune reaction has been considered theoretically useful for DC-based immunotherapy. However, gene transduction of DC generated from human peripheral blood monocytes has been difficult due to its low efficiency, even when adenoviral vector was used at high multiplicity of infection (MOI). In the present study, we examined the effect of centrifugal force to enhance efficiency of adenovirus-mediated gene transduction into human monocyte-derived DC at various rotor speeds at various temperatures for various times. We judged the transduction efficiency using enhanced green fluorescence protein (EGFP)-expressing adenoviral vector, and the best condition for centrifugal transduction was determined as 2000 x g at 37 degrees C for 2 h at an MOI of 10 or greater. At an MOI of 50 without centrifugation, the gene transduction efficiency was about 66% and mean fluorescence intensity (MFI) of EGFP expression was about 150 (at 37 degrees C for 2 h). With centrifugal transduction (2000 x g at an MOI of 50 at 37 degrees C for 2 h), 86% or more DC were gene-modified, and especially, MFI of EGFP expression was highly enhanced (MFI: about 3100 or greater). Centrifugally gene-transduced DC were not damaged and were thoroughly functional as measured by mixed lymphocyte reaction (MLR). The centrifugal method was also applicable to human monocytes and K562 cells. The centrifugal transduction method with adenoviral vector might be helpful for the generation of gene-modified DC.
- (キーワード)
- Dendritic cells / Adenovirus vector / Centrifugation
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/S0022-1759(01)00360-X
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11384673
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0035400376
(DOI: 10.1016/S0022-1759(01)00360-X, PubMed: 11384673, Elsevier: Scopus) H Nokihara, Seiji Yano, Yasuhiko Nishioka, M Hanibuchi, T Higasida, T Tsuruo and Saburo Sone :
A new quinoline derivative MS-209 reverse multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells,
Japanese Journal of Cancer Research, Vol.92, No.7, 785-792, 2001.- (要約)
- Development of distant metastases and acquired multidrug resistance (MDR) are major problems in therapy for human small cell lung cancer (SCLC). MS-209 is a novel quinoline compound, which reverses P-glycoprotein (P-gp)-mediated MDR. We previously reported that MS-209 reversed in vitro MDR of human SCLC (SBC-3 / ADM and H69 / VP) cells expressing P-gp. In the present study, we determined the therapeutic effect of MS-209 in combination with chemotherapy against multiorgan metastases of MDR SCLC cells. SBC-3 / ADM cells expressing P-gp were highly resistant to etoposide (VP-16), adriamycin (ADM), and vincristine (VCR) in vitro, compared with parental SBC-3 cells lacking P-gp expression. MS-209 restored chemosensitivity of SBC-3 / ADM cells to VP-16, ADM, and VCR in a dose-dependent manner in vitro. Intravenous injection with SBC-3 or SBC-3 / ADM cells produced metastatic colonies in the liver, kidneys and lymph nodes in natural killer (NK) cell-depleted severe combined immunodeficiency (SCID) mice, though SBC-3 / ADM cells more rapidly produced metastases than did SBC-3 cells. Treatment with VP-16 and ADM reduced metastasis formation by SBC-3 cells, whereas the same treatment did not affect metastasis by SBC-3 / ADM cells. Although MS-209 alone had no effect on metastasis by SBC-3 or SBC-3 / ADM cells, combined use of MS-209 with VP-16 or ADM resulted in marked inhibition of metastasis formation by SBC-3 / ADM cells to multiple organs. These findings suggest that MS-209 reversed the MDR of SBC-3 / ADM cells, but not SBC-3 cells, growing in the various organs, and inhibited metastasis formation in vivo. Therefore, this chemosensitizing agent, MS-209, may be useful for treatment of refractory SCLC patients with multiorgan metastases.
- (キーワード)
- Animals / Antineoplastic Agents / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Small Cell / Doxorubicin / Drug Resistance, Multiple / Drug Screening Assays, Antitumor / Etoposide / Humans / Lung Neoplasms / Male / Mice / Mice, SCID / Neoplasm Metastasis / P-Glycoprotein / Quinolines / Vincristine / Xenograft Model Antitumor Assays
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11473730
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0034879931
(PubMed: 11473730, Elsevier: Scopus) Naoki Nishimura, Yasuhiko Nishioka, Tsutomu Shinohara and Saburo Sone :
Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells.,
Human Gene Therapy, Vol.12, No.4, 333-346, 2001.- (要約)
- Transduction of dendritic cells (DCs) with genes encoding tumor-associated antigen or with other genes that enhance immune reaction has been theorized to be potentially useful for enhancing the efficiency of DC-based immunotherapy. However, gene transduction of DCs generated from human peripheral blood monocytes has been of limited use because of the low efficiency. Here, we report that the efficiency of in vitro adenovirus-mediated gene transduction into human monocyte-derived DCs can be dramatically enhanced by centrifugation. The best conditions for centrifugal gene transduction were determined to be as follows: 2000 x g at 37 degrees C for 2 hr at a multiplicity of infection (MOI) of 10 or greater. By this centrifugal method, approximately 88 and 70% of DCs were gene transducible at an MOI of 50 and 10, respectively. Functional analysis showed that DCs transduced with human interleukin 12 (IL-12)-expressing adenoviral vector under the optimal conditions of centrifugation stably produced IL-12 protein at high levels (8.1 ng/10(6) cells/48 hr). IL-12 gene-modified DCs (DC/IL-12) displayed a more mature phenotype than nontransduced DCs, as judged by decreased expression of CD1a and increased expression of CD83, B7.1 (CD80), B7.2 (CD86), and MHC class I and II molecules. DC/IL-12 showed a high phagocytic ability similar to nontransduced DCs and were significantly superior to control DCs in the stimulation of autologous and allogeneic T lymphocyte responses. The centrifugal transduction method with adenoviral vector might be useful for efficient generation of gene-modified DCs because it is very simple, highly efficient, reproducible, and not cytopathic. IL-12 gene-modified human DCs may be therapeutically useful as a good adjuvant in DC-based immunotherapy.
- (キーワード)
- Adenoviridae / Apoptosis / Cell Division / Cell Survival / Centrifugation / Dendritic Cells / Flow Cytometry / Gene Transfer Techniques / Genetic Vectors / Green Fluorescent Proteins / Humans / Interleukin-12 / Luminescent Proteins / Monocytes / Phagocytosis / T-Lymphocytes / Transduction, Genetic
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1089/10430340150503966
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11242526
- ● Search Scopus @ Elsevier (PMID): 11242526
- ● Search Scopus @ Elsevier (DOI): 10.1089/10430340150503966
(DOI: 10.1089/10430340150503966, PubMed: 11242526) Saburo Sone, Tsutomu Shinohara, Yasuhiko Nishioka and Seiji Yano :
Symposium on molecular pathogenesis of respiratory diseases and its clinical implication. 4. Molecular pathogenesis of lung cancer and its molecular targeted therapy,
Internal Medicine, Vol.40, No.2, 167-170, 2001.- (キーワード)
- Angiogenesis Inhibitors / Antineoplastic Agents / Cell Transformation, Neoplastic / Clinical Trials as Topic / Cocarcinogenesis / Drug Design / Endothelial Growth Factors / Humans / Lung Neoplasms / Lymphokines / Matrix Metalloproteinases / Models, Biological / Neoplasm Metastasis / Neoplasm Proteins / Neovascularization, Pathologic / Oncogenes / Receptor Protein-Tyrosine Kinases / Receptors, Growth Factor / Receptors, Vascular Endothelial Growth Factor / Vascular Endothelial Growth Factor A / Vascular Endothelial Growth Factors
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.40.167
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11300157
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0347139186
(DOI: 10.2169/internalmedicine.40.167, PubMed: 11300157, Elsevier: Scopus) 兼松 貴則, 大串 文隆, 小川 博久, 西岡 安彦, 篠原 勉, 楊河 宏章, 曽根 三郎 :
嚢胞状変化を呈した肺サルコイドーシスの1例,
日本呼吸器学会雑誌, Vol.39, No.2, 117-121, 2001年. Hiroshi Nokihara, Hiroaki Yanagawa, Yasuhiko Nishioka, Seiji Yano, Naofumi Mukaida, Kouji Matsushima and Saburo Sone :
Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice.,
Cancer Research, Vol.60, No.24, 7002-7007, 2000. Naoki Nishimura, Yasuhiko Nishioka, Tsutomu Shinohara, Kenji Tani and Saburo Sone :
Down-regulation by a new anti-inflammatory compound, FR167653, of differentiation and maturation of human monocytes and bone marrow CD34(+) cells to dendritic cells,
International Journal of Immunopharmacology, Vol.22, No.7, 501-514, 2000. Stephan Lang, Yoshinari Atarashi, Yasuhiko Nishioka, Joanna Stanson, Norbert Meidenbauer and Theresa L. Whiteside :
B7.1 on human carcinomas:costimulation of T cells and enhanced tumor-induced T-cell death,
The Journal of Molecular and Cellular Immunology, Vol.1, No.2, 132-143, 2000. Hitoe Torisu, Mayumi Ono, Hiromaro Kiryu, Masutaka Furue, Yasukazu Ohmoto, Juichiro Nakayama, Yasuhiko Nishioka, Saburo Sone and Michihiko Kuwano :
Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFα and IL-1α,
International Journal of Cancer, Vol.85, No.2, 182-188, 2000.- (要約)
- We examined whether macrophage infiltration is associated with angiogenesis in cutaneous melanoma. The numbers of macrophages and microvessels increased significantly with increasing depth of tumor and with tumor angiogenesis. Macrophage infiltration thus appeared to provide a useful diagnostic marker for the progression of cutaneous melanoma. We further examined whether human melanoma cells produce angiogenic factors in response to macrophage-derived cytokines, tumor necrosis factor alpha (TNFalpha) and interleukin-1 alpha (IL-1alpha). Treatment of melanoma cells with TNFalpha and IL-1alpha in vitro enhanced the production of interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF), and of basic fibroblast growth factor (bFGF) to a lesser degree, in human melanoma cells. Lipopolysaccharide (LPS)-activated human monocytes enhanced production of IL-8, VEGF, TNF alpha, as well as IL-1alpha, but not bFGF. Co-culture of human monocytes and human melanoma cells was also found to significantly enhance production of IL-8 and VEGF in the absence and presence of LPS, compared with either monocytes or melanoma cells alone. The production of IL-8 and VEGF from co-cultured melanoma cells and LPS-activated monocytes was blocked when anti-TNF-alpha antibody or anti-IL-1alpha antibody was co-administrated. This is direct evidence that production of the potent angiogenic factors IL-8 and VEGF from melanoma cells is up-regulated through TNFalpha and/or IL-1alpha secreted by activated monocytes/macrophages, influencing both tumor growth and angiogenesis in melanomas.
- (キーワード)
- Adult / Aged / Aged, 80 and over / Angiogenesis Inducing Agents / Cell Communication / Cell Movement / Endothelial Growth Factors / Humans / Interleukin-1 / Interleukin-8 / Lymphokines / Macrophages / Melanoma / Middle Aged / Monocytes / Neoplasm Staging / Neovascularization, Pathologic / Tumor Cells, Cultured / Tumor Necrosis Factor-alpha / Vascular Endothelial Growth Factor A / Vascular Endothelial Growth Factors
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10629075
- ● Search Scopus @ Elsevier (PMID): 10629075
- ● Search Scopus @ Elsevier (DOI): 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M
(DOI: 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M, PubMed: 10629075) Masaki Hanibuchi, Yasuhiko Nishioka, Hiroaki Yanagawa, Seiji Yano, Parajuli Prahlad, Bando Masashi and Saburo Sone :
Human interferon-gamma enhances expression of ganglioside GM2 on human lung cancer cells and their susceptibility for antiganglioside GM2 monoclonal antibody-dependent cellular cytotoxicity.,
Oncology Research, Vol.12, No.4, 173-179, 2000.- (要約)
- Interferons are known to modulate several cellular functions by the induction of various proteins. In this study, we demonstrated that human interferon-gamma (HuIFN-gamma) enhanced the expression of ganglioside GM2 (GM2), which is a kind of tumor-associated antigen substantially expressed in human lung cancer and that human lung cancer cells expressing GM2 became more susceptible to anti-GM2 monoclonal antibody (mAb)-dependent tumor cell killing mediated by human effector cells after HuIFN-gamma treatment. GM2 expression on human lung cancer cells treated with or without HuIFN-gamma was measured by flow cytometry. The antibody-dependent cellular cytotoxicity (ADCC) activity was assessed by 4-h 51Cr release assay. HuIFN-gamma enhanced GM2 expression on human small-cell lung cancer (SCLC), SBC-3, and human non-small-cell lung cancer (NSCLC), A549 cells in a dose-dependent manner. The optimal concentration of HulIFN-gamma was 1,000 U/ml. The effect of HulFN-gamma reached maximum after 4 days of culture. HulFN-gamma did not have any effect to enhance the expression of other gangliosides in SBC-3 cells. No other cytokines used in this study modulated GM2 expression in SBC-3 cells. Anti-GM2 mAb-dependent ADCC activities induced by lymphocytes and monocytes were more potent against IFN-gamma-treated SBC-3 and A549 cells than nontreated cells. Taken together, HulFN-gamma combined with anti-GM2 mAb may be useful for immunotherapy against GM2-positive human lung cancer.
- (キーワード)
- Antibodies, Monoclonal / Carcinoma, Non-Small-Cell Lung / Carcinoma, Small Cell / Dose-Response Relationship, Drug / Flow Cytometry / G(M2) Ganglioside / Humans / Immunotherapy / Interferon-gamma / Lung Neoplasms / Lymphocytes / Monocytes / Time Factors / Tumor Cells, Cultured
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3727/096504001108747657
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11341466
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0034574911
(DOI: 10.3727/096504001108747657, PubMed: 11341466, Elsevier: Scopus) Yasuhiko Nishioka, Motohiro Hirao, Paul D. Robbins, Michael T. Lotze and Hideaki Tahara :
Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.,
Cancer Research, Vol.59, No.16, 4035-4041, 1999.- (要約)
- Bone marrow-derived dendritic cells (BM-DCs) retrovirally transduced with genes encoding murine interleukin (IL)-12 stably expressed bioactive IL-12 protein at high levels. Intratumoral injection with IL-12 gene-modified BM-DCs resulted in regression of day 7 established weakly immunogenic tumors (MCA205, B16, and D122). This antitumor effect was substantially better than that of IL-12-transduced syngeneic fibroblasts or nontransduced BM-DCs. Furthermore, intratumoral injection with IL-12-transduced dendritic cells (DCs) induced specific TH1-type responses to the tumor in regional lymph nodes and spleen at levels greater than those of IL-12-transduced fibroblasts or nontransduced BM-DCs. Trafficking studies confirmed that intratumorally injected IL-12-transduced DCs, but not fibroblasts, could migrate to the draining lymph node to the same extent as nontransduced BM-DCs. This strategy designed to deliver genetically modified DCs to tumor sites is associated with systemic and therapeutic antitumor immunity and is an alternative approach to those that use delivery of DCs loaded with tumor antigen. These results support the clinical application of IL-12 gene-modified DCs in patients with cancer.
- (キーワード)
- Animals / Cytotoxicity, Immunologic / Dendritic Cells / Immunotherapy, Adoptive / Interleukin-12 / Neoplasms, Experimental / Tumor Cells, Cultured
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10463604
- ● CiNii @ 国立情報学研究所 (CRID): 1570009751812374016
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0033566984
(PubMed: 10463604, CiNii: 1570009751812374016, Elsevier: Scopus) Seiji Yano, Masaki Hanibuchi, Yasuhiko Nishioka, Hiroshi Nishihara, Naoki Nishimura, Takashi Tsuruo and Saburo Sone :
Combined therapy with anti-p-glycoprotein antibody and macrophage colony-stimulating factor gene transduction for multiorgan metastases of multidrug-resistant human small cell lung cancer in nk cell-depleted scid mice,
International Journal of Cancer, Vol.82, No.1, 105-111, 1999.- (要約)
- Our aim was to determine the antimetastatic potential of anti-P-glycoprotein (P-gp) antibodies (Abs) against multidrug-resistant (MDR) human small cell lung cancer (SCLC) cells expressing P-gp. Human SCLC cells H69 (P-gp negative) and its etoposide-resistant variant H69/YP (P-gp positive) were used. H69 and H69/VP cells injected i.v. metastasized to the liver, kidneys and systemic lymph nodes of NK cell-depleted severe combined immunodeficient (SCID) mice. H69/VP cells, but not H69 cells, were resistant to treatments with vindesine. Treatment with mouse-human chimeric anti-P-gp Ab (MH162) and its mouse counterpart (MRK-16) reduced metastasis of H69/VP cells in various organs and prolonged the survival of tumor-bearing mice, although they were less effective if injected at late times (after 28 days). Treatment with another mouse anti-Pgp Ab, MRK-17, was effective only against liver metastasis. MH162 and MRK-16 efficiently induced Ab-dependent cellular cytotoxicity (ADCC) by peritoneal macrophages against H69/VP cells in vitro, but MRK-17 was less effective, in accordance with their in vivo antimetastatic potential. Gene transfection of macrophage colony-stimulating factor (M-CSF) into H69/VP cells to augment macrophage-mediated ADCC resulted in inhibition of metastasis to the liver and lymph nodes, but not kidneys. Combined treatment with a low dose of MRK-16 completely cured metastasis of M-CSF transfectant, but not of the mock transfectant. Our findings suggest that while anti-P-gp Abs had antimetastatic potential against SCLC cells expressing P-gp, combined treatment with M-CSF gene transduction to augment the therapeutic efficacy of anti-P-gp Abs may be beneficial for eradicating metastatic MDR SCLC in humans.
- (キーワード)
- Animals / Antibodies, Monoclonal / Antibody-Dependent Cell Cytotoxicity / Carcinoma, Small Cell / Combined Modality Therapy / Drug Resistance, Multiple / Gene Therapy / Humans / Killer Cells, Natural / Lung Neoplasms / Macrophage Colony-Stimulating Factor / Male / Mice / Mice, SCID / Neoplasm Metastasis / P-Glycoprotein / Tumor Cells, Cultured
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/(SICI)1097-0215(19990702)82:1<105::AID-IJC18>3.0.CO;2-C
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10360828
- ● Search Scopus @ Elsevier (PMID): 10360828
- ● Search Scopus @ Elsevier (DOI): 10.1002/(SICI)1097-0215(19990702)82:1<105::AID-IJC18>3.0.CO;2-C
(DOI: 10.1002/(SICI)1097-0215(19990702)82:1<105::AID-IJC18>3.0.CO;2-C, PubMed: 10360828) Prahlad Parajuli, Yasuhiko Nishioka, Naoki Nishimura, Sukh Mahendra Singh, Masaki Hanibuchi, Hiroshi Nokihara, Hiroaki Yanagawa and Saburo Sone :
Cytolysis of human dendritic cells by autologous lymphokine-activated killer cells: participation of both T cells and NK cells in the killing.,
Journal of Leukocyte Biology, Vol.65, No.6, 764-760, 1999.- (要約)
- Dendritic cells (DC) play a key role in the initiation of immune response by stimulating the naive T cells. The fate of DC after the initiation of immune response is not clearly understood. Although there are few reports implicating natural killer (NK) cells in the elimination of DC, killing of DC by LAK cells, and specifically by T cells, has not been studied. In this study, we observed that DC, generated from monocytes, in vitro in the presence of granulocyte-macrophage colony-stimulating factor, interleukin-4 (IL-4), and tumor necrosis factor alpha were susceptible to cytolysis by lymphokine-activated killer (LAK) cells induced in the presence of IL-2 and IL-15 but not IL-12 alone. However, LAK cells induced by a combination of IL-12 and suboptimal dose of IL-2 were cytotoxic to DC. When purified lymphocytes were activated with IL-2, the CD8+/CD57- fraction (T-LAK), but not the CD8-/CD57+ fraction (NK-LAK) was cytotoxic to autologous DC. However, when unseparated peripheral blood mononuclear cells were used to generate LAK cells, both T-LAK and NK-LAK fractions showed equal cytotoxicity against autologous DC. Monoclonal antibodies against CD54, CD11a, and CD18 significantly inhibited the cytolysis, indicating that the killing involves the engagement of CD54 with its ligands.
- (キーワード)
- Antibodies, Blocking / Antibodies, Monoclonal / CD18 Antigens / Cytotoxicity, Immunologic / Dendritic Cells / Humans / Intercellular Adhesion Molecule-1 / Interleukin-12 / Interleukin-2 / Killer Cells, Lymphokine-Activated / Killer Cells, Natural / Leukocytes, Mononuclear / Lymphocyte Function-Associated Antigen-1 / Macrophages / Tリンパ球 (T lymphocytes)
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/jlb.65.6.764
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10380897
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0033003373
(DOI: 10.1002/jlb.65.6.764, PubMed: 10380897, Elsevier: Scopus) Hiroshi Nokihara, Yasuhiko Nishioka, Seiji Yano, Naofumi Mukaida, Kouji Matsushima, Takashi Tsuruo and Saburo Sone :
Monocyte chemoattractant protein-1 gene modification of multidrug-resistant human lung cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID mice,
International Journal of Cancer, Vol.80, No.5, 773-780, 1999.- (要約)
- Distant metastases and multidrug resistance are critical problems in the therapy of human small cell lung cancer (SCLC). In this study, we investigated whether transduction of the monocyte chemoattractant protein-1 (MCP-1) gene into multidrug-resistant (MDR) human lung cancer cells affected the formation of metastases or their inhibition by the anti-P-glycoprotein (P-gp) monoclonal antibody (MAb) MRK16. MDR human SCLC (H69/VP) cells were transduced with the human MCP-1 gene inserted into the expression vector BCMGSNeo. MCP-1 gene transduction had no effect on drug sensitivity, the expression of surface antigens or the in vitro proliferation of H69/VP cells. Using the metastatic model of NK cell-depleted SCID mice, H69/VP cells transduced with the MCP-1 gene were inoculated intravenously (i.v.) and formed metastatic colonies in the liver, kidneys and lymph nodes, similar to those formed by parent or mock-transduced cells. However, systemic treatment of the mice with MRK16 reduced the metastases of H69/VP cells in the liver, kidneys and lymph nodes, and was significantly more effective in inhibiting the metastases of MCP-1 producing H69/VP than those of mock-transduced cells. MCP-1 gene transduction significantly prolonged the survival of tumor-bearing mice treated with MRK16. Our findings suggest that local production of MCP-1 in the tumor site increases the anti-P-gp antibody-dependent cell-mediated cytotoxicity, and the MCP-1 gene-induced modification of MDR human SCLC cells thereby enhances the antimetastatic effect of therapy with anti-P-gp antibody. Thus, the accumulation of effector cells in the tumor site is a very important factor in the therapy using the anti-P-gp antibody.
- (キーワード)
- Animals / Antibodies, Monoclonal / Carcinoma, Small Cell / Chemokine CCL2 / Clone Cells / Drug Resistance, Multiple / Etoposide / Humans / Immunotherapy / Lung Neoplasms / Mice / Mice, SCID / Neoplasm Metastasis / Organ Specificity / P-Glycoprotein / Recombinant Proteins / Transfection / Tumor Cells, Cultured
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/(SICI)1097-0215(19990301)80:5<773::AID-IJC23>3.0.CO;2-E
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10048981
- ● Search Scopus @ Elsevier (PMID): 10048981
- ● Search Scopus @ Elsevier (DOI): 10.1002/(SICI)1097-0215(19990301)80:5<773::AID-IJC23>3.0.CO;2-E
(DOI: 10.1002/(SICI)1097-0215(19990301)80:5<773::AID-IJC23>3.0.CO;2-E, PubMed: 10048981) Prahlad Parajuli, Seiji Yano, Yasuhiko Nishioka, Hiroshi Nokihara, Masaki Hanibuchi, Naoki Nishimura, Teruhiro Utsugi and Saburo Sone :
Therapeutic Efficacy of a New Topoisomerase I and II Inhibitor TAS-103, Against Both P-Glycoprotein Expressing and Non-expressing Drug-Resistant Human Small-Cell Lung Cancer,
Oncology Research, Vol.11, No.5, 219-224, 1999.- (要約)
- We examined the effect of a novel topoisomerase I and II (topo I and II) inhibitor, TAS-103, on P-glycoprotein (P-gp)-expressing and -nonexpressing drug-resistant human small-cell lung cancer (SCLC) cells in vitro and in vivo. We observed that TAS-103 was effective in inhibiting in vitro proliferation of human SCLC (SBC-3 and H69) cells and their drug-resistant variants SBC-3/ADM or SBC-3/CDDP and H-69/VP, respectively. SBC-3/ADM and H-69/VP expressed high P-gp, whereas SBC-3/CDDP did not. TAS-103 also effectively reduced the tumor growth (more than 50% inhibition) of the parental as well as MDR SCLC cells grown SC in nude mice. Adriamycin (ADM) and cisplatin (CDDP), on the other hand, were effective only against the parental cells, while these drugs failed to inhibit the respective drug-resistant variants in vitro or in vivo. TAS-103 was observed to induce apoptosis dose dependently in the parental as well as drug-resistant SCLC cells as analyzed after 48 h of in vitro treatment, suggesting that the stabilization of cleavable topo I- or II-DNA complexes by topo I and II inhibitors like TAS-103 is followed by apoptosis of the cells. Overall, our study suggests that TAS-103 may have clinical application against drug-resistant human SCLC.
- (キーワード)
- ATP-Binding Cassette, Sub-Family B, Member 1 / Aminoquinolines / Animals / Antineoplastic Agents / Apoptosis / Carcinoma, Small Cell / Drug Resistance, Neoplasm / Humans / Indenes / Lung Neoplasms / Male / Mice / Mice, Inbred BALB C / Mice, Nude / Neoplasm Proteins / Topoisomerase I Inhibitors / Topoisomerase II Inhibitors / Tumor Cells, Cultured
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10608616
- ● Search Scopus @ Elsevier (PMID): 10608616
(PubMed: 10608616) Saburo Sone, Seiji Yano, Masaki Hanibuchi, Hiroshi Nokihara, Naoki Nishimura, Toyokazu Miki, Yasuhiko Nishioka and Tsutomu Shinohara :
Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient mice,
Cancer Chemotherapy and Pharmacology, Vol.43, No.Supplement 1, S26-S31, 1999.- (要約)
- Lung cancer is a major cause of cancer deaths, most of which can be attributed to distant multiorgan metastases. To examine the cellular and molecular mechanisms of lung cancer metastasis to distant organs, we have established novel models of human lung cancer (small cell and non-small cell lung cancer) metastasis in natural killer cell-depleted severe combined immunodeficient (SCID) mice. We investigated whether local production of the cytokines responsible for regulation of macrophage function at tumor growth sites affects the pattern of lung cancer metastasis in distant organs. Several lung cancer cell lines were genetically engineered to produce human macrophage colony-stimulating factor (M-CSF) and monocyte chemoattractant protein-1 (MCP-1), and their metastatic potentials were assessed. Interestingly, M-CSF gene transduction had an antimetastatic effect for the liver and lymph nodes, but not the kidneys. In contrast, MCP-1 gene-modified lung cancer cells and their parent cells had identical metastatic potentials. These findings indicate a possible role for cytokines and suggest that lung cancer has metastatic heterogeneity. Examining ways of controlling human lung cancer metastases, we investigated the antimetastatic effect of chimeric monoclonal antibodies (MAbs) against P-glycoprotein and ganglioside GM2 (MH162 and KM966, respectively). Both MAbs, when given on days 2 and 7, inhibited the development of distant metastases of lung cancer in a dose-dependent fashion. Combined use of anti-P-glycoprotein MAb with M-CSF or MCP-1 gene transduction caused complete inhibition of metastasis of H69/VP cells. The antimetastatic effect of these MAbs in vivo was mainly due to an antibody-dependent cell-mediated cytotoxicity reaction mediated by mouse macrophages. These findings suggest that the mouse-human chimeric MAb in combination with cytokine gene transduction may be useful for the eradication of lung cancer metastases in humans.
- (キーワード)
- Animals / Antibodies, Monoclonal / Carcinoma, Non-Small-Cell Lung / Carcinoma, Small Cell / Chemokine CCL2 / Cytokines / G(M2) Ganglioside / Granulocyte-Macrophage Colony-Stimulating Factor / Humans / Kidney Neoplasms / Killer Cells, Natural / Liver Neoplasms / Lung Neoplasms / Lymphatic Metastasis / Mice / Mice, SCID / Neoplasm Transplantation / P-Glycoprotein / Recombinant Fusion Proteins / Transduction, Genetic / Tumor Cells, Cultured
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10357555
- ● Search Scopus @ Elsevier (PMID): 10357555
(PubMed: 10357555) Takuya Takayama, Yasuhiko Nishioka, Lina Lu, Michael T. Lotze, Hideaki Tahara and Angus W. Thomson :
Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness,
Transplantation, Vol.66, No.12, 1567-1574, 1998. Masaki Hanibuchi, Seiji Yano, Yasuhiko Nishioka, Hiroaki Yanagawa, Tetsuya Kawano and Saburo Sone :
Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice,
International Journal of Cancer, Vol.78, No.4, 480-485, 1998.- (要約)
- The development of distant metastases to multiple organs is a critical problem in the treatment of human lung cancer. In this study, we evaluated the therapeutic efficacy of a mouse-human chimeric anti-ganglioside GM2 (GM2) monoclonal antibody (MAb), KM966 against metastasis formation of GM2-positive human lung cancer cells inoculated intravenously (i.v.) into natural killer (NK) cell-depleted severe combined immunodeficient (SCID) mice. GM2-positive human small cell lung cancer (SCLC), SBC-3 cells (1 x 10(6)), injected through a tail vein into NK cell-depleted SCID mice, formed large number of metastatic colonies in the liver, kidneys and lymph nodes by 42 days after inoculation (day 42). KM966, but not control MAb, given on days 2 and 7, almost completely inhibited metastasis formation of SBC-3 cells in the liver, kidneys and lymph nodes in a dose-dependent fashion. Moreover, treatment with KM966 at advanced stages of metastasis (even from day 28) significantly suppressed multiple organ metastases of SBC-3 cells. The anti-metastatic effect of KM966 in vivo was mainly due to an antibody-dependent cell-mediated cytotoxicity (ADCC) reaction mediated by macrophages of the SCID mice. Our findings suggest that the mouse-human chimeric anti-GM2 MAb, KM966 may be useful for eradicating multiple organ micrometastases of lung cancer in humans.
- (キーワード)
- Animals / Antibodies, Monoclonal / Antibody-Dependent Cell Cytotoxicity / Carcinoma, Small Cell / G(M2) Ganglioside / Humans / Immunotherapy / Killer Cells, Natural / Lung Neoplasms / Male / Mice / Mice, SCID / Neoplasm Invasiveness / Neoplasm Staging / Neoplasm Transplantation / Recombinant Fusion Proteins
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/(SICI)1097-0215(19981109)78:4<480::AID-IJC14>3.0.CO;2-A
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9797137
- ● Search Scopus @ Elsevier (PMID): 9797137
- ● Search Scopus @ Elsevier (DOI): 10.1002/(SICI)1097-0215(19981109)78:4<480::AID-IJC14>3.0.CO;2-A
(DOI: 10.1002/(SICI)1097-0215(19981109)78:4<480::AID-IJC14>3.0.CO;2-A, PubMed: 9797137) Seiji Yano, Hiroaki Yanagawa, Masaki Hanibuchi, Kalpana Pai, Yasuhiko Nishioka, Takashi Tsuruo and Saburo Sone :
The role of cyclosporin A on antibody-dependent monocyte-mediated cytotoxicity against human multidrug-resistant cancer cells,
The Journal of Medical Investigation : JMI, Vol.44, No.3-4, 185-191, 1998.- (要約)
- A P-glycoprotein (P-gp) inhibitor, cyclosporin A (CsA) was found to enhance the susceptibility of multidrug resistant (MDR) cancer cells to anti-P-gp antibody-dependent cellular cytolysis (ADCC) by monocytes, but the exact mechanism is unknown. In this study, we examined whether CsA enhanced the susceptibility of MDR cells through its inhibitory effect of P-gp function by using anti-ganglioside GM2 (GM2) monoclonal antibody (Ab), KM966, instead of anti-P-gp Ab, MRK16. Monocyte-ADCC induced by both KM966 and MRK16 against P-gp positive human MDR ovarian cancer cells was significantly augmented by addition of CsA. KM966, but not MRK16, induced monocyte-ADCC against P-gp negative human ovarian cancer cells and CsA enhanced this ADCC activity, indicating that suppressive effect of P-gp function by CsA was not essential to the enhancement of ADCC. Moreover, pretreatment of tumor cells with CsA augmented their susceptibility to monocyte-ADCC irrespective of P-gp expression. Interestingly, KM966 or MRK16 induced monocyte-ADCC against various human lung cancer cells expressing either GM2 or P-gp, but CsA did not affect these ADCC. These findings suggest that CsA may enhance the susceptibility to the monocyte-ADCC of ovarian cancer cells, but not of lung cancer cells, irrespective of its suppressive effect of P-gp function.
- (キーワード)
- Antibodies, Monoclonal / Cell Line / Cyclosporine / Cytotoxicity, Immunologic / Drug Resistance, Multiple / Humans / Monocytes / Neoplasms
- (徳島大学機関リポジトリ)
- ● Metadata: 110665
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9597807
- ● Search Scopus @ Elsevier (PMID): 9597807
(徳島大学機関リポジトリ: 110665, PubMed: 9597807) Yasuhiko Nishioka, Seiji Yano, Fujio Fujiki, Naofumi Mukaida, Kouji Matsushima, Takashi Tsuruo and Saburo Sone :
Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: The possibility of immunological overcoming of multidrug resistance,
International Journal of Cancer, Vol.71, No.2, 170-177, 1997.- (要約)
- We determined whether transduction of the monocyte chemoattractant protein-1 (MCP-1) gene into MDR human lung cancer cells affected their tumorigenicity and sensitivity to antibody-dependent cellular cytotoxicity (ADCC) reaction mediated by the anti-P-glycoprotein (P-gp) monoclonal antibody MRK16. The human MCP-1 gene inserted into an expression vector (BCMGSNeo) was transfected into MDR human small-cell lung cancer (H69/VP) cells. Monocyte chemotactic activity was found in culture supernatants collected from MCP-1-transfected H69/VP cells, but not in supernatants of parent and mock-transfected cells. In an in vitro experiment, recombinant MCP-1 did not affect monocyte-mediated ADCC against H69/VP cells when added to the monocyte culture in either the activation or the effector phase at sufficient concentrations to attract and activate monocytes. Tumorigenicity and growth rates of MCP-1-producing H69/VP cells in nude mice were similar to those of parental cells and mock-transfected cells. However, systemic treatment with MRK16 was more effective in inhibiting the formation of tumors by MCP-1-gene-transfected cells than by mock-transfected cells. Systemic treatment with MRK16 also inhibited the growth of a mixture (1:1) of MCP-1-producing cells and mock-transfected cells. These results suggest that combination therapy with MRK16 and MCP-1 gene transduction may be a useful immunological strategy to inhibit the growth of human MDR cancer cells expressing P-gp.
- (キーワード)
- Animals / Antibodies, Monoclonal / Antibody-Dependent Cell Cytotoxicity / Carcinoma, Small Cell / Chemokine CCL2 / Dose-Response Relationship, Drug / Drug Resistance, Multiple / Humans / Killer Cells, Natural / Lung Neoplasms / Mice / Mice, Nude / Neoplasm Transplantation / P-Glycoprotein / RNA, Messenger / Time Factors / Transfection / Tumor Cells, Cultured
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/(SICI)1097-0215(19970410)71:2<170::AID-IJC8>3.0.CO;2-Y
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9139838
- ● Search Scopus @ Elsevier (PMID): 9139838
- ● Search Scopus @ Elsevier (DOI): 10.1002/(SICI)1097-0215(19970410)71:2<170::AID-IJC8>3.0.CO;2-Y
(DOI: 10.1002/(SICI)1097-0215(19970410)71:2<170::AID-IJC8>3.0.CO;2-Y, PubMed: 9139838) Seiji Yano, Yasuhiko Nishioka, Hiroshi Nokihara and Saburo Sone :
Macrophage colony-stimulating factor gene transduction into human lung cancer cells differentially regulates metastasis formations in various organ microenvironments of natural killer cell-depleted SCID mice,
Cancer Research, Vol.57, No.4, 784-790, 1997.- (要約)
- We investigated whether local production of macrophage colony-stimulating factor (M-CSF), responsible for migration and activation of monocytes/macrophages at a tumor growth site, affected the metastatic pattern of lung cancer. For this, highly metastatic human squamous (RERF-LC-AI) or small (H69/VP) cell lung carcinoma cells were transduced with the human M-CSF gene inserted into pRc/CMV-MCSF to establish M-CSF-producing clones (MCSF-AI-9-18, MCSF-AI-9-24, and MCSF-VP-5). M-CSF gene transduction had no effect on the expression of surface antigen or on in vitro proliferation. After s.c. injection into SCID mice, the growth rates of M-CSF-producing cells were slower than those of parent or mock-transduced cells. In the metastatic model in SCID mice depleted of natural killer cells, RERF-LC-AI cells formed metastases mainly in the liver and kidneys, whereas H69/VP cells metastasized mainly to the liver and systemic lymph nodes. The numbers of metastatic colonies of MCSF-AI-9-18 and MCSF-AI-9-24 cells in the liver but not the kidneys were significantly reduced. The development of lymph node metastases of MCSF-VP-5 cells was also less than that of parent or mock-transduced cells. Treatment of SCID mice with anti-human M-CSF antibody resulted in a significant increase in liver metastases of their M-CSF gene transfectants. No significant differences were observed in the distributions in mice or in the in vitro invasive potentials of MCSF-AI-9-18 cells and Neo-AI-3 cells. These findings indicate that the antimetastatic effect of M-CSF may be specific to particular organs, suggesting the influence of heterogeneity of organ microenvironments on the metastasis of lung cancer.
- (キーワード)
- Animals / Antibodies, Monoclonal / Carcinoma, Non-Small-Cell Lung / Carcinoma, Small Cell / Humans / Kidney Neoplasms / Killer Cells, Natural / Liver Neoplasms / Lung Neoplasms / Lymphatic Metastasis / Macrophage Colony-Stimulating Factor / Mice / Mice, SCID / Neoplasm Invasiveness / Transfection
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9044861
- ● Search Scopus @ Elsevier (PMID): 9044861
(PubMed: 9044861) Seiji Yano, Hiroaki Yanagawa, Yasuhiko Nishioka, Naofumi Mukaida, Kouji Matsushima and Saburo Sone :
T helper 2 cytokines differently regulate monocyte chemoattractant protein-1 production by human peripheral blood monocytes and alveolar macrophages,
The Journal of Immunology, Vol.157, No.6, 2660-2665, 1996.- (要約)
- Th2 cytokines, such as IL-4, IL-10, and IL-13, suppress proinflammatory cytokine production by monocytes/macrophages. Since monocyte chemoattractant protein-1 (MCP-1) is presumed to play an important role in monocyte recruitment and activation during inflammatory and immune responses, we examined here the effects of these Th2 cytokines on MCP-1 production by human blood monocytes and alveolar macrophages. Unstimulated, highly purified blood monocytes did not produce MCP-1 spontaneously, while LPS treatment induced the production of MCP-1 and its mRNA expression. All Th2 cytokines tested suppressed LPS-induced MCP-1 production and its mRNA expression, although the suppressive effect of IL-13 was weaker than that of IL-4 or IL-10. In contrast, IL-10, but neither IL-4 nor IL-13, induced unstimulated peripheral blood monocytes to produce biologically active MCP-1 protein within 4 h, reaching a maximal level at 12 h. IL-10-induced MCP-1 production was reduced by pretreatment of IL-10 with anti-IL-10 Ab, negating the involvement of contaminated endotoxin. Moreover, IL-10 induced MCP-1 mRNA expression in unstimulated monocytes, independent of de novo protein synthesis. Furthermore, human alveolar macrophages produced MCP-1 spontaneously, and the production was inhibited by IL-4 or IL-13, but was augmented by IL-10. These findings suggest that IL-10 regulates MCP-1 production by monocytes/macrophages in a different way from other Th2 cytokines, such as IL-4 and IL-13, and contributes to host defense responses.
- (キーワード)
- Cells, Cultured / Chemokine CCL2 / Cytokines / Humans / Leukocytes / Macrophages, Alveolar / Monocytes / Th2 Cells
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8805671
- ● Search Scopus @ Elsevier (PMID): 8805671
(PubMed: 8805671) Seiji Yano, Yasuhiko Nishioka, K Izumi, Takashi Tsuruo, T Tanaka, M Miyasaka and Saburo Sone :
Novel metastasis model of human lung cancer in SCID mice depleted of NK cells,
International Journal of Cancer, Vol.67, No.2, 211-217, 1996.- (要約)
- Metastasis is a critical problem in the treatment of human lung cancer. Thus, a suitable animal model of metastasis of human lung cancer is required for in vivo biological and preclinical studies. In this study, we tried to establish a suitable model for this, using SCID mice. Neither human SCLC H69/VP cells (5 x 10(6)) nor squamous-cell carcinoma RERF-LC-AI cells (1 x 10(6)), injected through a tail vein, formed metastases in untreated SCID mice. Pre-treatment of SCID mice with anti-asialo GM1 serum resulted in only a few metastases of H69/VP cells, but pre-treatment with anti-mouse IL-2 receptor beta chain Ab (TM-beta 1) resulted in numerous lymph-node metastases 56 days after tumor inoculation. H69/VP-M cells, an in vivo-selected variant line, formed significant numbers of lymph-node metastases even in SCID mice pre-treated with anti-asialo GM1 serum. SCID mice depleted of NK cells by treatment with TM-beta 1 showed different patterns of metastasis when inoculated intravenously with the 2 different human lung cancer cell lines (H69/VP and RERF-LC-AI cells): H69/VP cells formed metastases mainly in systemic lymph nodes and the liver, whereas RERF-LC-AI cells formed metastases mainly in the liver and kidneys, with only a few in lymph nodes. A histopathological study showed that the metastatic colonies consisted of cancer cells. The numbers of metastatic colonies formed by the 2 cell lines increased with the number of cells inoculated. TM-beta 1 treatment of SCID mice efficiently removed NK cells from peripheral blood for at least 6 weeks, whereas, after treatment of the mice with anti-asialo GM1 serum, NK cells were recovered within 9 days. These findings suggest that NK-cell-depleted SCID mice may be useful as a model in biological and pre-clinical studies on metastasis of human lung cancer.
- (キーワード)
- Animals / Antibodies / Disease Models, Animal / G(M1) Ganglioside / Humans / Immune Sera / Killer Cells, Natural / Liver Neoplasms / Lung Neoplasms / Lymphatic Metastasis / Male / Mice / Mice, SCID / Neoplasm Metastasis / Receptors, Interleukin-2 / Tumor Cells, Cultured
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/(SICI)1097-0215(19960717)67:2<211::AID-IJC11>3.0.CO;2-E
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8760590
- ● Search Scopus @ Elsevier (PMID): 8760590
- ● Search Scopus @ Elsevier (DOI): 10.1002/(SICI)1097-0215(19960717)67:2<211::AID-IJC11>3.0.CO;2-E
(DOI: 10.1002/(SICI)1097-0215(19960717)67:2<211::AID-IJC11>3.0.CO;2-E, PubMed: 8760590) Saburo Sone, Takashi Tsuruo, S Sato, Seiji Yano, Yasuhiko Nishioka and Tsutomu Shinohara :
Transduction of the macrophage colony-stimulating factor gene into human multidrug resistant cancer cells: enhanced therapeutic efficacy of monoclonal anti-P-glycoprotein antibody in nude mice,
Japanese Journal of Cancer Research, Vol.87, No.7, 757-764, 1996.- (要約)
- To develop a therapeutic modality for overcoming multidrug-resistant (MDR) cancer with anti-MDR1 antibody, we examined the effect of macrophage colony-stimulating factor (M-CSF) gene transfection into MDR AD10 cells on therapy of MDR cancer with anti-MDR1 antibody (MRK17) in nude mice. MDR human ovarian cancer (AD10) cells were transduced with the human M-CSF gene inserted into an expression vector to establish gene-modified cells capable of producing low (ML-AD10), intermediate (MM-AD10) nd high (MH-AD10) amounts of M-CSF. Systemic administration of MRK17 resulted in significant dose-dependent inhibition of subcutaneous growth of ML-AD10 tumors. In contrast, systemic administration of recombinant M-CSF in combination with MRK17 did not augment the therapeutic efficacy of MRK17 alone, but rather promoted the growth of the parent AD10 cells. To test the efficacy of in vivo M-CSF gene therapy combined with antibody, we mixed the parent AD10 cells with MH-AD10 cells producing a large amount of M-CSF, and inoculated the mixed cells subcutaneously. Treatment with MRK17 inhibited growth of the mixed cells more than that of the parent cells alone. Thus, combined therapy with anti-MDR1 mAb and M-CSF gene modification of MDR cancer cells may provide a new immunotherapeutic modality for overcoming MDR in humans.
- (キーワード)
- ATP-Binding Cassette, Sub-Family B, Member 1 / Animals / Antibodies, Monoclonal / Drug Resistance, Multiple / Female / Genetic Therapy / Humans / Macrophage Colony-Stimulating Factor / Macrophages, Peritoneal / Mice / Mice, Inbred BALB C / Mice, Nude / Neoplasms / Tumor Cells, Cultured
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1349-7006.1996.tb00289.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8698627
- ● Search Scopus @ Elsevier (PMID): 8698627
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.1996.tb00289.x
(DOI: 10.1111/j.1349-7006.1996.tb00289.x, PubMed: 8698627) Masaki Hanibuchi, Seiji Yano, Yasuhiko Nishioka, Hiroaki Yanagawa and Saburo Sone :
Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes,
Japanese Journal of Cancer Research, Vol.87, No.5, 497-504, 1996.- (要約)
- Ganglioside GM2 (GM2) frequently appears on the cell surface of human cancers of neuroendocrine origin. A mouse-human chimeric monoclonal antibody (mAb), KM966, against GM2 was previously found to promote the lysis of various cancer cells by human blood mononuclear cells (MNC). In this study, we analyzed the effector cells responsible for the chimeric mAb-dependent cell-mediated cytotoxicity (ADCC) against small cell lung cancer (SCLC) cells and examined the enhancing effect of various cytokines on the ADCC activity. The ADCC activity was assessed by 4-h 51Cr release assay. Highly purified lymphocytes (> 99%) and monocytes (> 90%) were separated by centrifugal elutriation from peripheral blood MNC of the same healthy donor. KM966 induced lysis of SCLC cells mediated by both lymphocytes and monocytes to similar extents, in a dose-dependent manner. Pretreatment of lymphocytes with various cytokines [interleukin (IL)-2, IL-12 and interferon-gamma] and that of monocytes with macrophage-colony-stimulating factor significantly augmented the killer activity against SCLC cells in the presence of KM966 mAb. KM966 was also effective for the lysis of non-small cell lung cancer cells in direct proportion to the GM2 expression levels. These findings suggest that combined treatment of KM966 mAb with cytokines may be therapeutically useful for in vivo killing of lung cancer cells expressing GM2 through the ADCC reaction.
- (キーワード)
- Adenocarcinoma / Antibodies, Monoclonal / Antibody-Dependent Cell Cytotoxicity / Carcinoma, Small Cell / Carcinoma, Squamous Cell / Female / G(M2) Ganglioside / Humans / Interferon-gamma / Interleukin-2 / Lung Neoplasms / Lymphocytes / Macrophage Colony-Stimulating Factor / Monocytes / Ovarian Neoplasms / Tumor Cells, Cultured
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1349-7006.1996.tb00251.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8641987
- ● Search Scopus @ Elsevier (PMID): 8641987
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.1996.tb00251.x
(DOI: 10.1111/j.1349-7006.1996.tb00251.x, PubMed: 8641987) Masaharu Kan, Fumihiko Kanai, Mitsuru Iida, Hideaki Jinnouchi, Mikio Todaka, Takanobu Imanaka, Kimio Ito, Yasuhiko Nishioka, Tetsuo Ohnishi, Seika Kamohara, Hideaki Hayashi, Takashi Murakami, Susumu Kagawa, Hiroyuki Sano, Naotake Hashimoto, Sho Yoshida, Hideichi Makino and Yousuke Ebina :
Frequency of Mutations of Insulin Receptor Gene in Japanese Patients with NIDDM,
Diabetes, Vol.44, No.9, 1081-1086, 1995.- (要約)
- To examine the prevalence of abnormalities in the insulin receptor structure gene in Japanese with non-insulin-dependent diabetes mellitus (NIDDM), a population of 51 patients with NIDDM was screened for mutations in this gene. Patient genomic DNAs of both alleles corresponding to 22 exons of the gene were amplified by polymerase chain reaction (PCR). The PCR products on pUC19 were sequenced. Three patients with heterozygous missense mutation Thr831-->Ala831 in exon 13 and one patient with heterozygous missense mutation Tyr1334-->Cys1334 in exon 22 of the beta-subunits were identified. Linkage analysis of one of the families plus statistical studies showed that the mutation Thr831-->Ala831 is possibly responsible for the onset of NIDDM. In COS cells transiently expressing both mutant receptor cDNAs and a cDNA of a M(r) 85,000 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase), the mutation Tyr1334-->Cys1334 impaired binding of the receptor with the M(r) 85,000 subunit of PI 3-kinase, but linkage analysis of the family showed that the mutation did not cosegregate with NIDDM in the pedigree. Therefore, one missense mutation (Thr831-->Ala831) in the insulin receptor, as found in three patients, is possibly involved in the etiology of a subset of the 51 NIDDM patients.
- (キーワード)
- Adult / Aged / Alanine / Amino Acid Sequence / Animals / Base Sequence / Cell Line / Cercopithecus aethiops / Cysteine / DNA / DNA Primers / Diabetes Mellitus, Type 2 / Exons / Female / Genetic Linkage / Humans / Insulin / Japan / Kinetics / Macromolecular Substances / Male / Middle Aged / Molecular Sequence Data / Pedigree / Phosphatidylinositol 3-Kinases / Phosphotransferases (Alcohol Group Acceptor) / Point Mutation / Polymerase Chain Reaction / Receptor, Insulin / Recombinant Proteins / Threonine / Transfection / Tyrosine
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2337/diab.44.9.1081
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7657032
- ● Search Scopus @ Elsevier (PMID): 7657032
- ● Search Scopus @ Elsevier (DOI): 10.2337/diab.44.9.1081
(DOI: 10.2337/diab.44.9.1081, PubMed: 7657032) Seiji Yano, Saburo Sone, Yasuhiko Nishioka, Naofumi Mukaida, Kouji Matsushima and Takeshi Ogura :
Differential effects of anti-inflammatory cytokines (IL-4, IL-10 and IL-13) on tumoricidal and chemotactic properties of human monocytes induced by monocyte chemotactic and activating factor.,
Journal of Leukocyte Biology, Vol.57, No.2, 303-309, 1995.- (要約)
- The effect of recombinant human IL-4, IL-10, and IL-13 on the chemotaxis and antitumor activity of human blood monocytes induced by monocyte chemotactic and activating factor (MCAF) was examined. MCAF alone did not induce monocyte-mediated cytotoxicity against human melanoma (A375-M) cells whereas it significantly enhanced the cytotoxicity by norMDP-stimulated monocytes. MCAF, unlike IFN-gamma, had no priming effect on monocyte activation by norMDP. MCAF acted with norMDP or LPS to enhance the production of both IL-1 beta and TNF-alpha. Enhanced cytotoxicity of monocytes stimulated with MCAF plus norMDP was reduced by IL-1 receptor antagonist and anti-TNF-alpha antibody. IL-4, IL-10, and IL-13 suppressed the generation of antitumor activity and cytokine production (IL-1 beta and TNF-alpha) of monocytes stimulated with MCAF plus norMDP or LPS. Chemotaxis of monocytes induced by MCAF was not affected by norMDP or any of the anti-inflammatory cytokines (IL-4, IL-10, and IL-13). Moreover, the pretreatment of monocytes with anti-inflammatory cytokines did not suppress monocyte-chemotaxis. These findings suggest that in vivo recruitment and anti-tumor expression of blood monocytes induced by MCAF may be differently regulated by anti-inflammatory cytokines in vivo.
- (キーワード)
- Acetylmuramyl-Alanyl-Isoglutamine / Cells, Cultured / Chemokine CCL2 / Chemotactic Factors / Chemotaxis, Leukocyte / Cytokines / Humans / Interleukin-10 / Interleukin-13 / Interleukin-4 / Interleukins / Monocytes / Recombinant Proteins / Stimulation, Chemical
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/jlb.57.2.303
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7852846
- ● Search Scopus @ Elsevier (PMID): 7852846
- ● Search Scopus @ Elsevier (DOI): 10.1002/jlb.57.2.303
(DOI: 10.1002/jlb.57.2.303, PubMed: 7852846) Roustem Nabioullin, Saburo Sone, Kazuto Mizuno, Seiji Yano, Yasuhiko Nishioka, Takashi Haku and Takeshi Ogura :
Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages,
Journal of Leukocyte Biology, Vol.55, No.4, 437-442, 1994.- (要約)
- The effects of purified human interleukin-10 (IL-10) on the expression of antitumor activity of human monocytes and alveolar macrophages (AMs) obtained by centrifugal elutriation and bronchoalveolar lavage, respectively, from the same healthy donors were examined. Monocytes and AMs were incubated for 16 h in medium with lipopolysaccharide (LPS) in the presence or absence of IL-10 or IL-4, and then their tumoricidal activity was assayed by measuring 125I-IUdR release from human melanoma (A375) cells. Addition of IL-10 to cultures of monocytes or AMs with LPS resulted in dose-dependent suppression of their cytotoxicity against A375 cells, the suppression of the activity of monocytes being the higher. IL-10 also suppressed the synergistic effects of interferon-gamma and desmethyl muramyldipeptide in activation of monocytes. IL-10 inhibited the early induction phase of monocyte activation but not the effector phase (monocyte-mediated cytotoxicity). IL-10 plus IL-4 inhibited the antitumor activities of AMs and monocytes much more than either IL-10 or IL-4 alone. IL-10 and IL-4 at suboptimal concentrations also showed synergistic inhibitory effects. These findings suggest that IL-10 may be important in vivo in down-regulating the antitumor activities of monocytes and AMs in the lung by inhibiting their productions of antitumor effector molecules.
- (キーワード)
- Acetylmuramyl-Alanyl-Isoglutamine / Cells, Cultured / Cytotoxicity, Immunologic / Humans / Interferon-gamma / Interleukin-10 / Interleukin-4 / Macrophages, Alveolar / Monocytes / Neoplasms
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1002/jlb.55.4.437
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8145013
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0028326235
(DOI: 10.1002/jlb.55.4.437, PubMed: 8145013, Elsevier: Scopus) Saburo Sone, E Orino, Kazuto Mizuno, Seiji Yano, Yasuhiko Nishioka, Takashi Haku, A Nii and Takeshi Ogura :
Production of IL-1 and its receptor antagonist is regulated differently by IFN-gamma and IL-4 in human monocytes and alveolar macrophages,
The European Respiratory Journal, Vol.7, No.4, 657-663, 1994.- (要約)
- Interleukin-4 (IL-4) has previously been found to downregulate interleukin-1 (IL-1) production, but to upregulate the production of IL-1 receptor antagonist (IL-1ra) in human monocytes stimulated with lipopolysaccharide (LPS). In the present study we wanted to determine whether the production of IL-1ra in human monocytes and alveolar macrophages (AMs) is regulated differently at the protein and messenger ribonucleic acid (mRNA) levels by IL-4 and interferon-gamma (IFN-gamma). AMs and monocytes obtained from healthy donors by bronchoalveolar lavage and centrifugal elutriation were stimulated with LPS in the presence or absence of IL-4 or IFN-gamma, and the expression of mRNA for IL-1 and IL-1ra was measured by Northern blot analysis. The production of IL-1 and IL-1ra was quantitated by enzyme immunoassays (EIAs). Spontaneous IL-1ra production was seen in AMs after incubation for 4 h in medium alone, but not in blood monocytes, at both the protein and mRNA levels. The spontaneous expression of the IL-1ra gene in AMs was augmented by incubation with IL-4. Interleukin-1 beta (IL-1 beta) production by LPS-stimulated AMs and monocytes was upregulated by IFN-gamma, but downregulated by IL-4. Interestingly, when stimulated with LPS, IFN-gamma inhibited IL-1ra production by monocytes, but up-regulated its production in human AMs at the protein and mRNA levels.(ABSTRACT TRUNCATED AT 250 WORDS)
- (キーワード)
- Adult / Blotting, Northern / Humans / Interferon-gamma / Interleukin-1 / Interleukin-4 / Lipopolysaccharides / Macrophages, Alveolar / Male / Monocytes / RNA, Messenger / Receptors, Interleukin-1
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8005245
- ● Search Scopus @ Elsevier (PMID): 8005245
(PubMed: 8005245) Seiji Yano, Saburo Sone, Yasuhiko Nishioka, M Naito, Takashi Tsuruo and Takeshi Ogura :
Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes,
Japanese Journal of Cancer Research, Vol.85, No.2, 194-203, 1994.- (要約)
- Cyclosporin A (CsA) was previously found to bind to P-glycoprotein expressed on multidrug-resistant (MDR) cancer cells. In the present study, the effect of CsA on anti-P-glycoprotein monoclonal antibody (mAb)-dependent cell-mediated cytotoxicity (ADCC) against human MDR cells was examined. The ADCC reaction was assessed by 4-h 51Cr-release assay. Highly purified lymphocytes (> 99%) and monocytes (> 99%) obtained from blood mononuclear cells (MNC) of healthy donors were used as effector cells. CsA decreased the cytotoxic activity of MNC against MDR cells, but enhanced their ADCC activity in the presence of anti-P-glycoprotein mAb MRK16. Lymphocyte-mediated ADCC and natural killer activity against MDR cells were also suppressed by addition of CsA. CsA induced a significant dose-dependent increase in monocyte-mediated ADCC activity. Interestingly, pretreatment of MDR cancer cells, but not of monocytes, with CsA significantly enhanced ADCC activity mediated by monocytes, but not by lymphocytes. A CsA analog (PSC833) and FK-506, but not verapamil also increased the sensitivity of MDR cells to ADCC by monocytes. CsA did not affect the binding of monocytes to MDR cells in the presence of MRK16 mAb. These results indicate that CsA may directly enhance the susceptibility of MDR cancer cells to the monocyte-mediated ADCC reaction.
- (キーワード)
- ATP-Binding Cassette, Sub-Family B, Member 1 / Antibodies, Monoclonal / Antibody-Dependent Cell Cytotoxicity / Antineoplastic Agents / Biological Availability / Carrier Proteins / Cyclosporine / Cyclosporins / Drug Resistance / Female / Humans / KB Cells / Killer Cells, Natural / Leukemia, Myeloid / Lymphocytes / Membrane Glycoproteins / Monocytes / Neoplasm Proteins / Ovarian Neoplasms / Protein Binding / Tacrolimus / Tumor Cells, Cultured / Verapamil
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1349-7006.1994.tb02082.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7511575
- ● Search Scopus @ Elsevier (PMID): 7511575
- ● Search Scopus @ Elsevier (DOI): 10.1111/j.1349-7006.1994.tb02082.x
(DOI: 10.1111/j.1349-7006.1994.tb02082.x, PubMed: 7511575) Fumihiko Kanai, Yasuhiko Nishioka, Hideki Hayashi, Seika Kamohara, Mikio Todaka and Yousuke Ebina :
Direct demonstration of insulin-induced GLUT4 translocation to the surface of intact cells by insertion of a c-myc epitope into an exofacial GLUT4 domain.,
The Journal of Biological Chemistry, Vol.268, No.19, 14523-14526, 1993. Hideki Hayashi, Yasuhiko Nishioka, Seika Kamohara, Fumihiko Kanai, Kazuo Ishii, Yasuhisa Fukui, Futoshi Shabisaki, Tadaomi Takenawa, Hiroshi Kido, Nobuhiko Katsunuma and Yousuke Ebina :
The alpha-Type 85-kDa subunit of Phosphatidylinositol 3-Kinase is Phosphorylatedat Tyrosines 368, 580, and 607 by the Insulin Receptor,
The Journal of Biological Chemistry, Vol.268, No.10, 7107-7117, 1993. Hideki Hayashi, Seika Kamohara, Yasuhiko Nishioka, Fumihiko Kanai, Noriaki Miyake, Yasuhisa Fukui, Futoshi Shibasaki, Tadaomi Takenawa and Yousuke Ebina :
Insulin treatment stimulates the tyrosine phosphorylation of the alpha-type 85-kDa subunit of phosphatidylinositol 3-kinase in vivo.,
The Journal of Biological Chemistry, Vol.267, No.31, 22575-22580, 1992. 曽根 三郎, 仁井 昌彦, 西岡 安彦, 折野 悦子, 前田 健一, 水野 和人, 小倉 剛 :
ヒト単球・マクロファージの機能発現とIL-4による制御,
日本網内系学会誌, Vol.32, No.4, 321-324, 1992年.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3960/jslrt1961.32.321
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.3960/jslrt1961.32.321
(DOI: 10.3960/jslrt1961.32.321) Yasuhiko Nishioka, Saburo Sone, E. Orino, A. Nii and T. Ogura :
Down-regulation by interleukin 4 of activation of human alveolar macrophages to the tumoricidal state,
Cancer Research, Vol.51, No.20, 5526-5531, 1991. Saburo Sone, Eiji Kunishige, Farid Fawzy, Hiroaki Yanagawa, Akihiko Nii, Kenichi Maeda, Shinji Atagi, Yuji Heike, Yasuhiko Nishioka, Kazuhito Mizuno and Takeshi Ogura :
Interleukin-2-inducible killer activity and its regulation by blood monocyte from autologous lymphocytes of lung cancer patigents,
Japanese Journal of Cancer Research, Vol.82, No.6, 716-723, 1991.- (要約)
- The ability of blood lymphocytes of newly diagnosed lung cancer patients to respond to interleukin 2 (IL-2) to become IL-2-activated killer (LAK) cells and its regulation by autologous monocytes were examined. LAK activity was measured by 51Cr release assay. The abilities of lymphocytes among blood mononuclear cells (MNC) of subjects of different ages without malignancies to generate LAK activity against NK-cell resistant Daudi cells and lung adenocarcinoma (PC-9) cells were very similar. The LAK activity of blood MNC of lung cancer patients was also nearly the same as that of blood MNC of control subjects. There was no significant difference in IL-2-inducible LAK activity between MNC of patients with small cell lung cancer (SCLC) and those of patients with non-SCLC. Monocytes and lymphocytes were separated from blood MNC on a one-step Percoll gradient. Monocytes of lung cancer patients were found to augment in vitro induction of LAK activity by IL-2 of autologous blood lymphocytes. In contrast, endotoxin-stimulated monocytes suppressed LAK induction of autologous lymphocytes of cancer patients. These findings suggest that administration of IL-2 and LAK cells induced in vitro may be of benefit in the treatment of lung cancer.
- (キーワード)
- Aged / Carcinoma, Non-Small-Cell Lung / Carcinoma, Small Cell / Cell Line / Cytotoxicity, Immunologic / 女性 (female) / Humans / Interleukin-2 / Killer Cells, Lymphokine-Activated / Killer Cells, Natural / Lung Neoplasms / Lymphocytes / 男性 (male) / Middle Aged / Recombinant Proteins / Reference Values
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/j.1349-7006.1991.tb01908.x
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 1649813
- ● Summary page in Scopus @ Elsevier: 2-s2.0-0025735201
(DOI: 10.1111/j.1349-7006.1991.tb01908.x, PubMed: 1649813, Elsevier: Scopus) 曽根 三郎, 楊河 宏章, 福田 克之, 中西 美枝, Singh M. Sukh, 稲村 典昭, 前田 健一, 大久保 明夫, 西岡 安彦, 安宅 信二, 小倉 剛 :
ヒト単球-マクロファージのIL-2活性化キラー(LAK)発現調節におけるGM-CSFの役割,
BIOTHERAPY, Vol.4, No.3, 342-346, 1990年. 稲村 典昭, 曽根 三郎, 大久保 明夫, 中西 美枝, 前田 健一, 西岡 安彦, 小倉 剛 :
ヒト末梢血単球のgranulocyte-macrophage colony-stimulating factorに対する反応性,
医学のあゆみ, Vol.151, No.8, 461-462, 1989年. 大久保 明夫, 曽根 三郎, 福田 克之, 中西 美枝, 前田 健一, 西岡 安彦, 山下 親正, 小倉 剛 :
肺癌患者肺胞マクロファージの腫瘍壊死因子産生能,
医学のあゆみ, Vol.151, No.2, 127-128, 1989年. - MISC
- 矢葺 洋平, 大塚 憲司, 竹内 栄治, 葉久 貴司, 兼松 貴則, 西村 直樹, 豊田 優子, 埴淵 昌毅, 軒原 浩, 西岡 安彦 :
高齢者進行・再発非小細胞肺癌に対する Pemetrexed + Bevacizumab 併用療法の有効性と安全性の検討,
第62回日本肺癌学会学術集会, 2021年. 後東 久嗣, 青野 純典, 西岡 安彦 :
肺の生体防御機構におけるサーファクタント蛋白Aの役割,
日本肺サーファクタント·界面医学会雑誌, Vol.43, 9-15, 2012年.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1570572701190395520
(CiNii: 1570572701190395520) 庄野 文章, 西岡 安彦, 清水 一郎, 田代 征記, 濱 佳子, 伊東 進, 水口 和生 :
徳島大学医学部附属病院における抗菌薬適正使用の取り組みと使用状況,
医療薬学, Vol.29, No.5, 611-615, 2003年.- (要約)
- The working committee for the proper use of antibiotics was organized at Tokushima University Hospital in March 2002, and the institutional guidelines for the selection and use of antibiotics were established. The infection control team (ICT) also started monitoring the use of particular antibiotics, including third- and fourthgeneration cephalosporins, calbapenems and anti-MRSA antibiotics, and reported on their use in August 2002. To assess these activities, we examined the status of antibiotic use for injections and compared our findings with the previous data. The results were as follows : 1) the reports required were presented in 47% of the total antibiotics used ; 2) after starting the surveillance, the use of the third- and fourth-generation cephalosporins and calbapenems shifted to the first- and second-generation drugs, while the use of anti-MRSA drugs clearly decreased ; 3) these changes resulted in a savings of more than two million yen in medical expenditures in a month. These results suggest that closely monitoring the use of antibiotics may thus be beneficial not only for promoting the proper use of antibiotics but also for reducing overall medical costs.
- (キーワード)
- 抗生物質 (antibiotics) / anti-MRSA antibiotics / proper use / ICT
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.5649/jjphcs.29.611
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390282679752865920
- ● Search Scopus @ Elsevier (DOI): 10.5649/jjphcs.29.611
(DOI: 10.5649/jjphcs.29.611, CiNii: 1390282679752865920)
- 総説・解説
- 西岡 安彦 :
肺繊維症に対する抗線維化薬開発:がんと線維化肺の接点を捉えたトランスレーショなるリサーチ,
医学のあゆみ, Vol.288, No.2, 148-161, 2024年1月. 佐藤 正大, 村上 行人, 西岡 安彦 :
肺線維症におけるfibrocyteの役割,
呼吸器内科, Vol.44, No.3, 336-341, 2023年9月. 三橋 惇志, 西岡 安彦 :
1細胞解析による腫瘍内fibrocyteの同定,
細胞, Vol.55, No.1, 55-59, 2023年6月. 佐藤 正大, 西岡 安彦 :
PF-ILDと抗線維化薬について,
日本臨牀, Vol.81, No.5, 764-770, 2023年5月. 西岡 安彦, 佐藤 正大 :
特発性間質性肺炎(IIPs)・肺線維症,
日本医事新報, Vol.5157, 42-43, 2023年2月. 豊田 優子, 西岡 安彦 :
全身性エリテマトーデス,
呼吸器内科, Vol.42, No.6, 616-621, 2022年12月. 西岡 安彦, 村上 行人, 小山 壱也, 佐藤 正大 :
肺線維化機序,
日本臨牀, Vol.80, No.9, 1351-1355, 2022年9月. 村上 行人, 西岡 安彦 :
びまん性肺疾患の病態から考察するMDD診断の重要性について,
呼吸器内科, Vol.41, No.2, 142-148, 2022年2月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1522262181157043456
(CiNii: 1522262181157043456) 荻野 広和, 西岡 安彦 :
間質性肺炎合併非小細胞肺癌に対する薬物療法について,
BIO Clinica, Vol.36, No.11, 41-47, 2021年10月. 小山 壱也, 西岡 安彦 :
肺の線維化 : 肺線維症と抗線維化薬 (特集 組織の線維化),
臨床免疫·アレルギー科, Vol.76, No.2, 139-146, 2021年8月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1521136281215665152
(CiNii: 1521136281215665152) 佐藤 正大, 西岡 安彦 :
間質性肺炎,
レジデントノート, Vol.23, No.8, 77-84, 2021年8月. 西岡 安彦 :
免疫チェックポイント阻害薬によるがん医療,
日本内科学会雑誌, Vol.110, No.3, 520-525, 2021年3月.- (キーワード)
- がん免疫療法 / 細胞傷害性Tリンパ球 / PD-1/PD-L1 / CTLA-4 / 免疫関連有害事象 (irAE) / ガン メンエキ リョウホウ / サイボウ ショウガイセイ Tリンパキュウ / メンエキ カンレン ユウガイ ジショウ (irAE)
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1520009409715539200
(CiNii: 1520009409715539200) 河野 弘, 西岡 安彦 :
グッドパスチャー症候群,
日本医師会雑誌, Vol.149, No.2, 244-246, 2020年10月. 西岡 安彦 :
間質性肺炎:診断と治療の最前線,
日本内科学会雑誌, Vol.109, No.9, 1899-1905, 2020年9月.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/naika.109.1899
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390007857411974144
- ● Search Scopus @ Elsevier (DOI): 10.2169/naika.109.1899
(DOI: 10.2169/naika.109.1899, CiNii: 1390007857411974144) 三橋 惇志, 西岡 安彦 :
血管新生阻害剤に対する耐性獲得メカニズム,
実験医学, Vol.38, No.15, 157-162, 2020年9月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1010853567272655106
(CiNii: 1010853567272655106) 軒原 浩, 西岡 安彦 :
間質性肺炎合併非小細胞肺癌の治療戦略,
肺癌, Vol.60, No.2, 74-80, 2020年4月.- (要約)
- <p>血管新生阻害薬，ドライバー遺伝子変異に対する阻害薬，免疫チェックポイント阻害薬の登場により進行非小細胞肺癌に対する薬物療法は大きく変貌した．一方，間質性肺炎合併非小細胞肺癌に対する薬物療法は限られた薬物の使用にとどまり，そのエビデンスは乏しい．間質性肺炎合併非小細胞肺癌に対する血管新生阻害薬や免疫チェックポイント阻害薬の有効性や安全性の情報は乏しく，臨床医にとってclinical questionとなっている．近年，間質性肺炎合併非小細胞肺癌に対する薬物療法の前向き臨床試験がいくつか実施され，その結果が報告されている．本稿ではそれらをもとに間質性肺炎合併非小細胞肺癌に対する薬物療法について概説する．</p>
- (キーワード)
- 肺癌 / 間質性肺炎 / 化学療法 / 血管新生阻害薬 / 免疫チェックポイント阻害薬
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2482/haigan.60.74
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390848250109705088
- ● Search Scopus @ Elsevier (DOI): 10.2482/haigan.60.74
(DOI: 10.2482/haigan.60.74, CiNii: 1390848250109705088) 佐藤 正大, 西岡 安彦 :
特発性肺線維症の血清学的所見,
薬局, Vol.71, No.3, 26-31, 2020年3月. 西岡 安彦 :
特発性肺線維症のガイドラインの変遷,
薬局, Vol.71, No.3, 16-20, 2020年3月. 佐藤 正大, 西岡 安彦, Martin Kolb :
線維化肺組織の細胞外基質が線維細胞のmiR-21発現に及ぼす影響の検討,
分子呼吸器病, Vol.24, No.1, 76-79, 2020年3月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1522825129960952064
(CiNii: 1522825129960952064) 豊田 優子, 佐藤 正大, 河野 弘, 西岡 安彦 :
関節リウマチ治療薬と肺病変,
呼吸器内科, Vol.36, No.6, 618-626, 2019年12月.- (キーワード)
- rheumatoid arthritis (RA) / drug-induced pneumonia / methotrexate (MTX) / biological drug / disease modifying antirheumatic drugs (DMARDs)
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1523388080905010944
(CiNii: 1523388080905010944) 西岡 安彦 :
最新醫學の編集委員を担当して,
最新医学, Vol.74, No.6, 125, 2019年6月. 後東 久嗣, 吾妻 雅彦, 中瀬 勝則, 豊﨑 纒, 宇都宮 正登, 西岡 安彦 :
COPD・肺がんにならないために,
四国医学雑誌, Vol.75, No.1,2, 23-30, 2019年4月.- (要約)
- Chronic obstructive pulmonary disease (COPD) is a long-standing, crippling disease characterized by the accelerated decline of lung function, commonly brought by aging and long-time inhalation of toxic chemicals such as tobacco smoking. Consequently, most COPD patients suffer from chronic cough, sputum and dyspnea on exertion. Moreover, in addition to the decline of lung function due to the destruction of the alveolar structure, COPD is closely related to other diseases such as osteoporosis, cardiovascular diseases, diabetes, muscle dysfuncion, and lung cancer. Therefore, COPD is currently recognized as a systemic disease that the comprehensive management and care are necessary. Although COPD represents an increasing burden throughout the world and is one of the major causes of death word-wide, the issue has been arisen that the recognition of COPD in the general society is still low, especially in Japan. On the other hand, lung cancer is a life-threatening disease with the leading cause of malignancy-related death world-wide, the etiology of which is also closely related to tobacco smoking. Because the pathogenesis and the mortality of COPD and lung cancer are closely related each other, the action to prevent these diseases could be made simultaneously, primarily by the smoking cessation and the detection survey. In this article, we describe the present situation of COPD and lung cancer, the importance of smoking cessation, and the effort of Tokushima City Medical Association to manage COPD in Tokushima.
- (キーワード)
- COPD / lung cancer / smoking cessation / detection survey
- (徳島大学機関リポジトリ)
- ● Metadata: 113743
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1050282813476936320
(徳島大学機関リポジトリ: 113743, CiNii: 1050282813476936320) 西岡 安彦 :
肺がん腫瘍環境におけるfibrocyte-like cellの病的意義,
炎症と免疫, Vol.27, No.3, 31-35, 2019年4月. 河野 弘, 西岡 安彦 :
間質性肺炎・慢性閉塞性肺疾患,
薬局, Vol.70, No.5, 85-90, 2019年4月. 三橋 惇志, 西岡 安彦 :
免疫チェックポイント阻害薬の効果を増強する併用療法,
分子呼吸器病, Vol.23, No.1, 49-53, 2019年3月.- (キーワード)
- 免疫チェックポイント阻害薬 / 化学療法 / 血管新生阻害薬
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1521417755561804800
(CiNii: 1521417755561804800) 小山 壱也, 西岡 安彦 :
テロメア伸長と肺線維症,
呼吸器内科, Vol.34, No.3, 300-303, 2018年9月. 荻野 広和, 後東 久嗣, 西岡 安彦 :
咳嗽の原因として見逃してはならない腫瘍,
呼吸器ジャーナル, Vol.66, No.3, 458-465, 2018年8月. 豊田 優子, 西岡 安彦 :
薬剤性肺障害,
呼吸器内科, Vol.34, No.Suppl.1, 454-461, 2018年7月. 豊田 優子, 西岡 安彦 :
ニンテダニブ単独療法,
呼吸器ジャーナル, Vol.66, No.2, 229-235, 2018年5月. 西岡 安彦 :
間質性肺炎の診断と治療∼最近の進歩∼,
日本内科学会雑誌, Vol.107, No.3, 54-55, 2018年3月. 後東 久嗣, 西條 敦郎, 西岡 安彦 :
がんの進展における線維細胞の機能と役割∼血管新生阻害薬耐性とがん幹細胞様細胞の誘導∼,
分子呼吸器病, Vol.22, No.1, 49-51, 2018年3月. 森住 俊, 河野 弘, 豊田 優子, 小山 壱也, 西村 春佳, 香川 耕造, 後東 久嗣, 西岡 安彦 :
ブレオマイシン肺線維症モデルにおける線維芽細胞増殖因子受容体阻害薬の抗線維化効果の検討,
分子呼吸器病, Vol.22, No.1, 96-98, 2018年3月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1520573330524696832
(CiNii: 1520573330524696832) Hisatsugu Goto and Yasuhiko Nishioka :
Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression,
International Journal of Molecular Sciences, Vol.19, No.1, 98, Jan. 2018.- (要約)
- An adequate blood supply is essential for cancer cells to survive and grow; thus, the concept of inhibiting tumor angiogenesis has been applied to cancer therapy, and several drugs are already in clinical use. It has been shown that treatment with those anti-angiogenic drugs improved the response rate and prolonged the survival of patients with various types of cancer; however, it is also true that the effect was mostly limited. Currently, the disappointing clinical results are explained by the existence of intrinsic or acquired resistance to the therapy mediated by both tumor cells and stromal cells. This article reviews the mechanisms of resistance mediated by stromal cells such as endothelial cells, pericytes, fibroblasts and myeloid cells, with an emphasis on fibrocytes, which were recently identified as the cell type responsible for regulating acquired resistance to anti-angiogenic therapy. In addition, the other emerging role of fibrocytes as mediator-producing cells in tumor progression is discussed.
- (徳島大学機関リポジトリ)
- ● Metadata: 112410
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3390/ijms19010098
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29286323
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85039915228
(徳島大学機関リポジトリ: 112410, DOI: 10.3390/ijms19010098, PubMed: 29286323, Elsevier: Scopus) 荻野 広和, 西岡 安彦 :
がん転移の臨床研究の歴史と展望,
日本臨牀, Vol.75, No.8, 15-20, 2017年11月. 豊田 優子, 西岡 安彦 :
Precision Medicine;コンパニオン診断と特発性肺線維症,
呼吸器内科, Vol.32, No.3, 292-299, 2017年9月. 西岡 安彦, 阿部 真治 :
ポドプラニンを標的とした悪性胸膜中皮腫に対する新規抗体医薬開発,
生化学, Vol.89, No.4, 564-567, 2017年8月.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.14952/SEIKAGAKU.2017.890564
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390283684847016832
- ● Summary page in Scopus @ Elsevier: 2-s2.0-85042868606
(DOI: 10.14952/SEIKAGAKU.2017.890564, CiNii: 1390283684847016832, Elsevier: Scopus) 大塚 憲司, 西岡 安彦 :
肺癌における標準治療としての免疫チェックポイント阻害薬,
癌と化学療法, Vol.44, No.8, 655-660, 2017年8月. 後東 久嗣, 西岡 安彦 :
血管新生阻害薬耐性のメカニズム,
日本臨牀, Vol.75, No.7, 1039-1043, 2017年7月. 後東 久嗣, 西岡 安彦 :
線維細胞による肺がんに対する血管新生阻害薬の耐性メカニズム,
最新医学, Vol.72, No.4, 132-137, 2017年4月. 豊田 優子, 西岡 安彦 :
間質性肺炎のバイオマーカーの探索と活用法,
Medical Ptactice, Vol.34, No.4, 627-628, 2017年4月. 後東 久嗣, 三橋 惇志, 西岡 安彦 :
血管新生阻害薬耐性とfibrocyte,
分子呼吸器病, Vol.21, No.1, 4-7, 2017年3月. 岡﨑 弘泰, 西岡 安彦 :
加齢と肺線維化,
The Lung Perspectives, Vol.24, No.3, 50-54, 2016年8月. 埴淵 昌毅, 西岡 安彦 :
特集 COPD合併肺癌: 病因論から治療まで. COPDにおける肺癌合併の分子機構,
呼吸と循環, Vol.64, No.8, 743-747, 2016年8月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390565159920348544
(CiNii: 1390565159920348544) 西岡 安彦 :
間質性肺炎 Update 序論,
最新医学, Vol.71, No.7, 1233-1234, 2016年7月. 吾妻 安良太, 小倉 高志, 西岡 安彦 :
間質性肺炎 Update 座談会 抗線維化薬時代の間質性肺炎診療を考える,
最新医学, Vol.71, No.7, 1235-1248, 2016年7月. 河野 弘, 西岡 安彦 :
膠原病における肺病変へのアプローチ,
リウマチ科, Vol.55, No.4, 345-352, 2016年4月. 佐藤 正大, 西岡 安彦 :
ニンテダニブ 新薬の最近の話題,
分子呼吸病, Vol.20, No.1, 100-102, 2016年3月. 佐藤 正大, 大谷 直子, 原 英二, 西岡 安彦 :
がん抑制遺伝子による細胞と個体老化の制御,
がん分子標的治療, Vol.14, No.1, 76-81, 2016年3月. 後東 久嗣, 青野 純典, 三橋 惇志, 西岡 安彦 :
慢性炎症とfibrocyte,
呼吸と循環, Vol.64, No.2, 149-155, 2016年2月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390002209966590976
(CiNii: 1390002209966590976) 西岡 安彦, 佐藤 正大 :
ニンテダニブ,
分子呼吸器病, Vol.20, No.1, 100-102, 2016年. Yasuhiko Nishioka :
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis,
Core Evidence, Vol.10, 89-98, Aug. 2015.- (要約)
- Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of the lungs. Other growth factors, including fibroblast growth factor and vascular endothelial growth factor, are also thought to contribute to the pathogenesis of pulmonary fibrosis. Nintedanib is an inhibitor of multiple tyrosine kinases, including receptors for PDGF, fibroblast growth factor, and vascular endothelial growth factor. In the Phase II TOMORROW trial, treatment with 150 mg of nintedanib twice daily showed a trend to slow the decline in lung function and significantly decrease acute exacerbations in patients with IPF, while showing an acceptable safety profile. The Phase III INPULSIS trials demonstrated a significant decrease in the annual rate of decline in forced vital capacity in IPF patients treated with 150 mg nintedanib twice daily. In the INPULSIS-2 trial, the time to the first acute exacerbation significantly increased in IPF patients who were treated with 150 mg of nintedanib twice daily. Pirfenidone, another antifibrotic drug, was shown to limit the decline in pulmonary function in patients with IPF in the ASCEND trial. Combination therapy with nintedanib and pirfenidone is anticipated, although further evaluation of its long-term safety is needed. There is limited evidence for the safety of the combination therapy although a Phase II trial conducted in Japan demonstrated that combination therapy with nintedanib and pirfenidone was tolerable for 1 month. Available antifibrotic agents (ie, pirfenidone and N-acetylcysteine) have limited efficacy as single therapies for IPF; therefore, further study of combination therapy with antifibrotic agents is needed.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2147/CE.S82905
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26346347
- ● Search Scopus @ Elsevier (PMID): 26346347
- ● Search Scopus @ Elsevier (DOI): 10.2147/CE.S82905
(DOI: 10.2147/CE.S82905, PubMed: 26346347) 西岡 安彦 :
IPFの病因論,
THE LUNG perspective, Vol.23, No.3, 66-69, 2015年8月. 埴淵 昌毅, 西岡 安彦 :
Current topics from major journals―英文抄読会から ALK陽性非小細胞肺癌に対する1次治療でのクリゾチニブと化学療法の比較試験,
日本胸部臨床, Vol.74, No.6, 717, 2015年6月. 西岡 安彦 :
薬物療法におけるステロイドの位置づけとは?,
Modern Physician 6, Vol.35, No.6, 766-768, 2015年6月. 西岡 安彦 :
肺線維症,
呼吸と循環, Vol.63, No.4, 315-322, 2015年4月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390002209967124736
(CiNii: 1390002209967124736) 西岡 安彦, 阿部 秀一, 佐藤 正大, 後東 久嗣 :
Fibroocyte,
Respiratory Medical Reserch, Vol.3, No.2, 60-63, 2015年4月. 西岡 安彦 :
がん免疫療法の過去と未来:エビデンスが示した新たな可能性,
日本口腔科学会雑誌, Vol.64, No.1, 1-11, 2015年3月. 埴淵 昌毅, 西岡 安彦 :
抗がん剤の副作用と支持療法―より適切な抗がん剤の安全使用をめざして― III. 抗がん剤の副作用に対する評価と処置 4.抗がん剤の副作用の予防的治療,
日本臨牀, Vol.73, No.Suppl. 2, 93-97, 2015年2月. 西岡 安彦, 後東 久嗣, 埴淵 昌毅, 柿内 聡司 :
呼吸器抄読会,
呼吸, Vol.34, No.2, 233, 2015年2月. 後東 久嗣, 西岡 安彦 :
血管新生阻害剤に対する耐性メカニズム,
医学のあゆみ, Vol.252, No.7, 814-818, 2015年2月. 豊田 優子, 河野 弘, 西岡 安彦 :
間質性肺炎の免疫療法は有効か?,
呼吸器内科, Vol.28, No.6, 451-455, 2015年. 西岡 安彦 :
COPD診療の現状と徳島県での取り組み,
阿南医報, Vol.175, 20-21, 2014年10月. 西岡 安彦 :
肺線維症と増殖因子シグナル,
呼吸と循環, Vol.62, No.9, 873-878, 2014年9月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390565159920649344
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84906822612
(CiNii: 1390565159920649344, Elsevier: Scopus) Yasuhiko Nishioka :
Physician scientists in respiratory medicine,
Respiratory Investigation, Vol.52, No.5, 279, Sep. 2014.- (キーワード)
- Education, Medical, Graduate / Japan / Physicians / Pulmonary Medicine
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1016/j.resinv.2014.07.001
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25169842
- ● Search Scopus @ Elsevier (PMID): 25169842
- ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2014.07.001
(DOI: 10.1016/j.resinv.2014.07.001, PubMed: 25169842) 西岡 安彦 :
新薬治療薬の開発状況と将来展望,
日本医師会雑誌, Vol.143, No.5, 1011, 2014年8月. 後東 久嗣, 西岡 安彦 :
新薬の最近の話題「デノスマブ」,
分子呼吸器病, Vol.18, No.1, 109-111, 2014年3月. Hisatsugu Goto, Atsushi Mitsuhashi and Yasuhiko Nishioka :
Role of surfactant protein A in non-infectious lung diseases,
The Journal of Medical Investigation : JMI, Vol.61, No.1,2, 1-6, Feb. 2014.- (要約)
- Surfactant protein A (SP-A) is a large multimeric protein found in the airways and alveoli of the lungs. SP-A is a member of the collectin family of proteins, characterized by NH2-terminal collagen-like regions and COOH-terminal lectin domains. Although other surfactant proteins such as SP-B function to reduce surface tension in the lungs, SP-A as well as SP-D regulates the pulmonary immune response. To date, a number of studies have shown the immunoregulatory function of SP-A, mainly in the field of infectious diseases. By binding to a wide variety of pathogens, SP-A opsonizes and enhances pathogen uptake by phagocytes. In addition to the effect on pathogens, recent studies have shown that SP-A also modulates lung immune system in the area of non-infectious lung diseases. In this review, the potential role of SP-A in the multiple aspects of pulmonary host defense will be discussed, focusing mainly on non-infectious lung diseases such as acute and chronic pulmonary fibrosis and lung cancer. J. Med. Invest. 61: 1-6, February, 2014.
- (キーワード)
- Humans / Immune System / Lung / Lung Diseases / 肺線維症 (pulmonary fibrosis) / Pulmonary Surfactant-Associated Protein A
- (徳島大学機関リポジトリ)
- ● Metadata: 109489
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.61.1
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705741
- ● Search Scopus @ Elsevier (PMID): 24705741
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.61.1
(徳島大学機関リポジトリ: 109489, DOI: 10.2152/jmi.61.1, PubMed: 24705741) Yasuhiko Nishioka :
New wave of immunotherapy against lung cancer rolls in to clinic,
Translational Lung Cancer Research, Vol.3, No.1, 1, Feb. 2014.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3978/j.issn.2218-6751.2013.12.02
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25806275
- ● Search Scopus @ Elsevier (PMID): 25806275
- ● Search Scopus @ Elsevier (DOI): 10.3978/j.issn.2218-6751.2013.12.02
(DOI: 10.3978/j.issn.2218-6751.2013.12.02, PubMed: 25806275) 西岡 安彦, 後東 久嗣 :
肺胞上皮傷害と修復,
呼吸と循環, Vol.61, No.12, 1146-1151, 2013年12月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1522543655341362816
(CiNii: 1522543655341362816) 後東 久嗣, 西岡 安彦 :
放射線肺臓炎.,
日本臨牀, Vol.71, No.6, 526-529, 2013年11月. 西岡 安彦 :
徳島大学大学院ヘルスバイオサイエンス研究部呼吸器・膠原病内科学分野のご紹介.,
徳島県医師会報, Vol.508, 32-33, 2013年10月. 西岡 安彦, 青野 純典 :
Fibrocyteの役割.,
日本胸部臨床, Vol.72, S186-S189, 2013年8月. 西岡 安彦 :
分子標的治療と免疫療法.,
癌と化学療法, Vol.40, No.8, 1004-1008, 2013年8月.- (キーワード)
- Humans / Immunotherapy / Molecular Targeted Therapy / Neoplasms
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24151656
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84886458611
(PubMed: 24151656, Elsevier: Scopus) 佐藤 正大, 西岡 安彦, 曽根 三郎 :
ヒト肺癌多臓器転移モデルとmacrophage stimulatuing protein.,
THE LUNG perspectives, Vol.21, No.3, 72-77, 2013年8月. Yasuhiko Nishioka, Momoyo Azuma, Masami Kishi and Yoshinori Aono :
Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis.,
The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 175-183, Aug. 2013.- (要約)
- Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disease characterized by the proliferation of fibroblasts and deposition of extracellular matrix. Since the prognosis of IPF is still poor, novel therapeutic modalities are strongly required. For this reason, to find molecular target for therapy of IPF is of much importance. The recent understanding of pathogenesis in IPF indicates the critical role of alveolar epithelial type II cells (AECII) and fibroblasts. Although the detailed mechanisms involved in IPF is still unclear, various profibrotic mediators which are produced by the injured AECII are thought to play a role in the progression of pulmonary fibrosis via stimulating fibroblasts. Among them, platelet-derived growth factor (PDGF) is one of critical growth factors by stimulating the proliferation and migration of fibroblasts. In this review, we discuss the role of PDGF in pulmonary fibrosis and the possibility as a therapeutic target for IPF.
- (徳島大学機関リポジトリ)
- ● Metadata: 106354
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2152/jmi.60.175
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190033
- ● Search Scopus @ Elsevier (PMID): 24190033
- ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.175
(徳島大学機関リポジトリ: 106354, DOI: 10.2152/jmi.60.175, PubMed: 24190033) 西岡 安彦 :
IPFの臨床試験を考える(巻頭言).,
呼吸と循環, Vol.61, No.7, 603, 2013年7月.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.11477/mf.1404102259
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390002209966491904
- ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1404102259
(DOI: 10.11477/mf.1404102259, CiNii: 1390002209966491904) 後東 久嗣, 柿内 聡司, 西岡 安彦 :
肺がん細胞の骨転移に関与する遺伝子の探索,
生体の科学, Vol.64, No.3, 279-282, 2013年6月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390846634845643392
(CiNii: 1390846634845643392) 西岡 安彦 :
間質性肺炎の診断と治療:最近の進歩,
日本臨床内科医会会誌, Vol.28, No.1, 46-50, 2013年6月. 西岡 安彦, 青野 純典 :
間質性肺炎と増殖因子,
アレルギーの臨床, Vol.443, No.33, 421-424, 2013年5月. 西岡 安彦 :
難治性呼吸器疾患の分子病態解明と新規治療法の開発.,
四国医学雑誌, Vol.69, No.1, 2, 52-56, 2013年4月.- (要約)
- Respiratory diseases include several intractable diseases such as lung cancer and pulmonary fibrosis. Particularly, lung cancer is a leading cause of death among various cancers. The reason why lung cancer shows poor prognosis could be due to early and multi-organ metastasis. We have performed the research to explore the mechanisms involved in the metastasis using multi-organ metastasis model in SCID mice, which enable us to study the organ-specific mechanism of metastasis. On the other hand, idiopathic pulmonary fibrosis (IPF) also shows the prognosis similar to lung cancer. The molecular pathogenesis in IPF is still unclear. Recent findings show the several origins of lung fibroblasts. Fibroblasts derived from circulating fibrocytes or epithelial-mesenchymal transition are thought to play a role in the fibrogenesis in the lungs. To analyze how these cells contribute to pulmonary fibrosis might lead to develop the novel therapy. Since many clinical trials are now going on worldwide for IPF, the forward and reverse translational research seems to be crucial to rapidly produce the outcome for patients.
- (キーワード)
- respiratory disease / lung cancer / metastasis / pulmonary fibrosis / fibroblast
- (徳島大学機関リポジトリ)
- ● Metadata: 109614
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1050001337464972160
(徳島大学機関リポジトリ: 109614, CiNii: 1050001337464972160) 柿内 聡司, 西岡 安彦 :
mTOR阻害薬による肺障害とその対応,
分子呼吸器病, Vol.17, No.1, 42-45, 2013年3月. 岸 潤, 西岡 安彦 :
関節リウマチと間質性肺病変,
リウマチ科, Vol.49, No.2, 161-165, 2013年2月. 西岡 安彦, 青野 純典, 阿部 秀一 :
肺線維症における繊維芽細胞の由来,
呼吸器内科, Vol.23, No.1, 20-24, 2013年1月. 西岡 安彦 :
がん分子標的治療における一体化開発の現状と展望,
がん分子標的治療, Vol.10, No.4, 267-275, 2012年10月. Yasuhiko Nishioka :
Malignant pleural effusion: further translational research is crucial,
Translational Lung Cancer Research, Vol.1, No.3, 167-169, Sep. 2012.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.3978/j.issn.2218-6751.2012.09.06
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25806178
- ● Search Scopus @ Elsevier (PMID): 25806178
- ● Search Scopus @ Elsevier (DOI): 10.3978/j.issn.2218-6751.2012.09.06
(DOI: 10.3978/j.issn.2218-6751.2012.09.06, PubMed: 25806178) 青野 純典, 西岡 安彦 :
がん分子標的薬に合併する間質性肺炎,
メディカル・サイエンス・ダイジェスト, Vol.38, No.9, 396-399, 2012年8月. 西岡 安彦 :
難治性呼吸器疾患の治療法の開発を目指して,
呼吸, Vol.31, No.7, 587-588, 2012年7月. 西岡 安彦, 曽根 三郎 :
呼吸器疾患におけるトランスレーショナルリサーチ:現状と将来展望,
呼吸器内科, Vol.21, No.6, 483-484, 2012年6月. 埴淵 昌毅, 西岡 安彦 :
特集 がんの分子病態診断-免疫染色と遺伝子診断の進歩- トピックス 肺がんと炎症,
最新医学, Vol.67, No.3, 479-484, 2012年3月. 青野 純典, Wright Rae Jo, 西岡 安彦 :
肺線維症におけるSP-Dの防御的役割,
分子呼吸器病, Vol.16, No.1, 147-150, 2012年3月. 岸 潤, 西岡 安彦 :
サルコイドーシスモデルと新規治療標的,
分子呼吸器病, Vol.16, No.1, 56-58, 2012年3月. Toshifumi Tezuka, Masahiko Azuma, Hisatugu Goto, Yasuhiko Nishioka and Saburo Sone :
Psychiatric symptoms in a patient with Churg-Strauss syndrome.,
Internal Medicine, Vol.51, No.3, 301-303, Feb. 2012.- (要約)
- We report a case of Churg-Strauss syndrome (CSS) in a patient with multiple cerebral infarctions and psychotic symptoms. A 67-year-old man presented a high-grade fever and delirium. He was clinically diagnosed with Churg-Strauss syndrome on the basis of the presence of asthma, neuropathy, blood eosinophilia, and increased myeloperoxidase-specific anti-neutrophil cytoplasmic antibody (MPO-ANCA) activities. Though multiple cerebral infarctions are irreversible, this patient's psychiatric symptoms improved with steroid treatment. Psychiatric symptoms associated with CSS are very rare.
- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2169/internalmedicine.51.6447
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22293807
- ● Summary page in Scopus @ Elsevier: 2-s2.0-84856576402
(DOI: 10.2169/internalmedicine.51.6447, PubMed: 22293807, Elsevier: Scopus) 青野 純典, 西岡 安彦 :
膠原病と関連したびまん性肺疾患,
綜合臨牀, Vol.60, No.12, 2463-2469, 2011年12月.- (キーワード)
- 膠原病肺 / 間質性肺炎 / びまん性肺疾患
- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1520291855323080448
(CiNii: 1520291855323080448) Seiji Yano, W Wang, Q Li, T Yamada, S Takeuchi, K Matsumoto, Yasuhiko Nishioka and Saburo Sone :
SHGF-MET in resistance to EGFR tyrosine kinase inhibitors in lung cancer.,
Current Signal Transduction Therapy, Vol.6, No.2, 228-233, May 2011.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.2174/157436211795659928
- (文献検索サイトへのリンク)
- ● Summary page in Scopus @ Elsevier: 2-s2.0-79957941582
(DOI: 10.2174/157436211795659928, Elsevier: Scopus) 後東 久嗣, G. Julie Ledford, Sambuddho Mukherjee, 西岡 安彦, 曽根 三郎, Rae Jo Wright :
急性肺損傷におけるSurfactant Protein Aの役割,
分子呼吸器病, Vol.15, No.1, 74-76, 2011年3月. 木下 勝弘, 西岡 安彦, 岸 昌美, 竹﨑 彰夫, 青野 純典, 東 桃代, 岸 潤, 上原 久典, 泉 啓介, 曽根 三郎 :
FAKシグナルの肺線維化における役割-ブレオマイシン肺線維症モデルでの検討,
分子呼吸器病, Vol.15, No.1, 124-127, 2011年. 木下 勝弘, 西岡 安彦 :
薬剤性肺障害の最新の知見,
分子呼吸器病, Vol.15, No.1, 66-68, 2011年. 西岡 安彦 :
Gremlin と特発性間質性肺炎,
呼吸, Vol.30, No.11, 955-958, 2011年. 曽根 三郎, 倉本 卓哉, 佐藤 正大, 三橋 惇志, 柿内 聡司, 後東 久嗣, 多田 浩也, 西岡 安彦 :
がん分子標的治療,
日本臨牀, Vol.68, No.6, 997-1006, 2010年6月.- (要約)
- Recent insights into the molecular mechanism of cancer progression have given rise to specific target-directed therapies, including monoclonal antibodies and small molecular compounds, and the advent of target-specific therapeutics has remarkably improved the outcomes of patients with various malignancies. Recent advance also lead to the identification of prognostic biomarkers as predictive factors in determining response to molecular targeted drugs. Future studies also need to develop biomarkers to further increase the power of patient selection for molecular targeted therapy. Here we review the recent progress in developing new molecular targeted drugs and the resistance to treatments as well as the importance of measuring the QOL by patient-reported outcome, for personalized therapy.
- (キーワード)
- 癌 (cancer) / 分子標的 (molecular target) / biomarker / クオリティ・オブ・ライフ (QOL) / personalized therapy
- (文献検索サイトへのリンク)
- ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20535947
- ● CiNii @ 国立情報学研究所 (CRID): 1520854805289092480
- ● Summary page in Scopus @ Elsevier: 2-s2.0-77955861105
(PubMed: 20535947, CiNii: 1520854805289092480, Elsevier: Scopus) 西岡 安彦, 馬原 文彦, 曽根 三郎 :
会議報告「徳島県でのパンデミック(H1N1)2009に対する医療連携の取り組み今後の課題」,
徳島県医師会報, Vol.467, 11-13, 2010年4月. 西岡 安彦 :
肺線維症に対する分子生物学的アプローチ,
呼吸と循環, Vol.58, No.2, 179-187, 2010年2月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390846634897347200
- ● Summary page in Scopus @ Elsevier: 2-s2.0-76249132851
(CiNii: 1390846634897347200, Elsevier: Scopus) 岸 潤, 西岡 安彦 :
関節リウマチの検査・診断 画像検査 CT,
関節リウマチ(第2版)-寛解を目指す治療の新時代, Vol.68, No.5, 280-283, 2010年. 豊田 優子, 岸 潤, 西岡 安彦, 曽根 三郎 :
混合性結合組織病にともなう肺高血圧に対してステロイドとボセンタンの併用が著効した症例.,
Modern Physician, Vol.30, 54-56, 2010年. 西岡 安彦, 曽根 三郎 :
ARDS(急性呼吸窮迫症候群)の診断と治療のすすめかた,
Medical Practice, Vol.27, No.4, 619-622, 2010年. 西岡 安彦, 青野 純典, 東 桃代, 岸 潤 :
「間質性肺炎の治療法の展開」-イマチニブ-,
呼吸と循環, Vol.58, No.4, 389-395, 2010年.- (文献検索サイトへのリンク)
- ● Summary page in Scopus @ Elsevier: 2-s2.0-77950638413
(Elsevier: Scopus) 西岡 安彦, 曽根 三郎 :
特発性肺線維症とその周辺 - 治療の最前線 - 期待される薬剤と現況 イマチニブ(グリベック),
最新医学, Vol.60, No.12, 2577-2582, 2005年12月. 西岡 安彦, 曽根 三郎 :
肺炎: 診断と治療の進歩 VII.特殊病態における肺炎 3.人工呼吸器関連肺炎,
日本内科学会雑誌, Vol.94, No.11, 83-89, 2005年11月. 西岡 安彦, 東 桃代, 曽根 三郎 :
ボリコナゾール,
分子呼吸器病, Vol.9, No.6, 76-77, 2005年11月. 西岡 安彦, 青野 純典, 曽根 三郎 :
肺線維症に対する抗線維化薬としてのイマチニブの可能性を探る,
分子呼吸器病, Vol.9, No.6, 31-32, 2005年11月. 西岡 安彦 :
海外文献紹介 : 突発性肺線維症患者に対するピルフェニドンのプラゼボ対照二重盲検試験 , 肺傷害後の線維細胞fibrocyteのCCR2を介した肺胞腔への集積,
The Lung perspectives, Vol.13, No.3, 112-113, 2005年7月. 西岡 安彦, 曽根 三郎 :
癌治療とサイトカイン,
Biotherapy, Vol.19, No.2, 151-158, 2005年3月. 西岡 安彦, 曽根 三郎 :
特発性肺線維症治療の最近の動向:イマチニブ(グリベック),
日本胸部臨床, Vol.64, No.2, 131-138, 2005年2月. 西岡 安彦, 阿部 真治, 楊河 宏章, 苛原 稔, 曽根 三郎 :
樹状細胞による肺癌の免疫療法,
コンセンサス癌治療, Vol.4, No.4, 218-219, 2005年. 西岡 安彦, 曽根 三郎 :
期待される薬剤と現状 イマチニブ(グリベック),
最新医学, Vol.60, No.12, 2577-2582, 2005年. 西岡 安彦, 曽根 三郎 :
人工呼吸器関連肺炎,
日本内科学会雑誌, Vol.94, No.11, 2335-2341, 2005年. 西岡 安彦, 東 桃代, 曽根 三郎 :
Drug Information ボリコナゾール,
分子呼吸器病, Vol.9, No.6, 544-545, 2005年. 西岡 安彦, 青野 純典, 曽根 三郎 :
肺線維症に対する抗線維化薬としてのイマチニブの可能性を探る,
分子呼吸器病, Vol.9, No.6, 499-500, 2005年. 曽根 三郎, 西岡 安彦 :
ブレオマイシン誘発性のマウスの肺線維イマチニブの抗線維化作用を証明した,
毎日メディカルジャーナル, Vol.1, No.5, 492-495, 2005年. 西岡 安彦, 曽根 三郎 :
特発性肺線維症治療薬の最近の動向 イマチニブ(グリベック),
日本胸部臨床, Vol.64, No.2, 131-138, 2005年. 西岡 安彦, 阿部 真治, 楊河 宏章, 苛原 稔, 曽根 三郎 :
特集:コンセンサス肺癌の治療， トピックス:樹状細胞による肺癌の免疫療法,
コンセンサス癌治療, Vol.4, No.4, 218-219, 2005年. 西岡 安彦, 曽根 三郎 :
第3次対がん10か年総合戦略 7.免疫療法の現状と展望,
BIO Clinica, Vol.19, No.11, 46-51, 2004年10月. 西岡 安彦, 東 桃代, 香川 征, 曽根 三郎 :
SARSの基礎と臨床ー院内感染対策を中心にー,
四国医学雑誌, Vol.60, No.5-6, 112-117, 2004年.- (キーワード)
- 重症急性呼吸器症候群 / コロナウイルス / 個人防護用具 / 感染対策
- (徳島大学機関リポジトリ)
- ● Metadata: 44166
(徳島大学機関リポジトリ: 44166) 西岡 安彦, 曽根 三郎 :
免疫療法の現状と展望,
BIO Clinica, Vol.19, No.11, 898-903, 2004年. 曽根 三郎, 矢野 聖二, 西岡 安彦 :
分子標的治療,
癌と化学療法, Vol.31, No.4, 647-655, 2004年. 西岡 安彦, 中川 達夫, 水口 和生, 曽根 三郎 :
難治性固形癌に対する癌抗原ペプチドパルス樹状細胞を用いた癌ワクチン療法 - トランスレーショナルリサーチとしての展開 -,
四国医学雑誌, Vol.59, No.6, 280-286, 2003年12月.- (徳島大学機関リポジトリ)
- ● Metadata: 39620
(徳島大学機関リポジトリ: 39620) 西岡 安彦, 青野 純典, 曽根 三郎 :
肺線維化の細胞分子病態,
日本胸部臨床, Vol.62, No.11, 147-154, 2003年. 西岡 安彦, 中川 達夫, 水口 和生, 曽根 三郎 :
難治性固形癌に対する癌抗原ペプチドパルス樹上細胞を用いた癌ワクチン療法ートランスレーショナルリサーチとしての展開ー,
四国医学雑誌, Vol.69, No.6, 280-286, 2003年. 西岡 安彦, 曽根 三郎 :
細胞周期よりみた分子標的療法,
癌治療と宿主, Vol.13, No.4, 330-335, 2001年10月. 西村 直樹, 西岡 安彦, 曽根 三郎 :
樹状細胞を用いた癌免疫遺伝子療法,
The Lung Perspectives, Vol.9, No.4, 487-492, 2001年. 西岡 安彦, 曽根 三郎 :
肺癌の特異的免疫療法,
臨床雑誌 内科, Vol.88, No.5, 873-878, 2001年. 西岡 安彦, 曽根 三郎 :
樹状細胞ー肺樹状細胞の特徴と呼吸器疾患ー,
分子呼吸器病学, Vol.5, No.6, 13(497)-16(500), 2001年. 西岡 安彦, 曽根 三郎 :
細胞周期よりみた分子標的療法,
メディカルレビュー社, Vol.13, No.4, 48(330)-53(335), 2001年. 西岡 安彦, 曽根 三郎 :
肺癌に対する特異的免疫療法,
分子呼吸器病, Vol.5, No.4, 70(342)-72(344), 2001年. 西岡 安彦, 曽根 三郎 :
樹状細胞 - 肺樹状細胞の特徴と呼吸器疾患 -,
分子呼吸器病, Vol.5, No.6, 497-500, 2001年. 西岡 安彦, 曽根 三郎 :
肺癌に対する特異的免疫療法,
分子呼吸器病, Vol.5, No.4, 342-344, 2001年. 曽根 三郎, 篠原 勉, 西岡 安彦, 矢野 聖二 :
呼吸器疾患の分子病態と臨床, --- 4)肺癌の分子病態と臨床 ---,
日本内科学会雑誌, Vol.89, No.9, 97-124, 2000年9月. 西岡 安彦, 曽根 三郎 :
再興感染症としての肺結核, --- IV 治療 1.化学療法指針 ---,
日本内科学会雑誌, Vol.89, No.5, 73-80, 2000年5月. 西岡 安彦, 青野 純典, 曽根 三郎 :
III 特発性間質性肺炎の病因・病態 4.肺線維化の細胞分子病態,
日本胸部臨床, Vol.62, S147-S154, 2000年. 曽根 三郎, 西岡 安彦, 大串 文隆 :
結核病棟を持つ大学の立場から,
Kekkaku, Vol.75, No.2, 103-124, 2000年. 西村 直樹, 西岡 安彦, 曽根 三郎 :
21世紀における非特異的癌免疫療法 - 現状をふまえて,
癌治療と宿主, Vol.12, No.4, 336-344, 2000年. 西岡 安彦, 大串 文隆, 曽根 三郎 :
肺アスペルギローマ,
総合臨床, Vol.49, No.9, 2459-2462, 2000年. 西岡 安彦, 曽根 三郎 :
進歩めざましい話題のがん治療 - 免疫療法 -,
臨床と研究, Vol.77, No.7, 78-82, 2000年. 西岡 安彦, 曽根 三郎 :
dendritic cellへの遺伝子導入法と機能付加,
分子呼吸器病, Vol.4, No.4, 17-23, 2000年. 西岡 安彦 :
遺伝子導入樹状細胞とその応用,
最新医学, Vol.55, No.6, 124-130, 2000年. 西岡 安彦 :
IL-12遺伝子導入樹状細胞を用いた癌免疫療法,
BIOTHERAPY TODAY, Vol.7, No.1, 37-42, 2000年. 西岡 安彦, Pralad Parajuli, 埴淵 昌毅, 曽根 三郎 :
Dendritic cellの分化誘導に対するCAMの調節作用,
The Japanese Journal of Antibiotics, Vol.52, No.suppl A, 1999年. - 講演・発表
- Atsushi Mitsuhashi, Kazuya Koyama, Afroj Tania, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka :
The identification and analysis of fibrocyte regulating the tumor immune microenvironment,
The 9th Joint Meeting 2023 (Tokushima Univ., Gifu Univ., SNU, and IBS-KAIST)., Daejeon, Oct. 2023. Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Murakami Kojin, Yuya Yamashita, Danzan NandinErdene, Bando Hiroki, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka :
A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis,
ERS International Congress 2023, Milano, Sep. 2023. Hiroki Bando, Seidai Satou, Hirohisa Ogawa, Kazuya Koyama, Murakami Kojin, Yuya Yamashita, Danzan Nandin-Erdene, Keiko Haji, Nobuhito Naito, Hiroshi Kawano and Yasuhiko Nishioka :
Anamorelin, a ghrelin receptor agonist, inhibited the allergic airway inflammation in mice,
ERS International Congress 2023, Milano, Sep. 2023. Murakami Kojin, Nishimura Haruka, Hiroshi Kawano, Danzan Nandin-Erdene, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kazuya Koyama, Seidai Satou and Yasuhiko Nishioka :
Analysis of the Anti-fibrotic Potential of JAK Inhibitors in a Bleomycin-induced Pulmonary Fibrosis Model,
ATS 2023, Washington, DC, May 2023. Kazuya Koyama, Seidai Satou, Hiroshi Kawano, Hiroshi Kawano, Atsushi Mitsuhashi, Murakami Kojin, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hirohisa Ogawa and Yasuhiko Nishioka :
Evaluation of fibrocytes in silica-induced and bleomycin-induced pulmonary fibrosis model in mice by single cell RNA-seq analysis,
APSR 2022, Seoul, Nov. 2022. Yabuki Yohei, Kenji Otsuka, Hirokazu Ogino, Takeuchi Eiji, Haku Takashi, Takanori Kanematsu, Nishimura Naoki, Yuko Toyoda, Masaki Hanibuchi, Atsushi Mitsuhashi, Tsukazaki Yuki, Ryohiko Ozaki, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka :
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer,
APSR 2022, Seoul, Nov. 2022. Imakura Takeshi, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Murakami Kojin, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka :
Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis,
ERS International Congress 2022, Barcelona, Sep. 2022. Ryohiko Ozaki, Hiroshi Nokihara, Yabuki Youhei, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino and Yasuhiko Nishioka :
The examination of the second-line chemotherapy in SCLC patients with interstitial lung disease,
ERS International Congress 2022, Barcelona, Sep. 2022. Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka :
A Novel Senolytic Agent, ARV-825, Ameliorates Bleomycin-InducedPulmonary Fibrosis in Mice,
ATS 2022 International Conference, San Francisco, May 2022. Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka :
Computational Drug Repositioning Approach Identifies Polo-Like KinaseInhibitors as Potential Therapeutics for Pulmonary Fibrosis,
ATS 2022 International Conference, San Francisco, May 2022. Kazuya Koyama, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Seidai Satou, Hirohisa Ogawa and Yasuhiko Nishioka :
Single Cell RNA-seq Analysis of Fibrocytes in Silica Induced Mouse Pulmonary Fibrosis Model,
ATS 2022 International Conference, San Francisco, May 2022. Nguyen Na Thi, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Afroj Tania, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
S-1 reduces myeloid-derived suppressor cells in murine mesothelioma model and enhances the anti-tumor activity of anti-PD-1 antibody,
APSR 2021, Kyoto and online, Nov. 2021. Imakura Takeshi, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kohjin Murakami, Yuya Yamashita, Takahashi Naoki, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka :
Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice,
APSR 2021, Kyoto and online, Nov. 2021. Kohjin Murakami, Takahashi Naoki, Seidai Satou, Imakura Takeshi, Yuya Yamashita, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka :
Therapeutic effect of oligonucleotide therapeutics PK-7010 in mouse model of bleomycin-induced lung fibrosis,
APSR 2021, Kyoto and online, Nov. 2021. Ryohiko Ozaki, Hiroshi Nokihara, Atsushi Mitsuhashi, Kondou Kensuke, YABUKI Yohhei, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka :
The clinical efficacy and safety of the second-line chemotherapy in extensive-disease small cell lung cancer patients with interstitial lung disease,
APSR 2021, Kyoto and online, Nov. 2021. Nobuhito Naito, Hiroshi Kawano, Imakura Takeshi, Yuya Yamashita, Kohjin Murakami, Kozo Kagawa, Kazuya Koyama, Seidai Satou, Hiroshi Nokihara, Inagaki Yutaka and Yasuhiko Nishioka :
Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain,
APSR 2021, Kyoto and online, Nov. 2021. Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, YABUKI Yohhei, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka :
Association of immune-related adverse events with therapeutic response to Nivolumab in patients with malignant pleural mesothelioma,
APSR 2021, Kyoto and online, Nov. 2021. Hirokazu Ogino, Afroj Tania, Atsushi Mitsuhashi, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Nguyen Thi Na, Kozo Kagawa, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka :
Antigen-presenting capacity of fibrocytes and its regulation by anti-PD-1/PD-L1 antibodies,
APSR 2021, Kyoto and online, Nov. 2021. Kozo Kagawa, Kazuya Koyama, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Yuya Yamashita, Takahashi Naoki, Nobuhito Naito, Hiroshi Kawano and Yasuhiko Nishioka :
A Lck-specific inhibitor, A-770041, attenuates pulmonary fibrosis via the suppression of TGF-b production in regulatory T cells,
APSR 2021, Kyoto and online, Nov. 2021.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/resp.14150_945
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1111/resp.14150_945
(DOI: 10.1111/resp.14150_945) Hiroshi Kawano, Nishimura Haruka, Imakura Takeshi, Yuya Yamashita, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka :
Analysis of anti-fibrotic potential of JAK inhibitors in bleomycin-induced pulmonary fibrosis model,
APSR 2021, Kyoto and online, Nov. 2021.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/resp.14150_915
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1111/resp.14150_915
(DOI: 10.1111/resp.14150_915) Masahiko Azuma, Hirohisa Ogawa, Toshifumi Tezuka, Mayo Kondou and Yasuhiko Nishioka :
A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells,
APSR 2021, Kyoto and online, Nov. 2021. Yasuhiko Nishioka, Ogura Takashi, Inase Naohiko, Takizawa Ayako, Taniguchi Atsushi and Inoue Yoshikazu :
Effects of nintedanib on forced vital capacity categorical changes and disease progression in Japanese patients with progressive fibrosing interstitial lung diseases: Subanalysis of INBUILD study,
APSR 2021, Kyoto and online, Nov. 2021.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/resp.14150_981
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1111/resp.14150_981
(DOI: 10.1111/resp.14150_981) Kozo Kagawa, Kazuya Koyama, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Takahashi Naoki, Nobuhito Naito, Nishimura Haruka, Hiroshi Kawano and Yasuhiko Nishioka :
Anti-fibrotic efficacy of Lck inhibitor via the suppression of TGF-β production in regulatory T cells,
ERS International Congress 2021, WEB, Sep. 2021.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.congress-2021.PA3285
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2021.PA3285
(DOI: 10.1183/13993003.congress-2021.PA3285) Prasse Antje, Maher M Toby, Jenkins Gisli R, Cottin Vincent, Yasuhiko Nishioka, Noth Imre, Selman Moises, Song Woo Jin, Ittrich Carina, Diefenbach Claudia, Rohr B. Klaus, Stowasser Susanne and White S. Eric :
Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial,
The 61st DGP Annual Congress, Jun. 2021. Maher M Toby, Stowasser Susanne, Yasuhiko Nishioka, White S Eric, Cottin Vincent, Noth Imre, Selman Moises, Rohr B Klaus, Wachtlin Daniel, Ittrich Carina, Diefenbach Claudia and Jenkins Gisli R :
Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study,
The 61st DGP Annual Congress, WEB, Jun. 2021. Takahashi Naoki, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka :
Oligonucleotide therapeutics PK-7010 in combination with nintedanib ameliorates bleomycin-induced pulmonary fibrosis in mice,
ATS 2021, 米国(WEB), May 2021.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444
(DOI: 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444) Kazuya Koyama, Hiroshi Kawano, Yuya Yamashita, Imakura Takeshi, Takahashi Naoki, Nobuhito Naito, Seidai Satou and Yasuhiko Nishioka :
Clinical Features of the Acute Exacerbation of Rheumatoid Arthritis-Associated Interstitial Lung Disease,
ATS 2021, 米国(WEB), May 2021. Isshiki Takuma, Homma Sakae, Yabe Matsuko, Kazuya Koyama, Yasuhiko Nishioka, Yamaguchi Tetsuo, Uchida Keisuke, Eishi Yoshinobu, Shibuya Kazutoshi, Sakamoto Susumu and Kishi Kazuma :
Usefulness of Immunohistochemical detection of Propionibacterium acnes in granulomas for the differentiation of sarcoidosis and other granulomatous diseases,
ATS 2021, 米国(WEB), May 2021. Song Woo Jin, Selman Moises, Jenkins Gisli R, White S Eric, Cottin Vincent, Yasuhiko Nishioka, Noth Imre, Prasse Antje, Strobel Benjamin, Leparc German, Ittrich Carina, Diefenbach Claudia, Rohr Klaus, Stowasser Susanne and Maher M Toby :
Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) in the INMARK trial,
KATRD International Conference 2020, Seoul, Nov. 2020. Song Woo Jin, Jenkins Gisli R, Noth Imre, Selman Moises, Cottin Vincent, Yasuhiko Nishioka, Prasse Antje, White S Eric, Ittrich. Carina, Diefenbach Claudia, Rohrr B Klaus, Stowasser Susanne and Mahe M Toby :
Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial,
KATRD International Conference 2020, Seoul, Nov. 2020. Hirohisa Ogawa, Masahiko Azuma, Umeno Aya, Shimizu Mayuko, Takaaki Tsunematsu, Mayo Kondou, Murotomi Kazutoshi, Koichi Tsuneyama and Yasuhiko Nishioka :
Nerve growth factor exacerbates airway hyperresponsiveness via epithelial damage by neutrophils-derived singlet oxygen in a mouse model of asthma with mixed inflammation,
JSA/WAO Joint Congress 2020, WEB, Sep. 2020. Takahashi Naoki, Seidai Satou, Imakura Takeshi, Murakami Kojin, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka :
The novel oligonucleotide therapeutics PK-7010 for TGF-β1 ameliorates bleomycin-induced pulmonary fibrosis in micen,
ERS International Congress 2020 Virtual, WEB, Sep. 2020.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.congress-2020.3373
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2020.3373
(DOI: 10.1183/13993003.congress-2020.3373) Atsushi Mitsuhashi, Afroj Tania, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Kazuya Koyama, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka :
The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents,
ERS International Congress 2020 Virtual, WEB, Sep. 2020.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.congress-2020.1134
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2020.1134
(DOI: 10.1183/13993003.congress-2020.1134) Seidai Satou, Yamamoto Takushi, Waki Kana, Morimoto Yuki, Imakura Takeshi, Murakami Kojin, Takahashi Naoki, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Koichi Tsuneyama and Yasuhiko Nishioka :
Analysis of localization of nintedanib and cyclophosphamide in pulmonary fibrosisusing the iMScope TRIOS,
ERS International Congress 2020 Virtual, WEB, Sep. 2020.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.congress-2020.3385
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2020.3385
(DOI: 10.1183/13993003.congress-2020.3385) Arai Naoki, Saito Takefumi, Ogura Takashi, Tomii Keisuke, Kamio Koichiro, Sakamoto Susumu, Miyazaki Yasunari, Tomioka Hiromi, Hisata Shu, Handa Tomohiro, Homma Sakae, Yasuhiko Nishioka and Azuma Arata :
inal Results of the Primary Endpoint and Other Supportive Analysis: TAS-115 Phase 2 Study in Patients with Idiopathic Pulmonary Fibrosis,
ATS 2020 VIRTUAL, WEB, Aug. 2020.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4547
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4547
(DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4547) Selman Moises, Jenkins Gisli R, White S Eric, Cottin Vincent, Yasuhiko Nishioka, Noth Imre, Prasse Antje, Song Woo Jin, Strobel Benjamin, Leparc German, Ittrich Carina, Diefenbach Claudia, Rohr B Klaus, Stowasser Susanne and Maher M Toby :
Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) in the INMARK Trial,
ATS 2020 VIRTUAL, WEB, Aug. 2020.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A6146
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A6146
(DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A6146) Kazuya Koyama, Sakamoto Susumu, Homma Sakae, Seidai Satou, Masaki Hanibuchi, Masuda Kiyoshi, Imoto Isei, Yuko Toyoda, Isshiki Takuma, Miyoshi Shion, Kato Motoyasu, Takahashi Kazuhisa, Kataoka Kensuke, Kondoh Yasuhiro and Yasuhiko Nishioka :
The Relationship Between Single-Nucleotide Polymorphisms Within Tollip and the Efficacy of Inhaled N-Acetylcysteine Therapy in Idiopathic Pulmonary Fibrosis,
ATS 2020 VIRTUAL, WEB, Aug. 2020.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1494
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1494
(DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1494) Yasuhiko Nishioka :
Update immunotherapy therapy for mesothelioma,
APSR 2019(Symposium), Hanoi, Nov. 2019. Yasuhiko Nishioka :
Biomarkers of Disease Progression in Asian Subjects with Idiopathic Pulmonary Fibrosis Treated with Nintedanib: Subgroup Analysis of the INMARK Trial,
APSR 2019, Hanoi, Nov. 2019.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1111/resp.13699_243
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1111/resp.13699_243
(DOI: 10.1111/resp.13699_243) Kozo Kagawa, Koyama Kazuya, Seidai Satou, Takahashi Naoki, Nishimura Haruka, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda and Yasuhiko Nishioka :
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice.,
ERS International Congress 2019, Madrid, Oct. 2019.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.congress-2019.PA5372
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2019.PA5372
(DOI: 10.1183/13993003.congress-2019.PA5372) Koyama Kazuya, Sakamoto Susumu, Homma Sakae, Seidai Satou, Masaki Hanibuchi, Masuda Kiyoshi, Issei Imoto, Yuko Toyoda, Isshiki Takuma, Miyoshi Shion, Kato Motoyasu, Takahashi Kazuhisa, Kataoka Kensuke, Kondoh Yasuhiro and Yasuhiko Nishioka :
Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis.,
ERS International Congress 2019, Madrid, Sep. 2019.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.congress-2019.PA2243
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2019.PA2243
(DOI: 10.1183/13993003.congress-2019.PA2243) Jenkins Gisli R, Maher M Toby, Cottin Vincent, Yasuhiko Nishioka, Noth Imre, White S Eric, Ittrich Carina, Diefenbach Claudia, Rohr B Klaus, Stowasser Susanne and investigators Selman on behalf of the INMARK trial Moises :
Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial.,
ERS International Congress 2019, Madrid, Sep. 2019.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.congress-2019.PA2254
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2019.PA2254
(DOI: 10.1183/13993003.congress-2019.PA2254) Ogura Takashi, Yasuhiko Nishioka, Saito Takefumi, Tomii Keisuke, Kamio Koichiro, Tomioka Hiromi, Hisata Shu, Sakamoto Susumu, Handa Tomohiro, Miyazaki Yasunari, Homma Sakae and Azuma Arata :
Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis.,
ERS International Congress 2019, Madrid, Sep. 2019.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1183/13993003.congress-2019.PA1296
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2019.PA1296
(DOI: 10.1183/13993003.congress-2019.PA1296) Seidai Satou, Upagupta Chandak, Yanagihara Toyoshi, Kolb RJ Martin and Yasuhiko Nishioka :
Expression of pro-fibrotic microRNA of fibrocytes in bronchoalveolar lavage fluid.,
ATS 2019 International Conference, Dallas, May 2019.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5273
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5273
(DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5273) Maher M Toby, Stowasser Susanne, Yasuhiko Nishioka, White S Eric, Cottin Vincent, Noth Imre, Selman Moises, Rohr B Klaus, Wachtlin Daniel, Ittrich Carina, Diefenbach Claudia and investigators Gisli Jenkins on behalf of the INMARK trial R :
Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study.,
ATS 2019 International Conference, Dallas, May 2019.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4085
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4085
(DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4085) Koyama Kazyua, Nobuhito Naito, Kozo Kagawa, Nishimura Haruka, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka :
Acute Respiratory Failure in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease,
ATS 2019 International Conference, Dallas, May 2019.- (出版サイトへのリンク)
- ● Publication site (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1445
- (文献検索サイトへのリンク)
- ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1445
(DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1445) Hiroshi Kawano, Koyama Kazuya, Nishimura Haruka, Yuko Toyoda, Kagawa Kozo, Seidai Satou, Naito Nobuhito, Hisatsugu Goto, Inagaki Yutaka and Yasuhiko Nishioka :
Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain,
ERS International Congress, Paris, Sep. 2018. Hisatsugu Goto, Yamago Taito, Atsuro Saijo, Hirokazu Ogino, Tobiume Makoto, Otsuka Kenji, Hiroyuki Kozai, Yoneda Hiroto, Hiroshi Nokihara and Yasuhiko Nishioka :
Involvement of insulin-like growth factor in RANKL-targeted therapy in mouse model of lung cancer bone metastasis.,
ATS 2018 International Conference, San Diego, May 2018. Koyama Kazuya, Kagawa Kozo, Nishimura Haruka, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Hirohisa Ogawa, Hisanori Uehara and Yasuhiko Nishioka :
Novel Multi-tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Pulmonary Fibrosis In Mice.,
ATS 2018 International Conference, San Diego, May 2018. Hisatsugu Goto, Mitsuhashi Atsushi and Yasuhiko Nishioka :
Mechanism of acquired resistance to anti-angiogenic therapy mediated by fibrocytes.,
The 22nd Congress of Asian Pacific Society of Respirology, Sydney, Nov. 2017. Hirokazu Ogino, Hisatsugu Goto, Okano Yoshio, Machida Hisanori, Hatakeyama Nobuo, Ogushi Fumitaka, Haku Takashi, Takanori Kanematsu, Tomoyuki Urata, Souji Kakiuchi, Masaki Hanibuchi, Saburo Sone and Yasuhiko Nishioka :
Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer.,
ERS International Congress 2017, Milan, Italy, Sep. 2017. Atsuro Saijo, Hisatsugu Goto, Mayuri Nakano, Mitsuhashi Atsushi, Hirokazu Ogino, Makoto Tobiume, Kenji Ohtsuka, Hiroto Yoneda, Masaki Hanibuchi and Yasuhiko Nishioka :
Bone Marrow-Derived Fibrocytes Promote Stem Cell-Like Properties of Lung Cancer Cells.,
ATS 2017 International Conference, Washington, D.C., May 2017. Yuko Toyoda, Morizumi Shun, Seidai Satou, Okazaki Hiroyasu, Chen Yanjuan, Hisatsugu Goto, Hirohisa Ogawa, Nishimura Haruka, Koyama Kazuya, Hiroshi Kawano, Yoshinori Aono, Hisanori Uehara and Yasuhiko Nishioka :
Role of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Signal in Bleomycin-Induced Pulmonary Fibrosis in Mice.,
ATS 2017 International Conference, Washington, D.C., May 2017. Hisatsugu Goto, Mitsuhashi Atsushi, Atsuro Saijo, Hirokazu Ogino, Kenji Ohtsuka, Makoto Tobiume, Hiroto Yoneda, Masaki Hanibuchi and Yasuhiko Nishioka :
Fibrocytes as a Possible Cellular Biomarker for Anti-Angiogenic Therapy in Lung Cancer.,
ATS 2017 International Conference, Washington, D.C., May 2017. Masaki Hanibuchi, Akira Kanoh, Takuya Kuramoto, Hisatsugu Goto, Atsuro Saijo, Hirokazu Ogino and Yasuhiko Nishioka :
Assessment of clinical usability of a cfDNA-based assay detecting EGFR T790M mutation in EGFR-TKI refractory NSCLC patients,
The IASLC 17th World Conference on Lung Cancer, Dec. 2016. S Morizumi, S Sato, Shinji Abe, H Okazaki, C Yanjuan, Hisatsugu Goto, Masaki Hanibuchi, Yoshinori Aono, Hirohisa Ogawa, Masaki Hanibuchi, Hisanori Uehara and Yasuhiko Nishioka :
Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity.,
ERS2016 International Conference, Sep. 2016. Yasuhiko Nishioka :
Introduction of Session 152 - Repair pathways: from lung development to aging of the lung-,
ERS2016, Sep. 2016. Hirokazu Ogino, Hisatsugu Goto, Souji Kakiuchi, Atsuro Saijo, Satoshi Sakaguchi, Makoto Tobiume, Kenji Otsuka, Hiroto Yoneda, Masaki Hanibuchi and Yasuhiko Nishioka :
Receptor tyrosine kinase-like orphan receptor 2, ROR2, regulates the proliferation of malignant pleural mesothelioma cells,
ATS 2016 International Conference, May 2016. Seidai Satou, Hisatsugu Goto, Shun Morizumi, Hiroyasu Okazaki, Yajuan Chen, Hiroshi Kawano, Yuko Toyoda, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka :
Effect of blockade of fibroblast growth factor receptor signaling in experimental pulmonary fibrosis in mice,
ATS 2016 International Conference, May 2016. Atsuro Saijo, Hisatsugu Goto, Atsushi Mitsuhashi, Mayuri Nakano, Hirokazu Ogino, Yoshinori Aono, Satoshi Sakaguchi, Makoto Tobiume, Kenji Otsuka, Masaki Hanibuchi and Yasuhiko Nishioka :
Bone-marrow derived fibrocytes maintain stem cell-like properties of lung cancer,
ATS 2016 International Conference, May 2016. Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Yoshinori Aono, Hisanori Uehara, Masaki Hanibuchi and Yasuhiko Nishioka :
Fibrocytes mediate acquired resistance to anti-angiogenic therapy with bevacizumab in thoracic tumors,
ATS 2016 International Conference, May 2016. Hisatsugu Goto, Mitsuhashi Atsushi, Atsuro Saijo, Yoshinori Aono, Hirokazu Ogino, Hirohisa Ogawa, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka :
The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer,
International Conference of Cancer Immunotherapy and Macrophages 2015, Tokyo, Jul. 2015. Hirokazu Ogino, Mitsuhashi Atsushi, Hisatsugu Goto, Atsuro Saijo, Kuramoto Takuya, Tabata Sho, Hisanori Uehara, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka :
Characterization of sphere-forming stem-like population of lung cancer cell line in multi-organ metastasis model,
ATS 2015 International Conference, Denver, May 2015. Hisatsugu Goto, Mitsuhashi Atsushi, Atsuro Saijo, Kuramoto Takuya, Tabata Sho, Yoshinori Aono, Hisanori Uehara, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka :
The role of fibrocytes in the acquired resistance to anti-angiogenic therapy with bevacizumab in malignant pleural mesothelioma,
ATS 2015 International Conference, Denver, May 2015. Seidai Satou, Hisatsugu Goto, Abe Shuichi, Yoshijima Terumi, Okazaki Hiroyasu, Takezaki Akio, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka :
Effect of kinase inhibitors for growth factor receptors on the differentiation of human fibrocytes,
ATS 2015 International Conference, Denver, May 2015. Yasuhiko Nishioka, Shuichi Abe, Seidai Satou, Yoshinori Aono, Hisatsugu Goto, Masami Kishi, Terumi Yoshijima, Hiroyasu Okazaki and Masaki Hanibuchi :
Role of human fibrocytes in regulating pulmonary fibrosis: comprehensive analysis of their gene expression profile and growth factor production,
The 18th International Colloquium on Lung and Airway Fibrosis, Mont-Tremblant, Quebec Canada, Sep. 2014. Yasuhiko Nishioka, Shuichi Abe, Seidai Sato, Yoshinori Aono, Hisatsugu Goto, Masami Kishi, Terumi Yoshijima, Hiroyasu Okazaki and Masaki Hanibuchi :
Role of human fibrocytes in regulating pulmonary fibrosis: comprehensive analysis of their gene expression profile and growth factor production,
The 18th International Colloquium on Lung and Airway Fibrosis (ICLAF), Mont-TremblantQuebec Canada, Sep. 2014. Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Trung The Van, Yoshinori Aono, Hirohisa Ogawa, Soji Kakiuchi, Masaki Hanibuchi, Seiji Yano, Keisuke Izumi and Yasuhiko Nishioka :
The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer,
ATS 2014 International Conference (Mini-symposium), San Diego, May 2014. Seidai Satou, Hisatsugu Goto, Shuichi Abe, Masami Kishi, Katsuhiro Kinoshita, Momoyo Azuma, Akio Takezaki, Jun Kishi, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka :
Effect of Nintedanib (BIBF1120) on fibrocyte-induced fibroblast activation,
ATS 2014 International Conference, San Diego, May 2014. Hisatsugu Goto and Yasuhiko Nishioka :
The role of surfactant protein A in the host defense of the lung,
The 117th Conference of KATRD (Invited lecture), Buan, Korea, Apr. 2014. Hisatsugu Goto and Yasuhiko Nishioka :
The role of surfactant protein A in the host defense of the lung,
The 117th Conference of KATRD (Invited lecture)., Buan, Korea, Apr. 2014. Hisatsugu Goto, Ogushi Fumitaka, Haku Takashi, Tomoyuki Urata, Takanori Kanematsu, Souji Kakiuchi, Masaki Hanibuchi, Saburo Sone and Yasuhiko Nishioka :
Phase study of S-1 with patient-reported outcome evaluation in elderly patients with advanced non-small cell lung cancer.,
18th Congress of the Asian Pacific Society of Respirology, Yokohama, Nov. 2013. Masaki Hanibuchi, Kim Sun-Jin, Otsuka Kenji, Mitsuhashi Atsushi, Hisatsugu Goto, Yasuhiko Nishioka and Fidler J. Isaiah :
Therapeutic efficacy of endothelin receptor blockade on experimental brain metastases of human non-small cell lung cancer.,
18th Congress of the Asian Pacific Society of Respirology, Yokohama, Nov. 2013. Mitsuhashi Atsushi, Hisatsugu Goto, Kuramoto Takuya, Tabata Sho, Yukishige Sawaka, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Ledford G Julie, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response.,
18th Congress of the Asian Pacific Society of Respirology, Yokohama, Nov. 2013. Yoshinori Aono, Abe Shuichi, Katsuhiro Kinoshita, Kishi Masami and Yasuhiko Nishioka :
Fibrocyte regulates lung fibroblast acivation via producing growth factors.,
18th Congress of the Asian Pacific Society of Respirology., Yokohama, Nov. 2013. Katsuhiro Kinoshita, Yoshinori Aono, Hisatsugu Goto, Momoyo Azuma, Takezaki Akio, Yoshijima Terumi, Kishi Masami, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Abe Shuichi, Toshifumi Tezuka, Hisanori Uehara, Keisuke Izumi and Yasuhiko Nishioka :
Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.,
18th Congress of the Asian Pacific Society of Respirology, Yokohama, Nov. 2013. Takashi Iwase, Shoichiro Takao, Masashi Akaike, Takayuki Ise, Shusuke Yagi, Koji Yamaguchi, Hirotsugu Yamada, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata :
Differentiation of left ventricular systolic dysfunction related to cardiac sarcoidosis and other heart diseases using contrast-enhanced cardiovascular magnetic resonance.,
ESC Congress 2013, Amsterdam, Aug. 2013. Momoyo Azuma, Keiji Murakami, Katuhiko Hirota, Tsuneko Ono, Yoichiro Miyake and Yasuhiko Nishioka :
The relationship between antibiotic tolerance and severity of clinical isolated Pseudomonas aeruginosa in respiratory disease patients,
The28th International Congress of Chemotherapy and Infection and the 14th Asia-pacific Society of Clinical Microbiology and Infection, 横浜, Jun. 2013. Yasuhiko Nishioka, Abe Shuichi, Yoshinori Aono, Katsuhiro Kinoshita, Makino Hideki, Kishi Masami and Masaki Hanibuchi :
Fibrocytes regulate function of lung fibroblasts by producing profibrotic growth factors.,
ATS 2013 Conference, Philadelphia, May 2013. Hisatsugu Goto, Mitsuhashi Atsushi, Kuramoto Takuya, Tabata Sho, Yukishige Sawaka, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Ledford G. Julie, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization.,
ATS 2013 Conference, Philadelphia, May 2013. Hirohisa Ogawa, Yoshinori Aono, Yasuhiko Nishioka and Keisuke Izumi :
Surfactant Protein D Attenuates Sub-Epithelial Fibrosis In A Model Of Allergic Airways Disease Trough Regulation Of TGF-,
San Francisco, May 2013. Huang Jun, Liu Dai-Shun, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka :
Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice.,
AACR Annual Meeting 2013, Washington, D.C., Apr. 2013. Atsushi Mitsuhashi, Hisatsugu Goto, Trung The Van, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Saburo Sone and Yasuhiko Nishioka :
Acquired resistance to anti-VEGF therapy via angiogenic switch in orthotopically implanted human malignant pleural mesothelioma in SCID mice.,
Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research, Maui, Feb. 2013. Sawaka Yukishige, Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization.,
Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research, Maui, Feb. 2013. Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G Ledford, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response,
Joint Meeting to Seoul National University, Seoul, Dec. 2012. Masaki Hanibuchi, Sun-Jin Kim, Kenji Otsuka, Sho Tabata, Takuya Kuramoto, Hisatsugu Goto, Yasuhiko Nishioka and Isaiah J Fidler :
Eradication of experimental brain metastases of human non-small cell lung cancer by macitentan, a dual antagonist of the endothelin A and B receptor, combined with paclitaxel,
A Joint Meeting by ASCO, EORTC, and NCI on Markers in Cancer, Hollywood, Oct. 2012. Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Atsuro Saijo, Souji Kakiuchi, Masaki Hanibuchi, Yoichi Maekawa, Koji Yasutomo, Shin-ichi Akiyama, Saburo Sone and Yasuhiko Nishioka :
Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity,
14th International Biennial Congress of the Metastasis Research Society, Brisbane, Sep. 2012. Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Masaki Hanibuchi, Souji Kakiuchi, Sho Tabata, Atsuro Saijo, Jo R Wright, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model,
14th International Biennial Congress of the Metastasis Research Society, Brisbane, Sep. 2012. Yasuhiko Nishioka, Shinji Abe, Yuki Morita, Mika K Kaneko, Masaki Hanibuchi, Hisatsugu Goto, Souji Kakiuchi, Yoshinori Aono, Jun Huang, Atsushi Mitsuhashi, Seidai Sato, Kazuo Minakuchi and Yukinari Kato :
Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma,
14th International Biennial Congress of the Metastasis Research Society, Brisbane, Sep. 2012. Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Masaki Hanibuchi, Souji Kakiuchi, Sho Tabata, Atsuro Saijo, Shin-ichi Akiyama, Jo R Wright, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model,
ATS 2012 International Conference, San Francisco, May 2012. Yasuhiko Nishioka, Shinji Abe, Mika K Kaneko, Yoshinori Aono, Jun Huang, Hisatsugu Goto, Masatoshi Kishuku, Masaki Hanibuchi, Saburo Sone, Kazuo Minakuchi and Yukinari Kato :
Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma via ADCC,
ATS 2012 International Conference, San Francisco, May 2012. Yoshinori Aono, Masami Kishi and Yasuhiko Nishioka :
Different functions of PDGF receptor-alpha and beta in lung fibrosis.,
ATS 2012 International Conference, San Francisco, May 2012. Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Seidai Sato, Souji Kakiuchi, Masaki Hanibuchi, Yoichi Maekawa, Koji Yasutomo, Shin-ichi Akiyama, Saburo Sone and Yasuhiko Nishioka :
Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity,
AACR Annual Meeting 2012, Chicago, Apr. 2012. Masaki Hanibuchi, Shinji Abe, Masatoshi Kishuku, Souji Kakiuchi, Kazuyoshi Kawazoe, Kazuo Minakuchi, Mika K. Kaneko, Yukinari Kato and Yasuhiko Nishioka :
Targeted therapy for mesothelioma using anti-podoplanin antibody NZ-1 via ADCC,
5th EORTC-NCI-ASCO Annual Meeting on 'Molecular Markers in Cancer', Brussels, Belgium, Oct. 2011. Yasuhiko Nishioka :
Novel targets for treatment of pulmonary fibrosis: lessons from animal study for the clinic.,
The 19th Catholic allergic and Respiratory Workshop, Seoul, Jun. 2011. Katsuhiro Kinoshita, Yasuhiko Nishioka, Masami Kishi, Momoyo Azuma, Yoshinori Aono, Hisanori Uehara, Akio Takezaki, S. Hatakeyama, E. Kawahara and Saburo Sone :
Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.,
ATS 2011 International Conference, Denver, May 2011. Yoshinori Aono, J.G. Ledford, Yasuhiko Nishioka, Saburo Sone, M.F. Beers and J.R. Wright :
SP-D attenuates bleomycin induced lung fibrosis via regulating recruitment and activation of macrophages and fibrocytes.,
ATS 2011 International Conference, Denver, May 2011. Atsushi Mitsuhasi, Hisatsugu Goto, Takuya Kuramoto, Souji Kakiuchi, Seidai Sato, Van The Trung, Atsuro Saijo, Makoto Tobiume, Kenji Otsuka, Yasuhiko Nishioka, Rae Jo Wright and Saburo Sone :
Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model,
ATS 2011 International Conference, Denver, May 2011. Momoyo Azuma, Yasuhiko Nishioka, El-morshedy Mohammed Reham, Jun Kishi, Masami Kishi, Katsuhiro Kinoshita, Hisanori Uehara, Keisuke Izumi and Saburo Sone :
The role of sphingosine 1-phospate (SIP) signaling in pulmonary fibrosis.,
ATS 2011 International Conference, Denver, May 2011. Yasuhiko Nishioka, Hisatsugu Goto, Souji Kakiuchi, Masaki Hanibuchi, Yano Seiji and Saburo Sone :
Bone metastasis of lung cancer and its molecular-targeted therapy.,
Joint Metastasis Research Society-AACR Conference, Philadelphia, Sep. 2010. Huang Jun, Yasuhiko Nishioka, Shinji Abe, Morita Yuki, Ozaki Shuji, Verma Kumar Vinod, Kishuku Masatoshi, Minakuchi Kazuo, Sekido Yoshitaka, Matsumoto Toshio and Saburo Sone :
Anti-HM1.24 antibodies induce antibody-dependent cellular cytitixicity against mesothelioma cells.,
IMIG2010 (The 10th International Conference of the International Mesothelioma Interest Group), Kyoto, Sep. 2010. Trung The Van, Masaki Hanibuchi, Hisatsugu Goto, Souji Kakiuchi, Kuramoto Takuya, Sato Seidai, Tobiume Makoto, Atsuro Saijo, Tabata Sho, Yasuhiko Nishioka, Shin-ichi Akiyama and Saburo Sone :
TS-1 suppresses the growth of malignant pleural mesithelioma cells co-expressing dihydropyrimidine dehydrogenase and thymidine phosphorylase in an orthotopic model.,
The 10th International Conference of the International Mesothelioma Interest Group, Sep. 2010. Atsushi Mitsuhashi, Hisatsugu Goto, Hirokazu Ogino, Takuya Kuramoto, Seidai Sato, Makoto Tobiume, Masaki Hanibuchi, Souji Kakiuchi, Seiji Yano, Hisanori Uehara, Yasuhiko Nishioka and Saburo Sone :
Novel therapeutic strategy with E7080, an orally active inhibitor of multiple recepter tyrosine kinase, for controllong experomental metastasis by lung cancer in immunodeficient mice.,
第9回アジア臨床腫瘍学会学術集会, Gifu, Aug. 2010. Trung The Van, Hisatsugu Goto, Masaki Hanibuchi, Souji Kakiuchi, Kuramoto Takuya, Sato Seidai, Tobiume Makoto, Shin-ichi Akiyama, Yasuhiko Nishioka and Sone Saburo :
Therapeutic efficacy of TS-1 on the progression of human malignant pleural mesothelioma in severe combined immunodeficient mice.,
第9回アジア臨床腫瘍学会学術集会, Gifu, Aug. 2010. Momoyo Azuma, Takada Shinsuke, Sato Seidai, Hisatsugu Goto, Hiroaki Yanagawa, Yasuhiko Nishioka, Kenichi Maeda, Shin-ichi Akiyama and Saburo Sone :
Investigation of complementary and alternative medicine in lung cancer patients in Tokushima Univerity Hospital.,
第9回アジア臨床腫瘍学会学術集会, Gifu, Aug. 2010. Kishi Masami, Yasuhiko Nishioka, Momoyo Azuma, Yoshinori Aono, Batmunkh Rentsenkhand, El-morshedy Mohammed Reham, Katsuhiro Kinoshita, Jun Kishi, Uehara Hisanori, Izumi Keisuke and Saburo Sone :
Anifibrotic effects of APA5 and APB5, blocking antibodies specific for PDGF receptors on bleomycine-induced pulmonary fibrosis in mice.,
ATS 2010 International Conference, New Orleans, May 2010. Momoyo Azuma, Yasuhiko Nishioka, El-morshedy Mohammed Reham, Jun Kishi, Katsuhiro Kinoshita, Uehara Hisanori, Izumi Keisuke and Saburo Sone :
Effects of the novel immunomodulatory sphingosine l-phospate(S1P) receptor agonist FTY720 in bleomycine-induced pulmonaty fibrosis in mice.,
ATS 2010 International Conference, New Orleans, May 2010. M. Azuma, Yasuhiko Nishioka, Yoshinori Aono, M. Inayama, H. Makino, Hisanori Uehara, Keisuke Izumi and Saburo Sone :
Inhibition of bleomycin-induced pulmonary fibrosis in mice by imatinib (Gleevec) and erythromycin-a role of aipha-1-acid glycoprotein,
100th American thoracic society (ATS), San Diego, May 2005. Yoshinori Aono, Yasuhiko Nishioka, M. Inayama, H. Makino and M. Ugai :
Imatinib as a novel anti-fibrotic agent in bleomycin-induced lung fibrosis in mice,
100th American thoracic society (ATS), San Diego, May 2005. Yasuhiko Nishioka, M. Inayama, H. Makino, M. Ugai, Yoshinori Aono, Hisanori Uehara, Keisuke Izumi and Saburo Sone :
Anti-fibrotic effect of IKKB inhibitor IMD-0354 in bleomycin-induced pulmonary fibrosis,
100th American thoracic society (ATS), San Diego, May 2005. Mami Inayama, Yasuhiko Nishioka, Masahiko Azuma, Yoshinori Aono, Hideki Makino, Hisanori Uehara, Keisuke Izumi and Saburo Sone :
Anti-fibrotic effect of IKKB inhibitor IMD-0354 in bleomycin-induced pulmonary fibrosis,
100th American Thoracic Society Annual Meeting, San Diego, May 2005. Ali Jalili, Shuji Ozaki, Tomoko Hara, Etsuko Sekimoto, Yoichi Tanaka, Takashi Ohshima, Hironobu Shibata, Toshihiro Hashimoto, Masahiro Abe, Yasuhiko Nishioka and Toshio Matsumoto :
Generation of HM1.24-specific cytotoxic T lymphocytes from peripheral blood stem cell harvests of patients with multiple myeloma,
46th Annual Meeting: American Society of Hematology, San Francisco, Dec. 2004. Yoshinori Aono, Yasuhiko Nishioka, Hisanori Uehara, Keisuke Izumi and Saburo Sone :
Anti-fibrotic effect of STI571(Gleevec) in bleomycin-induced pulmonary fibrosis,
99th American thoracic society (ATS), Orlando, May 2004. Yasuhiko Nishioka, K. Manabe, J. Kishi, M. Inayama, Yoshinori Aono, M. Ugai, Kenji Tani and Saburo Sone :
Analysi of CXCR3 ligands, IP-10, MIG and I-TAC, in patients with pulmonary sarcoidosis,
99th American thoracic society (ATS), Orlando, May 2004. Yasuhiko Nishioka, Yoshinori Aono, M. Inayama, M. Ugai, J. Kishi, Hisanori Uehara, Keisuke Izumi and Saburo Sone :
Imatinib as a novel PDGF receptor-targeted drug to prevent bleomycin-induced lung fibrosis,
第44回日本呼吸器学会総会 International progam 3, Tokyo, Apr. 2004. Yasuhiko Nishioka, Jun Kishi, K. Manabe, M. Miki, Y. Makamura, F. Ogushi, T. Sano, H. Bando, Kenji Tani and Saburo Sone :
Analyses of Th1-and Th2-Type Chemokines in Bronchoalveolar Lavage Fluids from Patients with Interstitial Lung Diseases,
99th American thoracic society (ATS), Seattle, May 2003. Yoshinori Aono, Yasuhiko Nishioka, K. Mitani, K. Yamabe, M. Inayama, Hiroaki Yanagawa and Saburo Sone :
Soluble Fas in Malignant Pleural Effusion and Its Expresion in Lung Cancer Cells,
99th American thoracic society (ATS), Seattle, May 2003. Hirohisa Ogawa, Naoki Nishimura, Yasuhiko Nishioka, Masahiko Azuma, Hiroaki Yanagawa and Saburo Sone :
Effects of IL-12 gene-transduction into human bronchial epithelial cells on the phenotypic and functional expressions and its therapeutic implication,
7th Congress of Asian Pacific Society of Respirology(APSR), Taiwan, Oct. 2002. Yasuhiko Nishioka :
Cancer immunotherapy using gene -modified dendritic cells,
The 2nd Japan-China Joint Conference for Cancer Reseach, Tokushima, Jun. 2002. Yasuhiko Nishioka, J. Kishi, J. Miyata, M. Azuma, Kenji Tani and Saburo Sone :
Macrophage-derived chemokine and thymus and activation-regulated chemokine in bronchoalveolar lavage fluid of patients with interstitial lung diseases,
26th International congress of Internal Medicine, Kyoto, May 2002. Yasuhiko Nishioka, J. Miyata, Jun Kishi, S. Kakiuchi, Masahiko Azuma, M. Miki, Y. Nakamura, F. Ogushi, T. Sano, H. Bando, Kenji Tani and Saburo Sone :
Specific elevation of Th2-type chemokines, MDC and TARC, in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia,
98th American thoracic society(ATS), Atlanta, May 2002. Jun Kishi, L. Huang, Yasuhiko Nishioka, J. Miyata, F. Ogushi, Kenji Tani and Saburo Sone :
Thrombin promotes fibroblast proliteration in experimental radiation pneumonitis,
98th American thoracic society (ATS), Atlanta, May 2002. Masato Okamoto, S Furuichi, Yasuhiko Nishioka, T Oshikawa, G Ohe, H Nishikawa, T Tano, U S Armed, Y Moriya, T Matsubara, M Saito, Saburo Sone and Mitsunobu Sato :
Maturation and activation of human dendritic cells in vitro by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent: Involvement of Toll-like receptor 4,
American Association for Cancer Research (AAGR), USA, May 2002. Yasuhiko Nishioka :
Cancer immunotherapy using gene-modified dendritic cells,
International Symposium on dendritic cell-based cancer immunotherapy, Gwangju,Korea, Apr. 2002. Yasuhiko Nishioka, N. Nishimura, H. Tahara and Saburo Sone :
Intratumoral injection of dendritic cells genetically modified to express interleukin-12 inhibits spontaneous metastases od Lewis lung carcinoma,
97th American thoracic society(ATS), San Francisco, May 2001. Hirohisa Ogawa, Naoki Nishimura, Yoichi Nakamura, Yasuhiko Nishioka, Masahiko Azuma, Mari Miki, Fumitaka Ogushi and Saburo Sone :
Functionl analysis of human bronchial epithelial cell transduced with IL-12 gene by adenovirus vector,
American thoracic society (ATS) 2001 97th International Conference, San Francisco, May 2001. Naoki Nishimura, Yasuhiko Nishioka and Saburo Sone :
human dendritic cells transduced with interleukin-12 gene enhanced T cell activation:Centrifugal enhancement of the efficacy of adenovirus-mediated gene transduction,
99nd Annual Meeting of The American Association for Cancer Research, New Orleans, Mar. 2001. N. Nishimura, Yasuhiko Nishioka, Tsutomu Shinohara and Saburo Sone :
Centrifugal enhancement of adenovirus-mediated gene transduction into human dendritic cells,
American society for gene therapy(ASGT), Denver, Jun. 2000. Yasuhiko Nishioka, N. Nishimura, P.D. Robbins, M.T. Lotze, Saburo Sone and H. Tahara :
Intratumoral injection of dendritic cells genetically modified to express interleukin-12 induces antitumor immunity and inhibits established tumor growth and spontaneous metastases,
American society for gene therapy(ASGT), Denver, Jun. 2000. H. Ogawa, N. Nishimura, Y. Nakamura, Yasuhiko Nishioka, M. Azuma, M. Miki, F. Ogushi and Saburo Sone :
Function analysis of human bronchial epithelial cell transduced with IL-12 gene by adenovirus vector,
96th American thoracic society (ATS), San Francisco, May 2000. M. Hirao, Yasuhiko Nishioka, S.C. Watkins, P.D. Robbins, M.T. Lotze and H. Tahara :
Tumor specific cellular immune response induced with intratumoral injection of genetically modified immature dendritic cells,
American Association for Cancer Research(AACR), May 1999. T. Takayama, Yasuhiko Nishioka, L. Lu, M.T. Lutze, H. Tahara and A.W. Thomson :
Retroviral delivery of viral IL-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T cell hyporesponsiveness,
5th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology, Gwangju,Korea, Sep. 1998. T. Takayama, Yasuhiko Nishioka, L. Lu, W.J. Storkus, M. Lotze, H. Tahara and A.W. Thomson :
Viral IL-10 gene transduction abrogates the allostimulatory activity of dendritic cells,
ASTP Meeting, USA, May 1998. T. Takayama, Yasuhiko Nishioka, L. Lu, W.J. Storkus, M. Lotze, H. Tahara and A.W. Thomson :
Viral IL-10 gene transduction abrogates the allostimulatory activity of dendritic cells,
KEYSTONE SYMPOSIA in Molecular and Cellular Biology(USA), Mar. 1998. Yasuhiko Nishioka, M. Shurin, P.D. Robbins, W.J. Storkus, M.T. Lotze and H. Tahara :
Effective tumor immunotherapy using bone marrow(BM)-derived dendritic cells(DC) genetically engineered to express interleukin 12,
Society for biological therapy-12th annual scientific meeting(USA), Oct. 1997. 坂東 紀子, 坂東 弘基, 土師 恵子, 美馬 正人, 福家 麻美, 内藤 伸仁, 尾崎 領彦, 荻野 広和, 佐藤 正大, 河野 弘, 坂口 暁, 埴淵 昌毅, 西岡 安彦 :
当科における重症喘息に対する生物学的製剤の治療効果の検討,
第268回徳島医学会学術集会, 2024年3月. Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yugo Matumura, Seiya Ichihara, Takeshi Imakura, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Yuko Toyoda, Kayoko Hase, Eiji Takeuchi, Takashi Haku and Yasuhiko Nishioka :
The impacts of G-CSF on the therapeutic efficacy of chemo-immunotherapy for extensive-stage small cell lung cancer.,
2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024. Hirokazu Ogino, Nguyen Na Thi, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi and Yasuhiko Nishioka :
Fluoropyrimidine has a potential to be an immunologically optimal partner ofimmunotherapy for thoracic malignancies.,
024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024. 西岡 安彦 :
腫瘍微小環境のfibrocyte∼機能解析から標的治療へ∼,
日本がん分子標的治療学会 第19回トランスレーショナルリサーチワークショップ, 2024年1月. 鈴江 涼子, 坂東 弘基, 土師 恵子, 尾崎 領彦, 米田 浩人, 荻野 広和, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
抗横紋筋抗体陽性の重症irAE筋炎・心筋炎に対して早期の集学的治療が奏効した肺扁平上皮癌の1例,
第69回日本呼吸器学会中国・四国地方会, 2023年12月. 寺澤 翠, 坂東 弘基, 土師 恵子, 米田 浩人, 荻野 広和, 岡田 直子, 川中 崇, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
ペプチド受容体放射性核種療法が奏効した左下葉原発進行期非定型カルチノイドの1例,
第69回日本呼吸器学会中国・四国地方会, 2023年12月. 青井 優, 坂東 弘基, 土師 恵子, 高橋 啓輝, 米田 浩人, 阿部 あかね, 佐藤 正大, 東 桃代, 埴淵 昌毅, 西岡 安彦 :
気管支鏡検査で診断したCOVID-19関連肺アスペルギルス症の1例,
第32回日本呼吸器内視鏡学会中国四国支部会, 2023年12月. 中西 渓介, 坂東 弘基, 土師 恵子, 小倉 祐一郎, 美馬 正人, 内藤 伸仁, 阿部 あかね, 川真田 純, 杉浦 宏, 佐藤 正大, 東 桃代, 埴淵 昌毅, 西良 浩一, 西岡 安彦 :
結核性脊椎炎の治療中にparadoxical responseとして皮下膿瘍が出現した1例,
第74 回日本結核・非結核性抗酸菌症学会中国四国支部会, 2023年12月. 宮本 憲哉, 埴淵 昌毅, 坂東 弘基, 米田 浩人, 荻野 広和, 佐藤 正大, 西岡 安彦 :
気管支鏡後の呼吸器感染症のリスク因子および予防的抗菌薬投与の有用性についての検討,
第32回日本呼吸器内視鏡学会中国四国支部会, 2023年12月. 磯村 祐太, 坂東 弘基, 土師 恵子, 内藤 伸仁, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
悪性リンパ腫の治療経過中に発症したβ-Dグルカン陰性ニューモシスチス肺炎の1例,
第129回日本内科学会四国地方会, 2023年12月. 山本 浩生, 坂東 弘基, 土師 恵子, 山下 雄也, 内藤 伸仁, 佐藤 正大, 河野 弘, 埴淵 昌毅, 西岡 安彦 :
ステロイド抵抗性の気道病変に対してシクロホスファミドが著効した再発性多発軟骨炎の1例,
第129回日本内科学会四国地方会, 2023年12月. 河野 弘, 青井 優, 安宅 克博, 村上 行人, 山下 雄也, 内藤 伸仁, 荻野 広和, 佐藤 正大, 西岡 安彦 :
顕微鏡的多発血管炎の診断時にEBVの再活性化を呈し，リツキシマブにて寛解導入療法を行った1例,
第34回日本リウマチ学会中国・四国支部学術集会, 2023年12月. 青井 優, 河野 弘, 安宅 克博, 村上 行人, 山下 雄也, 内藤 伸仁, 荻野 広和, 佐藤 正大, 西岡 安彦 :
胸膜炎，間質性肺疾患を先行し，発熱性好中球減少症と肺病変の増悪で発症したSLEの1例,
第34回日本リウマチ学会中国・四国支部学術集会, 2023年12月. 塚﨑 佑貴, 飛梅 亮, 三橋 惇志, 尾崎 領彦, 矢葺 洋平, 米田 浩人, 荻野 広和, 埴淵 昌毅, 小川 博久, 滝沢 宏光, 西岡 安彦 :
非小細胞肺癌症例における腫瘍浸潤線維細胞の走化因子と疾患予後との関連性についての解析,
第64回日本肺癌学会学術集会, 2023年11月. 竹内 栄治, 荻野 広和, 近藤 健介, 岡野 義夫, 松村 有悟, 市原 聖也, 國重 道大, 門田 直樹, 町田 久典, 畠山 暢生, 軒原 浩, 篠原 勉, 西岡 安彦 :
好酸球増加は免疫チェックポイント阻害薬治療を受けた非小細胞肺癌患者の効果予測バイオマーカー,
第64回日本肺癌学会学術集会, 2023年11月. 荻野 広和, 香西 博之, 三橋 惇志, 塚﨑 佑貴, 矢葺 洋平, 尾崎 領彦, 米田 浩人, 埴淵 昌毅, 軒原 浩, 西岡 安彦 :
フッ化ピリミジンは胸部腫瘍の免疫原性細胞死を誘導し免疫チェックポイント阻害薬の至適併用薬となり得る,
第64回日本肺癌学会学術集会, 2023年11月. 尾崎 領彦, 軒原 浩, 塚﨑 佑貴, 矢葺 洋平, 三橋 惇志, 米田 浩人, 荻野 広和, 西岡 安彦 :
進展型小細胞肺癌において2次治療が受けられない患者の臨床的背景の検討,
第64回日本肺癌学会学術集会, 2023年11月. 三橋 惇志, 荻野 広和, 米田 浩人, 軒原 浩, 西岡 安彦 :
胸部腫瘍におけるfibrocyteの同定と新規治療標的としての展開,
第64回日本肺癌学会学術集会, 2023年11月. 佐藤 正大, 埴淵 昌毅, 三橋 惇志, 西岡 安彦 :
咳喘息治療における効果予測バイオマーカーの探索,
第72回日本アレルギー学会学術大会, 2023年10月. 坂東 弘基, 佐藤 正大, 村上 行人, 山下 雄也, 内藤 伸仁, 小山 壱也, 河野 弘, 小川 博久, 西岡 安彦 :
グレリン受容体作動薬アナモレリンのアレルギー性気道炎症モデルマウスにおける検討,
第72回日本アレルギー学会学術大会, 2023年10月. 小川 博久, 清水 真祐子, 平 修, 坂東 弘基, 佐藤 正大, 常山 幸一, 西岡 安彦 :
メタボローム解析による複数抗原感作喘息モデルにおける難治性因子の探索,
第72回日本アレルギー学会学術大会, 2023年10月. 尾崎 領彦, 小川 瑛, 軒原 浩, 三橋 惇志, 矢葺 洋平, 米田 浩人, 荻野 広和, 西岡 安彦 :
ALK融合遺伝子陽性非小細胞肺癌の効果予測因子に関する検討,
第61回日本癌治療学会学術集会, 2023年10月. 和田 拓也, 板倉 智史, 吉田 碧人, 山本 高成, 川田 敬, 佐藤 智恵美, 金子 美華, 加藤 幸成, 西岡 安彦, 阿部 真治 :
がん特異的抗podoplanin抗体chLpMab-23fのMPM胸腔内移植マウスモデルにおける抗腫瘍効果の検討,
第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), 2023年10月. 板倉 智史, 和田 拓也, 吉田 碧人, 山本 高成, 川田 敬, 佐藤 智恵美, 金子 美華, 加藤 幸成, 西岡 安彦, 阿部 真治 :
がん特異的抗podoplanin抗体chLpMab-2及びコアフコース除去抗体chLpMab-2fのin vivoにおける抗腫瘍効果の検討,
第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), 2023年10月. 吉田 碧人, 板倉 智史, 和田 拓也, 山本 高成, 川田 敬, 佐藤 智恵美, 金子 美華, 加藤 幸成, 西岡 安彦, 阿部 真治 :
がん特異的抗podoplanin抗体のコアフコース除去に伴うADCC増強とNK細胞活性化に関する検討,
第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), 2023年10月. 佐藤 正大, 小川 博久, 村上 行人, 山下 雄也, 土師 恵子, 河野 弘, 原 英二, 西岡 安彦 :
BRD4 阻害剤 ARV825 の線維化関連遺伝子の発現抑制と老化細胞除去を介した抗線維化効果の検討,
第3回日本びまん性肺疾患研究会, 2023年9月. 土師 恵子, 佐藤 正大, 小川 博久, 村上 行人, 山下 雄也, 小山 壱也, 河野 弘, 小林 克利, 諸星 俊郎, 西岡 安彦 :
オートタキシン阻害作用を有する 2ccPA の肺線維症における有効性の検討,
第3回日本びまん性肺疾患研究会, 2023年9月. 西岡 安彦 :
特発性樹枝状肺骨化症,
第3回日本びまん性肺疾患研究会, 2023年9月. 西岡 安彦 :
肺線維症に対する分子標的治療の開発を目指して∼増殖因子から fibrocyte へ∼,
第3回日本びまん性肺疾患研究会, 2023年9月. 矢葺 洋平, 三橋 惇志, 荻野 広和, Na T. Nguyen, 米田 浩人, 尾崎 領彦, 塚﨑 佑貴, 埴淵 昌毅, 軒原 浩, 西岡 安彦 :
HIF1A 阻害による腫瘍細胞由来 CXCL10/11 制御を介した抗 PDL1 抗体への耐性克服,
第82回日本癌学会学術総会, 2023年9月. 三橋 惇志, 小山 壱也, 荻野 広和, 杉本 正道, 根東 攝, 軒原 浩, 西岡 安彦 :
腫瘍内 fibrocyte 遊走・分化制御がもたらす腫瘍免疫微小環境への影響,
第82回日本癌学会学術総会, 2023年9月. 三橋 惇志, 小山 壱也, アフローズ タニア, 西條 敦郎, 飛梅 亮, 荻野 広和, 杉本 正道, 根東 攝, 軒原 浩, 西岡 安彦 :
腫瘍内 fibrocyte の同定と制御による新規がん治療開発への橋渡し研究,
第82回日本癌学会学術総会, 2023年9月. 原田 紗希, 坂東 弘基, 土師 恵子, 内藤 伸仁, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
当院において外科治療を施行した肺Mycobacterium avium complexの検討,
第267回徳島医学会学術集会, 2023年8月. 寺澤 翠, 坂東 弘基, 土師 恵子, 小路 貴俊, 米田 浩人, 佐藤 正大, 河野 弘, 埴淵 昌毅, 西岡 安彦 :
シクロスポリンが有効であった血清IL-18高値の重症成人発症スティル病の1例,
第128回日本内科学会四国地方会, 2023年7月. 中西 渓介, 坂東 弘基, 土師 恵子, 松村 有悟, 稲葉 香織, 米田 浩人, 荻野 広和, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
Carboplatin+etoposideや放射線治療に不応もnab-paclitaxelが奏効した肺原発大細胞神経内分泌癌の1例,
第128回日本内科学会四国地方会, 2023年7月. 三橋 惇志, 荻野 広和, Nguyen Na Thi, 矢葺 洋平, 米田 浩人, 杉本 正道, 根東 攝, 軒原 浩, 西岡 安彦 :
腫瘍内fibrocyteの同定と機能制御による新規複合がん免疫療法の開発,
第32回日本がん転移学会学術集会・総会, 2023年7月. 米田 浩人, 三橋 惇志, 荻野 広和, 軒原 浩, 阿部 真治, 金子 美華, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討,
第32回日本がん転移学会学術集会・総会, 2023年7月. 西岡 安彦 :
腫瘍微小環境のfibrocyte:機能解析から標的治療へ,
第32回日本がん転移学会学術集会・総会, 2023年7月. 山本 浩生, 坂東 弘基, 土師 恵子, 國重 道大, 梶本 達也, 小山 壱也, 香川 耕造, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
自然経過で嚢胞性画像変化および呼吸機能の改善を認めた重症COVID-19の1例,
第68回日本呼吸器学会中国・四国地方会, 2023年7月. 多田 里穂, 坂東 弘基, 土師 恵子, 新居 香織, 米田 浩人, 荻野 広和, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
抗PD-L1抗体投与により腫瘍随伴性小脳変性症が顕在化した小細胞肺癌の1例,
第61回日本肺癌学会中国・四国支部学術集会, 2023年7月. 遠藤 裕美, 坂東 弘基, 土師 恵子, 高橋 啓輝, 米田 浩人, 荻野 広和, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
包括的ゲノムプロファイリングにより診断し得たEGFR Exon19欠失変異陽性肺腺癌の1例,
第61回日本肺癌学会中国・四国支部学術集会, 2023年7月. 塚﨑 佑貴, 三橋 惇志, 尾崎 領彦, 矢葺 洋平, 米田 浩人, 荻野 広和, 西岡 安彦 :
肺癌における腫瘍浸潤線維細胞の走化因子とその疾患予後に及ぼす影響についての解析,
第27回日本がん分子標的治療学会学術集会, 2023年6月. 三橋 惇志, 荻野 広和, Nguyen Na Thi, 米田 浩人, 矢葺 洋平, 杉本 正道, 根東 攝, 軒原 浩, 西岡 安彦 :
Fibrocyte の分化制御による複合がん免疫療法への展開,
第27回日本がん分子標的治療学会学術集会, 2023年6月. 矢葺 洋平, 三橋 惇志, Nguyen Na Thi, 荻野 広和, 米田 浩人, 尾崎 領彦, 西岡 安彦 :
IFN-g 反応性ケモカイン産生制御機序の解明と新規複合がん免疫療法への応用,
第27回日本がん分子標的治療学会学術集会, 2023年6月. 吉田 碧人, 加藤 幸成, 西岡 安彦, 阿部 真治 :
がん特異的抗 podoplanin 抗体 chLpMab-2 のコアフコース除去に伴う ADCC 増強とNK 細胞活性化に関する検討,
第27回日本がん分子標的治療学会学術集会, 2023年6月. 坂東 弘基, 佐藤 正大, 村上 行人, 山下 雄也, 内藤 伸仁, 小山 壱也, 河野 弘, 小川 博久, 西岡 安彦 :
グレリン受容体作動薬アナモレリンのアレルギー性気道炎症モデルマウスにおける検討,
第63回日本呼吸器学会学術講演会, 2023年4月. 佐藤 正大, 埴淵 昌毅, 三橋 惇志, 西岡 安彦 :
咳喘息における呼気中一酸化窒素と血清ペリオスチンの臨床的意義の検討,
第63回日本呼吸器学会学術講演会, 2023年4月. 埴淵 昌毅, 三橋 惇志, 西條 敦郎, 佐藤 正大, 西岡 安彦 :
スクリーニング質問票を用いたCOPD検診システムの有用性の検討,
第63回日本呼吸器学会学術講演会, 2023年4月. 村上 行人, 佐藤 正大, 山下 雄也, 土師 恵子, 坂東 弘基, 内藤 伸仁, 小山 壱也, 河野 弘, 稲村 典昭, 蓮見 惠司, 西岡 安彦 :
新規可溶性エポキシヒドロラーゼ阻害薬SMTP-44Dの肺線維症に対する有効性の検討,
第63回日本呼吸器学会学術講演会, 2023年4月. 阿部 あかね, 東 桃代, 泉 侑希, 西岡 安彦 :
当院におけるClostridioides difficile検査に対するDiagnostic stewardshipの取り組みの経過報告,
第97回日本感染症学会総会・学術講演会, 2023年4月. 今倉 健, 佐藤 正大, 西岡 安彦 :
ERS2022に参加して,
第63回日本呼吸器学会学術講演会, 2023年4月. 西岡 安彦 :
日本呼吸器学会将来計画委員会報告,
第63回日本呼吸器学会学術講演会, 2023年4月. Yasuhiko Nishioka :
Molecular pathogenesis of pulmonary fibrosisupdate by novel technology,
The 63rd Annual Meeting of the Japanese Respiratory Society, Apr. 2023. 西岡 安彦, T M Maher, R G Jenkins., F Bonella, S Assassi, C Diefenbach, C Ittrich, K B Rohr, M Kolb :
PF-ILD患者の循環バイオマーカーへのニンテダニブの影響,
第63回日本呼吸器学会学術講演会, 2023年4月. 河野 弘, 小路 貴俊, 安宅 克博, 村上 行人, 山下 雄也, 内藤 伸仁, 荻野 広和, 佐藤 正大, 西岡 安彦 :
リンパ球特異的チロシンキナーゼ阻害薬A-770041は制御性T細胞によるTGF-βs産生抑制を介して肺線維症を改善する,
第67回日本リウマチ学会総会・学術集会, 2023年4月. 荻野 広和, 尾崎 領彦, 大塚 憲司, 三橋 惇志, 塚﨑 佑貴, 矢葺 洋平, 米田 浩人, 軒原 浩, 西岡 安彦 :
間質性肺炎を合併する進行期肺癌に対する二次化学療法の有効性および安全性に関する検討,
第120回日本内科学会講演会, 2023年4月. Tsukazaki Yuki, Ogawa Ei, Hiroshi Nokihara, Atsushi Mitsuhashi, Kondo Kensuke, Yabuki Youhei, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
The prognostic factors for the efficacy of anaplastic lymphoma kinase inhibitors in non-small cell lung cancer,
2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023. Ryohiko Ozaki, Hiroshi Nokihara, Tukazaki Yuki, Yabuki Yohei, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
Clinical factors of not receiving second-line chemotherapy in ED-SCLC patients,
2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023. Hirokazu Ogino, Kondo Kensuke, Atsushi Mitsuhashi, Tsukazaki Yuki, Ryohiko Ozaki, Yabuki Yohei, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka :
The novel prognostic system for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer,
2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023. 佐藤 正大, 山本 卓志, 西岡 安彦 :
イメージング質量顕微鏡iMScope TRIOによる抗線維化薬の線維性肺組織内局在分布の検討,
第14回呼吸機能イメージング研究会学術集会, 2023年1月. 松村 有悟, 土師 恵子, 鈴江 涼子, 米田 浩人, 香川 耕造, 荻野 広和, 佐藤 正大, 小川 博久, 埴淵 昌毅, 西岡 安彦 :
血清Krebs von den Lungen-6 が高値を示した悪性胸膜中皮腫の1例,
第127回日本内科学会四国地方会, 2022年12月. 新居 香織, 土師 恵子, 青井 優, 山下 雄也, 内藤 伸仁, 荻野 広和, 河野 弘, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
関節炎を呈したACTH 単独欠損症の1例,
第127回日本内科学会四国地方会, 2022年12月. 宮本 憲哉, 土師 恵子, 原田 紗希, 鈴江 涼子, 阿部 あかね, 東 桃代, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
当院における肺MAC症に対するアジスロマイシン併用療法の有効性・安全性の検討,
第73回日本結核・非結核性抗酸菌症学会中国四国支部会, 2022年12月. 森 彩花, 土師 恵子, 青井 優, 宮本 憲哉, 村上 行人, 塚崎 佑貴, 坂東 弘基, 尾崎 領彦, 香川 耕造, 荻野 広和, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
免疫チェックポイント阻害薬使用後に肺胞出血をきたした1例,
第31回日本呼吸器内視鏡学会中国四国支部会, 2022年12月. 寺澤 翠, 土師 恵子, 市原 聖也, 山下 雄也, 福家 麻美, 内藤 伸仁, 米田 浩人, 香川 耕造, 荻野 広和, 河野 弘, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
抗PD-L1抗体投与後に顕在化した抗ARS抗体陽性間質性肺炎の1例,
第67回日本呼吸器学会中国・四国地方会, 2022年12月. 中西 颯斗, 土師 恵子, 松村 有悟, 三橋 惇志, 小川 瑛, 今倉 健, 美馬 正人, 尾崎 領彦, 米田 浩人, 荻野 広和, 坂口 暁, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
同時に異なる3つの組織型を認めた多発性肺癌の1例,
第67回日本呼吸器学会中国・四国地方会, 2022年12月. 西岡 安彦 :
初期臨床研修医セミナーの再開と今後の課題,
第67回日本呼吸器学会中国・四国地方会, 2022年12月. 小路 貴俊, 内藤 伸仁, 河野 弘, 村上 行人, 山下 雄也, 美馬 正人, 荻野 広和, 佐藤 正大, 西岡 安彦 :
両側声帯麻痺を呈した多発血管炎性肉芽腫症に伴う肥厚性硬膜炎の1例,
第33回日本リウマチ学会中国・四国支部学術集会, 2022年12月. 安宅 克博, 河野 弘, 小路 貴俊, 村上 行人, 山下 雄也, 美馬 正人, 内藤 伸仁, 荻野 広和, 佐藤 正大, 西岡 安彦 :
劇症1型糖尿病と同時期に発症した両側特発性外眼筋炎の1例,
第33回日本リウマチ学会中国・四国支部学術集会, 2022年12月. 小川 瑛, 軒原 浩, 三橋 惇志, 近藤 健介, 塚崎 佑貴, 矢葺 洋平, 尾崎 領彦, 米田 浩人, 荻野 広和, 西岡 安彦 :
ALK融合遺伝子陽性非小細胞肺癌の効果予測因子に関する検討,
第63回日本肺癌学会学術集会, 2022年12月. Na T. Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka :
Eliminates MDSCs and enhances the efficacy of immune checkpoint inhibitor in thoracic tumors,
The 63rd Annual Meeting of the Japan Lung Cancer Society, Dec. 2022. 軒原 浩, 荻野 広和, 三橋 惇志, 近藤 健介, 小川 瑛, 尾崎 領彦, 矢葺 洋平, 米田 浩人, 西岡 安彦 :
胸水を伴うEGFR遺伝子変異陽性非小細胞肺がんに対するオシメルチニブの有効性の検討,
第63回日本肺癌学会学術集会, 2022年12月. 竹内 栄治, 近藤 健介, 岡野 義夫, 市原 聖也, 國重 道大, 門田 直樹, 町田 久典, 畠山 暢生, 荻野 広和, 軒原 浩, 篠原 勉, 西岡 安彦 :
好酸球は免疫チェックポイント阻害薬治療を受けた非小細胞肺癌患者の予後予測バイオマーカー,
第63回日本肺癌学会学術集会, 2022年12月. 西岡 安彦 :
肺線維症に対するトランスレーショナルリサーチ∼PPFに対する抗線維化薬の開発に向けて∼,
第122回日本呼吸器学会東海地方会, 2022年11月. 山田 圭一郎, 和泉 俊尋, 板倉 智史, 佐藤 智恵美, 金子 美華, 加藤 幸成, 西岡 安彦, 阿部 真治 :
がん特異的抗ポドプラニン抗体 chLpMab-2f の in vitro 及び in vivo における抗腫瘍効果の検討,
第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(広島), 2022年11月. 四宮 花奈, 和田 拓也, 佐藤 智恵美, 金子 美華, 加藤 幸成, 西岡 安彦, 阿部 真治 :
がん特異的ヒト化抗ポドプラニン抗体 humLpMab-23f のADCC 及び CDC に関する検討,
第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(広島), 2022年11月. 福田 曜, 吉田 碧人, 佐藤 智恵美, 金子 美華, 加藤 幸成, 西岡 安彦, 阿部 真治 :
コアフコース除去による抗ポドプラニン抗体の FcR 及び C1q 結合性の変化と細胞傷害活性への影響の検討,
第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(広島), 2022年11月. 尾崎 領彦, 軒原 浩, 塚崎 佑貴, 矢葺 洋平, 三橋 惇志, 米田 浩人, 荻野 広和, 西岡 安彦 :
間質性肺炎合併進展型小細胞肺癌における2次化学療法の有効性および安全性について,
第60回日本癌治療学会学術集会, 2022年10月. 内藤 伸仁, 西村 春佳, 山下 雄也, 村上 行人, 土師 恵子, 小山 壱也, 荻野 広和, 佐藤 正大, 河野 弘, 埴淵 昌毅, 西岡 安彦 :
ブレオマイシン誘発肺線維症モデルマウスを用いたJAK阻害薬の抗線維化効果についての検討,
第50回日本臨床免疫学会総会, 2022年10月. 小川 博久, 清水 真祐子, 佐藤 正大, 常山 幸一, 西岡 安彦 :
リゾホスファチジン酸(LPA)はLPA1受容体を介して粘液細胞過形成を促進する,
第71回日本アレルギー学会学術大会, 2022年10月. Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara and Yasuhiko Nishioka :
PD-1/PD-L1 blockade mediates antiangiogenic effects by tumorderived CXCL10/11 as a potential predictive biomarker,
The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022. Atsushi Mitsuhashi, Hirokazu Ogino, Sugimoto Masamichi, Hiroshi Nokihara and Yasuhiko Nishioka :
Fibrocyte drives antitumor immunity via T cell-costimulation in combination immunotherapy,
The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022. Hirokazu Ogino, Atsuro Saijo and Yasuhiko Nishioka :
Neoadjuvant vaccination with tumor-cell lysate induces CD8 T cell response in low-grade gliomas in randomized trial,
The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022. 中西 颯斗, 土師 恵子, 矢葺 洋平, 新居 香織, 高丸 利加子, 米田 浩人, 荻野 広和, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
セルペルカチニブが奏功したRET融合遺伝子陽性肺腺癌の1例,
第265回徳島医学会学術集会, 2022年7月. Hirokazu Ogino, Taylor Jennie, Nejo Takahide, Gibson David, Watchmaker Payal, Atsuro Saijo, Tedesco Meghan, Rabbitt Jane, Olin Michael, Moertel Christopher, Salazar Andres, Molinaro Annette, Phillips Joanna, Butowski Nicholas, Clarke Jennifer, Theodosopoulos Philip, Chang Susan, Yasuhiko Nishioka, Berger Mitchel and Okada Hideho :
Randomized trial of neoadjuvant vaccination with GBM6-AD tumor-cell lysate induces T cell response in low-grade gliomas,
The 26th Annual Meeting of Japanese Association of Cancer Immunology, Jul. 2022. 小倉 佑一朗, Keiko Haji, 近藤 健介, Kenji Otsuka, Hirokazu Ogino, Kazuya Koyama, 村上 行人, Hiroki Bandoh, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka :
間質性肺炎への治療反応性から肝肺症候群の併存が顕在化した一例,
第66回日本呼吸器学会中国・四国地方会, Jul. 2022. 松村 有悟, 土師 恵子, 美馬 正人, 矢葺 洋平, 大塚 憲司, 米田 浩人, 軒原 浩, 荻野 広和, 尾崎 領彦, 塚崎 佑貴, 佐藤 正大, 埴淵 昌毅, 西岡 安彦 :
小細胞肺癌への形質転換を認めたEGFR遺伝子変異陽性肺腺癌の3例,
第60回日本肺癌学会中国・四国支部学術集会, 2022年7月. 新居 香織, Yohhei Yabuki, Keiko Haji, 高丸 利加子, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka :
セルペルカチニブが奏効したRET融合遺伝子陽性肺腺癌の1例,
第60回日本肺癌学会中国・四国支部学術集会, Jul. 2022. 荻野 広和, 西條 敦郎, 西岡 安彦 :
腫瘍ライセートを用いた術前がんワクチン療法は低悪性度神経膠腫におけるT細胞免疫応答を誘導する,
第26回日本がん分子標的治療学会学術集会, 2022年6月. 三橋 惇志, 荻野 広和, Nguyen Thi Na, 米田 浩人, 大塚 憲司, 杉本 正道, 根東 攝, 軒原 浩, 西岡 安彦 :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内fibrocyteの機能解析,
第26回日本がん分子標的治療学会学術集会, 2022年6月. 米田 浩人, 三橋 惇志, 荻野 広和, 尾崎 領彦, 矢葺 洋平, 軒原 浩, 阿部 真治, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討,
第26回日本がん分子標的治療学会学術集会, 2022年6月. 土師 恵子, 矢葺 洋平, 美馬 正人, 米田 浩人, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
MET阻害薬が著効したMET遺伝子 exon14 skipping 変異陽性肺扁平上皮癌の1例,
第126回日本内科学会四国地方会, 2022年6月. 高橋 啓輝, 矢葺 洋平, 市原 聖也, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
重度の嚥下障害を合併した抗Ro52抗体陽性皮膚筋炎の1例,
第126回日本内科学会四国地方会, 2022年6月. 阿部 あかね, 東 桃代, 岡田 直人, 佐藤 雅美, 高橋 真理, 矢野 由美子, 西岡 安彦 :
当院における血液培養，Clostridioides difficile検査に対するDiagnostic stewardshipの取り組み,
第70回日本化学療法学会総会, 2022年6月. 東 桃代, 西岡 安彦, 森野 紗衣子, 大石 和徳 :
65歳以上の成人に対するPCV13-PPSV23連続接種の安全性と免疫原性の検討,
第70回日本化学療法学会総会, 2022年6月. 村上 行人, 原田 紗希, 今倉 健, 三橋 惇志, 小川 瑛, 塚崎 佑貴, 尾崎 領彦, 矢葺 洋平, 香川 耕造, 米田 浩人, 阿部 あかね, 荻野 広和, 小山 壱也, 佐藤 正大, 坂口 暁, 西岡 安彦 :
抗GM-CSF抗体測定が早期診断に有用であった自己免疫性肺胞蛋白症の一例,
第45回日本呼吸器内視鏡学会学術集会, 2022年5月. 今倉 健, 佐藤 正大, 原田 紗希, 三橋 惇志, 小川 瑛, 村上 行人, 塚崎 佑貴, 尾崎 領彦, 矢葺 洋平, 香川 耕造, 米田 浩人, 阿部 あかね, 荻野 広和, 坂口 暁, 西岡 安彦 :
肺門部・縦隔リンパ節腫大に対してEBUS-TBNAを実施し子宮頸癌再発と診断した1例,
第45回日本呼吸器内視鏡学会学術集会, 2022年5月. 河野 弘, 今倉 健, 山下 雄也, 村上 行人, 内藤 伸仁, 佐藤 正大, 西岡 安彦 :
ブレオマイシン誘発肺線維症モデルマウスにおけるJAK阻害薬の抗線維化効果に関する検討,
第66回日本リウマチ学会総会・学術集会, 2022年4月. Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka :
Antifibrotic and senolytic activity of novel BRD4 degrader ARV825 in experimental model of lung fibrosis,
The 62nd Annual Meeting of the Japanese Respiratory Society, Apr. 2022. 美馬 正人, 佐藤 正大, 原田 紗希, 鈴江 涼子, 山下 雄也, 尾崎 領彦, 土師 恵子, 内藤 伸仁, 河野 弘, 軒原 浩, 西岡 安彦 :
抗ARS抗体陽性間質性肺疾患の胸部画像所見の検討,
第62回日本呼吸器学会学術講演会, 2022年4月. 小山 壱也, 三橋 惇志, 今倉 健, 村上 行人, 香川 耕造, 佐藤 正大, 河野 弘, 小川 博久, 西岡 安彦 :
シングルセル解析を用いた肺線維症マウスモデルにおけるfibrocyteの検討,
第62回日本呼吸器学会学術講演会, 2022年4月. 河野 弘, 今倉 健, 村上 行人, 内藤 伸仁, 香川 耕造, 小山 壱也, 佐藤 正大, 軒原 浩, 西岡 安彦 :
レポーターマウスを用いた肺線維細胞の新規同定法,
第62回日本呼吸器学会学術講演会, 2022年4月. 今倉 健, 佐藤 正大, 小山 壱也, 新村 貴博, 村上 行人, 山下 雄也, 土師 恵子, 香川 耕造, 河野 弘, 座間味 義人, 石澤 啓介, 西岡 安彦 :
In silico解析により同定されたPLK阻害剤のブレオマイシン誘発肺線維症モデルマウスにおける効果の検討,
第62回日本呼吸器学会学術講演会, 2022年4月. 西岡 安彦 :
海外留学助成金制度の現状と未来,
第62回日本呼吸器学会学術講演会, 2022年4月. 福田 曜, 吉田 碧人, 和泉 俊尋, 古謝 景斗, 佐藤 智恵美, 金子 美華, 加藤 幸成, 西岡 安彦, 阿部 真治 :
抗ポドプラニン抗体 NZ-12 のコアフコース除去による FcR 及び C1q 結合性への影響,
日本薬学会第142年会 (名古屋online), 2022年3月. 川原 一輝, 和泉 俊尋, 四宮 花奈, 山田 圭一郎, 和田 拓也, 板倉 智史, 佐藤 智恵美, 金子 美華, 加藤 幸成, 西岡 安彦, 阿部 真治 :
がん特異的抗 podoplanin 抗体 chLpMab-23f による悪性胸膜中皮腫に対する抗体依存性細胞障害の検討,
日本薬学会第142年会 (名古屋online), 2022年3月. 矢葺 洋平, 大塚 憲司, 竹内 栄治, 葉久 貴司, 兼松 貴則, 西村 直樹, 豊田 優子, 埴淵 昌毅, 軒原 浩, 西岡 安彦 :
再発非小細胞肺癌に対するPemetrexed + Bevacizumab 併用療法の有効性と安全性の検討,
第264回徳島医学会学術集会, 2022年2月. 尾崎 領彦, 軒原 浩, 矢葺 洋平, 三橋 惇志, 米田 浩人, 大塚 憲司, 荻野 広和, 西岡 安彦 :
Second-line chemotherapy for extensive-disease small cell lung cancer with interstitial lung disease,
第19回日本臨床腫瘍学会学術集会, 2022年2月. 荻野 広和, W Jennie Taylor, Nejo Takahide, David Gibson, B Payal Watchmaker, Megh Okada Atsuro Saijo Tadesco Kaori, 西條 敦郎, Megh Tadesco, Jane Rabbitt, R Michael Olin, L Christopher Moertel, M Andres Salazar, 西岡 安彦, M Annette Molinaro, J Joanna Phillips, A Nicholas Butowski, L Jennifer Clarke, M Susan Chang, Mitchel Berger, Okada Hideho :
Neoadjuvant vaccination with GBM6-AD, lysate of glioblastoma stem cell line, induces T-cell response in low-grade glioma,
第19回日本臨床腫瘍学会学術集会, 2022年2月. 川西 智子, 河野 裕美, 坂東 典子, 香川 葉子, 谷 美紀, 平岡 葉月, 中尾 隆之, 西岡 安彦, 佐田 政隆, 谷口 浩一郎 :
α波の出現部位がPSG検査の睡眠ステージ判定に有用であった1症例,
第18回日本臨床検査医学合同地方会, 2022年2月. 漆原 南実, 寺本 継脩, 秦真 公人, 菅崎 幹樹, 中尾 隆之, 西岡 安彦, 佐田 政隆 :
自動分析装置による幼若血小板比率の検討,
第18回日本臨床検査医学合同地方会, 2022年2月. 森 建介, 倉橋 清衛, 河田 沙紀, 川原 綾香, 金子 遥祐, 高丸 利加子, 吉田 守美子, 遠藤 逸朗, 西岡 安彦, 安倍 正博 :
失語症のため治療説明に難渋し方針決定が遅れた異所性ACTH症候群の1例,
第33回日本老年医学会四国地方会, 2022年1月. 石田 卓也, 河野 弘, 今倉 健, 村上 行人, 山下 雄也, 美馬 正人, 内藤 伸仁, 荻野 広和, 佐藤 正大, 西岡 安彦 :
当院における膠原病関連間質性肺疾患に対するニンテダニブの使用経験,
第32回日本リウマチ学会中国・四国支部学術集会, 2021年12月. 市原 聖也, 河野 弘, 今倉 健, 村上 行人, 山下 雄也, 美馬 正人, 内藤 伸仁, 荻野 広和, 佐藤 正大, 西岡 安彦 :
再発性多発軟骨炎治療中の不明熱精査でUBA1遺伝子解析により診断したVEXAS症候群の1例,
第32回日本リウマチ学会中国・四国支部学術集会, 2021年12月. 西岡 安彦 :
With コロナ時代の呼吸器専門医の役割 ∼呼吸器専門医の未来∼,
第65回日本呼吸器学会中国・四国地方会，第30回日本呼吸器内視鏡学会中国四国支部会，第72回日本結核・非結核性抗酸菌症学会中国四国支部会 (3学会合同会長企画), 2021年12月. 市原 聖也, 矢葺 洋平, 村上 行人, 香川 耕造, 米田 浩人, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
亜急性に進行し，蜂巣肺様の所見を呈した薬剤性肺障害の1例,
第125回日本内科学会四国地方会, 2021年12月. 石田 卓也, 矢葺 洋平, 香川 耕造, 山下 雄也, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
成人Still病との鑑別を要した家族性地中海熱非典型例の1例,
第125回日本内科学会四国地方会, 2021年12月. 村上 尚哉, 矢葺 洋平, 尾崎 領彦, 香川 耕造, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
Sitafloxacinが奏効した肺Mycobacterium abscessus subsp. massiliense 症の1例,
第72回日本結核・非結核性抗酸菌症学会中国四国支部会, 2021年12月. 高丸 利加子, 矢葺 洋平, 磯村 祐太, 香川 耕造, 小山 壱也, 大塚 憲司, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
自然退縮を認めた気管支原発唾液腺型腫瘍の1例,
第30回日本呼吸器内視鏡学会中国四国支部会, 2021年12月. 小川 瑛, 矢葺 洋平, 青井 優, 香川 耕造, 小山 壱也, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
両側肺に多発する斑状影を呈した自己免疫性肺胞蛋白症の1例,
第65回日本呼吸器学会中国・四国地方会, 2021年12月. 原田 祥子, 矢葺 洋平, 美馬 正人, 尾崎 領彦, 香川 耕造, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
非結核性抗酸菌症との鑑別を要し，amikacin + minocyclineが奏効した肺ノカルジア,
第65回日本呼吸器学会中国・四国地方会, 2021年12月. 西岡 安彦 :
PF-ILDの診断と治療,
第62回日本肺癌学会学術集会(ランチョンセミナー), 2021年11月. 三橋 惇志, 荻野 広和, 米田 浩人, 大塚 憲司, 軒原 浩, 西岡 安彦 :
抗PD-1/PD-L1抗体による血管新生制御メカニズムの解析と治療効果予測バイオマーカーとしての応用,
第62回日本肺癌学会学術集会, 2021年11月. 尾崎 領彦, 軒原 浩, 三橋 惇志, 近藤 健介, 矢葺 洋平, 米田 浩人, 荻野 広和, 大塚 憲司, 西岡 安彦 :
間質性肺炎合併小細胞肺癌に対する二次化学療法の有効性及び安全性の検討,
第62回日本肺癌学会学術集会, 2021年11月. 米田 浩人, 軒原 浩, 三橋 惇志, 尾崎 領彦, 矢葺 洋平, 荻野 広和, 大塚 憲司, 西岡 安彦 :
悪性胸膜中皮腫患者におけるニボルマブの免疫関連有害事象と治療効果の相関性,
第59回日本癌治療学会学術集会, 2021年10月. 大塚 憲司, 三橋 惇志, 尾崎 領彦, 矢葺 洋平, 米田 浩人, 荻野 広和, 軒原 浩, 竹内 栄治, 杉浦 八十生, 知花 賢治, 田村 厚久, 安宅 信二, 西岡 安彦 :
進展型小細胞肺癌における予後規定因子,
第59回日本癌治療学会学術集会, 2021年10月. 小山 壱也, 河野 弘, 西岡 安彦 :
肺線維化におけるシングルセル解析,
第1回日本びまん性肺疾患研究会(基礎研究特別講演), 2021年10月. 西岡 安彦 :
TAS-115,
第1回日本びまん性肺疾患研究会(シンポジウム), 2021年10月. 今倉 健, 佐藤 正大, 小山 壱也, 新村 貴博, 村上 行人, 高橋 直希, 香川 耕造, 座間味 義人, 石澤 啓介, 西岡 安彦 :
In silico 解析を用いた肺線維症に対する新規治療薬の探索,
第1回日本びまん性肺疾患研究会, 2021年10月. 村上 行人, 高橋 直希, 佐藤 正大, 今倉 健, 山下 雄也, 香川 耕造, 小山 壱也, 河野 弘, 谷川原 万顕, 鳥海 亙, 西岡 安彦 :
ブレオマイシン誘発肺線維症モデルマウスにおける新規核酸医薬の有効性の検討,
第1回日本びまん性肺疾患研究会, 2021年10月. 佐藤 正大, 西岡 安彦, Kolb Martin :
線維化肺組織の細胞外基質が線維細胞の線維化促進性miRNA 発現に及ぼす影響の検討,
第1回日本びまん性肺疾患研究会, 2021年10月. 三橋 惇志, 荻野 広和, 西條 敦郎, 大塚 憲司, 杉本 正道, 軒原 浩, 西岡 安彦 :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法におけるfibrocyteの役割,
第80回日本癌学会学術総会, 2021年10月. 花房 翠, 矢葺 洋平, 今倉 健, 米田 浩人, 阿部 あかね, 美馬 正人, 山下 雄也, 内藤 伸仁, 香川 耕造, 大塚 憲司, 佐藤 正大, 軒原 浩, 西岡 安彦 :
ステロイドパルス療法後に増悪し二度目のパルス療法が奏効したCOVID-19肺炎の1例,
第63回日本呼吸器学会中国・四国地方会, 2021年8月. 坂口 暁, 矢葺 洋平, 今倉 健, 米田 浩人, 村上 行人, 小山 壱也, 香川 耕造, 小川 瑛, 荻野 広和, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
索状の小葉間隔壁の肥厚を認め胸腔鏡下肺生検にて診断した間質性肺炎の1例,
第63回日本呼吸器学会中国・四国地方会, 2021年8月. 中内 友合江, 矢葺 洋平, 土師 恵子, 米田 浩人, 三橋 惇志, 青井 優, 石田 卓也, 村上 尚哉, 荻野 広和, 佐藤 正大, 軒原 浩, 西岡 安彦 :
Tepotinibが著効したMET遺伝子exon14 skipping変異陽性肺腺癌の1例,
第59回日本肺癌学会中国・四国支部学術集会, 2021年8月. 市原 聖也, 矢葺 洋平, 尾崎 領彦, 近藤 健介, 米田 浩人, 大塚 憲司, 福家 麻美, 高丸 利加子, 原田 祥子, 荻野 広和, 佐藤 正大, 軒原 浩, 西岡 安彦 :
AtezolizumabのImmune-Related Adverse Eventによる急性腎障害を認めた非小細胞肺癌の1例,
第59回日本肺癌学会中国・四国支部学術集会, 2021年8月. 三橋 惇志, 荻野 広和, 米田 浩人, 大塚 憲司, 軒原 浩, 西岡 安彦 :
肺がん肝転移におけるspheroid形成がん幹細胞様分画の役割,
第30回日本がん転移学会学術集会・総会, 2021年7月. 三橋 惇志, Tania Afroj, NGUYEN NA THI, 荻野 広和, 米田 浩人, 大塚 憲司, 軒原 浩, 西岡 安彦 :
抗PD-1/PD-L1抗体による腫瘍血管新生抑制メカニズムの解析と治療効果予測バイオマーカーとしての応用.,
第25回日本がん分子標的治療学会学術集会, 2021年5月. Na Thi Nguyen, Atsushi Mitsuhashi, Hiroyuki Kozai, Hiroto Yoneda, Afroj Tania, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
TS-1による腫瘍関連骨髄由来抑制細胞の制御を介した免疫チェックポイント阻害剤との併用効果の検討,
第25回日本がん分子標的治療学会学術集会, May 2021. 高丸 利加子, 内藤 伸仁, 原田 紗希, 山下 雄也, 尾崎 領彦, 高橋 直希, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
当科における全身性エリテマトーデスに対するベリムマブの使用経験,
第124回日本内科学会四国地方会, 2021年5月. 石田 卓也, 内藤 伸仁, 今倉 健, 香川 耕造, 佐藤 正大, 河野 弘, 軒原 浩, 高山 哲治, 西岡 安彦 :
レンバチニブによる薬剤性肺障害の1例,
第124回日本内科学会四国地方会, 2021年5月. 山下 雄也, 今倉 健, 高橋 直希, 内藤 伸仁, 佐藤 正大, 河野 弘, 西岡 安彦 :
関節リウマチに伴う間質性肺炎急性増悪の臨床的特徴 ∼特発性肺線維症急性増悪との比較検討∼,
第65回日本リウマチ学会総会・学術集会, 2021年4月. 西岡 安彦, C Valenzuela, T Maher, F Bonella, A Pesci, S Jouneau, N Patel, E Perez Fernandez, R Goeldner, V Cottin :
進行性線維化を伴う間質性肺炎(PF-ILD)でのニンテダニブの有効性に対するベースライン%FVC別評価:INBUILD試験追加解析,
第61回日本呼吸器学会学術講演会, 2021年4月. 小山 壱也, 埴淵 昌毅, 豊田 優子, 一色 琢磨, 三好 嗣臣, 坂本 晋, 加藤 元康, 髙橋 和久, 片岡 健介, 近藤 康博, 西岡 安彦, 本間 栄 :
特発性肺線維症におけるTOLLIP遺伝子多型とN-アセチルシステイン吸入療法の有効性の検討,
第61回日本呼吸器学会学術講演会, 2021年4月. 村上 行人, 佐藤 正大, 今倉 健, 西村 春佳, 高橋 直希, 内藤 伸仁, 香川 耕造, 小山 壱也, 河野 弘, 吾妻 雅彦, 軒原 浩, 西岡 安彦 :
抗線維化薬2剤を切り替えて使用した特発性肺線維症症例の後方視的検討,
第61回日本呼吸器学会学術講演会, 2021年4月. 近藤 健介, 軒原 浩, 佐藤 正大, 三橋 惇志, 米田 浩人, 香西 博之, 大塚 憲司, 西岡 安彦 :
非小細胞肺癌に対する免疫チェックポイント阻害剤の予後予測因子の検討,
第61回日本呼吸器学会学術講演会, 2021年4月. 荒井 直樹, 斎藤 武文, 小倉 髙志, 富井 啓介, 神尾 孝一郎, 坂本 晋, 宮崎 泰成, 冨岡 洋海, 久田 修, 半田 知宏, 本間 栄, 西岡 安彦, 吾妻 安良太 :
特発性肺線維症患者を対象とした第II相臨床試験におけるTAS-115の有効性と安全性,
第61回日本呼吸器学会学術講演会, 2021年4月. 香西 博之, 三橋 惇志, 尾崎 領彦, 米田 浩人, 大塚 憲司, 軒原 浩, 西岡 安彦 :
免疫原性細胞死を誘導する細胞傷害性抗癌剤についての検討,
第61回日本呼吸器学会学術講演会, 2021年4月. 西村 春佳, 佐藤 正大, 今倉 健, 村上 行人, 内藤 伸仁, 香川 耕造, 小山 壱也, 河野 弘, 軒原 浩, 西岡 安彦 :
ブレオマイシン誘発肺線維症モデルマウスにおけるJAK阻害剤の効果に関する検討,
第61回日本呼吸器学会学術講演会, 2021年4月. 高橋 直希, 佐藤 正大, 今倉 健, 村上 行人, 内藤 伸仁, 香川 耕造, 小山 壱也, 河野 弘, 軒原 浩, 谷川原 万顕, 鳥海 亙, 西岡 安彦 :
ブレオマイシン誘発肺線維症モデルマウスにおける核酸医薬PK-7010とnintedanibの併用効果の検討,
第61回日本呼吸器学会学術講演会, 2021年4月. 一色 琢磨, 本間 栄, 矢部 マツ子, 小山 壱也, 西岡 安彦, 山口 哲生, 内田 圭介, 江石 義信, 渋谷 和俊, 坂本 晋, 岸 一馬 :
サルコイドーシス診断におけるPAB抗体免疫染色の有用性の検討,
第61回日本呼吸器学会学術講演会, 2021年4月. 今倉 健, 内藤 伸仁, 山下 雄也, 原田 紗希, 香川 耕造, 米田 浩人, 佐藤 正大, 河野 弘, 長谷 加容子, 軒原 浩, 西岡 安彦 :
当科における成人発症スティル病症例の検討,
第262回徳島医学会学術集会, 2021年3月. 青井 優, 内藤 伸仁, 今倉 健, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
Atezolizumab投与後に著明な血小板減少症をきたした1例,
第262回徳島医学会学術集会, 2021年3月. 尾崎 領彦, 三橋 惇志, 米田 浩人, 大塚 憲司, 軒原 浩, 西岡 安彦, 櫻田 巧, 石澤 啓介 :
ペメトレキセド投与後の皮疹に対するデキサメタゾン予防投与の効果の検討,
第18回日本臨床腫瘍学会学術集会, 2021年2月. 美馬 正人, 内藤 伸仁, 原田 紗希, 今倉 健, 山下 雄也, 髙橋 直希, 佐藤 正大, 河野 弘, 西岡 安彦 :
当科における抗ARS抗体陽性症例の検討,
第31回日本リウマチ学会中国・四国支部学術集会, 2020年12月. 山下 雄也, 内藤 伸仁, 原田 紗希, 今倉 健, 髙橋 直希, 佐藤 正大, 河野 弘, 西岡 安彦 :
ST合剤による無菌性髄膜炎を呈したシェーグレン症候群の一例,
第31回日本リウマチ学会中国・四国支部学術集会, 2020年12月. 西岡 安彦 :
免疫チェックポイント阻害薬によるがん医療,
2020年度日本内科学会生涯教育講演会 Bセッション, 2020年11月. 原田 紗希, 内藤 伸仁, 岡本 悠里, 香川 耕造, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
不明熱の精査でMEFV遺伝子解析により診断した家族性地中海熱の1例,
第123回日本内科学会四国地方会, 2020年11月. 阿部 あかね, 内藤 伸仁, 大塚 憲司, 川上 行奎, 藤井 志朗, 岩本 誠司, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
非小細胞肺癌に合併した後天性血友病Aの1例,
第123回日本内科学会四国地方会, 2020年11月. 米田 浩人, 内藤 伸仁, 香西 博之, 大塚 憲司, 佐藤 正大, 河野 弘, 軒原 浩, 吾妻 雅彦, 西岡 安彦 :
当科における悪性胸膜中皮腫に対するnivolumab投与症例の検討,
第123回日本内科学会四国地方会, 2020年11月. 折野 逸人, 内藤 伸仁, 内藤 仁美, 髙橋 直希, 田中 宏典, 佐藤 正大, 河野 弘, 上原 久典, 軒原 浩, 高山 哲治, 西岡 安彦 :
肝肺症候群に進展したサルコイドーシスの1例,
第64回日本呼吸器学会中国・四国地方会, 2020年11月. 磯村 祐太, 内藤 伸仁, 山下 雄也, 福家 麻美, 小山 壱也, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
当科における胸水貯留を呈した膠原病および類縁疾患症例の検討,
第64回日本呼吸器学会中国・四国地方会, 2020年11月. 梶本 達也, 内藤 伸仁, 内藤 仁美, 佐藤 正大, 河野 弘, 軒原 浩, 吾妻 雅彦, 西岡 安彦 :
全身性強皮症に伴う間質性肺炎の増悪との鑑別を要した鳥関連過敏性肺炎の1例,
第29回日本呼吸器内視鏡学会中国四国支部会, 2020年11月. 國重 道大, 内藤 伸仁, 原田 紗季, 山下 雄也, 高橋 直希, 美馬 正人, 香西 博之, 佐藤 正大, 河野 弘, 西庄 俊彦, 浜田 大輔, 軒原 浩, 松浦 哲也, 西良 浩一, 西岡 安彦 :
当科における骨・関節病変を呈した非結核性抗酸菌症の検討,
第71回日本結核・非結核性抗酸菌症学会中国四国支部会, 2020年11月. 三橋 惇志, 櫻田 巧, 合田 光寛, 座間味 義人, 米田 浩人, 大塚 憲司, 軒原 浩, 石澤 啓介, 西岡 安彦 :
ペメトレキセド投与後の皮疹に対する低用量デキサメタゾン予防効果の検討,
第61回日本肺癌学会学術集会, 2020年11月. 大塚 憲司, 三橋 惇志, 米田 浩人, 軒原 浩, 竹内 栄治, 知花 賢治, 安宅 信二, 田村 厚久, 西岡 安彦 :
進展型小細胞肺癌の予後規定因子の検討,
第61回日本肺癌学会学術集会, 2020年11月. 吾妻 雅彦, 矢葺 洋平, 西岡 安彦 :
膠原病肺との鑑別が問題になった鳥関連過敏性肺炎の 1 例,
第51回日本職業・環境アレルギー学会総会・学術大会, 2020年11月. 瀬部 真由, 堤 理恵, 瀬野浦 聖佳, 岸 潤, 黒田 雅士, 木下 成三, 中屋 豊, 堤 保夫, 西岡 安彦, 阪上 浩 :
脂質の過剰摂取は関節リウマチ病態の増悪・骨格筋量の減少を引き起こす,
学会誌JSPEN, Vol.2, No.Suppl.1, 824, 2020年11月.櫻田 巧, 三橋 惇志, 米田 浩人, 大塚 憲司, 合田 光寛, 座間味 義人, 石澤 啓介, 軒原 浩, 西岡 安彦 :- (キーワード)
- *関節リウマチ(病因,合併症,実験的) 食品中の脂肪(毒性・副作用) 病勢悪化 *筋肉減少症(病因,合併症,実験的) *高脂肪食(有害作用) ヒト マウス 動物 中年(45~64) 女
ペメトレキセド投与後の皮疹に対する低用量のステロイド予防投与の前向き臨床試験,
第58回日本癌治療学会学術集会, 2020年10月. 香西 博之, 三橋 惇志, 米田 浩人, 大塚 憲司, 軒原 浩, 西岡 安彦 :
細胞障害性抗がん剤による腫瘍免疫原性細胞死誘導能の検討,
第58回日本癌治療学会学術集会, 2020年10月. 河野 弘, 山下 雄也, 内藤 伸仁, 佐藤 正大, 門田 宗之, 伊勢 孝之, 八木 秀介, 佐田 政隆, 軒原 浩, 西岡 安彦 :
高安動脈炎による難治性皮膚潰瘍に対してべペルミノゲン ペルプラスミド(ヒト肝細胞増殖因子プラスミドベクター)投与が奏効した1例,
第48回日本臨床免疫学会総会, 2020年10月. 川原 一輝, 阿部 真治, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫に対するがん特異的抗 podoplanin 抗体 chLpMab-23f の in vitro における抗腫瘍効果の検討,
第24回日本がん分子標的治療学会学術集会, 2020年10月. 西條 敦郎, 香西 博之, 後東 久嗣, 大塚 憲司, 米田 浩人, 三橋 惇志, 西岡 安彦 :
非小細胞肺がんに合併した悪性胸水に対する bevacizumab の有効性と耐性化機序の解析,
第24回日本がん分子標的治療学会学術集会, 2020年10月. Nguyen Thi Na, 三橋 惇志, Tania Afroj, 米田 浩人, 香西 博之, 大塚 憲司, 軒原 浩, 西岡 安彦 :
マウス中皮腫細胞株皮下移植モデルにおける細胞障害性抗癌剤の腫瘍関連骨髄由来抑制細胞への影響,
第24回日本がん分子標的治療学会学術集会, 2020年10月. Tania Afroj, 荻野 広和, 三橋 惇志, 米田 浩人, 香西 博之, 大塚 憲司, 軒原 浩, 安倍 正博, 西岡 安彦 :
腫瘍免疫における線維細胞の免疫調節機能の検討,
第24回日本がん分子標的治療学会学術集会, 2020年10月. 近藤 健介, 軒原 浩, 三橋 惇志, 米田 浩人, 香西 博之, 大塚 憲司, 西岡 安彦 :
非小細胞肺癌における免疫チェックポイント阻害剤の予後予測因子の検討,
第24回日本がん分子標的治療学会学術集会, 2020年10月. 米田 浩人, 吉村 彰紘, 後東 久嗣, 西岡 安彦, 山田 忠明 :
既治療非小細胞肺がんを対象としたドセタキセル+ラムシルマブ併用に関する多施設共同後方視的検討,
第24回日本がん分子標的治療学会学術集会, 2020年10月. 三橋 惇志, Tania Afroj, 荻野 広和, Nguyen Thi Na, 米田 浩人, 香西 博之, 大塚 憲司, 杉本 正道, 根東 攝, 軒原 浩, 西岡 安彦 :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内 fibrocyte-like cell の機能解析,
第24回日本がん分子標的治療学会学術集会, 2020年10月. 香西 博之, 三橋 惇志, Nguyen Thi Na, Tania Afroj, 米田 浩人, 大塚 憲司, 軒原 浩, 西岡 安彦 :
肺癌において細胞障害性抗癌剤が免疫原性細胞死に与える影響についての検討,
第24回日本がん分子標的治療学会学術集会, 2020年10月. 三橋 惇志, 荻野 広和, 西條 敦郎, 大塚 憲司, 杉本 正道, 軒原 浩, 西岡 安彦 :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内 fibrocyte-like cell の機能解析,
第79回日本癌学会学術総会, 2020年10月. 西岡 安彦, 佐藤 正大 :
進行性線維化性フェノタイプの分子病態,
第60回日本呼吸器学会学術講演会(シンポジウム), 2020年9月. 谷 望未, 吉村 彰紘, 山田 忠明, 大熊 裕介, 北台 留衣, 竹田 隆之, 兼松 貴則, 後東 久嗣, 米田 浩人, 西岡 安彦, 原田 大司, 山田 崇央, 伊達 紘二, 塩津 伸介, 永田 一洋, 千原 佑介, 内野 順治, 髙山 浩一 :
既治療非小細胞肺がんを対象としたドセタキセル+ラムシルマブ併用に関する多施設共同後方視的検討,
第60回日本呼吸器学会学術講演会, 2020年9月. 豊田 優子, 佐藤 正大, 小山 壱也, 香川 耕造, 上甲 剛, 江頭 玲子, 寺崎 泰弘, 蛇澤 晶, 萩原 弘一, 稲瀬 直彦, 西岡 安彦 :
特発性肺骨化症全国調査(中間報告),
第60回日本呼吸器学会学術講演会, 2020年9月. 髙橋 直希, 佐藤 正大, 小山 壱也, 香川 耕造, 内藤 伸仁, 今倉 健, 豊田 優子, 河野 弘, 谷川原 万顕, 鳥海 亙, 西岡 安彦 :
ブレオマイシン誘発肺線維症モデルマウスにおける核酸医薬PK-7010の抗線維化効果の検討,
第60回日本呼吸器学会学術講演会, 2020年9月. 香川 耕造, 小山 壱也, 佐藤 正大, 髙橋 直希, 西村 春佳, 河野 弘, 豊田 優子, 篠原 勉, 西岡 安彦 :
ブレオマイシン肺線維症マウスモデルにおけるLck阻害の抗線維化効果,
第60回日本呼吸器学会学術講演会, 2020年9月. 佐藤 正大, 森本 友樹, 山本 卓志, 丸尾 朋也, 脇 華菜, 西岡 安彦 :
イメージング質量顕微鏡によるニンテダニブの線維性肺組織内局在分布の検討,
第60回日本呼吸器学会学術講演会, 2020年9月. 西岡 安彦, 小山 壱也, 三橋 惇志, Afroj Tania, 河野 弘 :
肺線維症モデルにおけるscRNA-Seqを用いた線維細胞の解析,
第60回日本呼吸器学会学術講演会(シンポジウム), 2020年9月. 河野 弘, 内藤 伸仁, 安宅 克博, 今倉 健, 山下 雄也, 高橋 直希, 近藤 真代, 佐藤 正大, 豊田 優子, 西岡 安彦 :
当院における進行性線維化を伴う膠原病関連間質性肺疾患の検討,
第64回日本リウマチ学会総会・学術集会, 2020年8月. 佐藤 正大, 村上 行人, 豊田 優子, 小山 壱也, 西村 春佳, 香川 耕造, 髙橋 直希, 河野 弘, 吾妻 雅彦, 西岡 安彦 :
2剤の抗線維化薬を使用した特発性肺線維症症例の検討,
第117回日本内科学会講演会, 2020年8月. 西岡 安彦 :
間質性肺炎:診断と治療の最前線,
117回日本内科学会講演会(教育講演), 2020年8月. 瀬部 真由, 堤 理恵, 瀬野浦 聖佳, 岸 潤, 黒田 雅士, 木下 成三, 中屋 豊, 堤 保夫, 西岡 安彦, 阪上 浩 :
飽和脂肪酸の過剰摂取は関節リウマチ病態の増悪・骨格筋量の減少を引き起こす,
糖尿病, Vol.63, No.Suppl.1, S-329, 2020年8月.徳里 望, 阪上 浩, 堤 理恵, 黒田 雅士, 升本 早枝子, 瀬部 真由, 堤 理恵, 瀬野浦 聖佳, 黒田 雅士, 中屋 豊, 阪上 浩, 岸 潤, 木下 成三, 堤 保夫, 西岡 安彦 :- (キーワード)
- *関節リウマチ(食事療法) *脂肪酸(毒性・副作用) 骨格筋 病勢悪化 *筋肉減少症(化学的誘発) 筋量 ヒト 女
飽和脂肪酸の過剰摂取は関節リウマチを増悪させ骨格筋量の減少を引き起こす,
四国医学雑誌, Vol.76, No.1-2, 120-121, 2020年4月.青井 優, 香川 耕造, 内藤 伸仁, 佐藤 正大, 河野 弘, 三好 人正, 松浦 朋美, 柏原 秀也, 吉川 幸造, 豊田 優子, 坂東 良美, 軒原 浩, 高山 哲治, 島田 光生, 西岡 安彦 :- (キーワード)
- *Catechin *肥満(実験的) *Biflavonoids *Proanthocyanidins *認知機能低下(実験的) 消化管微生物叢 *Procyanidin マウス 動物 / 栄養評価 *関節リウマチ(実験的,合併症,診断) *脂肪酸(薬理学) *骨格筋 身体組成 筋肉減少症(実験的,合併症,診断) ヒト マウス 動物 中年(45~64) 女
好酸球性多発血管炎性肉芽腫症の治療中に回腸出血をきたし，血管炎との鑑別が困難であったCMV腸炎の1例,
第260回徳島医学会学術集会, 2020年2月. 瀬部 真由, 堤 理恵, 瀨野浦 聖佳, 岸 潤, 黒田 雅士, 木下 成三, 中屋 豊, 堤 保夫, 西岡 安彦, 阪上 浩 :
飽和脂肪酸の過剰摂取は関節リウマチ病態の憎悪・骨格筋量の減少を引き起こす,
第23回日本病態栄養学会年次学術集会, 2020年1月. 徳里 望, 阪上 浩, 堤 理恵, 黒田 雅士, 升本 早枝子, 瀬部 真由, 堤 理恵, 瀬野浦 聖佳, 岸 潤, 黒田 雅士, 木下 成三, 中屋 豊, 堤 保夫, 西岡 安彦, 阪上 浩 :
飽和脂肪酸の過剰摂取は関節リウマチ病態の増悪・骨格筋量の減少を引き起こす,
日本病態栄養学会誌, Vol.23, No.Suppl., S-1, 2020年1月.安宅 克博, 河野 弘, 今倉 健, 内藤 伸仁, 近藤 真代, 佐藤 正大, 豊田 優子, 西岡 安彦 :- (キーワード)
- *Catechin *肥満(実験的) *Biflavonoids *Proanthocyanidins *認知機能低下(実験的) 消化管微生物叢 *Procyanidin マウス 動物 / *関節リウマチ(化学的誘発,実験的) 危険因子 *脂肪酸(毒性・副作用) 骨格筋 病勢悪化 *過栄養(化学的誘発,実験的) *筋肉減少症(化学的誘発,実験的) 筋量 マウス 動物
蛋白濾出性胃腸症，クリオグロブリン血症を伴ったMCTDの1例,
第30回日本リウマチ学会中国・四国支部学術集会, 2019年12月. 内藤 伸仁, 河野 弘, 今倉 健, 近藤 真代, 佐藤 正大, 豊田 優子, 西岡 安彦 :
当科におけるANCA陽性間質性肺炎症例の検討,
第30回日本リウマチ学会中国・四国支部学術集会, 2019年12月. 岡本 悠里, 香川 耕造, 大塚 憲司, 宮本 直輝, 吉田 光輝, 米田 浩人, 豊田 優子, 吾妻 雅彦, 西岡 安彦 :
胸腔内に多発した石灰化線維性腫瘍の1例,
第121回日本内科学会四国地方会, 2019年12月. 石田 卓也, 香川 耕造, 米田 浩人, 西村 賢二, 山本 遥平, 佐藤 正大, 河野 弘, 軒原 浩, 西岡 安彦 :
顕微鏡的多発血管炎の治療中に重症筋無力症クリーゼを発症した1例,
第121回日本内科学会四国地方会, 2019年12月. 三橋 惇志, 荻野 広和, 木宿 昌俊, 大塚 憲司, 軒原 浩, 西岡 安彦 :
免疫チェックポイント阻害薬および血管新生阻害薬による複合がん免疫療法における腫瘍内fibrocytelike cellの機能解析,
第32回日本バイオセラピィ学会学術集会総会, 2019年11月. 佐古 雅宏, 香川 耕造, 飛梅 亮, 高橋 直希, 今倉 健, 内藤 伸仁, 香西 博之, 佐藤 正大, 豊田 優子, 軒原 浩, 吾妻 雅彦, 西岡 安彦 :
Mycobacterium malmoenseによる肺感染症の2例,
第70回日本結核病学会中国四国支部会, 2019年11月. 磯村 祐太, 香川 耕造, 米田 浩人, 軒原 浩, 大塚 憲司, 佐藤 正大, 飛梅 亮, 香西 博之, 坂口 暁, 吾妻 雅彦, 西岡 安彦 :
当科における悪性胸膜中皮腫の2次治療の検討,
第62回日本呼吸器学会中国・四国地方会, 2019年11月. 村上 行人, 香川 耕造, 小山 壱也, 吾妻 雅彦, 松本 大資, 坪井 光弘, 川上 行奎, 近藤 和也, 佐藤 正大, 大塚 憲司, 軒原 浩, 西岡 安彦 :
大量胸水および胸膜腫瘤を契機に診断された甲状腺濾胞癌の一例,
第28回日本呼吸器内視鏡学会中国四国支部会, 2019年11月. 後河内 美紗, 阿部 真治, 和泉 俊尋, 松井 朋, 縣 寛昌, 栗木 富美, 田中 朋子, 佐藤 智恵美, 加藤 幸成, 西岡 安彦 :
がん治療抗体のコアフコース除去による CDC 活性への影響,
第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2019年11月. 松井 朋, 阿部 真治, 和泉 俊尋, 後河内 美紗, 縣 寛昌, 栗木 富美, 宮河 真由, 田中 朋子, 佐藤 智恵美, 加藤 幸成, 西岡 安彦 :
がん特異的抗ポドプラニン抗体chLpMab-2fのADCC活性及びCDC活性に関する検討,
第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2019年11月. 縣 寛昌, 阿部 真治, 和泉 俊尋, 栗木 富美, 宮河 真由, 田中 朋子, 佐藤 智恵美, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫に対するマウス抗マウスポドプラニン抗体を用いたin vivo実験系の作成,
第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2019年11月. 堤 理恵, 瀬部 真由, 岸 潤, 瀨野浦 聖佳, 黒田 雅士, 西岡 安彦, 阪上 浩 :
飽和脂肪酸はインスリン抵抗性誘導を介して慢性関節リウマチを増悪させる,
第40回 日本肥満学会, 2019年11月. 栗木 富美, 阿部 真治, 和泉 俊尋, 縣 寛昌, 後河内 美紗, 松井 朋, 宮河 真由, 田中 朋子, 佐藤 智恵美, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫に対するポドカリキシンを標的とした新規腫瘍特異的抗体医薬の抗腫瘍効果に関する検討,
第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2019年11月. 西岡 安彦 :
がん免疫サイクルから考える肺癌に対する複合免疫療法,
第57回日本癌治療学会学術集会(シンポジウム), 2019年10月. 大塚 憲司, 米田 浩人, 三橋 惇志, 荻野 広和, 香西 博之, 飛梅 亮, 軒原 浩, 西岡 安彦 :
間質性肺炎合併非小細胞肺癌における2次化学療法の安全性と有効性の検討,
第57回日本癌治療学会学術集会, 2019年10月. 石田 卓也, 香川 耕造, 米田 浩人, 坂東 紀子, 内藤 伸仁, 荻野 広和, 佐藤 正大, 河野 弘, 西村 賢二, 山本 遥平, 豊田 優子, 軒原 浩, 西岡 安彦 :
顕微鏡的多発血管炎の治療中に重症筋無力症クリーゼを発症した1例,
第259回徳島医学会学術集会, 2019年8月. 吾妻 雅彦, 長宗 雅美, 岩田 貴, 西岡 安彦, 赤池 雅史 :
電子聴診器を用いた呼吸音聴診教育についての取り組み,
第51回日本医学教育学会大会, 2019年7月. 香川 耕造, 小山 壱也, 佐藤 正大, 高橋 直希, 西村 春佳, 内藤 伸仁, 河野 弘, 豊田 優子, 西岡 安彦 :
ブレオマイシン肺線維症マウスモデルにおけるLck阻害の抗線維化効果,
第61回日本呼吸器学会中国・四国地方会, 2019年7月. 近藤 健介, 西條 敦郎, 香川 耕造, 大塚 憲司, 佐藤 正大, 米田 浩人, 飛梅 亮, 後東 久嗣, 軒原 浩, 西岡 安彦 :
末梢血検査値を用いた非小細胞肺癌に対する免疫チェックポイント阻害剤の効果予測因子の検討,
第58回日本肺癌学会中国・四国支部学術集会, 2019年7月. 安宅 克博, 香川 耕造, 近藤 真代, 佐藤 正大, 米田 浩人, 荻野 広和, 飛梅 亮, 香西 博之, 大塚 憲司, 佐藤 正大, 軒原 浩, 西岡 安彦 :
Nivolumab投与により腹水の著明な減少を認めた悪性胸膜中皮腫の1例,
第58回日本肺癌学会中国・四国支部学術集会, 2019年7月. 近藤 圭大, 香川 耕造, 近藤 真代, 荻野 広和, 飛梅 亮, 米田 浩人, 大塚 憲司, 佐藤 正大, 軒原 浩, 西岡 安彦 :
当科における局所進行非小細胞肺癌患者に対する化学放射線療法後のDurvalumabによる治療の臨床的検討,
第58回日本肺癌学会中国・四国支部学術集会, 2019年7月. 内藤 仁美, 香川 耕造, 近藤 真代, 佐藤 正大, 内藤 伸仁, 河野 弘, 豊田 優子, 吾妻 雅彦, 軒原 浩, 西岡 安彦 :
関節リウマチで治療中に抗MDA5抗体陽性をみとめ，無筋症性皮膚筋炎と診断された間質性肺炎の2例,
第61回日本呼吸器学会中国・四国地方会, 2019年7月. 大塚 憲司, 後東 久嗣, 埴淵 昌毅, 荻野 広和, 西條 敦郎, 香西 博之, 米田 浩人, 飛梅 亮, 西岡 安彦 :
化学療法は腫瘍内の骨髄由来抑制細胞を減少させることにより抗PD-1抗体の抗腫瘍効果を増強する,
第28回日本がん転移学会学術集会・総会, 2019年7月. 西村 春佳, 米田 浩人, 香川 耕造, 小山 壱也, 飛梅 亮, 荻野 広和, 西條 敦郎, 宮本 憲哉, 原田 紗希, 坂東 紀子, 豊田 優子, 西岡 安彦 :
癌性リンパ管症の診断にBAL が有用であった多発すりガラス陰影を呈した肺腺癌の1 例,
第42回日本呼吸器内視鏡学会学術集会, 2019年7月. 米田 浩人, 西村 春佳, 香川 耕造, 飛梅 亮, 荻野 広和, 小山 壱也, 西條 敦郎, 豊田 優子, 西岡 安彦 :
気管支鏡検査にて診断し得たリンパ脈管筋腫症の1 例,
第42回日本呼吸器内視鏡学会学術集会, 2019年7月. 西岡 安彦 :
がん免疫サイクルを考慮した複合がん免疫療法,
2019年一般社団法人 日本・多国間臨床試験機構ワークショッ(教育講演), 2019年6月. 小川 博久, 吾妻 雅彦, 梅野 彩, 室富 和俊, 近藤 真代, 坂東 弘基, 常山 幸一, 西岡 安彦 :
気管支喘息における一重項酸素酸化ストレスは気道過敏性を亢進させる,
第68回日本アレルギー学会学術大会, 2019年6月. 西岡 安彦, 荻野 広和, 三橋 惇志 :
血管新生阻害薬耐性とその克服,
第23回日本がん分子標的治療学会学術集会(シンポジウム), 2019年6月. 西條 敦郎, 後東 久嗣, 香西 博之, 荻野 広和, 大塚 憲司, 西岡 安彦 :
非小細胞肺がんに合併した悪性胸水に対するbevacizumabの有効性と耐性化機序の解析,
第23回日本がん分子標的治療学会学術集会, 2019年6月. 三橋 惇志, 後東 久嗣, 荻野 広和, 大塚 憲司, 杉本 正道, 根東 攝, 西岡 安彦 :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における fibrocyte-like cell の機能解析,
第23回日本がん分子標的治療学会学術集会, 2019年6月. 和泉 俊尋, 阿部 真治, 後東 久嗣, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫に対するがん特異的抗podoplanin抗体chLpMab-2のin vitroにおける抗腫瘍効果の検討,
第23回 日本がん分子標的治療学会学術集会, 2019年6月. 福家 麻美, 豊田 優子, 荻野 広和, 河野 弘, 後東 久嗣, 軒原 浩, 吾妻 雅彦, 西岡 安彦 :
Stevens-Johnson症候群後に合併した閉塞性細気管支炎にステロイドおよびタクロリムスが有効であった1例,
第6回日本呼吸ケア・リハビリテーション学会 中国・四国支部学術集会, 2019年6月. 佐藤 正大, 西岡 安彦, Martin Kolb :
線維化肺組織の細胞外基質が線維細胞のmiR-21発現に及ぼす影響の検討,
第18回肺サーファクタント分子病態研究会, 2019年6月. 西岡 安彦 :
特発性肺線維症Update -抗線維化療法を基礎と臨床から考える-,
第234回日本呼吸器学会関東地方会 教育セミナー, 2019年5月. 宮高 絋輔, 吉田 守美子, 遠藤 ふうり, 枡田 志保, 三井 由加里, 倉橋 清衛, 黒田 暁生, 明比 祐子, 遠藤 逸朗, 粟飯原 賢一, 福本 誠二, 船木 真理, 松立 吉弘, 軒原 浩, 西岡 安彦, 安倍 正博, 松久 宗英 :
免疫チェックポイント阻害薬投与後に1型糖尿病を発症した2例,
第62回日本糖尿病学会年次学術集会, 2019年5月. 三橋 惇志, 飛梅 亮, 荻野 広和, 近藤 真代, 豊田 優子, 後東 久嗣, 吉田 光輝, 小川 博久, 軒原 浩, 西岡 安彦 :
肺多形癌における上皮間葉転換 (EMT)の検討,
第120回日本内科学会四国地方会, 2019年5月. 髙橋 直希, 内藤 伸仁, 近藤 真代, 荻野 広和, 河野 弘, 豊田 優子, 三木 浩和, 吾妻 雅彦, 軒原 浩, 西岡 安彦 :
治療抵抗性のSLEに伴う赤芽球癆にシクロホスファミドパルス療法が著効した1例,
第120回日本内科学会四国地方会, 2019年5月. 安宅 克博, 中村 信元, 大浦 雅博, 曽我部 公子, 原田 武志, 藤井 志朗, 三木 浩和, 賀川 久美子, 西岡 安彦, 安倍 正博 :
長期にわたる血小板減少が先行した芽球性形質細胞様樹状細胞腫瘍の1例,
第120回日本内科学会四国地方会, 2019年5月. 吾妻 雅彦, 中瀬 勝則, 豊崎 纏, 宇都宮 正登, 西岡 安彦 :
徳島市COPD啓発推進事業の5年間の成果,
第116回日本内科学会講演会, 2019年4月. 内藤 伸仁, 河野 弘, 近藤 真代, 荻野 広和, 佐藤 正大, 豊田 優子, 後東 久嗣, 西岡 安彦 :
間質性肺炎合併関節リウマチに対するJAK阻害薬の使用経験,
第63回日本リウマチ学会総会・学術集会, 2019年4月. Afroj Tania, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Kisyuku Masatoshi, Atsuro Saijo, Atsushi Mitsuhashi, Koyama Kazuya, Hisatsugu Goto and Yasuhiko Nishioka :
Analyses of immuno-modulatory function of fibrocytes in tumor immunity,
The 59th Annual Meeting of the Japanese Respiratory Society, Apr. 2019. Seidai Satou, Upagupta Chandak, Yanagihara Toyoshi, Kolb RJ. Martin and Yasuhiko Nishioka :
Fibrotic extracellular matrix upregulates pro-fibrotic miRNA expression of fibrocytes,
The 59th Annual Meeting of the Japanese Respiratory Society, Apr. 2019. 榎本 紀之, 本間 栄, 稲瀬 直彦, 滝澤 始, 井上 義一, 石井 寛, 田口 善夫, 泉 信有, 山野 泰彦, 谷野 功典, 西岡 安彦, 豊嶋 幹生, 横村 光司, 妹川 史朗, 小清水 直樹, 須田 隆文 :
膠原病的背景を有する特発性間質性肺炎の予後に関する検討:多施設共同，前向きコホート研究,
第59回日本呼吸器学会学術講演会, 2019年4月. 岡﨑 弘泰, 佐藤 正大, 森住 俊, 小山 壱也, 小川 博久, 香川 耕造, 西村 春佳, Yajuan Chen, 青野 純典, 阿部 秀一, 東 桃代, 後東 久嗣, 河野 弘, 豊田 優子, 上原 久典, 小路 弘行, 西岡 安彦 :
ブレオマイシン肺線維症マウスモデルにおけるWnt/B-カテニン/CBPシグナル阻害薬PRI-724による抗線維化効果の検討,
第59回日本呼吸器学会学術講演会, 2019年4月. Hiroshi Nokihara, Masaki Hanibuchi, Souji Kakiuchi, Atagi Shinji, Ogushi Fumitaka, Shimizu Eiji, Haku Takashi, Yuko Toyoda, Masahiko Azuma, Mayo Kondou, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hisatsugu Goto and Yasuhiko Nishioka :
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced NSCLC patients with interstitial lung disease,
The 59th Annual Meeting of the Japanese Respiratory Society, Apr. 2019. 小山 壱也, 内藤 伸仁, 香川 耕造, 西村 春佳, 佐藤 正大, 河野 弘, 豊田 優子, 後東 久嗣, 吾妻 雅彦, 西岡 安彦 :
関節リウマチ合併間質性肺炎患者の急性呼吸不全の臨床的検討,
第59回日本呼吸器学会学術講演会, 2019年4月. 西岡 安彦, Toby Maher, Gisli Jenkins :
NMARK試験:IPF患者でのECM ターンオーバー―バイオマーカーと疾患進行の関連及びニンテダニブの効果を評価する試験,
第59回日本呼吸器学会学術講演会, 2019年4月. 西岡 安彦 :
日本呼吸器学会の海外留学支援と海外留学助成金制度(特別企画セッション),
第59回日本呼吸器学会学術講演会, 2019年4月. 西岡 安彦 :
肺がん腫瘍環境におけるfibrocyte-like cellの病的意義,
第59回日本呼吸器学会学術講演会(シンポジウム), 2019年4月. 森戸 克弥, 島田 明奈, 宮﨑 徹, 清水 良多, 高橋 尚子, 東 桃代, 小山 壱也, 西岡 安彦, 福田 達也, 小暮 健太朗, 田中 保 :
ヒト血漿中セラミド及びセラミド1-リン酸の分子種組成と動物細胞へ作用,
日本農芸化学会2019年度大会, 2019年3月. 縣 寛昌, 阿部 真治, 和泉 俊尋, 栗木 富美, 松井 朋, 佐藤 智恵美, 田中 朋子, 久米 哲也, 加藤 幸成, 西岡 安彦 :
マウス抗マウスポドプラニン抗体による 悪性胸膜中皮腫に対するADCC 活性およびCDC 活性の検討,
日本薬学会第139年会, 2019年3月. 和泉 俊尋, 阿部 真治, 縣 寛昌, 後河内 美紗, 佐藤 智恵美, 田中 朋子, 久米 哲也, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫に対する抗ポドカリキシン抗体のADCC 活性の検討,
日本薬学会第139年会, 2019年3月. 宮高 紘輔, 遠藤 ふうり, 三井 由加里, 枡田 志保, 倉橋 清衛, 吉田 守美子, 黒田 暁生, 明比 祐子, 遠藤 逸朗, 粟飯原 賢一, 船木 真理, 福本 誠二, 軒原 浩, 西岡 安彦, 安倍 正博, 松久 宗英 :
抗PD-1抗体投与後に1型糖尿病を発症した1例,
第258回徳島医学会学術集会 ポスターセッション, 2019年2月. 小山 壱也, 内藤 伸仁, 香川 耕造, 近藤 真代, 西村 春佳, 佐藤 正大, 河野 弘, 豊田 優子, 吾妻 雅彦, 後東 久嗣, 西岡 安彦 :
マウス肺線維症モデルにおける新規multi-tyrosine kinase inhibitor TAS-115の抗線維化効果の検討,
第258回徳島医学会学術集会, 2019年2月. 近藤 真代, 小川 博久, 手塚 敏史, 坂東 弘基, 吾妻 雅彦, 西岡 安彦 :
気管支喘息におけるリゾフォスファチジン酸(LPA)の役割とその阻害効果についての検討,
第1回日本アレルギー学会中国・四国支部地方会, 2019年2月. 西岡 安彦 :
肺癌治療における免疫チェックポイント阻害剤の位置づけと新展開,
第27回日本呼吸器内視鏡学会中国四国支部会 ランチョンセミナー, 2018年12月. 坂東 紀子, 近藤 真代, 河野 弘, 藤野 泰輝, 岡久 稔也, 豊田 優子, 軒原 浩, 吾妻 雅彦, 後東 久嗣, 高山 哲治, 西岡 安彦 :
潰瘍性大腸炎加療中に発症し，治療に難渋したニューモシスチス肺炎の一例,
第60回日本呼吸器学会中国・四国地方会, 2018年12月. 原田 紗希, 近藤 真代, 西村 春佳, 内藤 伸仁, 河野 弘, 大崎 裕亮, 坂東 良美, 髙橋 直希, 香川 耕造, 西岡 安彦, 荻野 広和, 飛梅 亮, 西條 敦郎, 軒原 浩, 豊田 優子, 吾妻 雅彦, 後東 久嗣, 上原 久典, 西岡 安彦 :
傍腫瘍性神経症候群を合併した小細胞肺癌の一例,
第60回日本呼吸器学会中国・四国地方会, 2018年12月. 坂東 弘基, 近藤 真代, 宮城 亮, 荻野 広和, 飛梅 亮, 尾矢 剛志, 小川 博久, 河野 弘, 豊田 優子, 軒原 浩, 吾妻 雅彦, 後東 久嗣, 西良 浩一, 西岡 安彦 :
エイの刺創後に発症した皮膚Mycobacterium massiliense症の一例,
第69回日本結核病学会中国四国支部会, 2018年12月. 佐藤 正大, 豊田 優子, 内藤 伸仁, 米田 浩人, 香川 耕造, 西村 春佳, 近藤 真代, 小山 壱也, 河野 弘, 後東 久嗣, 西岡 安彦 :
気管支肺胞洗浄液中fibrocyteにおけるmiR-21発現の疾患別差異に関する検討,
第27回日本呼吸器内視鏡学会中国四国支部会, 2018年12月. 荻野 広和, 大塚 憲司, 三橋 惇志, 木宿 昌俊, 西岡 安彦 :
肺癌・悪性胸膜中皮腫マウスモデルを用いた免疫チェックポイント阻害薬と化学療法の併用効果に関する検討,
第31回日本バイオセラピィ学会学術集会総会, 2018年12月. 宮本 憲哉, 近藤 真代, 内藤 伸仁, 山崎 博輝, 豊田 優子, 荻野 広和, 河野 弘, 後東 久嗣, 梶 龍兒, 西岡 安彦 :
免疫介在性壊死性ミオパチーの1例,
第119回日本内科学会四国地方会, 2018年12月. 金子 遥祐, 近藤 真代, 髙橋 直希, 飛梅 亮, 荻野 広和, 佐藤 正大, 三木 浩和, 後東 久嗣, 安倍 正博, 西岡 安彦 :
多発小結節影を認めたHIV陽性ニューモシスチス肺炎の1例,
第119回日本内科学会四国地方会, 2018年12月. 米田 浩人, 大塚 憲司, 荻野 広和, 西條 敦郎, 後東 久嗣, 軒原 浩, 西岡 安彦 :
間質性肺炎合併非小細胞肺癌に対する 2 次化学療法の検討,
第59回日本肺癌学会学術集会, 2018年12月. 山下 雄也, 河野 弘, 今倉 健, 内藤 伸仁, 近藤 真代, 荻野 広和, 佐藤 正大, 豊田 優子, 後東 久嗣, 西岡 安彦 :
TAFRO症候群の1例,
第29回日本リウマチ学会中国・四国支部学術集会, 2018年12月. 西條 敦郎, 香西 博之, 近藤 健介, 後東 久嗣, 荻野 広和, 軒原 浩, 豊田 優子, 西岡 安彦 :
非小細胞肺がんに対する免疫チェックポイント阻害剤の生存期間に関する予後不良因子の検討,
第59回日本肺癌学会学術集会, 2018年11月. 内藤 伸仁, 河野 弘, 近藤 真代, 荻野 広和, 佐藤 正大, 豊田 優子, 後東 久嗣, 西岡 安彦 :
EBウイルス再活性化を反復した高疾患活動性関節リウマチに対してアバタセプトが有効であった1例,
第29回日本リウマチ学会中国・四国支部学術集会, 2018年11月. 後東 久嗣, 三橋 惇志, 西條 敦郎, 西岡 安彦 :
線維細胞(fibrocytes)を標的とした血管新生阻害薬耐性メカニズムの解明と治療への展開,
第59回日本肺癌学会学術集会, 2018年11月. 埴淵 昌毅, 安宅 信二, 大串 文隆, 山崎 章, 葉久 貴司, 軒原 浩, 西岡 安彦 :
間質性肺炎合併未治療進行非小細胞肺癌に対する TS-1+CBDCA 併用療法の第 II 相臨床試験,
第59回日本肺癌学会学術集会, 2018年11月. 西岡 安彦 :
変化する特発性肺線維症のマネージメント―疾患理解と治療戦略―,
第59回日本肺癌学会学術集会, 2018年11月. 西岡 安彦, 阿部 真治, 金子 美華, 三橋 惇志, 大塚 憲司, 後東 久嗣, 加藤 幸成 :
悪性胸膜中皮腫に対する新規治療法開発を目指した前臨床研究,
第56回日本癌治療学会学術集会 (パネルディスカッション), 2018年10月. 米田 浩人, 荻野 広和, 豊田 優子, 河野 弘, 大塚 憲司, 西條 敦郎, 軒原 浩, 後東 久嗣, 西岡 安彦 :
高齢肺癌患者の若年者と比較した臨床的特徴,
第56回日本癌治療学会学術集会, 2018年10月. 西岡 安彦 :
特発性肺線維症の診断と治療∼抗線維化薬の意義∼,
第81回日本呼吸器学会・日本結核病学会・日本サルコイドーシス/肉芽腫性疾患学会九州支部秋季学術講演会 ランチョンセミナー, 2018年10月. 山田 慎二, 金子 美華, 国田 朱子, 阿部 真治, 板井 俊介, 深山 正久, 西岡 安彦, 加藤 幸成 :
がん特異的podoplaninを認識するヒトキメラ改変モノクローナル抗体,
第77回日本癌学会総会, 2018年9月. 板井 俊介, 大石 智一, 金子 美華, 山田 慎二, 阿部 真治, 西岡 安彦, 川田 学, 原田 浩之, 加藤 幸成 :
口腔扁平上皮癌における抗ポドカリキシン抗体のADCCによる抗腫瘍効果,
第77回日本癌学会総会, 2018年9月. 森戸 克弥, 清水 良多, 高橋 尚子, 下澤 伸行, 東 桃代, 河野 弘, 西岡 安彦, 福田 達也, 小暮 健太朗, 田中 保 :
ヒト血漿中セラミド及びセラミド1-リン酸の分子種組成と細胞への取り込み,
第91回日本生化学会大会, 2018年9月. 近藤 真代, 坂東 弘基, 香川 耕造, 西村 春佳, 小山 壱也, 佐藤 正大, 豊田 優子, 吾妻 雅彦, 小川 博久, 後東 久嗣, 西岡 安彦 :
リゾフォスファチジン酸を標的にしたアレルギー性気道炎症制御についての検討,
第257回徳島医学会学術集会, 2018年8月. 髙橋 直希, 荻野 広和, 埴淵 昌毅, 西條 敦郎, 飛梅 亮, 香西 博之, 米田 浩人, 福家 麻美, 三橋 惇志, 宮本 憲哉, 軒原 浩, 後東 久嗣, 西岡 安彦 :
当科における高齢者肺癌の臨床的検討,
第257回徳島医学会学術集会, 2018年8月. 森 あずさ, 内藤 伸仁, 山﨑 博輝, 林 理恵, 坂東 紀子, 原田 沙希, 河野 弘, 豊田 優子, 後東 久嗣, 梶 龍兒, 久保 宜明, 西岡 安彦 :
免疫介在性壊死性ミオパチーの1例,
第257回徳島医学会学術集会, 2018年8月. 宮上 慎司, 小野 広幸, 岸 誠司, 近藤 英司, 内藤 伸仁, 稲垣 太造, 湊 将典, 上田 紗代, 西村 賢二, 柴田 恵理子, 田蒔 昌憲, 岸 史, 村上 太一, 安部 秀斉, 西岡 安彦, 長井 幸二郎 :
ANCA関連血管炎との鑑別を要したIgG4関連疾患の1例,
第257回徳島医学会学術集会, 2018年8月. 荻野 広和, 埴淵 昌毅, 柿内 聡司, 安宅 信二, 大串 文隆, 清水 英治, 葉久 貴司, 大塚 憲司, 西條 敦郎, 軒原 浩, 後東 久嗣, 西岡 安彦 :
間質性肺炎合併未治療進行非小細胞肺癌に対するTS-1+CBDCA併用療法の第Ⅱ相臨床試験,
第16回日本臨床腫瘍学会学術集会, 2018年7月. 吾妻 雅彦, 湊 義彰, 木下 勝弘, 近藤 真代, 西岡 安彦 :
クリーニング業の夫婦に発症した夏型過敏性肺炎例,
第49回日本職業・環境アレルギー学会総会・学術大会, 2018年7月. 西條 敦郎, 後東 久嗣, 香西 博之, 飛梅 亮, 荻野 広和, 米田 浩人, 西岡 安彦 :
肺がんの悪性胸水に対する bevacizumab の有効性と耐性化機序の解析,
第27回日本がん転移学会 学術集会・総会, 2018年7月. 西岡 安彦 :
肺がん進展に関わる線維細胞の機能解析から治療への展開,
第27回日本がん転移学会 学術集会・総会 (シンポジウム), 2018年7月. 三橋 惇志, 香川 耕造, 米田 浩人, 西條 敦郎, 飛梅 亮, 荻野 広和, 近藤 真代, 髙橋 直希, 軒原 浩, 後東 久嗣, 西岡 安彦 :
当科における免疫チェックポイント阻害薬による薬剤性間質性肺疾患の検討,
第59回日本呼吸器学会中国・四国地方会/第57回日本肺癌学会中国・四国支部学術集会, 2018年7月. 森 文香, 米田 浩人, 近藤 真代, 荻野 広和, 飛梅 亮, 西條 敦郎, 福家 麻美, 軒原 浩, 後東 久嗣, 西岡 安彦 :
複視を発症し，斜台部腫瘍を契機に診断された非小細胞肺癌の1例,
第57回日本肺癌学会中国・四国支部学術集会, 2018年7月. 國重 道大, 米田 浩人, 河野 弘, 西條 敦郎, 飛梅 亮, 近藤 真代, 坂東 弘基, 小川 博久, 軒原 浩, 後東 久嗣, 西岡 安彦 :
腸型肺腺癌の1例,
第57回日本肺癌学会中国・四国支部学術集会, 2018年7月. 坂東 紀子, 豊田 優子, 河野 弘, 佐藤 正大, 小山 壱也, 西村 春佳, 香川 耕造, 内藤 伸仁, 吾妻 雅彦, 西岡 安彦 :
当科で経験した抗MDA5抗体陽性皮膚筋炎合併間質性肺炎の臨床像の検討,
第59回日本呼吸器学会中国・四国地方会, 2018年7月. 多幡 有莉乃, 荻野 広和, 西條 敦郎, 香西 博之, 近藤 真代, 坂東 良美, 松本 大資, 後東 久嗣, 滝沢 宏光, 西岡 安彦 :
悪性胸水を契機に診断された放射線誘発血管肉腫の1例,
第59回日本呼吸器学会中国・四国地方会, 2018年7月. 西岡 安彦 :
肺癌治療における免疫チェックポイント阻害剤の位置づけと新展開,
第108回日本肺癌学会関西支部学術集会 ランチョンセミナー, 2018年6月. 近藤 真代, 手塚 敏史, 小川 博久, 吾妻 雅彦, 西岡 安彦 :
リゾフォスファチジン酸を標的にしたアレルギー性気道炎症制御についての検討,
第67回日本アレルギー学会学術大会, 2018年6月. 小川 博久, 吾妻 雅彦, 近藤 真代, 西岡 安彦 :
神経成長因子(NGF)の難治性喘息における気道過敏性亢進に対する役割とそのメカニズム,
第67回日本アレルギー学会学術大会, 2018年6月. 内藤 伸仁, 森田 優, 香川 耕造, 近藤 真代, 西村 春佳, 河野 弘, 豊田 優子, 岸 潤, 後東 久嗣, 西岡 安彦 :
Tocilizumab が有効であった重症成人発症スティル病の1例,
第118回日本内科学会四国地方会, 2018年6月. 米田 浩人, 荻野 広和, 香西 博之, 大塚 憲司, 飛梅 亮, 西條 敦郎, 豊田 優子, 後東 久嗣, 軒原 浩, 西岡 安彦 :
当科における Pembrolizumab の使用経験,
第118回日本内科学会四国地方会, 2018年6月. 美馬 正人, 荻野 広和, 近藤 真代, 香西 博之, 大塚 憲司, 小山 壱也, 豊田 優子, 吾妻 雅彦, 後東 久嗣, 西岡 安彦 :
特発性肺骨化症の2例,
第118回日本内科学会四国地方会, 2018年6月. 宮本 綾香, 香西 博之, 荻野 広和, 近藤 真代, 大塚 憲司, 小山 壱也, 豊田 優子, 吾妻 雅彦, 西岡 安彦 :
肺M.chelonae 症の経過中に診断された肺M.massiliense 症の1例,
第118回日本内科学会四国地方会, 2018年6月. 豊田 優子, 小山 壱也, 西村 春佳, 香川 耕造, 西條 敦郎, 飛梅 亮, 荻野 広和, 米田 浩人, 西岡 安彦 :
乳癌患者の放射線治療後に発症した放射線肺炎における気管支肺胞洗浄液の臨床的検討,
第41回日本呼吸器内視鏡学会学術集会, 2018年5月. 香川 耕造, 豊田 優子, 西條 敦郎, 飛梅 亮, 荻野 広和, 米田 浩人, 小山 壱也, 西村 春佳, 西岡 安彦 :
EBUS-TBNA後に縦隔炎を発症した症例における危険因子の検討,
第41回日本呼吸器内視鏡学会学術集会, 2018年5月. 荻野 広和, 後東 久嗣, 大塚 憲司, 西條 敦郎, 埴淵 昌毅, 西岡 安彦 :
線維細胞が腫瘍免疫に及ぼす影響についての検討,
第22回日本がん分子標的治療学会学術集会, 2018年5月. 大塚 憲司, 後東 久嗣, 荻野 広和, 西條 敦郎, 埴淵 昌毅, 西岡 安彦 :
肺癌・悪性胸膜中皮腫マウスモデルにおける免疫チェックポイント阻害薬と化学療法の併用効果,
第22回日本がん分子標的治療学会学術集会, 2018年5月. 小山 壱也, 豊田 優子, 西村 春佳, 香川 耕造, 森住 俊, 河野 弘, 後東 久嗣, 西岡 安彦 :
マウス肺線維症モデルにおけるmulti-tyrosine kinase inhibitor TAS-115の抗線維化効果の検討．,
第58回日本呼吸器学会学術講演会., 2018年4月. 飛梅 亮, 荻野 広和, Tania Afroj, 後東 久嗣, 軒原 浩, 吉田 光輝, 川上 行奎, 滝沢 宏光, 小川 博久, 常山 幸一, 西岡 安彦 :
上皮間葉転換 (EMT)が肺多形癌の悪性化に寄与する可能性についての検討.,
第58回日本呼吸器学会学術講演会, 2018年4月. 西村 春佳, 森住 俊, 豊田 優子, 鈴江 涼子, 小山 壱也, 香川 耕造, 内藤 伸仁, 河野 弘, 後東 久嗣, 西岡 安彦 :
当院における特発性肺線維症に対するNintedanibの治療症例の検討．,
第58回日本呼吸器学会学術講演会, 2018年4月. 内藤 伸仁, 河野 弘, 山下 雄也, 近藤 真代, 荻野 広和, 豊田 優子, 岸 潤, 後東 久嗣, 西岡 安彦 :
アザチオプリン併用療法が有効であった間質性肺炎合併抗MDA5抗体陽性皮膚筋炎の3例．,
第62回日本リウマチ学会総会・学術集会, 2018年4月. 荻野 広和, 埴淵 昌毅, 西條 敦郎, 大塚 憲司, 豊田 優子, 後東 久嗣, 西岡 安彦 :
徳島大学病院の肺癌症例において高齢者と若年者を比較した後ろ向き研究．,
第115回日本内科学会総会・講演会, 2018年4月. 豊田 優子, 埴淵 昌毅, 柿内 聡司, 安宅 信二, 大串 文隆, 清水 英治, 葉久 貴司, 軒原 浩, 後東 久嗣, 西岡 安彦 :
間質性肺炎合併未治療進行非小細胞肺癌に対するTS-1+CBDCA併用療法の第Ⅱ相臨床試験．,
第115回日本内科学会総会・講演会, 2018年4月. 西岡 安彦 :
肺がん診療の最前線 ∼進む分子診断と個別化医療∼,
第17回日本癌治療学会市民公開講座, 2018年4月. 内藤 伸仁, 森田 優, 大塚 憲司, 河野 弘, 豊田 優子, 岸 潤, 後東 久嗣, 西岡 安彦 :
Tocilizumabが有効であった重症成人発症スティル病の1例．,
第256回徳島医学会学術集会, 2018年2月. 辻本 賀美, 内藤 伸仁, 近藤 真代, 香西 博之, 河野 弘, 大塚 憲司, 後東 久嗣, 岸 潤, 吾妻 雅彦, 西岡 安彦 :
多発単神経炎を合併した好酸球性多発血管炎性肉芽腫症(EGPA)において免疫グロブリン大量療法(IVIG)が有効であった3例,
第117回日本内科学会四国地方会, 2017年12月. 米田 浩人, 大塚 憲司, 西條 敦郎, 飛梅 亮, 荻野 広和, 香西 博之, 豊田 優子, 後東 久嗣, 軒原 浩, 西岡 安彦 :
当科におけるnivolumabの有害事象の検討,
第117回日本内科学会四国地方会, 2017年12月. 山下 雄也, 河野 弘, 岸 潤, 内藤 伸仁, 荻野 広和, 近藤 真代, 森住 俊, 豊田 優子, 後東 久嗣, 吾妻 雅彦, 西岡 安彦 :
全身性強皮症を背景にposterior reversible encephalopathy syndromeを発症した一例,
第28回日本リウマチ学会中国・四国支部学術集会, 2017年11月. 今倉 健, 内藤 伸仁, 山下 雄也, 荻野 広和, 岸 潤, 河野 弘, 近藤 真代, 森住 俊, 豊田 優子, 後東 久嗣, 吾妻 雅彦, 西岡 安彦 :
ループス心筋炎の2例,
第28回日本リウマチ学会中国・四国支部学術集会, 2017年11月. 河野 弘, 松本 満, 西岡 安彦 :
ほぼすべての胸腺髄質上皮細胞が成熟過程でAireを発現する機能を備えている,
第28回日本リウマチ学会中国・四国支部学術集会, 2017年11月. 荻野 広和, 豊田 優子, 河野 弘, 岸 潤, 近藤 真代, 森住 俊, 山下 雄也, 後東 久嗣, 吾妻 雅彦, 西岡 安彦 :
当院における肺病変合併全身性エリテマトーデス症例の臨床的検討,
第28回日本リウマチ学会中国・四国支部学術集会, 2017年11月. 西岡 安彦 :
間質性肺炎の診断と治療∼最近の進歩∼,
平成29年度日本内科学会生涯教育講演会Bセッション(第2回), 2017年10月. 鈴江 涼子, 西村 春佳, 荻野 広和, 大塚 憲司, 飛梅 亮, 河野 弘, 福家 麻美, 山下 雄也, 後東 久嗣, 西岡 安彦 :
心タンポナーデをきたした結核性心膜炎の1例,
第68回日本結核病学会中国四国支部会, 2017年10月. 美馬 正人, 香西 博之, 飛梅 亮, 大塚 憲司, 内藤 伸仁, 豊田 優子, 後東 久嗣, 岸 潤, 吾妻 雅彦, 西岡 安彦 :
抗 IFN- γ抗体が陽性であった播種性非結核性抗酸菌症の1例,
第68回日本結核病学会中国四国支部会, 2017年10月. 福田 喬太郎, 森田 優, 大塚 憲司, 西村 春佳, 森住 俊, 香川 耕造, 小山 壱也, 今倉 健, 後東 久嗣, 西岡 安彦 :
BAL により癌性リンパ管症と診断しえた多発スリガラス影を呈した肺腺癌の1例,
第26回日本呼吸器内視鏡学会中国四国支部会, 2017年10月. 森田 優, 豊田 優子, 大塚 憲司, 西條 敦郎, 米田 浩人, 近藤 真代, 香西 博之, 後東 久嗣, 軒原 浩, 西岡 安彦 :
放射線治療のアブスコパル効果による腫瘍縮小を認めた後に再発し，pembrolizumab が奏功した肺癌の1例,
第58回日本呼吸器学会中国・四国地方会, 2017年10月. 飛梅 亮, 森住 俊, 鈴江 涼子, 緋田 哲也, 荻野 広和, 大塚 憲司, 後東 久嗣, 上原 久典, 久保 宜明, 西岡 安彦 :
BRAF 陽性肺原発悪性黒色腫の1例,
第58回日本呼吸器学会中国・四国地方会, 2017年10月. 西岡 安彦 :
がん免疫療法の基礎と臨床∼最近の話題∼,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会ランチョンセミナー, 2017年10月. 西岡 安彦 :
IIPsの病態・治療からPM/DMに伴う間質性肺炎を考える.,
第9回筋炎ワークショップ, 2017年10月. 西條 敦郎, 埴淵 昌毅, 荻野 広和, 軒原 浩, 豊田 優子, 後東 久嗣, 西岡 安彦 :
再発小細胞肺癌に対するpaclitaxel療法の検討,
第58回日本肺癌学会学術集会, 2017年10月. 西岡 安彦 :
特発性肺線維症の治療戦略-抗線維化治療をいつ，誰に導入するのか?-,
第58回日本肺癌学会学術集会 ランチョンセミナー, 2017年10月. 阿部 真治, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫に対するポドプラニンを標的とした抗体療法の開発,
第24回石綿・中皮腫研究会, 2017年10月. 後東 久嗣, 西岡 安彦 :
悪性胸膜中皮腫に対する抗血管新生療法の可能性と耐性機序．,
第24回石綿・中皮腫研究会, 2017年10月. 西條 敦郎, 後東 久嗣, 荻野 広和, 軒原 浩, 西岡 安彦 :
骨髄由来線維細胞(fibrocyte)は肺癌のがん幹細胞様特性を促進する,
第76回日本癌学会学術総会, 2017年9月. 張 耀文, 国田 朱子, 金子 美華, 板井 俊介, 山田 慎二, 大石 智一, 阿部 真治, 西岡 安彦, 川田 学, 深山 正久, 加藤 幸成 :
ポドカリキシンを標的としたヒトキメラ型抗体chPcMab-47によるヒト大腸がん移植片モデルでの抗腫瘍効果の検討,
第76回日本癌学会総会, 2017年9月. 山田 慎二, 金子 美華, 国田 朱子, 大石 智一, 阿部 真治, 張 耀文, 板井 俊介, 川田 学, 深山 正久, 西岡 安彦, 加藤 幸成 :
がん特異的podocalyxinを認識するヒトキメラ改変モノクローナル抗体(chPcMab-6)の抗腫瘍効果および安全性,
第76回日本癌学会総会, 2017年9月. 吾妻 雅彦, 長宗 雅美, 岩田 貴, 川添 和義, 石澤 啓介, 竹谷 豊, 西岡 安彦, 赤池 雅史 :
徳島大学における担当患者を用いた多職種連携教育の取り組み,
第49回日本医学教育学会大会, 2017年8月. 山下 貴央, 西村 春佳, 荻野 広和, 大塚 憲司, 飛梅 亮, 豊田 優子, 後東 久嗣, 西岡 安彦 :
心タンポナーデをきたした結核性心膜炎の1例,
第255回徳島医学会学術集会, 2017年8月. 大西 一, 森住 俊, 緋田 哲也, 松立 吉弘, 荻野 広和, 大塚 憲司, 飛梅 亮, 後東 久嗣, 上原 久典, 久保 宜明, 西岡 安彦 :
BRAF陽性肺原発悪性黒色腫の1例,
第255回徳島医学会学術集会, 2017年8月. 岩城 真帆, 湊 将典, 岸 誠司, 村上 太一, 松浦 元一, 長井 幸二郎, 安部 秀斉, 土井 俊夫, 西條 敦郎, 西岡 安彦 :
ニボルマブの投与を契機としてIgA腎症を発症した扁平上皮癌の1例,
第255回徳島医学会学術集会, 2017年8月. 荻野 広和, 埴淵 昌毅, 西條 敦郎, 手塚 敏史, 後東 久嗣, 西岡 安彦 :
徳島大学病院における高齢者肺癌と若年者肺癌の臨床的特徴に関する比較検討,
第15回日本臨床腫瘍学会学術集会, 2017年7月. 西條 敦郎, 荻野 広和, 大塚 憲司, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
Clinical efficacy of bevacizumab for non-squamous non-small cell lung cancer patients with malignant pleural effusion.,
第15回日本臨床腫瘍学会学術集会, 2017年7月. 後東 久嗣, 西條 敦郎, 中野 万有里, 飛梅 亮, 大塚 憲司, 米田 浩人, 埴淵 昌毅, 西岡 安彦 :
がん幹細胞化の誘導を介したfibrocyteの肺がん進展・転移促進メカニズム,
第26回日本がん転移学会学術集会・総会, 2017年7月. 後東 久嗣, 三橋 惇志, 西條 敦郎, 埴淵 昌毅, 西岡 安彦 :
線維細胞(fibrocyte)を標的としたがん転移・進展メカニズムの解明と血管新生阻害薬耐性克服の試み．,
第26回日本がん転移学会学術集会・総会, 2017年7月. 鈴江 涼子, 森住 俊, 大塚 憲司, 豊田 優子, 河野 弘, 小山 壱也, 香西 博之, 西村 春佳, 後東 久嗣, 西岡 安彦 :
特発性肺線維症に対するnintedanibの使用経験,
第57回日本呼吸器学会中国・四国地方会, 2017年7月. 喜田 有佳里, 香川 耕造, 大塚 憲司, 荻野 広和, 飛梅 亮, 西條 敦郎, 軒原 浩, 後東 久嗣, 西岡 安彦 :
放射線治療のアブスコパル効果によると考えられる腫瘍縮小を認めた肺癌の1例,
第56回日本肺癌学会中国・四国支部学術集会., 2017年7月. 今倉 健, 大塚 憲司, 西條 敦郎, 飛梅 亮, 荻野 広和, 香西 博之, 後東 久嗣, 軒原 浩, 西岡 安彦 :
小細胞肺癌への転化を認めたEGFR遺伝子変異陽性肺腺癌の1例,
第56回日本肺癌学会中国・四国支部学術集会, 2017年7月. 美馬 正人, 吾妻 雅彦, 大塚 憲司, 山下 雄也, 後東 久嗣, 岸 潤, 吉田 光輝, 上原 久典, 西岡 安彦 :
Minute Pulmonary Meningothelial-like Noduleの1例,
第57回日本呼吸器学会中国・四国地方会, 2017年7月. 小川 博久, 吾妻 雅彦, 近藤 真代, 手塚 敏史, 西岡 安彦 :
IL-17/好中球は気道粘膜接着分子を障害しFGF-2産生を介した気道平滑筋肥厚を誘導する,
第66回日本アレルギー学会学術大会, 2017年6月. 近藤 真代, 手塚 敏史, 小川 博久, 吾妻 雅彦, 西岡 安彦 :
リゾフォスファチジン酸はアレルギー性気道炎症の誘導に関与している,
第66回日本アレルギー学会学術大会, 2017年6月. 大塚 憲司, 埴淵 昌毅, 後東 久嗣, 西岡 安彦 :
肺癌・悪性胸膜中皮腫に対する抗PD-1抗体，抗PD-L1抗体と化学療法の併用効果の基礎的検討,
第21回日本がん分子標的学会学術集会, 2017年6月. 山子 泰斗, 後東 久嗣, 西條 敦郎, 埴淵 昌毅, 西岡 安彦 :
肺がん骨転移におけるRANKL標的治療の限界と可能性,
第21回日本がん分子標的学会学術集会, 2017年6月. 和泉 俊尋, 阿部 真治, 荻野 広和, 後東 久嗣, 埴淵 昌毅, 加藤 幸成, 西岡 安彦 :
悪性胸膜中皮腫同所移植マウスモデルに対する新規マウス抗ポドプラニン抗体LpMab-21による抗腫瘍効果の検討,
第21回日本がん分子標的学会学術集会, 2017年6月. 西岡 安彦 :
間質性肺炎の診断と治療∼最近の進歩∼,
平成29年度日本内科学会生涯教育講演会Bセッション(第1回), 2017年6月. 西村 春佳, 手塚 敏史, 西條 敦郎, 河野 弘, 後東 久嗣, 岸 潤, 軒原 浩, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
肺扁平上皮癌治療後の空洞病変に認めた肺アスペルギルス症の1例,
第116回日本内科学会四国地方会, 2017年5月. 近藤 真代, 手塚 敏史, 河野 弘, 後東 久嗣, 岸 潤, 埴淵 昌毅, 吾妻 雅彦, 土師 正太郎, 梶 龍兒, 西岡 安彦 :
小脳浮腫および水頭症を認め開頭減圧術を要したNPSLEの1例,
第116回日本内科学会四国地方会, 2017年5月. 手塚 敏史, 小川 博久, 近藤 真代, 豊田 優子, 佐藤 正大, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
ダニ抗原誘導性のアレルギー性気道炎症および気道リモデリングはPAR-2 antagonistの投与により抑制される,
第57回日本呼吸器学会学術講演会, 2017年4月. 埴淵 昌毅, 中瀬 勝則, 豊崎 纏, 木下 成三, 島田 久夫, 鶴尾 美穂, 原田 和代, 水井 研治, 葉久 貴司, 西岡 安彦 :
徳島市におけるCOPD早期発見を目的とした検診システム,
第57回日本呼吸器学会学術講演会, 2017年4月. Hirokazu Ogino, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Toshifumi Tezuka, Yuko Toyoda, Satoshi Sakaguchi, Hisatsugu Goto, Kokichi Arisawa and Yasuhiko Nishioka :
Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital.,
The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017. Atsuro Saijo, Hisatsugu Goto, Mayuri Nakano, Mitsuhashi Atsushi, Hirokazu Ogino, Makoto Tobiume, Kenji Ohtsuka, Hiroto Yoneda, Masaki Hanibuchi and Yasuhiko Nishioka :
Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells.,
The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017. 豊田 優子, 岸 潤, 河野 弘, 森住 俊, 小山 壱也, 西村 春佳, 香川 耕造, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
当院における全身性エリテマトーデス合併間質性肺炎の臨床的検討,
第57回日本呼吸器学会学術講演会, 2017年4月. 西岡 安彦 :
特発性肺線維症:橋渡し研究の意義と展望,
第57回日本呼吸器学会学術講演会, 2017年4月. 大山 吉幸, 榎本 紀之, 鈴木 勇三, 河野 雅人, 中村 祐太郎, 藤澤 朋幸, 乾 直輝, 黒石 重城, 横村 光司, 豊嶋 幹生, 妹川 史朗, 大石 景士, 渡辺 知志, 笠原 寿郎, 馬場 智尚, 小倉 高志, 石井 寛, 渡辺 憲太朗, 西岡 安彦, 須田 隆文 :
Pleuroparenchymal fibroelastosisにおける尿中デスモシンの有用性の検討,
第57回日本呼吸器学会学術講演会, 2017年4月. Shun Morizumi, Seidai Satou, Hirokazu Ogino, Koyama Kazuya, Haruka Nishimura, Yuko Toyoda, Hiroshi Kawano and Yasuhiko Nishioka :
Inhibition of pan-fibroblast growth factor receptor signaling in bleomycin-induced pulmonary fibrosis in mice,
The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017. Yasuhiko Nishioka :
Blockade of growth factor signals in fibrogenesis of the lungtherapeutic efficacy and mechanism of action.,
The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017. 河野 弘, 豊田 優子, 岸 潤, 森住 俊, 近藤 真代, 山下 雄也, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
当院における間質性肺炎合併全身性エリテマトーデス症例の臨床的検討,
第61回日本リウマチ学会総会・学術集会, 2017年4月. 埴淵 昌毅, 加納 亮, 倉本 卓哉, 後東 久嗣, 西岡 安彦 :
癌患者血漿中遊離DNAを用いた遺伝子変異検査技術の比較,
第114回日本内科学会総会・講演会, 2017年4月. 髙島 拓也, 手塚 敏史, 近藤 真代, 飛梅 亮, 河野 弘, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
Exon19とexon21の遺伝子変異を同時に認めた肺腺癌の1例,
第56回日本呼吸器学会中国・四国地方会, 2016年12月. 菊地 高史, 手塚 敏史, 近藤 真代, 荻野 広和, 河野 弘, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
Stevens-Johnson 症候群後に発症した閉塞性細気管支炎にステロイドおよびタクロリムスが有効であった1例,
第56回日本呼吸器学会中国・四国地方会.岡山.2016年12月23, 2016年12月. 杉峯 優人, 手塚 敏史, 香川 耕造, 米田 浩人, 大塚 憲司, 河野 弘, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
EBUS-TBNA後に縦隔炎を発症した縦隔原発セミノーマの1例,
第25回日本呼吸器内視鏡学会中国四国支部会, 2016年12月. 原 倫世, 手塚 敏史, 近藤 真代, 河野 弘, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
EBによる末梢神経障害を呈した結核性胸膜炎の1例,
第67回日本結核病学会中国四国支部会, 2016年12月. 西岡 安彦 :
腫瘍免疫学の基礎と肺癌免疫療法の歩み,
第57回日本肺癌学会学術集会, 2016年12月. 埴淵 昌毅, 手塚 敏史, 西條 敦郎, 荻野 広和, 後東 久嗣, 西岡 安彦 :
当科における高齢者肺癌の若年者との比較検討,
第57回日本肺癌学会学術集会, 2016年12月. 荻野 広和, 後東 久嗣, 西條 敦郎, 柿内 聡司, 埴淵 昌毅, 西岡 安彦 :
徳島大学病院における進展型小細胞肺癌患者の予後因子に関する後ろ向き研究,
第57回日本肺癌学会学術集会, 2016年12月. 西條 敦郎, 手塚 敏史, 荻野 広和, 豊田 優子, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
悪性胸水を伴った非扁平上皮非小細胞肺癌に対する Bevacizumab 併用化学療法の検討,
第57回日本肺癌学会学術集会, 2016年12月. Yasuhiko Nishioka :
The mechanism of immunotherapy for lung cancer.,
第57回日本肺癌学会学術集会, Dec. 2016. 豊田 優子, 山下 雄也, 森住 俊, 近藤 真代, 荻野 広和, 河野 弘, 手塚 敏史, 岸 潤, 後東 久嗣, 埴淵 昌毅, 埴淵 昌毅, 西岡 安彦 :
当院における膠原病関連間質性肺炎の急性憎悪の臨床的検討,
第27回日本リウマチ学会中国・四国支部学術集会, 2016年12月. 荻野 広和, 岸 潤, 河野 弘, 手塚 敏史, 豊田 優子, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
関節リウマチの薬物療法における栄養状態の変化の検討,
第27回日本リウマチ学会中国・四国支部学術集会, 2016年12月. 山下 雄也, 豊田 優子, 荻野 広和, 河野 弘, 手塚 敏史, 岸 潤, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
当院におけるループス腎炎に対するIVCYとMMFの治療経験,
第27回日本リウマチ学会中国・四国支部学術集会, 2016年12月. 田中 こころ, 荻野 広和, 宮田 淳也, 山下 雄也, 森住 俊, 近藤 真代, 河野 弘, 手塚 敏史, 豊田 優子, 岸 潤, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
15年前より認める慢性腎機能障害に対してステロイド加療が奏功した腎サルコイドーシスの1例,
第27回日本リウマチ学会中国・四国支部学術集会, 2016年12月. 岡村 和美, 渡邊 浩良, 阿部 容子, 香美 祥二, 西條 敦郎, 坂口 暁, 西岡 安彦 :
アレクチニブが奏効したALK陽性肺腺癌の12歳男児例,
第58回日本小児血液・がん学会, 2016年12月. 米田 浩人, 手塚 敏史, 山下 雄也, 西條 敦郎, 河野 弘, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
多発性胃十二指腸潰瘍を伴ったMTX関連リンパ増殖性疾患の1例,
第115回日本内科学会四国地方会, 2016年11月. 香西 博之, 手塚 敏史, 山下 雄也, 西條 敦郎, 河野 弘, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
Gefitinib投与中にAchromobacter Xylosoxidansによる菌血症を発症した肺腺癌の1例,
第115回日本内科学会四国地方会, 2016年11月. 西岡 安彦 :
呼吸器疾患のトランスレーショナルリサーチ∼アカデミア発の創薬を目指した多職種連携∼,
第64回医療薬学公開シンポジウム, 2016年11月. 恒益 知宏, 阿部 真治, 和泉 俊尋, 佐藤 智恵美, 岡田 直人, 加藤 幸成, 西岡 安彦, 川添 和義 :
新規マウス抗PDPN抗体のin vitroにおけるADCC活性の検討,
第55回 日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2016年11月. Yasuhiko Nishioka :
Aquired resistance to anti-angiogenic therapy and new insights toward the overcoming,
JASMO 2016 Annual Meeting (International Symposium 10), Jul. 2016. 荻野 広和, 埴淵 昌毅, 大塚 憲司, 西條 敦郎, 坂口 暁, 手塚 敏史, 柿内 聡司, 後東 久嗣, 西岡 安彦 :
徳島大学病院における進展型小細胞肺癌患者の予後因子についての検討,
第14回日本臨床腫瘍学会学術集会, 2016年7月. 山本 清成, 手塚 敏史, 荻野 広和, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
下顎歯肉癌治療後に発生した放射線誘発血管肉腫の1例,
第253回徳島医学会学術集会, 2016年7月. 荻野 広和, 後東 久嗣, 西條 敦郎, 大塚 憲司, 埴淵 昌毅, 西岡 安彦 :
受容体チロシンキナーゼROR2は悪性胸膜中皮腫細胞の増殖を制御する,
第25回日本がん転移学会学術集会・総会, 2016年7月. 西條 敦郎, 後東 久嗣, 三橋 惇志, 中野 万有里, 大塚 憲司, 荻野 広和, 坂口 暁, 埴淵 昌毅, 西岡 安彦 :
骨髄由来線維細胞(fibrocyte)は肺癌のがん幹細胞様特性を促進する,
第25回日本がん転移学会学術集会・総会, 2016年7月. 大塚 憲司, 埴淵 昌毅, 後東 久嗣, 西岡 安彦 :
肺癌，悪性胸膜中皮腫に対する免疫チェックポイント阻害剤の有効性の基礎的検討,
第25回日本がん転移学会学術集会・総会, 2016年7月. 西岡 安彦 :
肺がんに対する血管新生阻害薬の耐性機構とその克服,
第176回日本肺癌学会関東支部学術集会, 2016年7月. 香川 耕造, 手塚 敏史, 大塚 憲司, 森住 俊, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 西岡 安彦 :
CrizotinibによるILDを発症後にAlectinibの投与が可能であったALK融合遺伝子陽性肺腺癌の1例,
第55 回日本肺癌学会中国・四国支部会, 2016年7月. 近藤 真代, 手塚 敏史, 米田 浩人, 豊田 優子, 後東 久嗣, 岸 潤, 吾妻 雅彦, 埴淵 昌毅, 村上 太一, 土井 俊夫, 河北 直也, 滝沢 宏光, 西岡 安彦 :
腹腔シンチグラフィにより診断し横隔膜縫合閉鎖術を行った横隔膜交通症の1例,
第55 回日本呼吸器学会中国・四国地方会, 2016年7月. 西岡 安彦 :
肺線維化の細胞分子病態と治癒戦略,
第37回日本炎症・再生学会, 2016年6月. 阿部 真治, 加藤 幸成, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
ポドプラニンを標的とした抗体療法とペメトレキセドの併用による悪性胸膜中皮腫に対する抗腫瘍効果の検討,
第20回日本がん分子標的治療学会学術集会, 2016年5月. 森住 俊, 佐藤 正大, 荻野 広和, 河野 弘, 坂口 暁, 後東 久嗣, 岸 潤, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
当院におけるニンテダニブの特発性肺線維症に対する使用経験,
第114回日本内科学会四国地方会, 2016年5月. 山下 雄也, 西條 敦郎, 佐藤 正大, 手塚 敏史, 坂口 暁, 後東 久嗣, 岸 潤, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
当院における膠原病合併肺癌の検討,
第114回日本内科学会四国地方会, 2016年5月. 湊 将典, 村上 太一, 上田 紗代, 岸 誠司, 松浦 元一, 長井 幸二郎, 安部 秀斉, 土井 俊夫, 近藤 真代, 西岡 安彦 :
横隔膜交通症の診断および交通部位同定に腹腔シンチグラフィが有用であった1例,
第114回内科四国地方会, 2016年5月. 河野 弘, 近藤 真代, 西條 敦郎, 豊田 優子, 岸 潤, 西岡 安彦 :
当院における膠原病に合併した肺癌の検討,
第60回日本リウマチ学会総会・学術集会, 2016年4月. 豊田 優子, 佐藤 正大, 岸 潤, 河野 弘, 森住 俊, 岸 昌美, 手塚 敏史, 坂口 暁, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
当院における膠原病関連間質性肺炎の急性増悪に関する臨床的検討,
第56回日本呼吸器学会学術講演会, 2016年4月. Yasuhiko Nishioka :
Role of fibrocytes and growth factors in lung fibrosis and cancer,
第56回日本呼吸器学会学術講演会(Inter-Assembly Symposium 2), Apr. 2016. 埴淵 昌毅, 中瀬 勝則, 豊﨑 纏, 木下 成三, 島田 久夫, 鶴尾 美穂, 吾妻 雅彦, 葉久 貴司, 西岡 安彦 :
徳島市におけるCOPD検診の現状,
第56回日本呼吸器学会学術講演会, 2016年4月. 手塚 敏史, 小川 博久, 近藤 真代, 吾妻 雅彦, 豊田 優子, 佐藤 正大, 岡崎 弘泰, 河野 弘, 岸 潤, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
RAS阻害剤 (XRP44X) を用いた喘息モデルマウスにおける検討,
第56回日本呼吸器学会学術講演会, 2016年4月. 阿部 真治, 加藤 幸成, 金子 美華, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
悪性胸膜中皮腫に対する新規抗ポドプラニン抗体NZ-12の効果,
第56回日本呼吸器学会学術講演会, 2016年4月. 和泉 俊尋, 阿部 真治, 佐藤 智恵美, 岡田 直人, 加藤 幸成, 西岡 安彦, 川添 和義 :
悪性胸膜中皮腫同所移植マウスに対する抗ポドプラニン抗体NZ-12とペメトレキセドの併用効果の検討,
日本薬学会第136年会, 2016年3月. 小山 広士, 佐藤 正大, 近藤 真代, 手塚 敏史, 後東 久嗣, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
胸膜炎や心外膜炎を契機に診断された成人Still病の2例,
第252回徳島医学会学術集会, 2016年2月. 湊 将典, 上田 紗代, 村上 太一, 小野 広幸, 吉本 咲耶, 柴田 恵理子, 田蒔 昌憲, 岸 史, 岸 誠司, 松浦 元一, 長井 幸二郎, 安部 秀斉, 土井 俊夫, 近藤 真代, 坂口 暁, 西岡 安彦, 新井 悠太, 新家 崇義, 音見 暢一, 河北 直也, 滝沢 宏光, 梶浦 耕一郎, 先山 正二 :
横隔膜交通症の診断および交通部位同定に腹腔シンチグラフィが有用であった1例,
第252回徳島医学会学術集会, 2016年2月. 西岡 安彦 :
がん免疫を考える∼進歩する基礎研究を臨床へどう活かすか?∼,
第24回日本呼吸器内視鏡学会中国四国支部会, 2015年12月. 四宮 由貴, 佐藤 正大, 竹﨑 彰夫, 近藤 真代, 瀧倉 輝実, 坂口 暁, 豊田 優子, 後東 久嗣, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
サルコイドーシス経過観察中に発症した結核性胸膜炎の1例,
第24回日本呼吸器内視鏡学会中国四国支部会, 2015年12月. 曽我部 洋平, 佐藤 正大, 西條 敦郎, 中野 万有里, 河野 弘, 坂口 暁, 豊田 優子, 後東 久嗣, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
癌性髄膜炎に対しアファチニブが奏効した2例,
第54回日本呼吸器学会中国・四国地方会, 2015年12月. 猪子 未希, 荻野 広和, 中野 万有里, 岡崎 弘泰, 大塚 憲司, 後東 久嗣, 岸 潤, 埴淵 昌毅, 坂東 良美, 常山 幸一, 西岡 安彦 :
脳，口蓋垂，喉頭および小腸への遠隔転移を形成する稀な臨床経過をたどった右上葉原発多形癌の一剖検例,
第54回日本呼吸器学会中国・四国地方会, 2015年12月. 米田 浩人, 佐藤 正大, 香川 耕造, 荻野 広和, 坂口 暁, 豊田 優子, 東 桃代, 後東 久嗣, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
骨髄異形成症候群に播種性結核症を合併し治療に難渋した一例,
第66回日本結核病学会中国四国支部会, 2015年12月. 阿部 容子, 岡村 和美, 渡邊 浩良, 香美 祥二, 佐々木 亜由美, 坂口 暁, 西岡 安彦 :
アレクチニブが奏効したALK陽性肺腺癌の1男児例,
第145回日本小児科学会徳島地方会, 2015年12月. 森住 俊, 佐藤 正大, 荻野 広和, 近藤 真代, 手塚 敏史, 豊田 優子, 後東 久嗣, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
当科で施行された胸膜癒着術におけるタルク製剤とOK-432の使用成績の比較,
第113回日本内科学会四国地方会, 2015年12月. 近藤 真代, 佐藤 正大, 手塚 敏史, 豊田 優子, 飛梅 亮, 後東 久嗣, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
胸膜炎・心外膜炎を契機に診断された成人Still病の2例,
第113回日本内科学会四国地方会, 2015年12月. 山下 雄也, 荻野 広和, 岸 潤, 豊田 優子, 森住 俊, 近藤 真代, 瀧倉 輝実, 佐藤 正大, 河野 弘, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
強膜炎，ネフローゼ症候群および僧房弁腱索断裂による重症僧房弁閉鎖不全症を呈した全身性エリテマトーデスの1例,
第26回日本リウマチ学会中国・四国支部学術集会, 2015年12月. 西岡 安彦 :
特発性肺線維症の細胞分子病態研究と治療の進歩,
第30回長崎DDS・再生医療研究会, 2015年12月. 西岡 安彦 :
がん免疫のABC:肺がんに対する免疫療法の理解に向けて,
第56回日本肺癌学会学術集会(シンポジウム), 2015年11月. 埴淵 昌毅, 加納 亮, 倉本 卓哉, 後東 久嗣, 坂口 暁, 豊田 優子, 手塚 敏史, 西條 敦郎, 西岡 安彦 :
癌患者血漿中遊離DNAを用いた遺伝子変異検査技術の比較,
第56回日本肺癌学会学術集会, 2015年11月. 西條 敦郎, 坂口 暁, 手塚 敏史, 柿内 聡司, 豊田 優子, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
当科における膠原病に合併した肺癌の検討,
第56回日本肺癌学会学術集会, 2015年11月. 西岡 安彦 :
日常診療における膠原病肺の鑑別法(教育講演),
日本呼吸器学会第36回生涯教育講演会(教育講演), 2015年11月. 荻野 広和, 三橋 惇志, 後東 久嗣, 西條 敦郎, 佐藤 正大, 坂口 暁, 手塚 敏史, 倉本 卓哉, 田畑 祥, 上原 久典, 埴淵 昌毅, 西岡 安彦 :
Sphere形成癌幹細胞様分画のヒト肺癌多臓器転移モデルマウスにおける役割についての解析,
第74回日本癌学会学術総会, 2015年10月. 阿部 真治, 加藤 幸成, 金子 美華, 大塚 憲司, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
新規ヒトキメラ型抗ポドプラニン抗体NZ-12の悪性胸膜中皮腫に対する抗腫瘍効果,
第74回日本癌学会学術総会, 2015年10月. 梶田 敬介, 佐藤 正大, 豊田 優子, 坂口 暁, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
PS不良ALK融合遺伝子陽性の若年者肺腺癌に対しクリゾチニブが奏効した1例,
第251回徳島医学会学術集会, 2015年8月. 西條 敦郎, 後東 久嗣, 三橋 惇志, 中野 万有里, 山子 泰斗, 坂口 暁, 柿内 聡司, 埴淵 昌毅, 西岡 安彦 :
Fibrocyteはがん幹細胞性維持により肺癌進展を促進する,
第24回日本がん転移学会学術集会・総会, 2015年7月. 猪子 未希, 荻野 広和, 坂口 暁, 岸 昌美, 豊田 優子, 近藤 真代, 中野 万有里, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
Nocardia wallacei感染症の1例,
第53回日本呼吸器学会中国・四国地方会, 2015年7月. 香川 耕造, 坂口 暁, 塚﨑 佑貴, 佐藤 正大, 飛梅 亮, 米田 浩人, 竹﨑 彰夫, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
癌性髄膜炎にafatinibが奏効したEGFR exon 18 G718A変異をもつ肺腺癌の1例,
第54回日本肺癌学会中国・四国支部会, 2015年7月. Yasuhiko Nishioka and Hisatsugu Goto :
Mechanisms of acquired resistance to anti-angiogenic therapy and new insights toward the overcoming,
第74回日本癌学会学術総会(Core Symposia 2), Jun. 2015. 大木 弘治, 西岡 安彦, 加藤 幸成 :
新規抗ポドプラニン抗体LpMab-7の抗腫瘍効果の検討,
第19回日本がん分子標的治療学会学術集会(ワークショップ), 2015年6月. 大塚 憲司, 埴淵 昌毅, 後東 久嗣, 西岡 安彦 :
肺癌に対する抗PD-L1抗体治療の基礎的検討,
第19回日本がん分子標的治療学会学術集会, 2015年6月. 三橋 惇志, 後東 久嗣, 西條 敦郎, 埴淵 昌毅, 西岡 安彦 :
線維細胞 (fibrocytes) が関わる血管新生阻害に対する獲得耐性メカニズム,
第19回日本がん分子標的治療学会学術集会, 2015年6月. 坂口 暁, 豊田 優子, 手塚 敏史, 竹﨑 彰夫, 中野 万有里, 瀧倉 輝実, 佐藤 正大, 岡崎 弘泰, 大塚 憲司, 柿内 聡司, 後東 久嗣, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
肺胞出血をきたした11症例の検討,
第38回日本呼吸器内視鏡学会学術集会, 2015年6月. 武井 美貴子, 近藤 真代, 佐藤 正大, 河野 弘, 豊田 優子, 埴淵 昌毅, 西岡 安彦, 三木 浩和, 田中 久美子, 高山 哲治 :
好酸球性胆管炎を合併した全身性エリテマトーデスの1例,
第112回日本内科学会四国地方会, 2015年6月. 瀧倉 輝実, 坂口 暁, 森住 俊, 大塚 憲司, 岸 昌美, 手塚 敏史, 西條 敦郎, 柿内 聡司, 埴淵 昌毅, 西岡 安彦 :
N-acetylcysteine吸入が有効であったピルフェニドン抵抗性特発性肺線維症の1例,
第112回日本内科学会四国地方会, 2015年6月. 豊田 優子, 瀧倉 輝実, 近藤 真代, 佐藤 正大, 尾崎 領彦, 岸 潤, 手塚 敏史, 河野 弘, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
膠原病に合併した血球貪食性リンパ組織球症の4症例,
第59回日本リウマチ学会総会・学術集会, 2015年4月. 佐藤 正大, 後東 久嗣, 森住 俊, 阿部 秀一, 吉嶋 輝実, 岡﨑 弘泰, 埴淵 昌毅, 西岡 安彦 :
肺線維芽細胞に対するfibrocyteの作用とnintedanibの抑制効果,
第55回日本呼吸器学会学術講演会, 2015年4月. 埴淵 昌毅, 中瀬 勝則, 豊﨑 纏, 木下 成三, 島田 久夫, 鶴尾 美穂, 吾妻 雅彦, 葉久 貴司, 西岡 安彦 :
徳島市におけるCOPD検診システムの構築,
第55回日本呼吸器学会学術講演会, 2015年4月. 西岡 安彦 :
新規分子標的薬とそのターゲット,
第55回日本呼吸器学会学術講演会(教育講演), 2015年4月. 手塚 敏史, 小川 博久, 豊田 優子, 竹﨑 彰夫, 佐藤 正大, 岡﨑 弘泰, 吉嶋 輝実, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
Plasminogen Activator Inhibitor-1阻害剤 (IMD-4690) の慢性喘息モデルマウスにおける検討,
第55回日本呼吸器学会学術講演会, 2015年4月. 柿内 聡司, 荻野 広和, 大塚 憲司, 坂口 暁, 西條 敦郎, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
当科における間質性肺炎合併肺癌の治療の現状,
第55回日本呼吸器学会学術講演会, 2015年4月. 西岡 安彦 :
日常診療における膠原病肺の鑑別法,
日本呼吸器学会第36回生涯教育講演会(教育講演), 2015年4月. 中野 万有里, 吉嶋 輝実, 埴淵 昌毅, 中村 信元, 三木 浩和, 賀川 久美子, 西岡 安彦 :
Pneumocystis jiroveciに対しST合剤の脱感作療法を行った4症例の検討,
第89回日本感染症学会総会, 2015年4月. 岩坂 麻衣子, 佐藤 正大, 荻野 広和, 坂口 暁, 豊田 優子, 中野 万有里, 森住 俊, 小川 博久, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
Idiopathic pleuroparenchymal fibroelastosis (IPPFE) における間質性肺炎マーカーの検討,
第112回日本内科学会講演会, 2015年4月. 阿部 真治, 土橋 有希, 佐藤 智恵美, 山本 香織, 宮本 理人, 土屋 浩一郎, 東 満美, 西岡 安彦 :
悪性胸膜中皮腫胸腔内移植マウスに対するヒト・キメラ型抗ポドプラニン抗体NZ-8の効果,
日本薬学会第135年会, 2015年3月. 荻野 広和, 豊田 優子, 中野 万有里, 東 桃代, 埴淵 昌毅, 西岡 安彦 :
皮膚筋炎に対してステロイドおよび免疫抑制剤による加療中に発症した播種性Mycobacterium avium症の1例,
第90回日本結核病学会総会, 2015年3月. 中野 万有里, 東 桃代, 瀧倉 輝実, 坂口 暁, 豊田 優子, 上回 紗代, 安倍 秀斉, 埴淵 昌毅, 土井 俊夫, 西岡 安彦 :
長期間ステロイド投与が発症の契機となったMycobacterium intracellulareによる関節炎と骨髄炎の2症例,
第65回日本結核病学会中国四国支部会, 2015年2月. 尾崎 領彦, 坂口 暁, 手塚 敏史, 大塚 憲司, 森積 俊, 岸 潤, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
胸膜直下に帯状に分布するすりガラス陰影で発症した，自己免疫性肺胞蛋白症の一例,
第23回日本呼吸器内視鏡学会中国四国支部会, 2015年2月. 東 桃代, 中曽 亜佐美, 藤原 範子, 畑 美智子, 加藤 真介, 西岡 安彦 :
「HYDRO AG」を用いたタッチパネル液晶保護フィルムの医療現場における有用性の検討,
第30回日本環境感染学会総会・学術集会, 2015年2月. 宇山 直人, 大塚 秀樹, 音見 暢一, 原田 雅史, 生島 仁史, 山子 泰斗, 豊田 優子, 埴淵 昌毅, 西岡 安彦, 滝沢 宏光, 坂東 良美 :
特異な経過を示した肺原発滑膜肉腫の一例,
第7回呼吸機能イメージング研究会学術集会, 2015年2月. 稲垣 太造, 荻野 広和, 坂口 暁, 豊田 優子, 中野 万有里, 森住 俊, 佐藤 正大, 小川 博久, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
Idiopathic pleuroparenchymal fibroelastosisにおける間質性肺炎マーカーの検討,
第250回徳島医学会学術集会, 2015年2月. 丸橋 朋子, 中村 信元, 曽我部 公子, 八木 ひかる, 高橋 真美子, 宇高 憲吾, 藤井 志朗, 三木 浩和, 賀川 久美子, 安倍 正博, 西條 敦郎, 中野 万有里, 東 桃代, 西岡 安彦, 近藤 憲保, 井内 新, 藤田 博己, 馬原 文彦 :
当院で経験した重症熱性血小板減少症候群の3例,
第250回徳島医学会学術集会, 2015年2月. 野田 和克, 東 桃代, 西迫 寛隆, 伏谷 秀治, 佐藤 雅美, 畑 美智子, 石澤 啓介, 西岡 安彦 :
真菌感染BUNDLEの徳島大学病院での活用について,
第250回徳島医学会学術集会, 2015年2月. 岩佐 あゆみ, 佐藤 正大, 坂口 暁, 豊田 優子, 田島 壮一郎, 櫻田 巧, 後東 久嗣, 柿内 聡司, 埴淵 昌毅, 西岡 安彦 :
UGT1A1遺伝子のヘテロ接合体 (*6または*28) を持つ患者における塩酸イリノテカン投与に関する検討,
第52回日本呼吸器学会中国・四国地方会, 2014年12月. 板東 智子, 荻野 広和, 坂口 暁, 手塚 敏史, 森住 俊, 吉嶋 輝実, 岸 潤, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
鳥特異的抗体が高値を呈した鳥関連過敏性肺炎の一例,
第52回日本呼吸器学会中国・四国地方会, 2014年12月. 埴淵 昌毅, 西岡 安彦 :
徳島大学病院の進捗状況,
第2回国際遠隔医療教育ネットワークに関する担当医師及び技術担当者全国合同会議, 2014年12月. Hiroshi Kawano, Junko Morimoto, Yasuhiro Mouri, Hitoshi Nishijima, Yasuhiko Nishioka and Mitsuru Matsumoto :
Unexpected disturbance of the development of medullary thymic epithelial cells at immature stages by the long-term ablation of mature Aire-expressing cells,
第43回日本免疫学会学術集会, Dec. 2014. 近藤 真代, 佐藤 正大, 豊田 優子, 岸 潤, 手塚 敏史, 吉嶋 輝実, 岸 昌美, 河野 弘, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
血小板減少を契機として診断された高齢者のSLEの2例,
第25回日本リウマチ学会中国・四国支部学術集会, 2014年12月. 栗原 健士, 吉嶋 輝実, 坂口 暁, 豊田 優子, 中野 万有里, 岸 潤, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
経過中に血球貪食症候群を発症し，シクロホスファミド間歇大量静注療法が奏効した重症SLEの1例,
第111回日本内科学会四国地方会, 2014年11月. 森住 俊, 佐藤 正大, 坂口 暁, 豊田 優子, 岸 昌美, 小川 博久, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
Idiopathic pleuroparenchymal fibroelastosisにおける間質性肺炎マーカーの検討,
第111回日本内科学会四国地方会, 2014年11月. 柿内 聡司, 大塚 憲司, 佐藤 正大, 西條 敦郎, 坂口 暁, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
当院における間質性肺炎合併肺癌の治療の現状,
第55回日本肺癌学会学術集会, 2014年11月. 櫻田 功, 柿内 聡司, 田島 壮一郎, 寺岡 和彦, 中村 敏己, 川添 和彦, 西岡 安彦, 楊河 宏章, 水口 和夫 :
肺癌薬物療法における薬剤性間質性肺炎の発症とそのリスク因子の解析,
第55回日本肺癌学会学術集会, 2014年11月. 櫻田 巧, 柿内 聡司, 堀ノ内 裕也, 西迫 寛隆, 岡田 直人, 寺岡 和彦, 中村 敏己, 川添 和義, 西岡 安彦, 石澤 啓介 :
ペメトレキセドによる発疹に関与する因子の同定とステロイド追加投与の有効性の検討,
第53回中国四国支部学術大会(広島), 2014年11月. 西岡 安彦 :
がん免疫療法の過去と未来:エビデンスが示した新たな可能性,
第62回日本口腔学会 中国・四国地方部会, 2014年10月. 松浦 元一, 上田 紗代, 小野 広幸, 吉本 咲耶, 柴田 恵理子, 田蒔 昌憲, 村上 太一, 長井 幸二郎, 安部 秀斉, 佐藤 正大, 岸 潤, 西岡 安彦, 土井 俊夫 :
関節リウマチに対してetanercept投与中に半月体形成性糸球体腎炎を来した1例,
第44回日本腎臓学会西部学術大会, 2014年10月. 後東 久嗣, 三橋 敦志, 西條 敦郎, 柿内 聡司, 埴淵 昌毅, 上原 久典, 矢野 聖二, 西岡 安彦 :
ベバシズマブに対する獲得耐性メカニズムとしての線維細胞 (fibrocytes) の役割,
第73回日本癌学会学術総会, 2014年9月. 加藤 幸成, 金子 美華, 小笠原 諭, 西岡 安彦 :
がん特異的抗ポドプラニン抗体の樹立,
第73回日本癌学会学術総会, 2014年9月. 埴淵 昌毅, 中曽 亜佐美, 藤原 範子, 東 桃代, 西岡 安彦 :
徳島大学病院における結核対策の現状,
第8回日本結核病学会中国四国支部研究会 (シンポジウム), 2014年9月. 坂口 暁, 後東 久嗣, 大串 文隆, 葉久 貴司, 兼松 貴則, 浦田 知之, 柿内 聡司, 埴淵 昌毅, 曽根 三郎, 西岡 安彦 :
高齢者進行NSCLC患者を対象としてPRO評価を取り入れたTS-1療法の臨床第Ⅱ相試験,
第52回日本癌治療学会学術集会, 2014年8月. 山下 雄也, 荻野 広和, 阿河 弘和, 岸 昌美, 坂口 暁, 吉嶋 輝実, 佐藤 正大, 柿内 聡司, 後東 久嗣, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
鳥特異的抗体が高値を呈した鳥関連過敏性肺炎の一例,
第249回徳島医学会学術集会, 2014年7月. 大塚 憲司, 後東 久嗣, 葉久 貴司, 兼松 貴則, 浦田 知之, 柿内 聡司, 埴淵 昌毅, 大串 文隆, 曽根 三郎, 西岡 安彦 :
高齢者進行非小細胞肺癌患者を対象としてPRO評価を取り入れたTS-1療法の臨床第Ⅱ相試験,
第12回日本臨床腫瘍学会学術集会, 2014年7月. 塚﨑 佑貴, 大塚 憲司, 岸 昌美, 近藤 真代, 吉嶋 輝実, 佐藤 正大, 岡埼 弘泰, 竹﨑 彰夫, 東 桃代, 埴淵 昌毅, 坂下 直美, 福田 悠, 西岡 安彦 :
Acute Fibrinous and Organizing Pneumonia (AFOP) の一剖検例,
第51回日本呼吸器学会中国・四国地方会, 2014年7月. 松本 康平, 尾崎 領彦, 豊田 優子, 中野 万有里, 森住 俊, 河野 弘, 岸 潤, 柿内 聡司, 埴淵 昌毅, 西岡 安彦 :
高Ca血症にて発症した多臓器サルコイドーシスの1例,
第51回日本呼吸器学会中国・四国地方会, 2014年7月. 阿河 弘和, 佐藤 正大, 近藤 真代, 塚﨑 佑貴, 手塚 敏史, 豊田 優子, 坂口 暁, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
当科における悪性胸水貯留例に対するタルク製剤の使用経験,
第53回日本肺癌学会中国・四国支部会, 2014年7月. 荻野 広和, 西條 敦郎, 大塚 憲司, 坂口 暁, 手塚 敏史, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
Lambert-Eaton筋無力症候群を契機に発見された小細胞肺癌の一例,
第53回日本肺癌学会中国・四国支部会, 2014年7月. 加藤 幸成, 西岡 安彦 :
血小板凝集因子Podoplaninに対するがん特異的抗体の開発,
第23回日本がん転移学会学術集会・総会, 2014年7月. 後東 久嗣, 三橋 惇志, 倉本 卓哉, 田畑 祥, 西條 敦郎, 柿内 聡司, 埴淵 昌毅, 上原 久典, 西岡 安彦 :
肺癌多臓器転移モデルにおけるsphere形成癌幹細胞様分画の役割,
第23回日本がん転移学会学術集会・総会, 2014年7月. 山子 泰斗, 後東 久嗣, 三橋 敦志, 倉本 卓哉, 田畑 祥, 西條 敦郎, 柿内 聡司, 埴淵 昌毅, 小川 博久, 上原 久典, 西岡 安彦 :
ヒト小細胞肺癌骨転移に対するRANKL標的治療におけるIGF-1の関与,
第23回日本がん転移学会学術集会・総会, 2014年7月. 後東 久嗣, 三橋 惇志, 西條 敦郎, 倉本 卓哉, 田畑 祥, 埴淵 昌毅, 柿内 聡司, 青野 純典, 上原 久典, 西岡 安彦 :
ベバシズマブに対する獲得耐性メカニズムとしての線維細胞 (fibrocytes) の役割,
第18回日本がん分子標的治療学会学術集会 (シンポジウム), 2014年6月. 大塚 憲司, 阿部 真治, 埴淵 昌毅, 木宿 昌俊, 川添 和義, 加藤 幸成, 西岡 安彦 :
胸膜中皮腫同所移植モデルにおける抗ポドプラニン抗体の抗腫瘍効果,
第18回日本がん分子標的治療学会学術集会, 2014年6月. 東 桃代, 西岡 安彦 :
緑膿菌感染患者におけるTolerance とバイオフィルム形成能の検討,
第88回日本感染症学会学術講演会, 2014年6月. 中野 万有里, 高橋 直希, 吉嶋 輝実, 西條 敦郎, 手塚 敏史, 東 桃代, 埴淵 昌毅, 西岡 安彦 :
当院で経験した重症熱性血小板減少症候群(severe fever with thrombocytopenia syndrome: SFTS)の1例,
第88回日本感染症学会学術講演会, 2014年6月. 近藤 真代, 森住 俊, 坂口 暁, 西條 敦郎, 吉嶋 輝実, 中野 万有里, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
PemetrexedとBevacizumabの併用療法が有効であった高齢者非小細胞肺癌の1例,
第110回日本内科学会四国地方会, 2014年6月. 尾崎 領彦, 豊田 優子, 岸 潤, 木下 勝弘, 岸 昌美, 佐藤 正大, 柿内 聡司, 埴淵 昌毅, 西岡 安彦 :
左腎動脈閉塞等により結節性多発動脈炎が疑われた血管内膜肉腫の1剖検例,
第110回日本内科学会四国地方会, 2014年6月. 西岡 安彦 :
間質性肺炎/肺線維症,
第61回日本麻酔科学会学術集会, 2014年5月. 佐藤 正大, 岸 昌美, 木下 勝弘, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
血清 SP-D 上昇を認めた Idiopathic pleuroparenchymal fibroelastosis (IPPFE) 症例の検討,
第54回日本呼吸器学会学術講演会, 2014年4月. 後東 久嗣, 三橋 惇志, 阿部 秀一, 青野 純典, 西岡 安彦 :
呼吸器疾患における慢性炎症と fibrocyte,
第54回日本呼吸器学会学術講演会(シンポジウム), 2014年4月. 後東 久嗣, 三橋 敦志, 阿部 秀一, 青野 純典, 西岡 安彦 :
呼吸器疾患における慢性炎症と fibrocyte,
第54回日本呼吸器学会学術講演会, 2014年4月. 西岡 安彦 :
英語論文の書き方と指導ポイント∼当科における経験から∼,
第54回日本呼吸器学会学術講演会, 2014年4月. 豊田 優子, 岸 潤, 河野 弘, 後東 久嗣, 埴淵 昌毅, 中島 利博, 西岡 安彦 :
関節リウマチ患者由来の線維芽細胞様滑膜細胞において thymidine phosphorylaseはCXCL10 を制御する,
第58回日本リウマチ学会総会学術集会, 2014年4月. 柿内 聡司, 大塚 憲司, 佐藤 正大, 西條 敦郎, 坂口 暁, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
当院における間質性肺炎合併肺癌の治療の現状,
第54回日本呼吸器学会学術講演会, 2014年4月. 岸 昌美, 青野 純典, 東 桃代, 木下 勝弘, 佐藤 正大, 吉嶋 輝実, 竹﨑 彰夫, 西岡 安彦 :
PDGFレセプター-α, β阻害抗体のブレオマイシン誘発肺線維症モデルマウスにおける抗線維化効果,
第54回日本呼吸器学会学術講演会, 2014年4月. 西岡 安彦 :
肺がん・中皮腫における血管新生阻害薬耐性,
第54回日本呼吸器学会学術講演会, 2014年4月. 阿部 真治, 加藤 幸成, 金子 美華, 東 満美, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
悪性胸膜中皮腫同所移植モデルにおける抗ポドプラニン抗体の抗腫瘍効果,
第54回日本呼吸器学会学術講演会, 2014年4月. 西岡 安彦 :
間質性肺炎合併肺癌の治療戦略,
第54回日本呼吸器学会学術講演会, 2014年4月. 櫻田 巧, 田島 壮一郎, 柿内 聡司, 堀ノ内 裕也, 寺岡 和彦, 久次米 敏秀, 川添 和義, 西岡 安彦, 水口 和生 :
ペメトレキセド治療における皮疹に対するデキサメタゾン投与量の検討,
日本薬学会第134年会, 2014年3月. 阿部 真治, 木宿 昌俊, 中瀬 真理, 佐藤 智恵美, 柴田 洋文, 川添 和義, 東 満美, 西岡 安彦, 水口 和生 :
悪性胸膜中皮腫移植マウスに対するNZ-1およびラットNK細胞併用投与の抗腫瘍効果,
日本薬学会第134年会, 2014年3月. 西岡 安彦 :
がん分子標的治療の基礎と臨床,
平成25年度徳島臨床細胞学会総会および学術集会, 2014年3月. 西岡 安彦 :
がん分子標的治療の基礎と臨床.,
平成25年度徳島臨床細胞学会総会および学術集会, 2014年3月. 西岡 安彦 :
高齢者肺炎診療の考え方,
第25回日本老年医学会四国地方会, 2014年2月. 西岡 安彦 :
高齢者肺炎診療の考え方.,
第25回日本老年医学会四国地方会, 2014年2月. 中瀬 勝則, 鶴尾 美穂, 島田 久夫, 木下 成三, 豊﨑 纏, 杉野 聡, 浦 聡明, 山下 恵美, 古味 勝美, 小田 芳栄, 服部 順子, 西岡 安彦, 埴淵 昌毅, 吾妻 雅彦 :
徳島市医師会のCOPD対策,
第248回徳島医学会学術集会, 2014年2月. 山本 聖子, 埴淵 昌毅, 森住 俊, 岸 昌美, 木下 勝弘, 河野 弘, 竹﨑 彰夫, 豊田 優子, 東 桃代, 後東 久嗣, 岸 潤, 西岡 安彦 :
左上葉無気肺を呈したアレルギー性気管支肺アスペルギルス症の一例,
第248回徳島医学会, 2014年2月. 津保 友香, 埴淵 昌毅, 滝沢 宏光, 吉田 光輝, 吉嶋 輝実, 大塚 憲司, 佐藤 正大, 西條 敦郎, 豊田 優子, 手塚 敏史, 柿内 聡司, 後東 久嗣, 坂東 良美, 先山 正二, 西岡 安彦 :
肺原発滑膜肉腫の一例.,
第248回徳島医学会, 2014年2月. 尾崎 領彦, 髙橋 直希, 後東 久嗣, 豊田 優子, 手塚 敏史, 大塚 憲司, 西條 敦郎, 坂口 暁, 木下 勝弘, 柿内 聡司, 小川 博久, 川上 行奎, 埴淵 昌毅, 近藤 和也, 先山 正二, 泉 啓介, 西岡 安彦 :
気管支鏡直視下生検にて診断に至ったoncocytic carcinoidの一例.,
第22回日本呼吸器内視鏡学会中国四国支部会, 2014年2月. 是松 麻美, 内藤 伸仁, 岸 昌美, 中野 万有里, 吉田 光輝, 川上 行奎, 木下 勝弘, 東 桃代, 吉嶋 輝実, 佐藤 正大, 岸 潤, 森河 由里子, 松山 友理子, 榊 美佳, 坂東 良美, 渡邉 俊介, 上原 久典, 泉 啓介, 先山 正二, 埴淵 昌毅, 西岡 安彦 :
胸水中に多数のLanghans型巨細胞を認めたMycobacterium avium症に伴う胸膜炎の一例.,
第64回日本結核病学会中国四国支部会, 2014年2月. 高橋 直希, 西條 敦郎, 柿内 聡司, 埴淵 昌毅, 滝沢 宏光, 西野 豪志, 森住 俊, 岸 昌美, 木下 勝弘, 後東 久嗣, 音見 暢一, 生島 仁史, 先山 正二, 西岡 安彦 :
PET/CTにて集積を認めなかった嚢胞状縦隔リンパ節腫大を伴う肺腺癌の一例,
第6回呼吸機能イメージング研究会学術集会, 2014年1月. 津保 友香, 埴淵 昌毅, 滝沢 宏光, 吉田 光輝, 吉嶋 輝実, 大塚 憲司, 佐藤 正大, 西條 敦郎, 豊田 優子, 手塚 敏史, 柿内 聡司, 後東 久嗣, 坂東 良美, 先山 正二, 西岡 安彦 :
肺原発滑膜肉腫の一例.,
第50回日本呼吸器学会中国・四国地方会, 2013年12月. 山本 聖子, 埴淵 昌毅, 森住 俊, 岸 昌美, 木下 勝弘, 河野 弘, 竹﨑 彰夫, 豊田 優子, 東 桃代, 後東 久嗣, 岸 潤, 西岡 安彦 :
左上葉無気肺を呈したアレルギー性気管支肺アスペルギルス症の一例.,
第50回日本呼吸器学会中国・四国地方会, 2013年12月. 内藤 伸仁, 河野 弘, 大塚 憲司, 豊田 優子, 岸 潤, 手塚 敏史, 木下 勝弘, 吉嶋 輝実, 岸 昌美, 埴淵 昌毅, 西岡 安彦 :
腹部大動脈周囲炎を伴った多発血管炎性肉芽腫症の2例.,
第24回日本リウマチ学会中国・四国支部学術集会, 2013年12月. 坂東 弘基, 埴淵 昌毅, 豊田 優子, 手塚 敏史, 吉嶋 輝実, 後東 久嗣, 柿内 聡司, 岸 潤, 西岡 安彦, 坂本 幸裕 :
気管支拡張症を呈した原発性線毛運動不全症の1例.,
第109回日本内科学会四国地方会, 2013年12月. 矢葺 洋平, 西條 敦郎, 木下 勝弘, 岸 昌美, 大塚 憲司, 埴淵 昌毅, 西岡 安彦, 井内 新, 青野 純典 :
徳島県で発生した重症熱性血小板減少症候群(severe fever with thrombocytopenia syndrome: SFTS)の1例.,
第109回日本内科学会四国地方会, 2013年12月. 西岡 安彦 :
特発性間質性肺炎の診断と治療-最近の話題-.,
第49回日本内科学会四国支部生涯教育講演会, 2013年12月. 手塚 敏史, 小川 博久, 木下 勝弘, 埴淵 昌毅, 西岡 安彦 :
Calpain inhibitor(Calpeptin)の喘息モデルマウスにおける検討.,
第63回日本アレルギー学会秋季学術大会, 2013年11月. 岡野 義夫, 後東 久嗣, 葉久 貴司, 兼松 貴則, 浦田 知之, 柿内 聡司, 埴淵 昌毅, 大串 文隆, 曽根 三郎, 西岡 安彦 :
高齢者進行非小細胞肺癌患者を対象としてPRO評価を取り入れたTS-1療法の臨床第Ⅱ相試験.,
第54回日本肺癌学会総会, 2013年11月. 西條 敦郎, 柿内 聡司, 手塚 敏史, 後東 久嗣, 山子 泰斗, 大塚 憲司, 埴淵 昌毅, 西岡 安彦 :
当院におけるBevacizumab長期維持投与症例の検討.,
第51回日本癌治療学会学術集会, 2013年10月. 手塚 敏史, 豊田 優子, 柿内 聡司, 大塚 憲司, 西條 敦郎, 木下 勝弘, 後東 久嗣, 櫻田 巧, 埴淵 昌毅, 西岡 安彦 :
当科の肺癌化学療法におけるshort-hydration Cisplatinの忍容性に関する検討.,
第51回日本癌治療学会学術集会, 2013年10月. 手塚 敏史, 小川 博久, 木下 勝弘, 埴淵 昌毅, 西岡 安彦 :
O57-4 Calpain inhibitor (Calpeptin)の喘息モデルマウスにおける検討(O57 気管支喘息 病態5,口演,第63回日本アレルギー学会秋季学術大会),
アレルギー, Vol.62, No.9, 1400, 2013年10月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390001205000905728
(CiNii: 1390001205000905728) Yasuhiko Nishioka :
肺癌におけるベバシズマブを用いた抗血管新生療法に対する獲得耐性メカニズム.,
第72回日本癌学会学術総会, Oct. 2013. 岩瀬 俊, 髙尾 正一郎, 赤池 雅史, 伊勢 孝之, 八木 秀介, 山口 浩司, 山田 博胤, 添木 武, 若槻 哲三, 西岡 安彦, 原田 雅史, 佐田 政隆 :
左室収縮不全を伴う心サルコイドーシスと他の心疾患鑑別におけるガドリニウム遅延造影定量評価の有用性,
第61回日本心臓病学会学術集会, 2013年9月. 柿内 聡司, 大塚 憲司, 西條 敦郎, 手塚 敏史, 豊田 優子, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
当院における間質性肺炎合併肺癌の治療の現状.,
第11回日本臨床腫瘍学会学術集会, 2013年8月. 西岡 安彦 :
Translational Research.,
第11回日本臨床腫瘍学会学術集会, 2013年8月. 矢葺 洋平, 西條 敦郎, 木下 勝弘, 東 桃代, 後東 久嗣, 柿内 聡司, 埴淵 昌毅, 西岡 安彦, 井内 新, 青野 純典, 福野 天, 朝田 完二, 長瀬 教夫, 藤田 博己, 馬原 文彦 :
徳島県で発生した重症熱性血小板減少症候群 (severe fever with thrombocytopenia syndrome: SFTS) の1例,
第247回徳島医学会学術集会, 2013年8月. 中瀬 勝則, 鶴尾 美穂, 島田 久夫, 木下 成三, 豊﨑 纏, 杉野 聡, 浦 聡明, 山下 恵美, 古味 勝美, 服部 順子, 西岡 安彦, 埴淵 昌毅, 吾妻 雅彦 :
徳島市医師会のCOPD対策,
第247回徳島医学会学術集会, 2013年8月. 猪子 未希, 西條 敦郎, 岸 昌美, 埴淵 昌毅, 青野 純典, 豊田 優子, 木下 勝弘, 手塚 敏史, 吉嶋 輝実, 河野 弘, 岸 潤, 西岡 安彦, 池田 真由美, 吉田 光輝, 先山 正二, 福田 悠 :
肺多発浸潤影と胸膜炎を初発症状とした多発性筋炎の1例,
第247回徳島医学会学術集会, 2013年8月. 西岡 安彦 :
がん分子標的治療の基礎と臨床,
日本放射線腫瘍学会 第15回放射線腫瘍学夏季セミナー, 2013年8月. 埴淵 昌毅, 柿内 聡司, 後東 久嗣, 西岡 安彦 :
呼吸器疾患のControversy -Pros & Cons- 高齢者肺癌にベバシズマブは必要か? -Proの立場から-,
第49回日本呼吸器学会中国・四国地方会 (第20回呼吸器セミナー), 2013年7月. 長瀬 紗季, 豊田 優子, 阿部 秀一, 岸 潤, 河野 弘, 手塚 敏史, 埴淵 昌毅, 池田 真由美, 先山 正二, 西岡 安彦 :
サルコイドーシスの経過観察中に肺腺癌を合併した1例,
第49回日本呼吸器学会中国・四国地方会, 2013年7月. 是松 麻美, 岸 昌美, 青野 純典, 竹﨑 彰夫, 東 桃代, 木下 勝弘, 阿部 秀一, 埴淵 昌毅, 吉田 光輝, 先山 正二, 福田 悠, 西岡 安彦 :
徳島大学病院における胸腔鏡 (VATS)下肺生検症例の検討,
第49回日本呼吸器学会中国・四国地方会, 2013年7月. 尾崎 領彦, 柿内 聡司, 手塚 敏史, 西條 敦郎, 山子 泰斗, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
徳島大学病院におけるBevacizumab長期維持投与例の検討,
第52回日本肺癌学会中国・四国支部会, 2013年7月. 西條 敦郎, 後東 久嗣, 田畑 祥, 三橋 惇志, 豊田 優子, 埴淵 昌毅, 柿内 聡司, 秋山 伸一, 西岡 安彦 :
がん細胞の遊走におけるthymidine phosphorylaseとCXCL11の役割,
第22回日本がん転移学会学術集会・総会, 2013年7月. 後東 久嗣, 三橋 惇志, 倉本 卓哉, 田畑 祥, 西條 敦郎, 埴淵 昌毅, 柿内 聡司, 青野 純典, 上原 久典, 曽根 三郎, 西岡 安彦 :
肺surfactant protein A (SP-A) の肺癌進展における機能解析,
第22回日本がん転移学会学術集会・総会, 2013年7月. 西岡 安彦 :
生活習慣病と睡眠時無呼吸症候群,
海部郡医師会学術講演会, 2013年7月. 梶浦 耕一郎, 先山 正二, 滝沢 宏光, 池田 真由美, 古川 尊子, 森本 雅美, 中川 靖士, 川上 行奎, 吉田 光輝, 近藤 和也, 豊田 優子, 手塚 敏史, 木下 勝弘, 青野 純典, 西岡 安彦, 丹黒 章 :
《ワークショップ》気管支鏡破損症例の検討,
第36回日本呼吸器内視鏡学会学術集会, 2013年6月. 三橋 惇志, 後東 久嗣, 西條 敦郎, 倉本 卓哉, 田畑 祥, 埴淵 昌毅, 矢野 聖二, 曽根 三郎, 西岡 安彦 :
悪性胸膜中皮腫同所移植マウスモデルにおける抗VEGF治療耐性化メカニズムの検討,
第17回日本がん分子標的治療学会学術集会, 2013年6月. 黄 俊, 田畑 祥, 埴淵 昌毅, 西岡 安彦 :
悪性中皮腫におけるPAPPAの機能解析と分子標的治療法開発の検討,
第17回日本がん分子標的治療学会学術集会, 2013年6月. 埴淵 昌毅, 大塚 憲司, 後東 久嗣, 倉本 卓哉, 三橋 惇志, 西岡 安彦, 曽根 三郎, Isaiah J Fidler :
Endothelin受容体拮抗剤による肺癌脳転移抑制効果の検討,
第17回日本がん分子標的治療学会学術集会, 2013年6月. 森住 俊, 大塚 憲司, 豊田 優子, 河野 弘, 岸 潤, 手塚 敏史, 吉嶋 輝実, 柿内 聡司, 埴淵 昌毅, 西岡 安彦 :
脳炎と腹部大動脈瘤を合併した多発血管炎性肉芽腫症の1例,
第108回日本内科学会四国地方会, 2013年6月. 高橋 直希, 埴淵 昌毅, 青野 純典, 木下 勝弘, 東 桃代, 岸 昌美, 竹崎 彰夫, 西條 敦郎, 後東 久嗣, 西岡 安彦 :
当院におけるidiopathic pleuroparenchymal fibroelastosis (IPPFE) 症例の検討,
第108回日本内科学会四国地方会, 2013年6月. 岸 潤, 中川 麻耶, 河野 弘, 西尾 進, 平田 有紀菜, 山田 博胤, 佐田 政隆, 西岡 安彦 :
膠原病の関節炎における腋窩リンパ節の超音波性状に関する検討,
第86回日本超音波医学会学術集会, 2013年5月. Huang Jun, Liu Dai-Shun, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka :
Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice.,
第53回日本呼吸器学会学術講演会, Apr. 2013. 阿部 真治, 加藤 幸成, 金子 美華, 木宿 昌俊, 川添 和義, 東 満美, 埴淵 昌毅, 水口 和生, 西岡 安彦 :
ヒトNK細胞を介した抗ポドプラニン抗体NZ-8の悪性胸膜中皮腫に対する抗腫瘍効果.,
第53回日本呼吸器学会学術講演会, 2013年4月. 吉嶋 輝実, 河野 弘, 手塚 敏史, 豊田 優子, 岸 潤, 西岡 安彦 :
原因不明の末梢閉塞性動脈疾患加療中に冠動脈瘤が発覚し高安動脈炎と診断した1例.,
第57回日本リウマチ学会総会・学術集会, 2013年4月. 青野 純典, 阿部 秀一, 竹﨑 彰夫, 岡﨑 弘泰, 岸 昌美, 西岡 安彦 :
DNAマイクロアレイ法を用いたFibrocyteと単球の遺伝子発現解析の検討.,
第53回日本呼吸器学会学術講演会, 2013年4月. 阿部 秀一, 青野 純典, 岡﨑 弘泰, 岸 昌美, 竹﨑 彰夫, 木下 勝弘, 東 桃代, 岸 潤, 西岡 安彦 :
肺線維症における増殖因子産生を介したfibrocyteの役割と検討.,
第53回日本呼吸器学会学術講演会, 2013年4月. 小川 博久, 青野 純典, 手塚 敏史, 後東 久嗣, 西岡 安彦 :
Surfactant Protein Dはダニ抗原慢性暴露による気道線維化を抑制する,
2013年4月. 後東 久嗣, 三橋 惇志, 青野 純典, 西岡 安彦 :
肺癌進展におけるSP-Aと腫瘍関連マクロファージ.,
第53回日本呼吸器学会学術講演会, 2013年4月. 埴淵 昌毅, 後東 久嗣, 近藤 真代, 山子 泰斗, 岡﨑 弘泰, 手塚 敏史, 西岡 安彦 :
当院におけるIdiopathic pleuroparenchymal fibroelastosis(IPPFE)症例の検討-IgG4関連疾患との関連性-.,
第110回日本内科学会講演会, 2013年4月. 柿内 聡司, 大塚 憲司, 山子 泰斗, 西條 敦郎, 手塚 敏史, 後東 久嗣, 青野 純典, 埴淵 昌毅, 西岡 安彦 :
当院における間質性肺炎合併肺癌の治療の現状.,
第110回日本内科学会講演会, 2013年4月. 阿部 真治, 谷口 友紀, 木宿 昌俊, 中瀬 真理, 柴田 洋文, 川添 和義, 東 満美, 西岡 安彦, 水口 和生 :
新規ヒト・キメラ型抗ポドプラニン抗体の悪性胸膜中皮腫に対する選択性の検討,
日本薬学会第133年会, 2013年3月. Takashi Iwase, Shoichiro Takao, Masashi Akaike, Takayuki Ise, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Ken-ichi Aihara, Tetsuzo Wakatsuki, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata :
Differentiation of Left Ventricular Systolic Dysfunction Related to Cardiac Sarcoidosis and Other Heart Diseases Using contrast-enhanced Cardiovascular Magnetic Resonance.,
第77回 日本循環器学会学術集会, Mar. 2013. 西岡 安彦 :
IPF細胞分子病態と治療の現状,
第4回京都IPF研究会, 2013年2月. 吉嶋 輝実, 埴淵 昌毅, 東 桃代, 豊田 優子, 河野 弘, 岸 潤, 竹﨑 彰夫, 岡﨑 弘泰, 長尾 多美子, 鈴木 麗子, 高開 登茂子, 先山 正二, 西岡 安彦 :
徳島大学病院職員における潜在性結核感染症の現状,
第63回日本結核病学会中国四国支部会, 2013年2月. 米田 浩人, 手塚 敏史, 青野 純典, 香川 耕造, 西條 敦郎, 山子 泰斗, 大塚 憲司, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 泉 啓介, 西岡 安彦 :
胸腔鏡下胸膜生検で診断しえた腎盂癌胸膜転移の1例,
第21回日本呼吸器内視鏡学会中国四国支部会, 2013年2月. 米田 浩人, 柿内 聡司, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
当科におけるBevacizumab長期維持投与例の検討,
第8回腫瘍分子標的治療セミナー, 2013年2月. 西岡 安彦 :
難治性呼吸器疾患の分子病態解明と新規治療薬法の開発,
第246回徳島医学会学術集会, 2013年2月. 西岡 安彦 :
難治性呼吸器疾患に対するトランスレーショナルリサーチ,
創薬等支援技術基盤プラットフォーム 第3回創薬PF特別講義, 2013年2月. 田畑 祥, 西岡 安彦, 秋山 伸一 :
ヒト癌細胞の生存におけるチミジン異化作用の役割,
がんと代謝シンポジウム2013, 2013年1月. 松田 華子, 河野 弘, 岸 潤, 青野 純典, 香川 耕造, 米田 浩人, 岡崎 弘泰, 竹﨑 彰夫, 東 桃代, 埴淵 昌毅, 西岡 安彦 :
ステロイド抵抗性器質化肺炎の加療中に気胸・肺血栓塞栓症を合併した1例,
第48回日本呼吸器学会中国・四国地方会, 2012年12月. 森住 俊, 豊田 優子, 手塚 敏史, 柿内 聡司, 大塚 憲司, 山子 泰斗, 西條 敦郎, 後東 久嗣, 櫻田 巧, 埴淵 昌毅, 西岡 安彦 :
Cisplatinのshort-hydration投与法の忍容性に関する検討,
第48回日本呼吸器学会中国・四国地方会, 2012年12月. 阿部 真治, 加藤 幸成, 金子 美華, 黄 俊, 埴淵 昌毅, 曽根 三郎, 西岡 安彦 :
悪性胸膜中皮腫に対するヒトキメラ型抗ポドプラニン抗体療法の検討,
第25回日本バイオセラピィ学会学術集会総会, 2012年12月. 村上 永尚, 島谷 佳光, 山子 泰斗, 大崎 裕亮, 宮城 愛, 森 敦子, 野寺 裕之, 和泉 唯信, 西岡 安彦, 梶 龍兒 :
多彩な神経症状を呈した小細胞肺癌の1例．,
第107回日本内科学会四国地方会, 2012年12月. 西岡 安彦 :
特発性肺線維症に対するアプローチ-細胞分子病態からみたピレスパの作用と臨床における使い方‐,
シオノギWebカンファレンス, 2012年12月. 香川 耕造, 河野 弘, 藤田 浩司, 村上 永尚, 岸 潤, 埴淵 昌毅, 梶 龍兒, 西岡 安彦 :
MPO-ANCA関連肥厚性硬膜炎の1例,
第107回日本内科学会四国地方会, 2012年12月. 米田 浩人, 大塚 憲司, 青野 純典, 豊田 優子, 手塚 敏史, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
難治性の腎性・肝性胸水に対して胸腔-腹腔シャントが奏功した1例,
第107回日本内科学会四国地方会, 2012年12月. 小川 博久, 手塚 敏史, 西岡 安彦 :
Surfactant Protein Dはダニ抗原慢性暴露による気道線維化を抑制する,
2012年11月. 田島 壮一郎, 櫻田 巧, 柿内 聡司, 上松 卓, 片島 るみ, 寺岡 和彦, 久次米 敏秀, 川添 和義, 西岡 安彦, 楊河 宏章, 水口 和生 :
UGT1A1遺伝子のヘテロ接合体(*6または*28)を持つイリノテカン投与患者における治療安全性ならびに継続性に関する検討,
第33回日本臨床薬理学会年会, 2012年11月. 三橋 惇志, 後東 久嗣, Van The Trung, 倉本 卓哉, 田畑 祥, 埴淵 昌毅, 西岡 安彦 :
悪性胸膜中皮腫同所移植マウスモデルにおける抗VEGF治療耐性化メカニズムの検討,
感染免疫リトリート, 2012年11月. 西岡 安彦 :
呼吸器疾患に対する薬物療法の進歩とDDSから見た課題,
創剤フォーラム第18回若手研究会, 2012年11月. 谷口 友紀, 阿部 真治, 木宿 昌俊, 東 満美, 川添 和義, 西岡 安彦, 水口 和生 :
ADCCを介したヒトキメラ型抗ポドプラニン抗体の悪性胸膜中皮腫に対する抗腫瘍効果の検討,
第51回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2012年11月. 豊田 優子, 柿内 聡司, 埴淵 昌毅, 手塚 敏史, 後東 久嗣, 西岡 安彦 :
Patient-Reported Outcome (PRO) による肺癌薬物療法の有用性の検討,
第53回日本肺癌学会総会, 2012年11月. 埴淵 昌毅, 阿部 真治, 加藤 幸成, 金子 美華, 木宿 昌俊, 川添 和義, 黄 俊, 三橋 惇志, 水口 和生, 西岡 安彦 :
抗ポドプラニン抗体NZ-1の悪性胸膜中皮腫に対する抗体依存性細胞障害活性と抗腫瘍効果,
第53回日本肺癌学会総会, 2012年11月. 大塚 憲司, 豊田 優子, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦, 監﨑 孝一郎, 福森 知治, 坂東 良美 :
多発結節影を呈したLangerhans cell histiocytosisの1例,
第105回日本内科学会四国地方会, 2012年11月. 西岡 安彦 :
特発性間質性肺炎の治療標的:線維芽細胞と増殖因子シグナル,
第20回肺リモデリング研究会, 2012年10月. 河野 弘, 豊田 優子, 岸 潤, 埴淵 昌毅, 西岡 安彦 :
抗CCP抗体高値を呈し関節炎を伴わずに発症したステロイド抵抗性器質化肺炎の1例,
第23回日本リウマチ学会中国・四国支部学術集会, 2012年10月. 三橋 惇志, 後東 久嗣, 倉本 卓哉, 柿内 聡司, 佐藤 正大, The Trung VAN, 西條 敦郎, 田畑 祥, 小川 博久, 上原 久典, 秋山 伸一, 西岡 安彦, Rae Jo WRIGHT, 曽根 三郎 :
肺サーファクタント蛋白SP-Aの肺がん進展における機能解析,
日本肺サーファクタント·界面医学会雑誌, Vol.43, 32, 2012年10月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1570009751236977280
(CiNii: 1570009751236977280) 西岡 安彦 :
間質性肺炎の診断と治療:最近の進歩,
第26回日本臨床内科医学会, 2012年10月. 埴淵 昌毅, 長尾 多美子, 鈴木 麗子, 高開 登茂子, 東 桃代, 先山 正二, 西岡 安彦 :
潜在性結核感染症 (latent tuberculosis infection: LTBI) に対する治療の現状と問題点,
第6回日本結核病学会中国四国支部研究会, 2012年9月. 西岡 安彦 :
間質性肺炎の診断と治療-最近の話題-,
板野郡医師会学術講演会, 2012年9月. 西岡 安彦 :
特発性肺線維症の細胞分子病態と抗線維化薬開発,
第7回城北呼吸器疾患フォーラム, 2012年9月. 加藤 幸成, 国田 朱子, 西岡 安彦 :
抗ポドプラニン抗体による転移抑制効果の検討,
第71回日本癌学会学術総会, 2012年9月. 田畑 祥, 池田 龍二, 山本 雅達, 古川 龍彦, 倉本 卓哉, 後東 久嗣, 埴淵 昌毅, 西岡 安彦, 曽根 三郎, 秋山 伸一 :
ヒト癌細胞の生存におけるチミジン異化作用の役割,
第71回日本癌学会学術総会, 2012年9月. 西岡 安彦, 阿部 真治, 木宿 昌俊, 川添 和義, 黄 俊, 埴淵 昌毅, 水口 和生, 曽根 三郎, 加藤 幸成 :
悪性胸膜中皮腫に対するラット-ヒトキメラ型抗ポドプラニン抗体NZ-8の抗腫瘍効果,
第71回日本癌学会学術総会, 2012年9月. Le T. Dat, Taisuke Matsuo, Tetsuro Yoshimaru, Souji Kakiuchi, Hisatsugu Goto, Kuramoto Takuya, Mitsuhashi Atsushi, Saburo Sone, Yasuhiko Nishioka and Toyomasa Katagiri :
LBMTF a novel transcriptional factor involved in lung cancer bone metastases,
The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012. 山子 泰斗, 柿内 聡司, 大塚 憲司, 西條 敦郎, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
PNA-LNA PCR Clamp法とCycleave法を用いたEGFR遺伝子変異測定の比較検討,
肺癌分子標的治療セミナー, 2012年9月. 西岡 安彦 :
リウマチ関連肺疾患の診断と治療,
プライマリーケア研究会, 2012年9月. 西岡 安彦 :
呼吸器・膠原病内科学-診療と研究の現状と展望-,
平成24年度青藍会高知県支部講演会, 2012年9月. 西岡 安彦 :
呼吸器疾患診療:最近の話題と診療のポイント,
第75回よろず・胸部疾患研究会, 2012年8月. 高橋 彩加, 岡﨑 弘泰, 岸 潤, 豊田 優子, 手塚 敏史, 松立 吉弘, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 久保 宜明, 西岡 安彦 :
刺青部分に肉芽腫性変化を起こしたサルコイドーシスの1例,
第245回徳島医学会学術集会, 2012年7月. 藤田 美香, 河野 弘, 近藤 真代, 竹﨑 彰夫, 岸 潤, 藤井 達也, 中瀧 恵実子, 青野 純典, 埴淵 昌毅, 武田 憲昭, 西岡 安彦 :
頸部・縦隔蜂窩織炎で急激に発症し窒息に至った劇症型A群溶血性レンサ球菌感染症 (Streptococcal Toxic Shock-like Syndrome;STSS) の1例,
第245回徳島医学会学術集会, 2012年7月. 西岡 安彦 :
ガイドラインからみた肺炎治療の考え方,
第79回西部臨床研究会, 2012年7月. 西岡 安彦 :
間質性肺炎診療の現状と課題,
第47回日本呼吸器学会中国・四国地方会 呼吸器セミナー, 2012年7月. 中西 嘉憲, 河野 弘, 阿部 秀一, 竹﨑 彰夫, 後東 久嗣, 青野 純典, 埴淵 昌毅, 先山 正二, 福田 悠, 西岡 安彦 :
特発性肺骨化症の1例,
第47回日本呼吸器学会中国・四国地方会, 2012年7月. 香川 耕造, 西條 敦郎, 柿内 聡司, 大塚 憲司, 山子 泰斗, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
測定法によりEGFR変異の測定結果に乖離がみられた非小細胞肺癌の3例,
第51回日本肺癌学会中国・四国支部会, 2012年7月. 米田 浩人, 青野 純典, 岸 昌美, 豊田 優子, 近藤 真代, 岡﨑 弘泰, 岸 潤, 埴淵 昌毅, 監﨑 孝一郎, 福田 悠, 西岡 安彦 :
高IgG血症の長期間の経過観察中に多中心性キャッスルマン病の診断に至った1例,
第47回日本呼吸器学会中国・四国地方会, 2012年7月. 西岡 安彦 :
COPDの診断と治療,
東四国医療セミナー, 2012年7月. 辻本 雄太, 国田 朱子, 西岡 安彦, 加藤 幸成 :
ヒトキメラ型抗ポドプラニン抗体による転移抑制効果の検討．,
第21回日本がん転移学会学術集会・総会, 2012年7月. 辻本 雄太, 国田 朱子, 西岡 安彦, 加藤 幸成 :
ヒトキメラ型抗ポドプラニン抗体による転移抑制効果の検討,
第21回日本がん転移学会学術集会・総会, 2012年7月. 三橋 惇志, 後東 久嗣, 倉本 卓哉, 田畑 祥, 小川 博久, 上原 久典, 秋山 伸一, Wright Jo Rae, 曽根 三郎, 西岡 安彦 :
肺surfactant protein A(SP-A)の肺癌進展における機能解析,
第21回日本がん転移学会学術集会・総会, 2012年7月. 倉本 卓哉, 後東 久嗣, 三橋 惇志, 田畑 祥, 上原 久典, 西條 敦郎, 柿内 聡司, 埴淵 昌毅, 前川 洋一, 安友 康二, 秋山 伸一, 曽根 三郎, 西岡 安彦 :
小細胞肺がん転移におけるDll4-Notchシグナルの臓器特異性に関する検討,
第21回日本がん転移学会学術集会・総会, 2012年7月. 大塚 憲司, 埴淵 昌毅, 後東 久嗣, 西岡 安彦, 曽根 三郎, Fidler Isaiah J :
Endothelin受容体拮抗剤による肺癌脳転移抑制効果の検討,
第21回日本がん転移学会学術集会・総会, 2012年7月. 西岡 安彦 :
リウマチ・膠原病に合併した肺病変の診断と治療.,
第5回徳島リウマチ医の会, 2012年7月. 加藤 幸成, 阿部 真治, 水口 和生, 西岡 安彦 :
ヒトキメラ型抗ポドプラニン抗体による転移抑制機序の解明,
第16回日本がん分子標的治療学会学術集会, 2012年6月. 田畑 祥, 池田 龍二, 山本 雅達, 古川 龍彦, 倉本 卓哉, 後東 久嗣, 埴淵 昌毅, 西岡 安彦, 曽根 三郎, 秋山 伸一 :
ヒト癌細胞のROS産生および生存におけるチミジン異化作用の役割,
第16回日本がん分子標的治療学会学術集会, 2012年6月. 西岡 安彦, 阿部 真治, 加藤 幸成, 木宿 昌俊, 川添 和義, 黄 俊, 埴淵 昌毅, 水口 和生, 曽根 三郎 :
悪性胸膜中皮腫に対するヒトキメラ型抗ポドプラニン抗体NZ-8の抗腫瘍効果,
第16回日本がん分子標的治療学会学術集会, 2012年6月. 倉本 卓哉, 後東 久嗣, 佐藤 正大, 三橋 惇志, 田畑 祥, 西條 敦郎, 上原 久典, Welm Alana L, 埴淵 昌毅, 秋山 伸一, 曽根 三郎, 西岡 安彦 :
ヒト肺がん多臓器転移モデルにおけるMacrophage-stimulating proteinの役割に関する検討,
第16回日本がん分子標的治療学会学術集会, 2012年6月. 西岡 安彦 :
肺癌の分子標的治療:最近の話題,
第2回高知病院肺癌講演会, 2012年6月. 豊田 優子, 埴淵 昌毅, 柿内 聡司, 櫻田 巧, 後東 久嗣, 手塚 敏史, 岸 潤, 青野 純典, 西岡 安彦 :
当科における終末期の鎮静についての検討,
第17回日本緩和医療学会学術大会, 2012年6月. 坂東 美佳, 山田 博胤, K Ogasawara, 仁木 敏之, N Tomita, J Hotchi, R Tamai, Y Hirata, D Hirota, S Nishio, S Bando, 伊勢 孝之, 上田 由佳, 山口 浩司, 岩瀬 俊, 竹谷 善雄, 添木 武, 若槻 哲三, 佐田 政隆, H Kawano, 西岡 安彦 :
肺動脈血栓に対してフォンダパリヌクスが著効した静脈血栓塞栓症の一例,
第100回日本循環器学会中国・四国合同地方会, 2012年6月. 田岡 志保, 河野 弘, 手塚 敏史, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 西岡 安彦, 岡本 耕一, 高山 哲治 :
FDG-PET/CTにより小腸転移を発見した肺癌の2症例．,
第106回日本内科学会四国地方会, 2012年6月. 大塚 憲司, 柿内 聡司, 後東 久嗣, 青野 純典, 埴淵 昌毅, 西岡 安彦 :
高用量のメロぺネムが奏効した細菌性肺炎症例,
徳島感染症講演会, 2012年6月. 大塚 憲司, 原 知也, 豊田 優子, 岸 潤, 青野 純典, 山口 浩司, 埴淵 昌毅, 佐田 政隆, 西岡 安彦 :
心筋炎を合併したChurg-Strauss症候群の1例,
第106回日本内科学会四国地方会, 2012年6月. 西條 敦郎, 柿内 聡司, 香西 博之, 大塚 憲司, 山子 泰斗, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 西岡 安彦 :
Cycleave法とPCR-Clamp法によるEGFR遺伝子変異測定結果とEGFRチロシンキナーゼ阻害剤の治療効果との相関,
第35回日本呼吸器内視鏡学会学術集会, 2012年5月. 西岡 安彦 :
ガイドラインから見た市中肺炎治療の考え方,
土佐長岡郡・香美郡医師会合同学術講演会, 2012年4月. 河野 弘, 岸 昌美, 手塚 敏史, 豊田 優子, 岸 潤, 西岡 安彦 :
腹部大動脈周囲炎を伴ったgranulomatosis with polyangiitisの1例,
第56回日本リウマチ学会総会・学術集会, 2012年4月. 西岡 安彦 :
睡眠時無呼吸症候群と生活習慣病,
第58回徳島臨床カンファランス, 2012年4月. 早稲田 優子, 松井 祥子, 山本 洋, 藤村 政樹, 有田 真知子, 石井 寛, 駒崎 義利, 杉山 幸比古, 渡辺 正樹, 臼井 裕, 河村 哲治, 小林 英夫, 西岡 安彦, 本間 栄, 小倉 高志 :
IgG4関連疾患(IgG4RD)の呼吸器病変における臨床画像病理学的検討,
第52回日本呼吸器学会学術講演会, 2012年4月. 青野 純典, Jo Rae Wright, 後東 久嗣, 西岡 安彦 :
肺損傷・修復とSP-D:抗線維化の視点から,
第52回日本呼吸器学会学術講演会, 2012年4月. Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Syo Tabata, Hirohisa Ogawa, Hisanori Uehara, Shin-ichi Akiyama, Jo Rae Wright, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response.,
第52回日本呼吸器学会学術講演会, Apr. 2012. 阿部 秀一, 岡﨑 弘泰, 岸 昌美, 竹﨑 彰夫, 木下 勝弘, 東 桃代, 岸 潤, 青野 純典, 西岡 安彦 :
Fibrocyteの肺線維芽細胞機能に及ぼす効果の検討,
第52回日本呼吸器学会学術講演会, 2012年4月. 岸 昌美, 青野 純典, 竹崎 彰夫, 東 桃代, 岸 潤, 西岡 安彦 :
当院におけるピルフェニドン投与症例の検討,
第52回日本呼吸器学会学術講演会, 2012年4月. 阿部 真治, 加藤 幸成, 金子 美華, 木宿 昌俊, 川添 和義, 東 満美, 水口 和生, 曽根 三郎, 西岡 安彦 :
悪性胸膜中皮腫に対する抗ポドプラニン抗体NZ-1の抗腫瘍効果に関する検討,
第52回日本呼吸器学会学術講演会, 2012年4月. Jun Huang, Shinji Abe, Yuki Morita, Shuji Ozaki, Masatoshi Kishuku, Kazuo Minakuchi, Masaki Hanibuchi, Toshio Matsumoto, Saburo Sone and Yasuhiko Nishioka :
Antibody-dependent cellular cytotoxicity against mesothelioma cells mediated by anti-HM 1.24 antibodies,
第52回日本呼吸器学会学術講演会, Apr. 2012. 柿内 聡司, 埴淵 昌毅, 後東 久嗣, 豊田 優子, 西條 敦郎, 手塚 敏史, 田岡 隆成, 高橋 正幸, 金山 博臣, 西岡 安彦 :
mTOR阻害剤投与症例における間質性肺障害の臨床的特徴,
第109回日本内科学会講演会, 2012年4月. 西岡 安彦 :
ガイドラインに基づいた肺炎のマネージメント,
徳島県病院薬剤師会 学術講演会, 2012年4月. 西岡 安彦 :
間質性肺炎に関する最近の話題,
徳島県臨床内科医会総会・学術講演会, 2012年3月. 阿部 真治, 谷口 友紀, 木宿 昌俊, 里吉 良子, 川添 和義, 東 満美, 西岡 安彦, 水口 和生 :
肺癌における新規癌抗原OFA-iLRP発現の検討,
日本薬学会第132年会, 2012年3月. 西岡 安彦 :
特発性肺線維症-細胞分子病態から見た治療の進歩-,
第47回愛媛びまん性肺疾患研究会, 2012年3月. 西岡 安彦 :
間質性肺疾患に対するトランスレーショナルリサーチ-細胞分子病態解析から治療法開発を目指して-,
第9回最新医学研究会, 2012年3月. 西岡 安彦 :
呼吸器疾患の日常診療とピットフォール,
第21回女性医学研究会, 2012年3月. 近藤 真代, 豊田 優子, 阿部 秀一, 河野 弘, 岸 昌美, 竹﨑 彰夫, 東 桃代, 柿内 聡司, 後東 久嗣, 青野 純典, 埴淵 昌毅, 西岡 安彦 :
病勢に関連してCA19-9の変動を認めた非結核性抗酸菌症の1例,
第20回日本呼吸器内視鏡学会中国四国支部会, 2012年3月. 香西 博之, 手塚 敏史, 河野 弘, 竹﨑 彰夫, 東 桃代, 柿内 聡司, 後東 久嗣, 岸 潤, 青野 純典, 埴淵 昌毅, 西岡 安彦 :
非結核性抗酸菌症を合併したサルコイドーシスの1例,
第20回日本呼吸器内視鏡学会中国四国支部会, 2012年3月. 竹﨑 彰夫, 西條 敦郎, 大塚 憲司, 岸 昌美, 手塚 敏史, 柿内 聡司, 後東 久嗣, 岸 潤, 青野 純典, 埴淵 昌毅, 西岡 安彦 :
当科で経験した肺胞出血4症例の臨床的検討,
第20回日本呼吸器内視鏡学会中国四国支部会, 2012年3月. 西岡 安彦 :
慢性咳と喘息-病態と治療における最近の話題-,
宇摩医師会学術講演会, 2012年2月. 矢野 祖, 近藤 真代, 河野 弘, 西條 敦郎, 豊田 優子, 柿内 聡司, 岸 潤, 埴淵 昌毅, 西岡 安彦, 古川 貴大, 藤田 浩司 :
神経サルコイドーシスの1例,
第244回徳島医学会学術集会, 2012年2月. 太田 理絵, 若槻 哲三, 岩瀬 俊, 髙尾 正一郎, 山田 博胤, 赤池 雅史, 坂東 左知子, 仁木 敏之, 能勢 隼人, 冨田 紀子, 山口 浩司, 竹谷 善雄, 添木 武, 西岡 安彦, 原田 雅史, 佐田 政隆 :
肺，皮膚病変診断4年後に心病変が顕在化したサルコイドーシスの1例,
第22回 日本心血管画像動態学会, 2012年1月. 岡崎 弘泰, 豊田 優子, 岸 潤, 河野 弘, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 榊 美佳, 西岡 安彦 :
組織診断が得られた肝サルコイドーシスの2症例,
第22回日本リウマチ学会中国・四国支部学術集会, 2011年12月. 西岡 安彦 :
分子標的治療における一体化開発への期待,
JAMTTC・JSGDT合同シンポジウム2011, 2011年12月. 阿部 真治, 加藤 幸成, 金子 美華, 黄 俊, 埴淵 昌毅, 曽根 三郎, 西岡 安彦 :
悪性胸膜中皮腫に対する抗ポドプラニン抗体療法の検討,
第24回日本バイオセラピィ学会学術集会総会, 2011年12月. 阿部 真治, 谷口 友紀, 木宿 昌俊, 加藤 幸成, 川添 和義, 東 満美, 西岡 安彦, 水口 和生 :
ポドプラニンを標的とした悪性胸膜中皮腫に対する新規抗体療法の検討,
第50回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, 2011年11月. 手塚 敏史, 小川 博久, 吾妻 雅彦, 西岡 安彦, 曽根 三郎 :
Plasminogen Activator Inhibitor-1阻害剤(IMD-4690)の慢性喘息モデルマウスにおける検討．,
第61回日本アレルギー学会秋季学術大会, 2011年11月. 大塚 憲司, 豊田 優子, 柿内 聡司, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦, 監﨑 孝一郎, 福森 知治, 坂東 良美 :
多発結節影を呈したLangerhans cell histiocytosisの1例,
第105回日本内科学会四国地方会, 2011年11月. 近藤 真代, 河野 弘, 柿内 聡司, 岸 潤, 埴淵 昌毅, 吾妻 雅彦, 近藤 絵里, 合田 正和, 石丸 直澄, 西岡 安彦 :
IgG4関連下垂体炎の1例,
第105回日本内科学会四国地方会, 2011年11月. 山崎 宙, 楠瀬 賢也, 伊勢 孝之, 竹谷 善雄, 若槻 哲三, 手塚 敏史, 柿内 聡司, 西岡 安彦, 坂東 良美, 佐田 政隆 :
稀な画像所見を呈する肺アスペルギルス症により治療抵抗性心不全を認めた1症例,
第105回 日本内科学会四国地方会, 2011年11月. 岩瀬 俊, 髙尾 正一郎, 赤池 雅史, 能勢 隼人, 伊勢 孝之, 小笠原 梢, 山崎 宙, 髙島 啓, 坂東 左知子, 仁木 敏之, 楠瀬 賢也, 發知 淳子, 冨田 紀子, 上田 由佳, 山口 浩司, 山田 博胤, 添木 武, 若槻 哲三, 西岡 安彦, 原田 雅史, 佐田 政隆 :
心臓MRIによるサルコイドーシス心病変検出の有用性,
第31回 日本サルコイドーシス/肉芽腫性疾患学会総会, 2011年10月. Yasuhiko Nishioka, Yukinari Kato, Masaki Hanibuchi and Saburo Sone :
Antimumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma,
70th Annual Meeting of the Japanese Cancer Association, Oct. 2011. Sho Tabata, Masatatsu Yamamoto, Ryuji Ikeda, Tatsuhiko Furukawa, Tatsuya Kuramoto, Yasuhiko Nishioka, Saburo Sone and Shin-ichi Akiyama :
Thymidine-derived sugars generated by thymidine phosphorylase entered glycolytic pathway,
70th Annual Meeting of the Japanese Cancer Association, Oct. 2011. Le T. Dat, Taisuke Matsuo, Tetsuro Yoshimaru, Takuya Kuramoto, Masaki Hanibuchi, Hisatsugu Goto, Souji Kakiuchi, Yasuhiko Nishioka, Saburo Sone and Toyomasa Katagiri :
Genome-wide gene expression profiling analysis of bone metastases of human non-smal cell lung cancer (NSCLC) in mice,
70th Annual Meeting of the Japanese Cancer Association, Oct. 2011. 岩瀬 俊, 髙尾 正一郎, 赤池 雅史, 能勢 隼人, 久岡 白陽花, 伊勢 孝之, 仁木 敏之, 楠瀬 賢也, 山口 浩司, 竹谷 善雄, 山田 博胤, 添木 武, 若槻 哲三, 西岡 安彦, 原田 雅史, 佐田 政隆 :
サルコイドーシス心病変検出における心臓MRI検査の有用性,
第59回 日本心臓病学会学術集会, 2011年9月. 藤岡 啓介, 西條 敦郎, 豊田 優子, 柿内 聡司, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦, 竹内 恭子, 藤井 志朗, 中村 信元, 賀川 久美子, 安倍 正博, 水谷 友哉 :
不明熱で発症し皮膚生検が診断に有効であった血管内リンパ腫の1例,
第243回徳島医学会学術集会, 2011年7月. 高橋 直希, 飛梅 亮, 手塚 敏史, 豊田 優子, 東 桃代, 後東 久嗣, 柿内 聡司, 岸 潤, 青野 純典, 埴淵 昌毅, 吾妻 雅彦, 曽根 三郎, 西岡 安彦, 高橋 美紀子, 福田 悠 :
間質性肺炎の精査により診断されたIgG4関連疾患の1例,
第46回日本呼吸器学会中国・四国地方会, 2011年7月. 香西 博之, 豊田 優子, 柿内 聡司, 竹﨑 彰夫, 岸 昌美, 大塚 憲司, 手塚 敏史, 後東 久嗣, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦 :
気胸を合併した肺癌10例についての検討,
第50回日本肺癌学会中国・四国支部会, 2011年7月. 田岡 隆成, 岸 昌美, 竹﨑 彰夫, 木下 勝弘, 豊田 優子, 柿内 聡司, 埴淵 昌毅, 井崎 博文, 高橋 正幸, 福森 知治, 金山 博臣, 西岡 安彦 :
当院におけるmTOR阻害薬投与患者に発症した間質性肺炎の臨床的検討,
第46回日本呼吸器学会中国・四国地方会, 2011年7月. 佐藤 正大, 後東 久嗣, 倉本 卓哉, 小川 博久, 三橋 惇志, テバン チュン, 柿内 聡司, 田畑 祥, 秋山 伸一, 西岡 安彦, 曽根 三郎 :
ヒト肺がん多臓器転移モデルにおけるMacrophage Stimulationg Proteinの役割に関する検討,
第20回日本がん転移学会学術集会, 2011年6月. 後東 久嗣, アデル ガブル, 埴淵 昌毅, 倉本 卓哉, 柿内 聡司, 佐藤 正大, 田畑 祥, テバン チュン, 小川 博久, 秋山 伸一, 西岡 安彦, 曽根 三郎 :
ヒト肺癌転移モデルにおけるerlotinibの宿主介在性抗腫瘍効果の検討,
第20回日本がん転移学会学術集会, 2011年6月. 三橋 惇志, 後東 久嗣, 倉本 卓哉, 柿内 聡司, 佐藤 正大, バン テ チュン, 西條 敦郎, 田畑 祥, 秋山 伸一, 西岡 安彦, 曽根 三郎 :
肺サーファクタント蛋白SP-Aの肺癌進展における機能解析,
第20回日本がん転移学会学術集会, 2011年6月. 西岡 安彦, 辻本 雄太, 加藤 幸成, 曽根 三郎 :
ヒトキメラ型抗ポドプラニン抗体の活性評価,
第20回日本がん転移学会学術集会, 2011年6月. 加藤 幸成, 西岡 安彦, 阿部 真治, 水口 和夫, 曽根 三郎 :
悪性グリオーマに対する抗ポドプラニン抗体NZ-1の活性評価,
第15回日本がん分子標的治療学会学術集会, 2011年6月. 西岡 安彦, 阿部 真治, 加藤 幸成, 木宿 昌俊, 川添 和義, 黄 俊, 埴淵 昌毅, 水口 和夫, 曽根 三郎 :
抗ポドプラニン抗体NZ-1の悪性胸膜中皮腫に対する抗体依存性細胞障害活性と抗腫瘍効果,
第15回日本がん分子標的治療学会学術集会, 2011年6月. 倉本 卓哉, 後東 久嗣, 柿内 聡司, 小川 博久, 三橋 惇志, 田畑 祥, 佐藤 正大, 前川 洋一, 安友 康二, 西岡 安彦, 秋山 伸一, 曽根 三郎 :
小細胞肺がん転移におけるDLL4-Notchシグナルの臓器特異性に関する検討,
第15回日本がん分子標的治療学会学術集会, 2011年6月. 田畑 祥, 山本 雅達, 池田 龍二, 古川 龍彦, 倉本 卓哉, 西岡 安彦, 曽根 三郎, 秋山 伸一 :
抗ポドプラニン抗体NZ-1の悪性胸膜中皮腫に対する抗体依存性細胞障害活性と抗腫瘍効果,
第15回日本がん分子標的治療学会学術集会(, 2011年6月. 佐藤 正大, 西岡 安彦, 曽根 三郎, 大谷 直子 :
がんマイクロRNAクラスターMir17-92発現の生体内イメージングとがん治療への応用,
第15回日本がん分子標的治療学会学術集会, 2011年6月. Dat LeTan, Taisuke Matsuo, Hisatsugu Goto, Souji Kakiuchi, Yasuhiko Nishioka, Saburo Sone and Toyomasa Katagiri :
Identification and characterization of a novel transcription factor invoved lung cancer bone metastases,
第15回日本がん分子標的治療学会学術集会, Jun. 2011. バン テ チュン, 埴淵 昌毅, 後東 久嗣, 柿内 聡司, 倉本 卓哉, レ タン ダー, 矢野 聖二, 秋山 伸一, 西岡 安彦, 曽根 三郎 :
血管新生阻害剤TSU-68の悪性胸膜中皮腫同所移植モデルにおける抗腫瘍効果の検討．,
第15回日本がん分子標的治療学会学術集会, 2011年6月. 吾妻 雅彦, 本淨 晃史, 手塚 敏史, 小川 博久, 米田 和夫, 葉久 貴司, 杉田 明美, 湊 義彰, 西岡 安彦, 曽根 三郎 :
徳島県における気管支喘息患者のコントロールに関する実態調査第2報,
第23回日本アレルギー学会春季臨床大会, 2011年5月. 太田 理絵, 岩瀬 俊, 久岡 白陽花, 山田 博胤, 西岡 安彦, 髙尾 正一郎, 坂東 左知子, 能勢 隼人, 楠瀬 賢也, 仁木 敏之, 冨田 紀子, 上田 由佳, 山口 浩司, 竹谷 善雄, 添木 武, 若槻 哲三, 赤池 雅史, 曽根 三郎, 佐田 政隆 :
心室固有調律が心病変診断のきっかけとなったサルコイドーシスの1例,
第98回 日本循環器学会 中国・四国合同地方会, 2011年5月. 木下 勝弘, 佐藤 正大, 後東 久嗣, 柿内 聡司, 埴淵 昌毅, 吾妻 雅彦, 西岡 安彦, 曽根 三郎 :
ベバシズマブが奏功した非小細胞肺癌の2症例,
第104回日本内科学会四国地方会, 2011年5月. 岸 昌美, 西岡 安彦, 豊田 優子, 岸 潤, 後東 久嗣, 吾妻 雅彦, 曽根 三郎 :
抗甲状腺薬服用中にMPO-ANCA関連血管炎症候群を発症した2例,
第104回日本内科学会四国地方会, 2011年5月. 安積 麻衣, 岩瀬 俊, 仁木 敏之, 若槻 哲三, 佐田 政隆, 赤池 雅史, 髙尾 正一郎, 原田 雅史, 西岡 安彦, 曽根 三郎 :
眼，肺，筋病変に続いて経過中に新病変の顕在化を認めたサルコイドーシスの一例,
第104回 日本内科学会四国地方会, 2011年5月. 竹﨑 彰夫, 東 桃代, 木下 勝弘, 後東 久嗣, 多田 浩也, 吾妻 雅彦, 西岡 安彦, 曽根 三郎 :
当院における慢性壊死性肺アスペルギルス症に対するアムビゾームの使用経験．,
第51回日本呼吸器学会学術講演会, 2011年4月. 木下 勝弘, 西岡 安彦, 岸 昌美, 東 桃代, 青野 純典, 竹﨑 彰夫, 上原 久典, 畠山 慎二, 河原 英治, 曽根 三郎 :
ブレオマイシン肺線維症モデルにおけるFAK阻害剤TAE226の抗線維化効果の検討．,
第51回日本呼吸器学会学術講演会, 2011年4月. 東 桃代, 西岡 安彦, Reham Elmorshedy Mohammed, 岸 潤, 岸 昌美, 木下 勝弘, 竹崎 彰夫, Huang Jun, 上原 久典, 泉 啓介, 秋山 伸一, 曽根 三郎 :
肺線維症におけるスフィンゴシン-1-リン酸シグナルの検討．,
第51回日本呼吸器学会学術講演会, 2011年4月. 手塚 敏史, 小川 博久, 吾妻 雅彦, 本浄 晃史, 西岡 安彦, 曽根 三郎 :
喘息モデルマウスの抗原感作におけるIKKβ-NF-κB経路の影響について．,
第51回日本呼吸器学会学術講演会, 2011年4月. 仁木 昌徳, 西條 敦郎, 後東 久嗣, 本淨 晃史, 木下 勝弘, 東 桃代, 多田 浩也, 吾妻 雅彦, 西岡 安彦, 曽根 三郎 :
Clarithromycin，Amikacin，Imipenem/cilastatin，Moxifloxacinの併用療法が有効であった肺Mycobacterium abscessus感染症の1例．,
第19回日本呼吸器内視鏡学会中国四国支部会, 2011年1月. 飛梅 亮, 佐藤 正大, 豊田 優子, 後東 久嗣, 多田 浩也, 西岡 安彦, 曽根 三郎 :
異なるEGFR遺伝子変異を有する多発肺腺癌の一例．,
第19回日本呼吸器内視鏡学会中国四国支部会, 2011年1月. 西岡 安彦 :
腫瘍免疫.,
第60回日本アレルギー学会秋季学術大会 教育講演, 2010年11月. 西岡 安彦, 吾妻 雅彦, 曽根 三郎 :
COPD(慢性閉塞性肺疾患)と喫煙-職業性COPDも含めて-,
第5回日本禁煙科学会学術総会 教育講演, 2010年11月. 後東 久嗣, 坂口 暁, 西岡 安彦, 曽根 三郎 :
肺癌の骨転移形成における性差のメカニズム．,
第13回癌と骨病変研究会, 2010年11月. 西岡 安彦, 後東 久嗣, 倉本 卓哉, 柿内 聡司, 埴淵 昌毅, 古垣 耕, 曽根 三郎 :
骨微小環境でのEGF受容体を標的とした肺癌の骨転移制御の検討．,
第13回癌と骨病変研究会, 2010年11月. 近藤 真代, 手塚 敏史, 佐藤 正大, 後東 久嗣, 吾妻 雅彦, 岸 潤, 多田 浩也, 西岡 安彦, 曽根 三郎 :
頭部MRI検査で多発性の高信号域を認めたChurg-Strauss 症候群の1例．,
第103回日本内科学会四国地方会, 2010年11月. 木宿 昌俊, 阿部 真治, 森田 結貴, 寺岡 和彦, 久次米 敏秀, 西岡 安彦, 川添 和義, 曽根 三郎, 水口 和生 :
成熟樹状細胞由来sVEGFR-1 の腫瘍血管新生に及ぼす影響,
第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2010年11月. 森田 結貴, 阿部 真治, 木宿 昌俊, 西岡 安彦, 川添 和義, 曽根 三郎, 水口 和生 :
HM1.24 を標的とした悪性胸膜中皮腫に対する抗体療法の開発,
第49回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2010年11月. 西岡 安彦 :
呼吸器感染症‐最近の話題‐,
第1回徳島県臨床内科医会総会・講演会, 2010年11月. 後東 久嗣, 富本 英樹, 多田 浩也, 西岡 安彦, 大串 文隆, 岡野 義夫, 土居 裕幸, 山本 晃義, 竹内 栄治, 兼松 貴則, 曽根 三郎 :
進行非小細胞肺癌患者を対象としたTS-1/CDDP併用療法の臨床第Ⅱ相試験．,
第51回日本肺癌学会総会, 2010年11月. 本淨 晃史, 小川 博久, 吾妻 雅彦, 手塚 敏史, 西岡 安彦, 谷 憲治, 曽根 三郎 :
P3-7 アレルギー性気道炎症モデルマウスにおけるTARC-PE38の投与効果の検討(P3 動物モデル,ポスター,第60回日本アレルギー学会秋季学術大会),
アレルギー, Vol.59, No.9, 1430, 2010年10月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390001204991911424
(CiNii: 1390001204991911424) 手塚 敏史, 小川 博久, 吾妻 雅彦, 本淨 晃史, 西岡 安彦, 曽根 三郎 :
P3-4 喘息モデルマウスの抗原感作に対するIKKβ-NF-κB経路の影響について(P3 動物モデル,ポスター,第60回日本アレルギー学会秋季学術大会),
アレルギー, Vol.59, No.9, 1429, 2010年10月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390001204991910144
(CiNii: 1390001204991910144) 小川 博久, 吾妻 雅彦, 本淨 晃史, 手塚 敏史, 西岡 安彦, 曽根 三郎 :
O17-2 慢性喘息モデルマウスにおける気道上皮産生NGFの気道過敏性への影響(O17 アレルギー動物モデル,口演,第60回日本アレルギー学会秋季学術大会),
アレルギー, Vol.59, No.9, 1387, 2010年10月.- (文献検索サイトへのリンク)
- ● CiNii @ 国立情報学研究所 (CRID): 1390282679970860160
(CiNii: 1390282679970860160) 西岡 安彦 :
肺線維症における細胞分子病態研究の進歩と臨床.,
第31回日本呼吸器学会生涯教育講演会(秋季セミナー), 2010年10月. Yasuhiko Nishioka, Hisatsugu Goto, Kuramoto Takuya, Souji Kakiuchi, Masaki Hanibuchi, Yano Seiji and Sone Saburo :
Bone metastasis of lung cancer and its molecular-targeted therapy.,
第69回日本癌学会学術総会, Sep. 2010. 柿内 聡司, 矢野 聖二, 後東 久嗣, 先山 正二, 近藤 和也, 冨田 章弘, 西岡 安彦, 曽根 三郎 :
EGFRチロシンキナーゼ阻害剤耐性関連遺伝子による治療効果予測．,
第69回日本癌学会学術総会, 2010年9月. 田畑 洋, 山本 雅達, 池田 龍二, 古川 龍彦, 南 謙太朗, 倉本 卓哉, 大塚 憲司, 武田 泰生, 山田 勝士, 西岡 安彦, 曽根 三郎, 秋山 伸一 :
チミジンホスホリラーゼによる活性酵素の産生機構．,
第69回日本癌学会学術総会, 2010年9月. 田畑 洋, 山本 雅達, 池田 龍二, 古川 龍彦, 倉本 卓哉, 武田 泰生, 山田 勝士, 西岡 安彦, 曽根 三郎, 秋山 伸一 :
チミジンホスホリラーゼによる血管新生の分子機構．,
第5回メタボロームシンポジウム, 2010年9月. 田畑 洋, 山本 雅達, 池田 龍二, 古川 龍彦, 南 謙太朗, 西岡 安彦, 曽根 三郎, 秋山 伸一 :
チミジンホスホリラーゼによる活性酸素の産生機構．,
第14回日本がん分子標的治療学会学術集会, 2010年7月. 西岡 安彦 :
キナーゼ阻害薬Update．,
第14回日本がん分子標的治療学会学術集会, 2010年7月. チュン バンテ, 後東 久嗣, 埴淵 昌毅, 柿内 聡司, レタン ダー, 矢野 聖二, 秋山 伸一, 西岡 安彦, 曽根 三郎 :
血管新生阻害剤TSU-68の悪性胸膜中皮腫同所移植モデルにおける抗腫瘍効果の検討．,
第14回日本がん分子標的治療学会学術集会, 2010年7月. 倉本 卓哉, 後東 久嗣, 小川 博久, 三橋 惇志, 前川 洋一, 安友 康二, 柿内 聡司, 西岡 安彦, 曽根 三郎 :
小細胞肺がん転移におけるDLL4-Notchシグナルの臓器特異性に関する検討,
第14回日本がん分子標的治療学会学術集会, 2010年7月. 後東 久嗣, アデル ガブル, 埴淵 昌毅, 倉本 卓哉, チュン バンテ, 小川 博久, 柿内 聡司, 佐藤 正大, 飛梅 亮, 秋山 伸一, 西岡 安彦, 曽根 三郎 :
ヒト肺癌転移モデスにおけるerlotinibの宿主介在性腫瘍効果の検討．,
第19回日本がん転移学会学術集会, 2010年6月. 阿部 秀一, 手塚 敏史, 木下 勝弘, 東 桃代, 多田 浩也, 西岡 安彦, 曽根 三郎 :
徳島大学病院における呼吸器検体から分離された薬剤耐性肺炎球菌の動向について.,
第50回日本呼吸器学会学術講演会, 2010年4月. 東 桃代, Mohammed Reham Elmorshedy, 岸 潤, 木下 勝弘, 岸 昌美, 西岡 安彦, 曽根 三郎 :
新規免疫抑制薬フィンゴリモド(FTY720)のマウスブレオマイシン誘発肺線維症に及ぼす効果の検討.,
第50回日本呼吸器学会学術講演会, 2010年4月. 岸 昌美, 西岡 安彦, 東 桃代, 木下 勝弘, 岸 潤, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルマウスにおけるPDGFレセプターα，β阻害抗体の抗線維化効果.,
第50回日本呼吸器学会学術講演会, 2010年4月. 西岡 安彦, 岸 潤, 豊田 優子, 曽根 三郎 :
関節リウマチの治療中に発生する肺病変の鑑別診断.,
第50回日本呼吸器学会学術講演会, 2010年4月. Wang Wei, Li Qi, Yamada Tadaaki, Yasuhiko Nishioka, Saburo Sone and Yano Seiji :
Stromal fibroblasts induce resistance of lung cancer to EGFR tyrosine kinase inhibitors.,
第50回日本呼吸器学会学術講演会English Mini-symposium, Apr. 2010. 西岡 安彦, 岸 潤, 豊田 優子, 曽根 三郎 :
関節リウマチの治療中に発生する肺病変の鑑別診断,
第50回日本呼吸器学会学術講演会シンポジウム. 日本呼吸器学会・日本リウマチ学会共同企画プログラム「新規抗リウマチ薬の諸問題」, 2010年4月. 小川 博久, 吾妻 雅彦, 本浄 晃史, 手塚 敏史, 西岡 安彦, 曽根 三郎 :
慢性喘息モデルマウスにおける気道上皮からのNGF産生と気道過敏性への影響.,
第50回日本呼吸器学会学術講演会, 2010年4月. Li Qi, Wang Wei, Yamada Tadaaki, Yasuhiko Nishioka and Saburo Sone :
Crosstalk straomal fibroblasts promotes malignant pleural mesothelioma progression.,
第50回日本呼吸器学会学術講演会English Mini-symposium, Apr. 2010. Souji Kakiuchi, Yano Seiji, Ogino Hirokazu, Sato Seidai, Hiroya Tada, Yasuhiko Nishioka and Saburo Sone :
Novel therapeutic efficacy of E7080 for controlling experimental metastases of human lung cancer cells in natural killer cell-depleted SCID mice.,
第50回日本呼吸器学会学術講演会English Mini-symposium, Apr. 2010. 富本 英樹, 後東 久嗣, 柿内 聡司, 多田 浩也, 西岡 安彦, 兼松 貴則, 近藤 和也, 先山 正二, 葉久 貴司, 米田 和夫, 坂東 弘康, 住友 正幸, 曽根 三郎 :
徳島県内における肺癌患者の疫学調査についての検討,
第50回日本呼吸器学会学術講演会, 2010年4月. 西岡 安彦 :
肺線維症における細胞分子病態研究の進歩と臨床.,
第31回日本呼吸器学会生涯教育講演会(春季セミナー), 2010年4月. 柿内 聡司, 組橋 由記, 埴淵 昌毅, 後東 久嗣, 富本 英樹, 豊田 優子, 坂口 暁, 多田 浩也, 西岡 安彦, 曽根 三郎 :
PRO評価に基づいた肺癌薬物療法の有用性の検討.,
第107回日本内科学会総会・講演会, 2010年4月. 富本 英樹, 後東 久嗣, 多田 浩也, 西岡 安彦, 大串 文隆, 土居 裕幸, 山本 晃義, 竹内 栄治, 兼松 貴則, 曽根 三郎 :
進行非小細胞肺癌患者を対象としたTS-1/CDDP併用療法の臨床第II相試験．,
第107回日本内科学会(, 2010年4月. 豊田 優子, 東 桃代, 後東 久嗣, 青野 純典, Rentsenhand Batmungh, 西岡 安彦, 曽根 三郎 :
放射線治療後の乳癌患者に発症した器質化肺炎におけるBALFの臨床的検討．,
第18回日本呼吸器内視鏡学会中国四国支部会, 2010年2月. 多田 浩也, 竹﨑 彰夫, 西岡 安彦, 曽根 三郎 :
肺血流イメージングから診断したHepatopulmonary syndrome (肝肺症候群)の一例．,
第2回呼吸機能イメージング研究会学術集会, 2010年1月. 阿部 真治, 西岡 安彦, 木宿 昌俊, 中野 沙織, 森田 結貴, 寺岡 和彦, 久次米 敏秀, 川添 和義, 曽根 三郎, 水口 和生 :
特異的癌抗原MAGE-3を標的とした癌免疫療法の検討,
第48回 日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2009年11月. 中野 沙織, 阿部 真治, 森田 結貴, 木宿 昌俊, 西岡 安彦, 川添 和義, 曽根 三郎, 水口 和生 :
新規癌抗原OFA-iLRPを標的とした肺癌に対する免疫療法の開発,
第48回 日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2009年11月. 阿部 真治, 木宿 昌俊, 西岡 安彦, 中村 敏己, 西迫 寛隆, 寺岡 和彦, 久次米 敏秀, 川添 和義, 曽根 三郎, 水口 和生 :
肺癌に対する腫瘍特異的免疫療法の検討,
第46回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, 148, 2007年11月. 西岡 安彦, Wang Wei, 尾崎 修治, 松本 俊夫, 曽根 三郎 :
肺癌におけるHM1.24抗原発現と抗HM1.24抗体による抗体療法の可能性,
第17回日本バイオセラピィ学会ワークショップ3抗体療法と臨床応用, 2004年11月. 西岡 安彦 :
SARSの基礎と臨床 - 院内感染対策を中心に -,
第229回徳島医学会学術集会シンポジウム, 2004年8月. 鵜飼 桃代, 西岡 安彦, 内山 恒夫, 小川 基彦, 高崎 智彦, 倉根 一郎, 曽根 三郎 :
ベトナムで感染·発症した発疹熱の一症例,
第78回日本感染症学会総会, 2004年4月. 西岡 安彦, 青野 純典, 稲山 真美, 岸 潤, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルにおける分子標的治療薬STI571(Gleevec)の抗線維化効果,
第6回間質性肺炎細胞分子病態シンポジウム, 2003年9月. 西岡 安彦, 中川 達夫, 楊河 宏章, 水口 和生, 曽根 三郎 :
難治性固形癌に対するMAGE-3ペプチドパルス成熟樹状細胞を用いた癌免疫療法の第I相臨床試験,
第3回トランスレーショナルリサーチワークショップ, 2003年9月. 西岡 安彦 :
肺癌に対する抗原ペプチドパルス樹状細胞を用いた癌ワクチン療法 - トランスレーショナルリサーチとしての展開 -,
第227回徳島医学会学術集会シンポシウム, 2003年7月. 西岡 安彦, 曽根 三郎 :
MAGE-3ペプチドパルス樹状細胞を用いた進行肺癌に対する特異的免疫療法 - トランスレーショナルリサーチとしての試み -,
第6回がん分子標的治療研究会総会 - パネルディスカッション -, 2002年6月. 宮田 淳也, 西岡 安彦, 岸 潤, 柿内 聡司, 吾妻 雅彦, 谷 憲治, 曽根 三郎, 三木 真理, 中村 陽一, 大串 文隆 :
びまん性肺疾患における気管支肺胞洗浄液中MDC,TARCの検討,
日本呼吸器学会総会, Vol.42, 2002年4月. 西岡 安彦, 宮田 淳也, 岸 潤, 曽根 三郎 :
ブレオマイシン肺線維症におけるToll-like receptorの関与,
日本呼吸器学会総会, Vol.42, 2002年4月. 西岡 安彦, 西村 直樹, 田原 秀晃, 曽根 三郎 :
樹状細胞におけるNO産出とIL-12の免疫調節作用における役割,
第31回日本免疫学会総会ワークショップ, 2001年12月. 西岡 安彦, Wen Hua, 西村 直樹, 曽根 三郎 :
ヒト単球由来樹状細胞によるNK活性増強効果,
第14回日本バイオテラピィ学会総会ワークショップ, 2001年12月. 西岡 安彦 :
遺伝子導入樹状細胞を用いた癌免疫療法,
OMCC SEMINAR(特別講演), 2001年11月. 西岡 安彦, 西村 直樹, 曽根 三郎 :
ヒト単球由来樹状細胞によるNK活性増強効果,
日本癌学会総会, Vol.60, 2001年9月. 西岡 安彦, 西村 直樹, 曽根 三郎 :
アデノウイルスベクターを用いたヒト末梢血単球由来樹状細胞へのIL-12遺伝子導入と免疫増強効果,
基盤的免疫研究会総会, Vol.5, 2001年7月. 西岡 安彦, 遠藤 健, 谷 憲治, 大串 文隆, 曽根 三郎 :
モデルマウスを用いた間質性肺炎の病態解析,
第41回日本呼吸器学会総会ワークショップ - 小動物モデルから臨床へ, 2001年4月. 西村 直樹, 西岡 安彦, 山本 早弥香, 曽根 三郎 :
IL-12遺伝子導入ヒト末梢血単球由来樹状細胞を用いた癌ワクチン療法の試み - 遠心法によるアデノウイルスベクターの遺伝子導入効率増強,
第13回バイオテラピ学会総会ワークショップ, 2000年12月. 山本 早弥香, 西村 直樹, 西岡 安彦, 曽根 三郎 :
ヒト樹状細胞へのアデノウイルスベクター導入効率増強を目指した遠心法の検討,
第13回バイオテラピ学会総会ワークショップ, 2000年12月. 山辺 一恵, 西岡 安彦, 三谷 嘉代, 楊河 宏章, 西村 直樹, 曽根 三郎 :
原発性肺癌における胸水中可溶性Fas,FasLの検討,
第13回バイオテラピ学会総会ワークショップ, 2000年12月. 西岡 安彦, 西村 直樹, 曽根 三郎 :
Hu-PBL-SCIDモデルを用いたヒト樹状細胞機能評価システムの検討,
第30回日本免疫学会総会ワークショップ9 - 樹状細胞, 2000年11月. 西岡 安彦, 西村 直樹, 篠原 勉, 曽根 三郎 :
Hu-PBL-SCIDモデルを用いた樹状細胞機能のin vivo評価システムの検討,
日本癌治療学会総会, Vol.38, 2000年10月. 西岡 安彦 :
樹状細胞療法の現状と遺伝子導入樹状細胞を用いた癌免疫療法,
第2回 東海分子呼吸器研究会(特別講演), 2000年7月. 西岡 安彦, 西村 直樹, 田原 秀晃, 曽根 三郎 :
IL-12遺伝子導入樹状細胞の腫瘍内投与による肺転移抑制効果,
第9回がん転移研究会総会ワークショップ, 2000年6月. 西岡 安彦 :
サイトカイン遺伝子導入樹状細胞を用いた癌免疫療法 - 樹状細胞への遺伝子導入技術とサイトカイン遺伝子導入 -,
Surgery Frontier, Vol.7, No.2, 43-48, 2000年. 西岡 安彦, 西村 直樹, 曽根 三郎 :
ヒト単球由来樹状細胞によるNK活性増強効果 - 樹状細胞より産出されるサイトカイン特にIL-15の重要性について -,
第29回日本免疫学会総会ワークショップ12 - マクロファージ・樹状細胞, 1999年12月. 西岡 安彦 :
遺伝子導入樹状細胞を用いた癌免疫療法,
第5回Young Oncologist Conference (特別講演), 1999年11月. 西岡 安彦, 西村 直樹, 兼松 貴則, 篠原 勉, 曽根 三郎 :
IL-12遺伝子導入樹状細胞の腫瘍内投与による肺転移抑制効果,
第37回日本癌治療学会総会プレジデントセッション7-サイトカインによる癌治療の現状と展望, 1999年10月. 西岡 安彦 :
IL-12遺伝子導入樹状細胞を用いた癌免疫療法,
第22回バイオセラピーカンファランス, 1999年9月. 西岡 安彦, 矢野 聖二, 埴淵 昌毅, 篠原 勉, 曽根 三郎 :
癌関連抗原に対する抗体治療の進歩,
第25回 日本医学会総会シンポジウム - 腫瘍免疫と癌治療 -, 1999年4月. 西岡 安彦, 西村 直樹, 田原 秀晃, 曽根 三郎 :
樹状細胞(dendritic cells)を用いた癌免疫遺伝子治療,
第39回日本呼吸器学会学術講演会 - シンポジウム - 呼吸器疾患遺伝子治療の進歩, 1999年4月. 西岡 安彦, 西村 直樹, 田原 秀晃, 曽根 三郎 :
樹状細胞(dendritic cells)を用いた癌免疫遺伝子治療,
第39回呼吸器病学会シンポジウム - 呼吸器疾患遺伝子治療の進歩, 1999年3月. 西岡 安彦 :
IL-12遺伝子導入樹状細胞を用いた癌免疫療法,
第16回癌治療カンファランス(特別講演 ), 1999年1月. 西岡 安彦 :
IL-12遺伝子導入樹状細胞を用いた癌免疫療法,
第6回新潟分子血液学研究会(特別講演), 1998年9月. 西岡 安彦, P.D. Robbins, M.T. Lotze, 曽根 三郎, 田原 秀晃 :
IL-12遺伝子導入dendritic cellを用いた癌免疫療法の検討,
第12回天城シンポジウム, 1998年8月.
- 研究会・報告書
- 西岡 安彦 :
知っておきたい肺の病気∼間質性肺炎とは?∼,
令和5年度徳島県立三好病院県民公開講座, 2024年1月. 宮本 直輝, 吉田 光輝, 大塚 憲司, 髙嶋 美佳, 松本 大資, 河北 直也, 坪井 光弘, 鳥羽 博明, 川上 行奎, 近藤 和也, 西岡 安彦, 滝沢 宏光, 丹黒 章 :
胸腔鏡下に確定診断を得たCalcifying fibrous tumorの1例,
第4回徳島外科医会, 2021年2月. 西岡 安彦 :
悪性胸膜中皮腫に対する特異的免疫療法の開発．,
平成24年度金沢大学がん進展制御研究書 共同利用・共同研究拠点 研究成果報告会, 2012年12月. 西岡 安彦 :
開講41年目の呼吸器・膠原病内科学分野-臨床と研究について-,
第43回三徳会高知同門研究会, 2012年7月. Mitsuhashi Atsushi, Hisatsugu Goto, Kuramoto Takuya, Tabata Syo, Ogawa Hirohisa, Uehara Hisanori, Akiyama Shin-ichi, Wright Rae Jo, Saburo Sone and Yasuhiko Nishioka :
Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response.,
2011感染免疫クラスター・ミニリトリート, Dec. 2011. 後東 久嗣, Gabr Gomaa Mohammed Adel, 埴淵 昌毅, 倉本 卓哉, 小川 博久, 田畑 祥, Van The Trung, 柿内 聡司, 秋山 伸一, 曽根 三郎, 西岡 安彦 :
ヒト肺癌転移モデルにおけるerlotinibの骨転移抑制効果の検討．,
第14回癌と骨病変研究会, 2011年11月. 三橋 惇志, 後東 久嗣, 倉本 卓哉, 柿内 聡司, 佐藤 正大, Van The Trung, 西條 敦郎, 田畑 祥, 小川 博久, 上原 久典, 秋山 伸一, 西岡 安彦, Wright Rae Jo, 曽根 三郎 :
肺サーファクタント蛋白SP-A肺がん進展における機能解析．,
日本肺サーファクタント・界面医学会第47回学術研究会, 2011年10月. 青野 純典, 西岡 安彦 :
肺線維症におけるSP-Dの防御的役割．,
日本肺サーファクタント・界面医学会第47回学術研究会, 2011年10月. 後東 久嗣, 青野 純典, 西岡 安彦 :
肺の生体防御機構におけるサーファクタント蛋白Aの役割．,
日本肺サーファクタント・界面医学会第47回学術研究会, 2011年10月. 原 知也, 岩瀬 俊, 高島 啓, 山崎 宙, 小笠原 梢, 坂東 左知子, 伊勢 孝之, 仁木 敏之, 楠瀬 賢也, 上田 由佳, 冨田 紀子, 山口 浩司, 竹谷 善雄, 山田 博胤, 添木 武, 若槻 哲三, 佐田 政隆, 赤池 雅史, 能勢 隼人, 髙尾 正一郎, 大塚 秀樹, 原田 雅史, 西岡 安彦 :
心サルコイドーシス診断の手引きにおける各種診断モダリティーの検討,
第16回中四国心筋症・心不全研究会, 2011年9月. 西岡 安彦 :
間質性肺炎 Update．,
第3回呼吸器・膠原病フォーラム, 2011年6月. 岸 昌美, 西岡 安彦, 木下 勝弘, 東 桃代, 竹﨑 彰夫, 曽根 三郎 :
ピルフェドニンが著効した肝硬変合併症IPFの一例．,
厚生労働科学研究 難治性疾患克服研究事業 びまん性肺疾患に関する調査研究班 平成22年度 第2回班会議総会, 2010年12月. 西岡 安彦 :
呼吸器感染症:最近の話題．,
海部郡医師会学術講演会, 2010年12月. 西岡 安彦 :
間質性肺炎の診断と治療．,
地域医療グループ勉強会, 2010年9月. 西岡 安彦 :
肺がん∼内科的治療∼,
洲本市健康大学講座「がん医療の今，未来」, 2010年8月. Tomoyuki Yuasa, Seiji Yano, Yasuhiko Nishioka, Yoshiaki Kubo, Masayuki Takahashi, Hiroyoshi Nakatsuji, Hisao Nagaya, Hiro-omi Kanayama, Seiji Arase, Saburo Sone and Yousuke Ebina :
Soluble insulin receptor ectodomain in the plasma is a possible broad-spectrum tumor marker,
第68回 日本癌学会学術総会記事, 450, Oct. 2009. 湯浅 智之, 小畑 利之, 矢野 聖二, 岡本 英治, 西岡 安彦, 久保 宜明, 高橋 正幸, 中逵 弘能, 長屋 寿雄, 金山 博臣, 荒瀬 誠治, 曽根 三郎, 蛯名 洋介 :
可溶化インスリン受容体細胞外ドメイン(sIR)は癌患者血清中で増加している,
第29回 日本分子腫瘍マーカー研究会 プログラム, 70-71, 2009年9月. 東 桃代, 西岡 安彦, 青野 純典, 稲山 真美, 上原 久典, 泉 啓介, 曽根 三郎 :
マウスbleomycin肺線維症モデルにおけるlmatinib(Gleevec)とErythromycin併用による抗線維化効果-α1-acid glycoproteinの役割,
間質性肺炎細胞分子病態研究会, Vol.8, 2005年8月. 稲山 真美, 西岡 安彦, 東 桃代, 青野 純典, 谷 憲治, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルにおけるIKK-β阻害剤IMD-0354の抗線維化効果の検討,
RMSB研究会, Vol.25, 2005年7月. 西岡 安彦, 東 桃代, 青野 純典, 稲山 真美, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレオマイシン肺線維症モデルにおけるimatinibの抗線維化効果とエリスロマイシンの併用の意義,
マクロライド研究会, Vol.12, 2005年7月. 稲山 真美, 西岡 安彦, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルにおけるIKKβ阻害剤IMD-0354の抗線維化効果の検討,
ALI研究会, Vol.9, 2005年2月. 稲山 真美, 西岡 安彦, 鵜飼 桃代, 青野 純典, 上原 久典, 泉 啓介, 谷 憲治, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルにおけるNF-κB阻害剤IMD-0354の抗線維化効果,
間質性肺炎細胞分子病態研究会 シンポジウム「間質性肺炎に対する新たな治療法」, Vol.7, 2004年8月. 西岡 安彦, 青野 純典, 稲山 真美, 鵜飼 桃代, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルにおける分子標的治療薬Gleevecの抗線維化効果の検討,
RMCB研究会, Vol.24, 2004年7月. 鵜飼 桃代, 西岡 安彦, 内山 恒夫, 小川 基彦, 高崎 智彦, 倉根 一郎, 曽根 三郎 :
輸入感染症として経験した発疹熱の一例,
徳島呼吸器感染症学術講演会, 2004年3月. 青野 純典, 西岡 安彦, 稲山 真美, 岸 潤, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルにおける分子標的治療薬STI571(Gleevec)の抗線維化効果,
ALI研究会, Vol.8, 2004年2月. 西岡 安彦, 青野 純典, 稲山 真美, 岸 潤, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルにおける分子標的治療薬STI571(Gleevec)の抗線維化効果,
間質性肺炎細胞分子病態研究会 シンポジウム「Molecular targeting drugと肺の炎症」, Vol.6, 2003年9月. 岸 潤, 西岡 安彦, 稲山 真美, 青野 純典, 真鍋 和義, 曽根 三郎 :
マウスP.acnes誘発肺肉芽腫モデルの作成とその解析,
RMCB研究会, Vol.23, 2003年7月. 西岡 安彦, 岡本 正人, 岸 潤, 泉 啓介, 佐藤 光信, 曽根 三郎 :
ブレオマイシン肺線維症におけるToll-like receptorの関与,
ALI研究会, Vol.7, 2003年2月. 西岡 安彦, 岸 潤, 宮田 淳也, 柿内 聡司, 吾妻 雅彦, 谷 憲治, 三木 真理, 中村 陽一, 大串 文隆, 曽根 三郎 :
びまん性肺疾患における気管支肺胞洗浄液中MDC,TARCの検討,
RMCB研究会, Vol.22, 2002年7月. 岸 潤, 西岡 安彦, 宮田 淳也, 谷 憲治, 曽根 三郎 :
びまん性肺疾患における気管支肺胞洗浄液中MDC,TARCの検討,
ALI研究会, Vol.6, 2002年2月. 西岡 安彦, 矢野 聖二, 篠原 勉, 鶴尾 隆, 曽根 三郎 :
多剤性肺癌に対する免疫遺伝子治療の基礎的検討,
RMCB研究会, Vol.18, 1999年1月. 西岡 安彦, 西村 直樹, 田原 秀晃, 曽根 三郎 :
肺癌に対する樹状細胞を用いた癌特異的免疫療法の検討,
RMCB研究会, Vol.18, 1999年1月. 西岡 安彦 :
日本アレルギー協会四国支部の活動報告,
infoAllergy, Vol.84, 6, 2018年6月. 青野 純典, 阿部 秀一, 西岡 安彦 :
肺線維症におけるFibrocyteのeffector cellとしての役割の検討,
難治性疾患克服事業 びまん性肺疾患に関する調査研究 平成24年度研究報告書, 321-325, 2013年3月. 青野 純典, 阿部 秀一, 西岡 安彦 :
Fibrocyteの肺線維芽細胞に対する作用の検討,
難治性疾患克服研究事業 びまん性肺疾患に関する調査研究 平成23年度研研究報告集, 299-303, 2012年3月. 西岡 安彦, 東 桃代, 木下 勝弘, 岸 昌美, 竹﨑 彰夫, 曽根 三郎 :
肺線維症におけるスフィンゴシン-1-リン酸シグナルの検討,
難治生疾患克服研究事業 びまん性肺疾患に関する調査研究 平成22年度研究報告書, 315-319, 2011年3月. 坂東 政司, 杉山 幸比古, 西岡 安彦, 岸 一馬, 井上 義一, 谷口 博之, 小倉 高志, 本間 栄 :
ピルフェニドン有効症例検討会のまとめ,
難治生疾患克服研究事業 びまん性肺疾患に関する調査研究 平成22年度研究報告書, 83-112, 2011年3月. 西岡 安彦, 岸 昌美, 青野 純典, 東 桃代, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルマウスにおけるPDGFレセプターα，β阻害抗体の抗繊維化効果,
難治性疾患克服研究事業 びまん性肺疾患に関する調査研究班 平成21年度報告書, 29-234, 2010年3月. 西岡 安彦, 東 桃代, 青野 純典, 稲山 真美, 曽根 三郎 :
ブレオマイシン肺線維症モデルにおけるimatinibの抗線維化効果:α1ーacid glycoproteinの重要性,
厚生科学研究 特定疾患対策研究事業 びまん性肺疾患研究班 平成16年度報告書, 170-174, 2005年3月. 西岡 安彦, 青野 純典, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレイオマイシン誘発肺線維症モデルにおける分子標的治療薬Imatinib(Gleevec)の抗線維化効果,
厚生省特定疾患 特発性間質性肺炎の画期的治療法による臨床研究報告書, 32-35, 2005年. 西岡 安彦, 東 桃代, 青野 純典, 稲山 真美, 曽根 三郎 :
ブレオマイシン肺線維症モデルにおけるimatinibの抗線維化効果:α1ーacid glycoproteinの重要性,
厚生科学研究 特定疾患対策研究事業 びまん性肺疾患研究班 平成16年度研究報告書, 600-603, 2005年. 西岡 安彦, 青野 純典, 上原 久典, 泉 啓介, 曽根 三郎 :
ブレオマイシン誘発肺線維症モデルにおける分子標的治療薬Imatinib(Gleevec)の抗線維化効果,
厚生科学研究 特定疾患対策研究事業 びまん性肺疾患研究班 平成15年度報告書, 77-84, 2004年3月. 西岡 安彦, 岸 潤, 曽根 三郎 :
間質性肺炎における気管支肺胞洗浄液中MDC,TARCの検討,
2002年度びまん性肺疾患調査研究, 56-60, 2003年3月. 曽根 三郎, 谷 憲治, 西岡 安彦, 黄 陸平 :
放射線肺臓炎におけるCD13/aminopeptidase Nの役割,
2001年度 びまん性肺疾患調査研究, 191-196, 2003年. 渋谷 雅之, 木戸 博, 林 良夫, 根本 尚夫, 佐野 茂樹, 安友 康二, 東 博之, 西岡 安彦, 寺尾 純二, 二川 健, 三澤 弘明, 松尾 繁樹, 馬場 嘉信, 松本 耕三, 三好 弘一, 曽根 三郎 :
徳島大学先端医療開発研究センター設置準備室成果報告書,
2002年12月. 西岡 安彦 :
樹状細胞の遺伝子操作によるがん免疫強化法に関する研究,
文部科学省 がん研究に係る特定領域研究C 研究報告集 平成13年度研究報告, 184, 2002年3月. 曽根 三郎, 谷 憲治, 西岡 安彦, 黄色 陸平 :
放射線肺臓炎におけるCD13/aminopeptidase Nの役割,
厚生科学研究 特定疾患対策研究事業 びまん性肺疾患研究班 平成13年度報告書, 191-196, 2002年3月. 曽根 三郎, 谷 憲治, 西岡 安彦, 黄 陸平 :
放射線肺臓炎における肺線維芽細胞増殖因子としてのトロンビンの関与,
2000年度 びまん性肺疾患調査研究, 201-205, 2001年. 曽根 三郎, 大串 文隆, 多田 浩也, 谷 憲治, 西岡 安彦 :
放射線肺臓炎 - 肺線維芽細胞のPDGF-βレセプター発現,
厚生科学研究 特定疾患対策研究事業 びまん性肺疾患研究班 平成11年度報告書, 60-63, 2000年3月.
- 特許
- 研究者総覧に該当データはありませんでした。
- 作品
- 研究者総覧に該当データはありませんでした。
- 補助金・競争的資金
- 腫瘍特異的抗体療法におけるADCC活性誘導機構の解明と新規抗体医薬開発への応用 (研究課題/領域番号: 23K06256 )
肺がん・中皮腫における新たな抗原提示細胞の同定から革新的複合がん免疫療法への展開 (研究課題/領域番号: 22H03079 )
安全性と有効性を両立した悪性胸膜中皮腫に対するがん細胞選択的抗体医薬の開発 (研究課題/領域番号: 20K07197 )
肺がん・中皮腫に対する新規複合がん免疫療法の免疫学的基盤確立から臨床への展開 (研究課題/領域番号: 19H03668 )
ADCCを介した腫瘍特異的抗体療法における制御因子の解明と抗がん作用増強への応用 (研究課題/領域番号: 16K08372 )
肺がん微小環境の新たな標的：線維細胞を基軸とした薬剤耐性克服と革新的治療への展開 (研究課題/領域番号: 16H05309 )
肝転移を標的とした小細胞肺癌に対する新規分子標的治療の開発 (研究課題/領域番号: 26670418 )
ポドプラニンを標的とした悪性胸膜中皮腫に対する新規抗体療法の開発 (研究課題/領域番号: 25460189 )
ＡＤＣＣ活性に基づく肺癌・中皮腫の抗体療法開発と免疫学的バイオマーカー探索 (研究課題/領域番号: 24390210 )
肺線維症に対する抗線維化ペプチド吸入療法の開発 (研究課題/領域番号: 23659434 )
チミジンホスホリラーゼの作用機構の解析と阻害剤TPIの前臨床試験 (研究課題/領域番号: 22501048 )
同所移植ヒト悪性胸膜中皮腫モデルを用いた新規抗血管新生療法の探索 (研究課題/領域番号: 22390166 )
呼吸器悪性腫瘍の微小環境の特性を標的とした新規制御法の開発 (研究課題/領域番号: 22112010 )
気管支喘息の慢性気導炎症の病態解明とその制御 (研究課題/領域番号: 20590899 )
骨髄由来fibrocyteの遊走阻害:PDGFの役割と肺線維症治療への展開 (研究課題/領域番号: 20390231 )
肺癌に対するHM1.24抗原を標的とした特異的免疫療法の開発 (研究課題/領域番号: 18590855 )
肺癌転移の臓器微小環境特性から見た分子標的治療法の開発 (研究課題/領域番号: 17016051 )
肺癌に対する成熟樹状細胞を用いた特異的免疫療法の臨床研究 (研究課題/領域番号: 15590812 )
抗P糖蛋白single chain Fv抗体とケモカインの融合蛋白作製と応用研究 (研究課題/領域番号: 13557053 )
樹状細胞の遺伝子操作によるがん免疫強化法に関する研究 (研究課題/領域番号: 13218093 )
ウイルスベクターによる樹状細胞への高効率遺伝子導入と癌免疫遺伝子治療への応用 (研究課題/領域番号: 12770230 )
肺線維化病態におけるシクロオキシゲナーゼ(COX)発現の分子生物学的解析 (研究課題/領域番号: 12670559 )
肺がんの転移・血管新生分子を標的とした生物学的制御法開発 (研究課題/領域番号: 12217099 )
肺がんの薬剤耐性と転移因子を分子標的とした免疫遺伝子治療 (研究課題/領域番号: 08266242 )
研究者番号（70274199）による検索
- その他
- 研究者総覧に該当データはありませんでした。
2024年4月26日更新
- 専門分野・研究分野
- 呼吸器内科学 (Respiratory Medicine)
- 所属学会・所属協会
- 社団法人 日本内科学会
一般社団法人日本呼吸器学会
日本癌学会
日本肺癌学会
社団法人 日本アレルギー学会
日本リウマチ学会
日本癌治療学会
日本バイオセラピー学会
日本呼吸器内視鏡学会
日本遺伝子治療学会
日本人類遺伝学会
米国遺伝子治療学会 - 委員歴・役員歴
- 社団法人 日本内科学会 (評議員)
一般社団法人日本呼吸器学会 (常務理事 [2018年4月], 理事 [2013年2月], 代議員 [2004年6月])
日本肺癌学会 (理事 [2018年12月], 評議員)
日本バイオセラピー学会 (評議員) - 受賞
- 1996年6月, 日米癌研究訓練計画奨励賞
1999年1月, 奨励賞 (RMCB研究会)
2000年10月, 優秀演題賞 (日本癌治療学会)
2010年12月, 徳島新聞医学研究賞 (徳島新聞社)
2014年8月, 岡本敏肺線維症研究基金 (社団法人 日本呼吸器学会)
2023年12月, 第60回ベルツ賞 (日本ベーリンガーインゲルハイム株式会社) - 活動
- 徳島県感染症審査協議会 (委員)
2024年4月21日更新
2024年4月27日更新
Ｊグローバル
- Jグローバル最終確認日
- 2024/4/27 01:25
- 氏名（漢字）
- 西岡 安彦
- 氏名（フリガナ）
- ニシオカ ヤスヒコ
- 氏名（英字）
- Nishioka Yasuhiko
- 所属機関
- 徳島大学 教授
リサーチマップ
- researchmap最終確認日
- 2024/4/21 01:50
- 氏名（漢字）
- 西岡 安彦
- 氏名（フリガナ）
- ニシオカ ヤスヒコ
- 氏名（英字）
- Nishioka Yasuhiko
- プロフィール
- リサーチマップAPIで取得できませんでした。
- 登録日時
- 2011/8/26 00:00
- 更新日時
- 2024/1/31 08:11
- アバター画像URI
- https://researchmap.jp/read0184060/avatar.jpg
- ハンドル
- リサーチマップAPIで取得できませんでした。
- eメール
- リサーチマップAPIで取得できませんでした。
- eメール（その他）
- リサーチマップAPIで取得できませんでした。
- 携帯メール
- リサーチマップAPIで取得できませんでした。
- 性別
- リサーチマップAPIで取得できませんでした。
- 没年月日
- リサーチマップAPIで取得できませんでした。
- 所属ID
- 0344000000
- 所属
- 徳島大学
- 部署
- 大学院医歯薬学研究部 呼吸器・膠原病内科学分野
- 職名
- 教授
- 学位
- 医学博士
- 学位授与機関
- 徳島大学
- URL
- リサーチマップAPIで取得できませんでした。
- 科研費研究者番号
- リサーチマップAPIで取得できませんでした。
- Google Analytics ID
- リサーチマップAPIで取得できませんでした。
- ORCID ID
- リサーチマップAPIで取得できませんでした。
- その他の所属ID
- リサーチマップAPIで取得できませんでした。
- その他の所属名
- リサーチマップAPIで取得できませんでした。
- その他の所属 部署
- リサーチマップAPIで取得できませんでした。
- その他の所属 職名
- リサーチマップAPIで取得できませんでした。
- 最近のエントリー
- リサーチマップAPIで取得できませんでした。
- Read会員ID
- リサーチマップAPIで取得できませんでした。
- 経歴
- リサーチマップAPIで取得できませんでした。
- 受賞
- リサーチマップAPIで取得できませんでした。
- Misc
- 論文
- 講演・口頭発表等
- リサーチマップAPIで取得できませんでした。
- 書籍等出版物
- リサーチマップAPIで取得できませんでした。
- 研究キーワード
- 研究分野
- 所属学協会
- リサーチマップAPIで取得できませんでした。
- 担当経験のある科目
- リサーチマップAPIで取得できませんでした。
- その他
- リサーチマップAPIで取得できませんでした。
- Works
- リサーチマップAPIで取得できませんでした。
- 特許
- リサーチマップAPIで取得できませんでした。
- 学歴
- リサーチマップAPIで取得できませんでした。
- 委員歴
- リサーチマップAPIで取得できませんでした。
- 社会貢献活動
- リサーチマップAPIで取得できませんでした。
2024年4月27日更新
- 研究者番号
- 70274199
- 所属（現在）
- 2024/4/1 : 徳島大学, 大学院医歯薬学研究部(医学域), 教授
- 所属（過去の研究課題
情報に基づく）*注記 - 2018/4/1 – 2024/4/1 : 徳島大学, 大学院医歯薬学研究部(医学域), 教授
2016/4/1 – 2017/4/1 : 徳島大学, 大学院医歯薬学研究部(医学系), 教授
2015/4/1 : 徳島大学, 大学院医歯薬学研究部, 教授
2011/4/1 – 2014/4/1 : 徳島大学, ヘルスバイオサイエンス研究部, 教授
2012/4/1 : 徳島大学, 大学院・ヘスルバイオサイエンス研究部, 教授
2011/4/1 – 2012/4/1 : 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 教授
2007/4/1 – 2010/4/1 : 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 准教授
2006/4/1 : 徳島大学, 大学院ヘルスバイオサイエンス研究部, 講師
2004/4/1 – 2005/4/1 : 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 講師
1999/4/1 – 2003/4/1 : 徳島大学, 医学部, 講師
- 審査区分/研究分野
-
研究代表者
医学 / 内科 / 内科学一般
生物系 / 医歯薬学 / 内科系臨床医学 / 呼吸器内科学
生物系
小区分53030:呼吸器内科学関連研究代表者以外
医学 / 内科 / 呼吸器内科学
生物系 / 医歯薬学 / 内科系臨床医学 / 呼吸器内科学
総合・新領域系 / 総合領域 / 腫瘍学 / 臨床腫瘍学
生物系 / 医歯薬学 / 薬学 / 医療系薬学
生物系
小区分47060:医療薬学関連
- キーワード
-
研究代表者
樹状細胞 / 遺伝子導入 / アデノウイルスベクター / IL-12 / 免疫遺伝子治療 / 腫瘍免疫 / 抗腫瘍効果 / 癌 / 免疫 / 遺伝子 / 遺伝子治療 / 肺線維症 / fibrocyte / PDGF / PDGFレセプター / イマチニブ / 肺線維芽細胞 / IGF-1 / bFGF / 肺腺維症 / ペプチド / 吸入療法 / 医療・福祉 / 抗体療法 / ADCC / ポドプラニン / 肺癌 / 悪性胸膜中皮腫 / 免疫療法 / バイオマーカー / 抗体治療 / 肝転移 / 小細胞肺癌 / 予後 / 予後因子 / 分子標的治療 / 特異的免疫療法 / 成熟樹状細胞 / MAGE-3 / 癌ワクチン / OK432 / lung cancer / specific immunotherapy / mature dendritic cells / cancer vaccine / OK-432 / 癌抗原 / HM1.24 / 抗体 / 抗原ペプチド / cancer antigen / HM1.24 antigen / antibody therapy / 線維細胞 / 肺がん / 血管新生 / がん幹細胞 / 免疫チェックポイント / がん免疫 / 免疫チェックポイント分子 / がん免疫療法 / 骨髄由来抑制細胞 / 抗原提示細胞 / CD200 / 破骨細胞様マクロファージ / 1細胞解析
研究代表者以外
肺がん / 転移 / 多剤耐性 / P糖蛋白質 / 遺伝子治療 / 免疫療法 / SCIDマウス / 肺癌 / 転移モデル / ガンクリオシドGM2 / モノクローナル抗体 / ADCC / NK細胞 / サイトカイン / 薬剤耐性 / 免疫遺伝子治療 / 抗体治療 / 血管新生 / PTHrP / VEGF / 癌性胸水 / VEGF受容体 / 骨転移 / 血管標的薬 / 多臓器転移 / 分子標的治療 / EGF受容体 / MMP / 臓器微小環境 / cDNAマイクロアレイ / 浸潤 / 樹状細胞 / KAI1 / CD82 / ガングリオシド / 抗体療法 / 肺線維化 / 線維芽細胞 / Th2サイトカイン / COX-2 / PGE2 / IL-1α自己抗体 / リウマチ肺 / サルコイドーシス / 破骨細胞 / 可溶性VEGF受容体 / EGFR阻害薬 / 肝細胞増殖因子 / 抗HM1.24抗原 / HGF / マルチキナーゼ阻害薬 / 胸膜中皮腫 / organotropism / 抗PTHrP抗体 / ビスフォスフォネート / HM1.24抗原 / 耐性 / ゲフィチニブ / マイクロアレイ / プロテオーム解析 / 脳転移 / 蛍光気管支鏡 / MYO18B / Src / CD9 / 閉塞性肺疾患 / アレルギー / 喘息 / ぜんそく / 微小環境 / 分子標的薬耐性 / EGFR変異肺がん / ALK肺がん / 中皮腫 / ALK阻害薬 / EGFRリガンド / EMT / 分子標的薬 / ヒストン脱メチル化酵素 / Met / 腫瘍 / EGFR-TKI / ALK-TKI / FGFR1 / PDGFR / 腫瘍血管 / EGFR / 非閉塞性肺疾患 / 悪性胸膜中皮腫 / 同所移植モデル / thymidine phosphorylase / 解糖経路 / ペントースリン酸経路 / IL-8 / TP / NADPH / NFkB / NADPH oxidase / ROS / pentose phosphate pathway / チミジンホスホリラーゼ / 解糖系 / トランスレーショナルリサーチ / 抗体医薬 / ポドプラニン / 個別医療 / MRK16 / single chain antibody fragment / P糖蛋白 / single chan抗体 / ケモカイン / MRK-16 / MCP-1 / Multi-drug resistance / P-glycoprotein / single chain antibody / 腫瘍免疫 / 薬学 / 癌 / 腫瘍特異的免疫療法 / CasMab
研究課題
研究成果
共同研究者